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Abstract 
 
The  re-emergence  of  plague  as  a  world-wide  health  concern  and  the  potential  risk 
posed by bioterrorism has led to an increased interest in available treatments for the 
disease.  The  bacterial  DNA  adenine-N6  methyltransferase,  Dam,  is  involved  in  the 
regulation of a range of pathogenic bacteria and has been validated as a target for the 
development of antimicrobial agents with activity against Yersinia pestis, the causative 
agent of plague. The lack of a functionally similar enzyme in mammals suggests that 
highly selective Dam inhibitors could be developed. A coupled, real-time break light 
Dam  activity  assay  has  been  optimised  for  HTS,  and  assays  for  the  validation  and 
characterisation of screening hits have also been developed. Screening of random and 
in  silico  enriched  compound  libraries,  and  the  subsequent  application  of  counter-
screening and hit confirmation assays, resulted in the identification of a single viable 
lead, (4-(N-(2-hydroxyethyl)sulfamoyl)phenyl) stibonic acid (13776). 
 
Screening of compounds analogous to 13776 identified a series of arylstibonic acids 
with activity against Dam. Kinetic characterisation of the most potent arylstibonic acid, 
4-stibonobenzenesulfonic acid (13746), revealed a DNA-competitive mode of action, 
and a K
i of 6.46 ± 0.07 nM. However, selectivity assays have revealed a potentially non-
specific  mode  of  action  for  the  stibonic  acids,  which  have  shown  activity  against  a 
range  of  DNA  and  protein  binding  enzymes.  Yersinia  cell  culture  experiments  have 
shown a single compound, (3-((2-hydroxyethyl)carbamoyl)phenyl)stibonic acid (13782), 
to  be capable  of  penetrating  Yersinia  cells and  partially  inhibiting  methylation,  and 
mRNA  profiling  experiments  have  shown  13782  to  induce  a  statistically  significant 
change  in  several  genes  involved  in  the  pathogenicity  of  Y.  pestis.  Attempts  at 
resynthesising 13782 have proved challenging, with only a fraction of the activity of 
the  original  sample  reproduced.  HPLC  analysis  of  the  original  and  resynthesised 
samples has shown the former to comprise two components, with only one present in 
both samples. 
 
The in vitro evaluation of a series of bisubstrate analogues designed to mimic both the 
methyl donor S-adenosylmethionine (AdoMet), and the methylation target (adenine) has 
shown that substitution of the AdoMet sulfur for nitrogen results in a significant but 
not total loss of activity. Furthermore, the addition of a bicyclic heteroaromatic adenine 
analogue mimic to this scaffold led to an increase in potency and selectivity for Dam 
over the human cytosine methyltransferase DNMT1 but a reduction in selectivity for 
Dam  over  the  restriction  enzyme  DpnI.  These  results  suggest  that  a  selective  and 
potent Dam inhibitor can be obtained by carefully modifying both components of the 
bisubstrate analogue inhibitor.      
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1  Introduction 
 
1.1 Antibiotics and the emergence of resistant bacteria 
 
1.1.1 Discovery and development of antibiotics 
The term antibiotic was first used by the biochemist Selman Waksman in the 1940s to 
describe a compound that antagonises the growth of a microbe (1). Although originally 
used to describe antibacterial agents of natural origin, the term is now frequently used 
to describe any compound that inhibits (bacteriostatic) or kills (bactericidal) microbes 
by specific interaction with bacterial targets (2).  
 
The  discovery  of  the  antibacterial  agent  penicillin  (Figure  1.1),  isolated  from 
Penicillium mould by Alexander Fleming in the early 20
th century is often considered as 
the  dawn  of  the  modern  age  of  antibiotics  (3,  4).  However  the  first  commercially 
available antibiotic was the synthetic drug prontosil, developed at Bayer by Gerhard 
Domagk and co-workers (5). The active component of prontosil was later identified by 
Daniel Bovet at the Pasteur Institute as sulfanilamide, a metabolite of prontosil formed 
in vivo and the parent compound of the sulfa drugs (Figure 1.1) (6). The first naturally 
derived  antibiotic,  tyrothricin  (a  mixture  of  tyrocidine  and  gramicidin),  was  isolated 
from the soil bacterium Bacillus brevis in 1939 by Rene Dubos (7). 
 
 
Figure 1.1 Structures of the early antibiotics prontosil and penicillin 
The prontosil metabolite and active component sulfanilamide, and the core penicillin 
structure (in this case for benzylpenicillin) are highlighted in red. 
 
Continuing  the  work  of  Fleming,  in  the  early  1940s  Florey  and  Chain  developed  a 
method for producing and purifying penicillin, with the purified antibiotic showing a 
broad-spectrum of activity and low levels of toxicity in humans (6, 8). The isolation and 
development  of  a  large  number  of  antibiotics  quickly  followed,  with  a  substantial 
proportion of new antibiotic classes introduced between 1930 and 1968 (Figure 1.2). 
Since  this  time  only  two  new  classes  of  antibiotic  have  been  introduced,  the 
oxazolidinones (linezolid, Pfizer) and the lipopeptides (daptomycin, Cubist) although 
other new antibiotics have been introduced within existing classes (9-11). J C McKelvie    Chapter 1   
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Figure 1.2 A timeline of antibiotic drug discovery 
Adapted from references (12, 13). 
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1.1.2 Antibiotic resistance 
The rapid increase in antibiotic use during the past century has been accompanied by 
the concurrent emergence of resistance to these drugs amongst bacterial populations. 
The first reports of sulfonamide resistance appeared in the late 1930s, shortly after the 
introduction of prontosil  (14). In the case of penicillin, a bacterial penicillinase was 
identified  prior  to  the  introduction  of  penicillin  onto  the  market,  with  resistance  in 
hospitals reported shortly after its introduction (2, 15). A similar course of events has 
been  observed  for  subsequent antibiotics  with  resistance emerging  soon after their 
introduction into the clinic (Table 1.1). 
 
Bacteria targeted by the first commercially available antibiotics were initially resistant 
to single antibiotics, for example penicillin-resistant Staphylococci aureus (16). Over 
time the continued selection pressure applied by different drugs has resulted in the 
emergence of multidrug resistant (MDR) bacteria with multiple resistance mechanisms. 
Examples of MDR bacteria include methicillin-resistant S. aureus (MRSA), which also 
displays  an  increased  level  of  virulence  over  methicillin-sensitive  strains,  and 
extensively drug-resistant (XDR) Mycobacterium tuberculosis, which can require the use 
of 6-7 different drugs during treatment (17, 18). J C McKelvie    Chapter 1   
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Table 1.1 Mode of action and resistance mechanisms of commonly used antibiotics 
Antibiotic 
Class# 
Original 
Example 
Target  Mode(s) of Resistance 
Sulfonamide  Prontosil 
(Sulfanilamide) 
C
1 Metabolism  Efflux; Altered target 
β-Lactam  Penicillin  Peptidoglycan 
biosynthesis 
Hydrolysis;  efflux;  altered 
target 
Aminoglycoside  Streptomycin  Translation  Phosphorylation; 
acetylation; 
nucleotidylation;  efflux; 
altered target 
Phenicol  Chloramphenicol  Translation  Acetylation;  efflux;  altered 
target 
Tetracycline  Chlortetracycline  Translation  Monooxygenation; efflux; 
altered target 
Macrolide  Erythromycin  Translation  Hydrolysis; glycosylation;  
phosphorylation;  efflux; 
altered target 
Glycopeptide  Vancomycin  Peptidoglycan 
biosynthesis 
Reprogramming  of 
peptidoglycan biosynthesis 
Streptogramin 
(types A and B) 
Virginiamycin  Translation  C-O  lyase  (type  B); 
acetylation  (type  A);  efflux; 
altered target 
Lincosamide  Lincomycin  Translation  Nucleotidylation;  efflux; 
altered target 
Ansamycin  Rifamycin  Transcription  ADP-ribosylation;  efflux; 
altered target 
Quinolone  Nalidixic acid  DNA 
replication 
Acetylation;  efflux;  altered 
target 
Oxazolidone  Linezolid  Translation  Efflux; altered target 
Lipopeptide  Daptomycin  Cell membrane  Altered target 
Adapted from references (13, 19). 
# In order of discovery. 
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Antibiotic resistance has evolved naturally in some bacteria, and occurs via intrinsic 
mechanisms encoded by genes located on the host chromosome. Other mechanisms of 
resistance are acquired through mutation or horizontal gene transfer (HGT). Mutation 
rates  among  bacterial  populations  are  typically  low,  helping  them  to  preserve  their 
genomes, however under stress, such as in the presence of an antibiotic, the number 
of  hypermutators  increases,  enhancing  the  probability  of  acquiring  resistance.  The 
transfer  of  genetic  material  encoding  resistance  occurs  via  bacteriophage  infection 
(transduction), conjugation of plasmids or transposons, and transformation of naked 
DNA (Figure 1.3) (17, 20). 
 
 
Figure 1.3 Acquisition of antibiotic resistance 
Copyright Nature Reviews Microbiology by Nature Publishing Group. 
Reproduced with permission from reference (21). 
 
Resistance mechanisms include the alteration of molecular targets (often by mutation), 
efflux,  and  the  chemical  inactivation  of  antibiotics,  with  many  resistant  bacteria 
employing a combination of these methods (19). Alteration of molecular targets can 
occur  at  the  drug  binding  site,  directly  affecting  binding  affinity,  or  by  the 
reprogramming of molecular pathways to bypass the affected process. Efflux pumps 
work by removing drug molecules from the cell at a faster rate than they can enter, 
keeping  the  intrabacterial  concentration  low  and  relatively  ineffectual.  Direct 
inactivation  of  antibiotics  occurs  either  by  their  degradation,  for  example  by 
hydrolysis, or through chemical modifications, such as acetylation or phosphorylation. J C McKelvie    Chapter 1   
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Both  methods  drastically  alter  drug  structure,  leading  to  decreased  binding  affinity 
(22). 
 
Antibiotics have revolutionised modern medicine, providing not only a treatment route 
for bacterial infections but enabling medical procedures to be carried out with minimal 
risk of infection (19). However, with ever increasing numbers of MDR bacterial species, 
methods  for  tackling  the  problem  of  resistance  must  be  identified.  Approaches  to 
solving this problem include the reduction of inappropriate antibiotic use, the isolation 
of  patients  colonized  with  potentially  dangerous  resistant  bacteria,  combination 
therapy, the development of further analogues of current antibiotic classes, and the 
development of novel antibiotics (14). 
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1.1.3 Antibiotic resistance in Yersinia pestis 
The pathogen of specific interest for this project is the bacterium Yersinia pestis, the 
causative agent of plague. Y. pestis is a gram-negative bacterium dependent on a host-
species  for survival,  alternating  between  flea  vectors and mammalian  (primarily  rat) 
hosts. In humans, the majority of naturally occurring plague cases are caused by the 
bite of a flea carried by an infected host (typically a wild rodent) resulting in the onset 
of bubonic plague symptoms within 2 to 6 days. Septicemic and pneumonic plague can 
occur as either a secondary infection to bubonic plague, or in a minority of cases, as 
the primary infection. Whilst 40-60% of untreated bubonic plague cases are fatal, the 
septicemic and pneumonic forms of the disease have a near 100% fatality rate if left 
untreated (23). 
 
Several major plague pandemics have occurred throughout human  history, claiming 
millions of lives. During the 15-year period from 1989 to 2003 an average 2,554 cases 
of  plague  were  reported  annually  to  the  World  Health  Organisation  (WHO),  with  an 
average 7% of these cases resulting in fatalities. Whilst improvements in sanitation and 
treatment routes make the outbreak of future pandemics unlikely, an increase in the 
number of cases reported to the WHO since the early 1990s and the re-emergence of 
plague in India (1994 and 2002), Indonesia (1997), and Algeria (2003) after a 30-50 
year period has led to plague being characterised as a re-emerging disease (24, 25). 
 
The outbreak of plague following the release of a biological weapon has also been 
identified as a plausible threat. Both United States and Soviet Union biological weapons 
programs  are  reported  to  have  developed  techniques  to  aerosolize  plague,  the 
dissemination of which  would cause primary pneumonic plague, resulting in a high 
number of fatalities (26). 
 
Treatment of plague is achieved by the rapid administration of antibiotics, typically 
streptomycin,  tetracycline  and  chloramphenicol.  The  successful  use  of  gentamicin, 
trimethoprim-sulfamethoxazole,  doxycycline  and  amoxicillin  has  also  been  reported 
(23, 26, 27).  Although  antibiotic  resistance  in  Y.  pestis  is  rare,  in  recent  years  two 
separate cases have been identified, both occurring in Madagascar in 1995 (28, 29). 
One of the isolated strains exhibited MDR, with resistance to 8 different antibiotics, 
including all of the drugs currently recommended for the treatment of plague.  
 
A  single,  conjugative  plasmid  (pIP1202)  was  found  to  encode  all  of  the  resistance 
genes. Experimental evidence has suggested the source of this plasmid to be HGT in 
the gut of the flea vector, where dense bacterial aggregates are formed, producing a 
favourable environment for the transfer of genetic material (Figure 1.4). The natural J C McKelvie    Chapter 1   
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development of two separate antibiotic resistant strains of Y. pestis implies that such 
an event is not an isolated occurrence, making the continued emergence of Y. pestis 
strains with antibiotic resistance highly likely (30, 31). 
 
 
Figure 1.4 Scanning electron micrograph depicting a mass of Yersinia pestis bacteria 
in the foregut of the flea vector 
Source – Rocky Mountain Laboratories, NIAID, NIH. 
 
The global re-emergence of plague, potential threat from biological weapons, and the 
isolation of antibiotic resistant Y. pestis strains have led to a renewed interest in the 
development of improved treatment methods. Such methods include immunotherapy, 
immunomodulatory  therapy,  phage  therapy,  bacteriocin  therapy,  symptomatic 
treatment,  and  the  inhibition  of  virulence  factors.  Therapeutic  agents  targeting 
virulence factors would be expected to interfere with infection rather than viability and 
are therefore unlikely to be affected by current resistance mechanisms, making them 
an attractive prospect for the development of novel antimicrobials (32). 
 
All  Yersinia  spp.  contain  a  plasmid  which  encodes  the  Yop  (Yersinia  outer  protein) 
virulon. This system is comprised of the type III secretion system apparatus (the Ysc), 
the  translocation  apparatus,  a  set  of  intracellular  effector  proteins,  and  a  control 
system. On contact with eukaryotic cells the Yops are secreted and the translocation 
apparatus delivers the effector proteins into the cell, inducing apoptosis (Figure 1.5). 
The Yop virulon is considered to be the main pathogenicity factor of Yersinia spp., with 
the ability to disarm host-immune response making it essential for virulence (32, 33). 
Inhibitors targeting specific proteins within the Yop virulon have been developed and 
some have shown attenuation in eukaryotic models (32, 34-37).  
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Figure 1.5 Yersinia type III secretion system (Ysc) 
YopB labelled B, effector proteins Yops E, H, M, O, P and T labelled E, H, M, O, P and T. 
Copyright Nature Reviews Genetics by Nature Publishing Group. 
Reproduced with permission from reference (38). 
 
An  alternative  approach  has  been  suggested  involving  the  inhibition  of  the  DNA 
adenine-N6 methyltransferase (Dam) which is involved in the regulation of virulence 
proteins,  including  Yops  (39).  A  Y.  pestis  dam  mutant  has  shown  a  2000-fold 
attenuation  in  mouse  models  (40),  and  the  inoculation  of  mice  with  a  Yersinia 
pseudotuberculosis  dam  mutant  led  to  their  subsequent  protection  from  plague 
infection (41). The potential for hypermutation due to the disruption of the mismatch 
repair mechanism in dam mutants mean it is unlikely they can be used as effective 
vaccines. However, Dam inhibitors may represent a valid target for the development of 
novel antimicrobials effective against plague (42). J C McKelvie    Chapter 1   
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1.2 Methyltransferases 
 
1.2.1 Overview 
Dam is a member of the S-adenosylmethionine-dependant methyltransferases (AdoMet-
dependant methyltransferases), a family of enzymes responsible for the transfer of a 
methyl group from the methyl donor AdoMet to a wide range of biological substrates. 
Methylation is known to occur at sulfur, carbon, nitrogen and oxygen atoms on small 
molecules, such as metabolites, and on biological macromolecules (43, 44). 
 
One of the most widely studied small molecule methyltransferases is the catechol-O-
methyltransferase  (COMT),  which  catalyses  the  transfer  of  a  methyl  group  to 
catecholamines  and  other  catechols  in  the  presence  of  magnesium  ions.  COMT 
catalysed methylation of these substrates leads to their inactivation, and can play a 
role  in  Parkinson‟s  disease,  with  COMT  inhibitors  being  used  in  the  treatment  of 
Parkinson‟s  as  an  adjunct  to  L-DOPA  therapy  (45,  46).  Other  examples  of  small 
molecule  methyltransferases  include:  glycine  N-methyltransferase  (GNMT),  which 
methylates  glycine  to  form  sarcosine,  and  has  been  implicated  in  the  regulation  of 
AdoMet (47, 48); histamine N-methyltransferase (HNMT), which forms the first step in 
the metabolism of histamine, and has been linked with allergic/inflammatory disease 
(49); phenylethanolamine N-methyltransferase (PNMT), which catalyses the formation 
of epinephrine (adrenaline) from norepinephrine (noradrenaline) and is implicated in a 
wide  range  of  central  nervous  system  (CNS)  related  conditions  (50);  and 
guanidinoacetate methyltransferase (GAMT), which catalyses the final step in creatine 
biosynthesis,  and  has  been  linked  to  speech  delay,  learning  disorders,  autism, 
epilepsy, hyperactivity and movement disorders (51). 
 
Fewer  examples  of  lipid  methyltransferases  are  known,  with  perhaps  the  most 
significant  example  being  the  phospholipid  methyltransferase 
phosphatidylethanolamine  N-methyltransferase  (PEMT)  which  methylates 
phosphatidylethanolamine  (PE)  to  form  the  membrane  protein  phosphatidylcholine 
(PC). PEMT is found primarily in the liver where it is responsible for the formation of 
~30% of hepatic PC, with the remainder coming from the CDP-choline pathway, which 
relies on dietary choline (52). 
 
The  protein  methyltransferases  form  a  much  larger  group  of  enzymes,  with 
methylation known to occur at arginine, lysine, histidine, proline and carboxyl groups 
(53).  Methyltransferases  which  methylate  arginine  are  known  as  protein  arginine 
methyltransferases (PRMTs) and can be broadly divided into three types: type I, which 
form  -monomethyl-  and  asymmetric  dimethyl-  arginine;  type  II,  which  form  -J C McKelvie    Chapter 1   
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monomethyl-  and  symmetric  dimethyl-  arginine;  and  type  III,  which  form  -
monomethylarginine  (Figure  1.6)  (54).  PRMTs  are  known  to  methylate  a  growing 
number of proteins, including histones, fibrillarin and STATs (signal transducer and 
activator of transcription), and have been implicated in numerous biological processes, 
including signal transduction, cellular proliferation and transcriptional processing (55).  
 
 
Figure 1.6 Protein arginine methylation by types I, II and III PRMTs 
 
Another  family  of  methyltransferases  methylate  lysine  residues,  within  which  the 
medically important family of histone methyltransferases (HMTs) have been particularly 
well studied. The vast majority of histone lysine methylation is carried out by the SET-
domain family of proteins, targeting the  -amino centre and resulting in the formation 
of mono-, di-, and tri-methylated lysine residues (56). Both lysine and arginine HMTs 
are involved in numerous cellular processes, including heterochromatin formation, X-
chromosome inactivation and transcription regulation and as such are associated with 
numerous human developmental disorders and diseases (57). 
 
Nucleic  acid  methyltransferases  include  both  RNA  and  DNA  methyltransferases,  the 
latter  of  which  will  be  discussed  in  detail  in  the  following  Section  (1.2.2).  The 
methylation  of  RNA  occurs  at  a  vast  array  of  positions  in  transfer  RNA  (tRNA), 
ribosomal RNA (rRNA), small nuclear RNA (snRNA) and messenger RNA (mRNA) (58). 
Biological  functions  of  RNA  methylation  include  the  maintenance  of  RNA  structures 
(specifically tRNA), the control of decoding specificity during translation and antibiotic 
resistance (44, 59, 60). J C McKelvie    Chapter 1   
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1.2.2 DNA methyltransferases 
DNA  methylation  is  catalysed  by  the  DNA  methyltransferases  and  occurs  at  the  N6 
position of adenine and the N4 or C5 position of cytosine (Figure 1.7). Whilst all three 
types of methylation are observed in prokaryotes, to date only cytosine-C5 methylation 
has  been  identified  in  higher  eukaryotes,  although  N6-methyladenine  has  been 
identified in several lower eukaryotes (61-63).  
 
 
Figure 1.7 Structures of the methylated bases 
 
The DNA methyltransferases of eukaryotes are involved in epigenetic processes such 
as  the  control  of  gene  transcription,  maintaining  genome  stability  and  integrity, 
genomic imprinting, and X-chromosome inactivation (44, 64). In mammals cytosine-C5 
methylation occurs primarily at CG-rich regions known as CpG islands, and is carried 
out by a group of enzymes called the DNMTs. The DNMTs include the maintenance 
methyltransferase DNMT1, the de novo methyltransferases DNMT3A and DNMT3B, and 
the activator DNMT3L (65). The enzyme DNMT2 has also been classed as a mammalian 
DNA methyltransferase due to sequence similarities with other DNMTs, however the 
DNA methyltransferase activity of this enzyme is poor, and the discovery of its ability 
to act as an RNA methyltransferase has led to the suggestion that DNMT2 may share 
an evolutionary origin with the DNMT1 and DNMT3 family (66). The hypo- and hyper-
methylation of CpG islands has been linked to many human diseases, including cancer, 
and is a validated target for the development of drugs targeting leukaemia (64, 67, 
68). 
 
In prokaryotes, DNA methyltransferases have a range of biological roles: as part of 
restriction-modification (RM) systems they are responsible for the protection of cells 
from invading foreign DNA, enabling the distinction of self and non-self DNA through 
the methylation of specific recognition sites, blocking cleavage by cognate restriction 
enzymes; DNA methyltransferases which are not part of an RM system, such as the 
adenine-N6 methyltransferases Dam and CcrM (cell-cycle regulated methyltransferase), 
play a role in DNA repair, the control of gene expression, phase variation, bacterial 
virulence, and cell cycle regulation; and in phage, methyltransferases can be used to 
improve survival of DNA in host-cells by mimicking the methyltransferases of host RM 
systems (44, 61). J C McKelvie    Chapter 1   
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Both prokaryotic and eukaryotic DNA methyltransferases have a two-domain structure 
consisting of a catalytic domain, which contains up to ten characteristic amino acid 
motifs and encompasses both the AdoMet binding site and the methyl transfer active 
site, and a smaller target recognition domain (TRD). DNA binding occurs at the cleft 
between the two domains, with sequence-specific DNA recognition controlled by the 
variable  TRD  (44, 61). The  catalytic  domains of all  DNA methyltransferases  share  a 
structural core common to the vast majority of AdoMet-dependant methyltransferases 
(43, 69). This core consists of alternating  -sheets and  -helices which form a seven-
stranded  -sheet, with each  -sheet flanked by one or two  -helices (Figure 1.8) (44, 
61). The mammalian DNMT1 and DNMT3 family of enzymes also possess an N-terminal 
regulatory domain, which in DNMT1 is thought to be required for the formation of the 
correct tertiary protein structure (70). 
 
 
Figure 1.8 Conserved central structure of the DNA methyltransferases  
Adapted from reference (61). 
 
DNA methyltransferases have been observed to show both distributive and processive 
modes  of  methylation,  with  a  distributive  mechanism  generally  identified  for  DNA 
methyltransferases involved in an RM system, and a processive mechanism generally 
observed  for  solitary  DNA  methyltransferases  (71).  In  both  cases  DNA  binding  is 
thought  to  follow  a  multi-step  process  in  which  the  enzyme  binds  non-specifically, 
diffusing linearly along the DNA until the target site is reached, with specific binding 
facilitated by the interaction between the TRD and the DNA recognition site (61). Once 
a specific interaction is formed the target nucleotide is rotated out of the double helix, 
and positioned into the catalytic domain active site pocket in a process known as base 
flipping (69, 72). In the case of cytosine-C5 methylation addition of a cysteine residue 
to the 6 position leads to the formation of a nucleophilic enamine which reacts with J C McKelvie    Chapter 1   
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the AdoMet (Figure 1.9). In the case of adenine-N6 and cytosine-N4 methylation, the 
reaction follows a simple direct S
N2 type mechanism (61, 73, 74). 
 
 
Figure 1.9 Methylation mechanisms for cytosine-C5 methylation 
Adapted from reference (61). 
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1.2.3 DNA adenine-N6 methyltransferase 
The  solitary  prokaryotic  DNA  methyltransferase  Dam  catalyses  the  methylation  of 
adenine at the N6 position in the recognition sequence GATC. Dam is found in a range 
of gram-negative proteobacteria such as Escherichia coli, Vibrio cholerae, Yersinia spp. 
and Salmonella spp.; it is also present in a number of bacteriophages such as HP1, P1, 
T1 and T4 phage (75). Adenine-N6 methylation decreases the thermodynamic stability 
of  DNA  and  alters  the  curvature  of  the  DNA  backbone  (Figure  1.10),  acting  as  an 
epigenetic signal by influencing protein:DNA binding interactions (76). As such Dam 
has  been  implicated  in  critical  cellular  processes  including  the  initiation  of 
chromosome  replication,  mismatch  repair,  the  regulation  of  gene  expression,  and 
pathogenicity (42, 75, 76). 
 
       
Figure 1.10 Effect of methylation of DNA backbone curvature 
(A-C): DNA duplex containing un- (A), hemi- (B) and fully (C) methylated GATC site, with 
DNA shown in blue, A of GATC site in yellow and transferred methyl group in red. 
(D):  Overlay  of  DNA  duplexes  containing  un-  (blue),  hemi-  (yellow)  and  fully  (red) 
methylated GATC site. 
Image created using pdb files 1OPQ (A), 1OQ2 (B) and 2KAL (C) with the program UCSF 
Chimera (77). 
 
Chromosome replication: Dam methylation occurs at the majority of hemimethylated 
GATC  sites,  where,  shortly  after  DNA  replication,  the  nascent  daughter  strand  is 
unmethylated and the parent strand methylated. At the origin of DNA replication (oriC) 
a  high  density  of  GATC  sites  facilitates  the  binding  of  the  protein  SeqA,  which 
preferentially binds to two or more hemimethylated GATC sites. Sequestration of the 
GATC  sites  at  OriC  by  SeqA  persists  for  approximately  one-third  of  the  cell  cycle, 
preventing re-initiation of chromosome replication from occurring more than once per 
cell cycle by delaying methylation and subsequent DnaA binding at OriC (78). 
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Mismatch repair: When a base mismatch is formed during DNA replication in E. coli it 
is recognised by the protein MutS, which binds DNA at the mismatch site. MutS then 
recruits the activator MutL and, in the presence of ATP, forms a ternary complex with 
MutH.  Upon  complex  formation  MutH  is  able  to  cleave  the  unmethylated  daughter 
strand at a hemimethylated GATC site adjacent to the mismatch, providing an initiation 
site for excision of the DNA containing the mismatch (79). Dam methylation acts as a 
signal, directing post-replication mismatch-repair to the nascent, unmethylated DNA 
strand. The absence or over-production of Dam results in increased mutation rates, 
with MutH unable to distinguish between the parent and daughter strands, leading to 
both being cleaved, sometimes simultaneously (80).  
 
Regulation  of  gene  expression:  The  blocking  of  methylation  by  the  binding  of 
regulatory proteins at or adjacent to GATC sites leads to the formation of heritable 
DNA methylation patterns. In cases where the methylation state of GATC sites affects 
the binding of regulatory proteins, gene expression can be influenced. An example of 
how DNA methylation patterns influence gene expression is provided by the regulation 
of phase variation in the pyelonephritis-associated pili (Pap) of uropathogenic E. coli. 
Pap  phase  variation  is  controlled  through  the  methylation  of  two  GATC  sites,  one 
proximal  to  the  pap  promoter  (GATC
prox)  and  one  located  upstream  of  GATC
prox 
(GATC
dist).  In  the  off-phase,  the  leucine-responsive  protein  (Lrp)  binds  at  sites 
overlapping GATC
prox, blocking methylation and allowing the unblocked GATC
dist site to 
become fully methylated. Switching to the on-phase occurs following replication, upon 
translocation of Lrp to binding sites overlapping GATC
dist in the presence of PapI and 
hemimethylated  GATC
dist;  methylation of GATC
prox  then  occurs  preventing  further Lrp 
binding at this site (Figure 1.11) (81, 82). 
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Figure 1.11 Regulation of Pap phase variation 
Where two black squares represent a fully methylated GATC site, one black and one 
white square represents a hemimethylated GATC site, and two white squares represent 
an unmethylated GATC site. 
Adapted from reference (81) 
 
Pathogenicity:  The  effect  of  Dam  methylation  on  bacterial  pathogenesis  has  been 
documented in a range of pathogens. In dam mutant strains of Salmonella enterica 
(83-85), Haemophilus influenzae (86), Y. pseudotuberculosis strain IP32953 (41) and Y. 
pestis (40) attenuation has been observed in animal models. Where Dam is essential for 
viability, Dam over-producing (Dam
OP) strains have been used as a tool to study the 
effects  of  alterations  in  Dam  levels  within  the  cell,  with  Dam
OP  strains  of  Y. 
pseudotuberculosis strain YPIII (87), V. cholerae (87), Pasteurella multocida (88) and 
Aeromonas hydrophila (89) also showing attenuation in animal models. The disruption 
of mismatch repair and the expression of virulence genes caused by changes in cellular 
Dam concentrations have been shown to produce a range of affects. Examples include 
the increased bile sensitivity and envelope instability of S. enterica dam mutants and 
the deregulation of Yop secretion in Y. pseudotuberculosis Dam
OP strains (39, 42, 75).   
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1.2.4 Structural  and  kinetic  characterisation  of  DNA  adenine-N6 
methyltransferase 
The structures of T4 and E. coli Dam have been solved in binary complexes with the 
methyl  donor  product  S-adenosylhomocysteine  (AdoHcy)  or  the  AdoMet  analogue 
sinefungin, and in tertiary complexes with either AdoHcy or sinefungin and DNA. Both 
E. coli and T4 Dam share the same two-domain structure as all DNA methyltransferases 
with the TRD of each comprising of a five-helix bundle and a  -hairpin loop which is 
conserved  across  the  GATC-specific  DNA  methyltransferases  (90-93).  Whilst  the 
sequence  similarity  between  the  two  enzymes  is  only  25%,  the  active  site  is  more 
highly conserved, with both enzymes containing the DPPY variant of the (D/N/S)PP(Y/F) 
active  site  motif  (Figure  1.12),  which  is  characteristic  of  the  adenine-N6 
methyltransferases (94). There is also sequence conservation between T4 and E. coli 
Dam and the Dams of other microorganisms, most notably between E. coli Dam and 
the Dams of pathogenic bacteria where there is a high level of sequence conservation 
(Figure 1.12). 
 
 
Figure 1.12 Neighbour joining tree for E. coli, T4 and some pathogenic Dams. 
Calculated by percentage identity using the program Jalview (95, 96). 
 
For  both  E.  coli  and  T4  bacteriophage  Dam  DNA  binding  has  been  shown  to  be 
regulated by the  -hairpin loop, and to a lesser extent the N-terminal loop. Transition 
from  non-specific  to  specific  DNA  binding  interactions  are  facilitated  by  binding 
interactions between the GATC recognition sequence and the specific residues within 
these  loops.  Specific  binding  re-orientates  the  protein  on  the  DNA,  allowing  the 
adenine  base  to  be  flipped  out  of  the  double  helix  and  into  the  active  site  for 
methylation to occur (Figure 1.13). The double helix is stabilised during base flipping J C McKelvie    Chapter 1   
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through  protein:DNA  stacking  and  hydrogen-bonding  interactions  (91,  92).  Studies 
using  the  stacking-interaction  dependent,  fluorescent  base  analogue,  2-aminopurine 
(2AP), have shown base-flipping to comprise of two steps, flipping of the target out of 
the  double  helix,  followed  by  binding  of  the  flipped  base  into  the  active  site. 
Interestingly the second step is not observed when AdoHcy is employed as a substrate, 
suggesting that different binding modes are employed for substrate and product (91, 
97, 98).  
 
   
Figure 1.13 Non-specific and specific DNA binding interactions of T4 Dam 
Non-specific T4  Dam:DNA:AdoHcy complex  (A) and specific  T4  Dam:DNA:Sinefungin 
complex (B). Protein shown in grey, DNA in blue, AdoHcy or sinefungin in red,  -hairpin 
loop in yellow and DPPY active site motif in orange. 
Image created using pdb files 1YF3 molecule A (A) and 1YFL molecule E (B) with the 
program UCSF Chimera (77). 
 
A combination of hydrogen bonding and stacking interactions mediated by the amino 
acids of the DPPY motif help to stabilise the flipped conformation and facilitate methyl 
transfer (91, 98). Dam catalysed methylation has been shown to occur in a processive 
manner (99-101), with subsequent methylations taking place prior to DNA release. E. 
coli Dam processivity has been shown to occur via intersite (methylation of multiple 
GATC sites on the same strand of DNA) and intrasite (methylation of both adenines in a 
fully unmethylated GATC site) mechanisms, with intersite processivity regulated by the 
DNA sequences flanking the recognition site (102-104). 
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Figure 1.14 The role of residues in the DPPY motif in methyl transfer 
The carbonyl of proline and the carboxylate of asparagine form hydrogen bonds to the 
N6 amine, with aspartic acid proposed to function as a base, removing a proton in 
concert with the methyl transfer step. 
Adapted from reference (61). 
 
The most detailed kinetic studies of the methylation reaction have used the E. coli and 
T4 Dam enzymes, as reported by the groups of Hattman, Reich and Jeltsch. An ordered 
bi-bi reaction mechanism in which AdoMet binds prior to the formation of a specific 
complex with DNA at the GATC recognition site has been proposed for both enzymes 
(99, 101, 105). The rate limiting step in this process has been identified as the release 
of  methylated  DNA,  again  for  both  T4  and  E.  coli  Dam  (104-106).  Monomeric  and 
dimeric forms of the enzyme have been observed, however T4 and E. coli Dam have 
each  been  shown  to  form  functional  dimers  only  under  single  turnover  conditions 
(103,  107).  Kinetic  parameters  have  been  determined  using  short  synthetic  DNA 
substrates and are tabulated below (Table 1.2).   
 
Table 1.2 Kinetic parameters for E. coli and T4 Dam 
Protein  Substrate  Methylation 
state* 
KMDNA 
nM 
KMAdoMet 
M 
kcat 
min-1 
Source 
E.  coli 
Dam 
21-mer duplex  UM  81 ± 4  -  0.91 ± 0.03  (104) 
20-mer duplex  UM  17.4 ± 3.0  5.6 ± 1.1  0.93 ± 0.06  (105) 
20-mer hairpin  UM  28.6 ± 0.16  6.4 ± 1.2  1.19 ± 0.33  (105) 
T4 Dam  24-mer duplex  UM  7.7  0.33  0.84  (108) 
20-mer duplex  UM  6.3 ± 1.5  0.49  0.9 ± 0.06  (109) 
HM  6.0 ± 1.3  -  0.6 ± 0.006  (109) 
* UM – Unmethylated GATC site, HM – hemimethylated GATC site. 
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The Michaelis-Menten constants (K
Ms) vary between T4 and E. coli Dam, with the latter 
showing  weaker  affinities  for  both  DNA  and  AdoMet.  Some  variation  in  K
M
DNA  is 
observed for E. coli Dam over different experiments, however the minimal difference in 
values  obtained  with  an  oligonucleotide  duplex  and  hairpin  suggest  that  both 
substrates are suitable for measuring the kinetic parameters of Dam. Constants for T4 
Dam were determined for both an unmethylated and hemimethylated version of the 
same duplex, with similar K
M
DNA and k
cat values obtained in both cases, demonstrating 
the lack of preference shown by T4 Dam for hemimethylated over unmethylated sites. 
A lack of preference for DNA methylation state has also been observed for E. coli Dam, 
which  methylates  unmethylated  and  hemimethylated  duplex  DNA  with  the  same 
efficiency in vitro (110). 
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1.2.5 Methyltransferase inhibitors 
The wide range of biological functions carried out by methyltransferases makes them 
attractive  targets  for  drug  development,  with  methyltransferase  inhibitors  currently 
being used in the treatment of cancer (111) and Parkinson‟s disease (112) amongst 
others.  As  a  common  reaction  product  for  all  AdoMet  catalysed  methyltransfer 
reactions, AdoHcy (Figure 1.15) has been widely investigated as a methyltransferase 
inhibitor. Whilst AdoHcy is a potent inhibitor of many different methyltransferases the 
use of the compound as a drug has been ruled out due to its poor selectivity, lack of 
cellular uptake, and rapid metabolism by AdoHcy hydrolase within cells (113). 
 
 
Figure 1.15 Structures of the methyl donor AdoMet and methyl donor product AdoHcy 
 
In  order  to  overcome  these  issues  AdoHcy  and  AdoMet  analogues  have  been 
synthesised, with modifications made to the sugar, amino acid and adenosine moieties 
(114-121).  In  addition  to  synthetic  AdoHcy  analogues  a  natural  product  analogue, 
sinefungin,  isolated  from  Streptomyces  griseolus  at  Lilly  (122),  was  found  to  have 
activity  against  a  wide  range  of  methyltransferases  (123-127).  Unfortunately,  the 
severe nephrotoxicity provoked by sinefungin in higher mammals makes it unfeasible 
as  a  drug  candidate  (128).  More  recent  efforts  with  analogues  have  attempted  to 
address  selectivity  issues  by  comparing  the  effects  of  inhibitors  on  multiple 
methyltransferases (129-131), however such studies often compare only closely related 
enzymes, with broader selectivity concerns overlooked.  
 
The  bisubstrate  nature  of  methyltransferases  makes  them  ideal  candidates  for 
multisubstrate  analogue  inhibitor  design,  a  process  in  which  two  or  more  enzyme 
substrates are combined to develop more potent and selective inhibitors (132, 133). A 
major  caveat  of  AdoHcy  analogue  inhibitors  is  the  lack  of  specificity  inherent  in 
compounds based on a product common to all AdoMet-dependent methyltransferases. 
By combining the structural features of AdoHcy and the individual methylation target, 
specificity  can  likely  be  improved  due  to  the  synergistic  effect  on  active  site 
recognition. In addition, potency is also likely to improve due to an increase in binding 
affinity. A multisubstrate analogue inhibitor design approach has been applied to a 
range  of  methyltransferases  including  HMTs  (134),  PRMTs  (135),  COMTs  (136-140), 
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Several inhibitors have also been designed based on the structure of the methyl target 
alone.  Perhaps  the  best  examples  of  such  compounds  are  the  cytidine  analogue 
inhibitors of cytosine-C5 methyltransferase, such as 5-azacytidine (azacitidine), 5-aza-
2‟-deoxycytidine  (decitabine),  β-D-arabinofuranosyl-5-azacytosine  (fazarabine),  and 
dihydro-5-azacytidine (DHAC) (143, 144). These compounds are incorporated into DNA 
and  inhibit  cytosine-C5  methyltransferases  by  forming  a  covalent  adduct  and 
preventing  further  methylation.  Other  examples  of  molecules  that  modify 
methyltransferase activity include antisense oligonucleotides, which are short synthetic 
nucleic  acids  designed  to  bind  to  specific  mRNA  sequences  and  block  translation, 
leading  to  the  downregulation  of  methyltransferase  expression  (144,  145),  and  the 
polyamines  spermidine  and  putrescine,  which  have  been  shown  to  inhibit  bacterial 
cytosine-C5 methyltransferases (146). 
 
The  importance  of  Dam  to  the  virulence  of  pathogenic  bacteria  and  the  lack  of  a 
functionally similar enzyme in mammals has made it a target for the development of 
novel antibacterial agents (84, 105). To this end several different strategies have been 
employed in the development of Dam inhibitors (Figure 1.16). In 2005 Benkovic et al. 
published a paper describing the identification of a series of bisubstrate borinic ester 
inhibitors  of  the  bacterial  adenine-N6  methyltransferase  CcrM  which  also  showed 
activity against Dam (147, 148). Subsequently Mashhoon et al. published the results of 
a  50,000  compound  high-throughput  screen,  identifying  57  small  molecule  Dam 
inhibitors with IC
50 (50% inhibitory concentration) values of 25  M or less. Of these 57 
compounds, 55 were found to be selective for Dam over DNMT1 and 38 were found to 
be selective for Dam over CcrM (149). Finally, Naumann et al. used a genetic selection 
method  combined  with  split  intein-mediated  ligation  of  peptides  and  proteins 
(SICLOPPS)  technology  to  identify  3  cyclic  peptide  Dam  inhibitors  with  IC
50  values 
ranging  from  50  to  144  M,  each  of  which  showed  selectivity  for  Dam  over  the 
bacterial cytosine-C5 methyltransferase M.HhaI (150).  
 
In silico methods have also been utilised for the identification of Dam inhibitors, with 
Cheng and co-workers identifying several small molecule inhibitors (Figure 1.16) from 
the National Cancer Institute‟s Developmental Therapeutics Program (NCI/DTP) library 
(151).  Compounds  were  identified  based  on  three-dimensional  docking  interactions 
with the active sites of both E. coli and T4 Dam, and validated as inhibitors using both 
biochemical and whole-cell assays.  
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Figure 1.16 Dam inhibitors 
Bisubstrate  borinic  esters  (A),  five  classes  of  inhibitor  identified  from  a  high-
throughput screen (B), cyclic peptides (C), single class of inhibitor identified from an in 
silico screen (D). 
Adapted from references (147, 149-151). 
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1.2.6 Methyltransferase assays 
The high level of interest in methyltransferases as potential therapeutic targets has led 
to a range of activity assays for the detection and characterisation of these enzymes 
being  developed.  Early  methyltransferase  assays  monitored  the  incorporation  of 
radiolabelled methyl groups from 
3H or 
14C labelled AdoMet into methylated products. 
The  separation  of  unreacted  labelled  substrate  from  labelled  product  was  then 
achieved through filter binding (152), chromatography (153, 154), gel electrophoresis 
(155), immobilisation of labelled product (e.g. through biotin/avidin interactions) (156-
158), or coupling to cellulose (159). Whilst such assays can be highly sensitive and are 
still widely used, they are time-consuming and often involve the undesirable use of 
radioactive material, making them less than ideal for high-throughput applications. 
 
The  difficulties  inherent  in  radiolabelling  assays  have  led  to  the  development  of  a 
number  of  alternative  methyltransferase  assays.  A  series  of  „universal‟  assays  with 
potential  for  use  against  all  methyltransferases  have  been  developed  in  which  the 
universal  methyl  donor  product,  AdoHcy,  is  modified  to  yield  a  detectable  product 
(Figure 1.17). Enzymes which catalyse the degradation of AdoHcy and its breakdown 
products,  such  as  AdoHcy  hydrolase,  AdoHcy  nucleosidase,  adenine  deaminase  and 
adenosine  deaminase,  are  used  alone  or  in  conjunction  with  derivatising  agents  to 
produce compounds which are detectable by absorbance or fluorescence spectroscopy 
(160-163).  
 
 
Figure 1.17 Universal AdoHcy-specific methyltransferase assays 
Adapted from references (160-163). J C McKelvie    Chapter 1   
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Although  the  removal  of  AdoHcy  is  advantageous,  preventing  potential  product 
inhibition, the adverse affect of coupling enzymes on potential inhibitors (especially 
those  based  on  AdoHcy)  mean  that  these  assays  are  not  suitable  for  the 
characterisation  of  some  classes  of  methyltransferase  inhibitors.  Another  common 
issue arising from the use of these assays is the possible interference of protein and 
substrates on the spectroscopic signal.  
 
Other „universal‟ methyltransferase assays include the detection of methylated product 
by mass spectrometry (164), and competitive fluorescence polarisation immunoassays 
(FIPAs), in which a fluorescent tracer (a fluorescein-AdoHcy conjugate) competes with 
AdoHcy  for  binding  of  an  AdoHcy  antibody  leading  to  a  decrease  in  fluorescence 
polarisation signal as the reaction progresses (165). Detection by mass spectrometry is 
highly accurate but not compatible with high-throughput applications, whereas FIPAs 
are conducive to high-throughput applications but can show high levels of background 
interference. 
 
Assay technologies specific to the DNA methyltransferases often rely on the ability of 
methylation-sensitive  restriction  enzymes  to  cleave  methylated  DNA  sequences. 
Examples include: DNA-modified gold nanoparticle assays in  which  methylation and 
subsequent cleavage induces DNA duplex dehybridisation, allowing the nanoparticles 
to  aggregate,  causing  a  red-to-blue  colour  change  (166);  a  methylation-responsive 
DNAzyme  strategy  in  which  methylation  and  subsequent  cleavage  activates  a 
horseradish peroxidise mimicking DNAzyme, which can then catalyse the H
2O
2 induced 
oxidation of 2,2‟-azino-bis(3-ethylbenzothiazoline)-6-sulfonate disodium salt (ABTS
2-) to 
a coloured radical (167); and an enzyme-linked immunosorbent (ELISA) based assay in 
which  methylation  leads  to  the  inhibition  of  restriction  enzyme  catalysed  cleavage, 
protecting a duplex labelled on either end with biotin (used to immobilise one strand 
to  a  streptavidin  coated  plate)  and  digoxigenin  which  is  recognised  by  Anti-Dig-
Alkaline phosphatase and detected by bound p-nitrophenyl phosphate (pNPP) (168). 
 
Another  DNA  methyltransferase  specific  assay  methodology  utilises  small  hairpin 
oligonucleotide probes known as „molecular break lights‟ (169) in the detection of DNA 
methylation.  In  the  hairpin  form  a  quencher  and  fluorophore  on  either  end  of  the 
oligonucleotide  are  held  in  close  proximity,  leading  to  fluorescence  quenching. 
Cleavage  of  the  probe  leads  to  the  separation  of  fluorophore  and  quencher  and  a 
subsequent increase in fluorescence (Figure 1.18). Methylation of a DNA recognition 
site within the probe can either protect from or promote restriction enzyme catalysed 
cleavage. This methodology has been applied by Mashhoon  et al., who employed a 
protection-based  assay  for  the  end-point  monitoring  of  Dam  activity,  utilising  the J C McKelvie    Chapter 1   
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methylation-sensitive restriction enzyme DpnII (149), and Li et al., who developed a 
real-time Dam activity assay which monitored the increase in fluorescence observed 
upon methylation promoted DpnI cleavage of an unmethylated break light probe (170).  
 
 
Figure 1.18 Molecular break light principle 
Adapted from reference (169). 
 
Although  the  method  proposed  by  Li  et  al.  enables  real-time  monitoring  of  Dam 
methylation in vitro it does not allow for the determination of kinetic parameters, as 
the  unmethylated  oligonucleotide  substrate  employed  requires  two  methylations, 
inducing a lag phase and preventing the easy determination of initial rate. To address 
this  problem  Wood  et  al.  employed  a  similar  method  using  a  hemimethylated 
oligonucleotide substrate which circumvented the issues experienced by Li et al. and 
allowed them to kinetically characterise Y. pestis Dam (171). Wood et al. successfully 
applied  the  same  approach  to  the  development  of  a  cytosine-C5  methyltransferase 
assay (172), demonstrating the broad applicability of this approach as a method for 
assessing  the  activity  of  DNA  methyltransferases,  provided  a  methylation  sensitive 
restriction enzyme is available. J C McKelvie    Chapter 1   
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1.3 Drug discovery 
 
The drug discovery process (Figure 1.19) is a complex multistep process that can take 
years of research effort and millions of pounds of investment. In addition, the process 
of developing a safe and profitable drug is fraught with problems that frequently result 
in the failure of the programme (173, 174). The first key stage in the process is the 
identification  and  validation  of  a  druggable  target.  In  the  most  widely  adopted 
approach assay techniques are then developed and used to screen compound libraries 
for „hits‟ with activity against the target of interest. Hit validation is then followed by 
hit-to-lead optimisation where potency, selectivity and physiochemical properties of the 
original hit compound are optimised. Compound absorption, distribution, metabolism, 
excretion  and  toxicology  (ADMET)  are  then  assessed,  with  successful  candidates 
progressing to clinical trials and, in a small minority of cases, to market (175).  
 
 
Figure 1.19 The de novo drug discovery process 
Adapted from reference (176). 
 
In  2006  the  number  of  drug  targets  was  estimated  at  324,  with  only  6%  of  novel 
therapeutics  targeting  previously  undrugged  domains  (177).  Established  targets 
include  kinases,  proteases,  phosphatases,  oxidoreductases,  phosphodiesterases, 
transferases, G-protein coupled receptors, nuclear hormone receptors and some ion 
channels  and  signalling  pathways  (178).  Examples  of  methods  involved  in  the 
identification  and  validation  of  novel  targets  include:  microarray  analysis, 
bioinformatics,  deletion  mutants,  gene  silencing  via  antisense  oligonucleotides  and 
small interfering RNAs (siRNAs), activation and repression  of genes with zinc finger 
proteins, haplotype analysis, and random chemical mutagenesis (179, 180). 
 
Once a target has been identified and validated, assay techniques must be developed 
to assess the effect of potential therapeutics. High-throughput assays are often based 
on fluorescent or colorimetric techniques as they are fast, highly sensitive and easy to 
miniaturise for use in a high-throughput format (181). Alternative techniques such as J C McKelvie    Chapter 1   
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X-ray  crystallography  (182),  NMR    (183),  mass  spectrometry  (184),  microcalorimetry 
(185)  and  biosensors  (186)  are  generally  used  in  a  lower  throughput  format  and, 
although  often  obtaining  more  detailed  information,  can  induce  artefacts  due  to 
labelling, immobilisation of target or ligand, and acquisition of measurements in gas 
or solid phase (187). The majority of assays are carried out in vitro using solution- or 
cell- based methods  (188), and validated using a range of techniques  which assess 
accuracy, detection limit, and reproducibility, amongst others (189). 
 
Initial  hit  discovery  is  usually  accomplished  via  high-throughput  screening  (HTS), 
fragment-based screening (FBS), in silico screening, or a combination of all three (190). 
In  silico  screening  can  be  used  in  its  own  right  or  to  enrich  HTS  and  FBS  libraries 
through „cherry-picking‟ structurally diverse compounds to cover the broadest possible 
range  of  chemical  space,  pharmacophore-based  screening  to  identify  ligand-like 
molecules, and docking compounds into the active site of a target to identify the most 
likely  binders  (191, 192).  HTS  campaigns  tend  to  employ  large  compound  libraries 
selected  randomly  or through  in  silico techniques as  described above. However the 
high rate of false positives and negatives observed in HTS due to non-specific binding, 
poor  solubility,  aggregation,  reactive  functionalities,  assay  signal  interference  and 
experimental error have provided the drive to develop alternative methodologies (193).  
 
FBS libraries contain small, structurally diverse „fragments‟ which are screened at high 
concentration to identify low-affinity binders which can be linked together to produce 
potent leads. The use of far fewer compounds means libraries can be easily pre-filtered 
to remove compounds with characteristics leading to artefacts in HTS, and that low 
throughput techniques, such as X-ray crystallography, can be used to identify binding 
sites and inform lead development (194, 195). Alternatively, structural knowledge of 
the target, privileged scaffolds or scaffold-hopping can be used in the rational design 
of small focussed libraries with improved chances of success (196-198). 
 
Validation of hits identified during screening involves counter-screening to eliminate 
false positives, such as „promiscuous binders‟ (199) or compounds interfering with the 
assay  signal,  and  confirmation  of  activity  via  a  secondary  assay.  Depending  on 
resources hit compounds are then re-synthesised and re-tested to ensure that activity 
is not a result of impurities present in the original sample. Hit-to-lead optimisation 
involves  the  determination  of  hit  potency,  selectivity,  mode  of  action  and  ADMET 
properties, followed by analogue screening to improve these parameters and obtain 
structure activity relationship (SAR) data. Once a lead compound has been identified, 
cell based and in vivo studies are required to assess pharmacokinetic properties and 
the potential for progression into clinical trials (200). J C McKelvie    Chapter 1   
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1.4 Aims of the project 
 
The re-emergent status of plague, the isolation of MDR strains of Y. pestis and the risk 
posed by bioterrorism have led to an increased interest in available treatments for the 
disease (24, 26, 28). The bacterial methyltransferase Dam,  which  is involved in the 
regulation  of  virulence  in  a  range  of  pathogenic  bacteria,  has  been  identified  as  a 
potential target for the development of antimicrobial agents (42, 201). Dam knockout 
strains of Y. pestis have shown a greater than 2000-fold level of attenuation in mouse 
models, validating Dam as a target for drug discovery (40). In addition, the lack of a 
functionally similar enzyme in mammals implies that highly selective Dam inhibitors 
could be developed, reducing the risk of unwanted side-effects (105). 
 
A  molecular  break  light  Dam  activity  assay  has  previously  been  used  in  an  HTS 
campaign (149), and a real-time version of this assay, suitable for the determination of 
kinetic parameters, has been developed by the Roach group in a 96 well plate format 
(171).  Validation  of  this  assay  for  HTS  has  shown  it  to  be  highly  robust  and 
reproducible, with a Z‟-value (202) of 0.71 ± 0.07 obtained over three separate 96 well 
plates. Dam inhibitors have previously been identified using  in silico docking (151), 
HTS (149), genetic selection (150), and rational design (147) techniques, and libraries 
employed have included large random libraries of small  molecules, potential cancer 
therapeutics and cyclic peptides, and small focussed libraries of bisubstrate mimics. 
Our approach involved the application of a combination of these screening techniques 
and library types to assess their effectiveness and achieve optimal results. In addition 
counter-screens,  validation  and  specificity  assays,  potency  and  mode  of  binding 
determination, and in cell and toxicity assays, were applied to establish the potential of 
screening hits as therapeutics. 
 
The objective of the project was to identify compounds that efficiently and selectively 
inhibit Dam and to assess their potential as antimicrobial compounds. This approach 
required the optimisation of the real-time molecular break light Dam activity assay to 
high-throughput screening conditions, and its subsequent use in the screening of both 
random and focused libraries. Further characterisation of screening hits was achieved 
through the development and application of assay methodologies for the validation 
and characterisation of identified hits.      
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2  Primary Assay Development 
 
2.1 Introduction 
 
2.1.1 Enzyme assays 
Enzyme activity can be measured by monitoring the consumption of substrate, or the 
accumulation of product over time, in an in vivo or in vitro format. Measurements can 
be  either  continuous,  monitoring  real-time  turnover  of  substrate  to  product,  or 
discontinuous,  determining  only  the  end-point  concentrations  of  reactants  and/or 
products. Whilst continuous assays are more informative, discontinuous assays tend to 
be favoured for high-throughput applications, due to the ease with which they can be 
adapted  to  this  format.  Ideally  enzymatic  reactions  should  be  monitored  directly; 
however this requires products or substrates to be spectroscopically active. Where this 
is not the case, coupled assays, in which a secondary enzyme or derivatising agent is 
used to convert reactants or products into a readily detectable form, are often applied 
(203).  
 
Typical  assay  formats  include  absorbance,  luminescence  and  fluorescence 
spectroscopy, isothermal titration calorimetry (ITC), radioactivity, and chromatography 
(187). The specific assay methodology selected is dependent on a number of variables, 
in  particular:  the  cost  and  availability  of  reagents,  specialist  equipment  and 
consumables; the speed of processing; and the level of sensitivity required. Once a 
format  has  been  selected  initial  assay  parameters,  such  as  measurement  detection 
limits,  buffer  conditions,  temperature,  substrate  concentrations,  coupling 
enzyme/derivatising  agent  concentration,  target  enzyme  concentration,  and  reagent 
stability are optimised to ensure accurate and reliable assay performance is achieved 
(204, 205). 
 
Assessment of enzyme activity is typically carried out under initial velocity conditions, 
where less than 10% of the substrate has been depleted, helping to ensure that the 
reaction  proceeds  linearly  with  respect  to  enzyme  concentration  and  allowing 
Michaelis-Menten  kinetics  to  be  applied  (203,  205).  Where  enzyme  inhibition  is 
reversible,  inhibitors  are  typically  classed  as  competitive,  uncompetitive  or 
noncompetitive with respect to individual substrates (Figure 2.1) (206). In the case of 
competitive inhibition, uncompetitive inhibition, and noncompetitive inhibition where   
 1, the concentration of substrate directly affects the observed inhibition constant (K
i), 
with  higher  substrate  concentrations  favouring  uncompetitive  inhibitors  and  lower 
substrate concentrations favouring competitive inhibitors. Identification of all inhibitor J C McKelvie      Chapter 2   
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modalities is therefore best achieved by holding substrate concentrations at or close to 
K
M (203, 204). 
 
 
Figure 2.1 Reversible enzyme inhibition in a single substrate system 
Where E = enzyme, S = substrate, I = inhibitor, P = product, K
M = the Michaelis-Menten 
constant, K
i = the dissociation constant for the equilibrium between free and bound 
enzyme  and  inhibitor  and    =  a  constant  describing  the  degree  to  which  inhibitor 
binding affects the affinity of the enzyme for substrate. For competitive inhibition   
tends  towards  ,  for  noncompetitive  inhibition  0  <    <    and  for  uncompetitive 
inhibition   tends towards 0. 
 
After  initial  optimisation,  assays  are  validated  to  determine  their  quality  and 
consistency (189, 205). Specifically: the effective assay range can be established by 
determining the linearity of reaction rate with respect to target enzyme concentration; 
the stability of the target enzyme during the life-time of the assay can be determined 
by evaluating reaction progress curves at different target enzyme concentrations; and 
the  reproducibility  and  quality  of  the  assay  can  be  assessed  by  determining  the 
coefficient  of  variation  (CV,  Equation  2.1)  and  effective  screening  window  (Z‟-value 
(202), Equation 2.2 and Figure 2.3) over multiple measurements. 
 
CV =  100 
Equation 2.1 Coefficient of variation 
Where µ = average and   = standard deviation. 
 J C McKelvie      Chapter 2   
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( ) ( )
( ) ( )
-
33
Z' = 1  
Equation 2.2 The Z‟-value 
Where 
(+) = standard deviation of the positive controls, 
(-) = standard deviation of the 
negative  controls,  µ
(+)  =  average  of  the  positive  controls  and  µ
(-)  =  average  of  the 
negative controls. 
 
 
Figure 2.2 The screening window 
Parameters as for Equation 2.2. 
Z‟-values of 0.5 and above represent an acceptable screening window and values of 0.7 
and above an excellent screening window. 
 
If an assay is to be adapted for high-throughput application, further optimisation and 
validation is required. Specifically: solvents and reagents used must be compatible with 
HTS  consumables  such  as  microplates  and  pipette  tips;  the  assay  format  must  be 
amenable to miniaturisation for use in low volume microplates; equipment used should 
minimise plate variations such as edge effects and the appropriate controls should be 
employed  to  ensure  minimal  impact  on  results;  and  the  compound  library  solvent 
(typically dimethyl sulfoxide (DMSO)) must be tested for its affect on target enzyme 
activity and an appropriate concentration of this solvent used for HTS (205). Validation 
is  then  repeated,  with  CV  and  Z‟-value  determinations  used  to  assess  the 
reproducibility and quality of the assay under HTS conditions. 
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2.1.2 The real-time break light DNA adenine-N6 methyltransferase activity assay 
In  the  real-time  break  light  Dam  activity  assay  a  hemimethylated  break  light 
oligonucleotide  probe  is  fully  methylated  by  Dam  and  subsequently  cleaved  by  the 
methylation specific restriction enzyme DpnI, producing a fluorescence signal (Figure 
2.3) (171). Including an excess of DpnI in the reaction ensures that restriction is not 
rate limiting, the fluorescence increase therefore becomes directly proportional to the 
rate of Dam catalysed methylation and can be used to continuously determine initial 
rates in real-time. 
 
 
Figure 2.3 Real-time break light Dam activity assay  
A  hemimethylated  break  light  oligonucleotide  substrate  (ODN1)  containing  a  GATC 
methylation site is fully methylated by Dam to form ODN2, which is a substrate for the 
restriction  enzyme  DpnI.  Cleavage  by  DpnI  results  in  the  separation  of  fluorophore 
(fluorescein)  and  quencher  (dabcyl)  and  a  subsequent  proportional  increase  in 
fluorescence. 
 
Similar assays have been developed using DpnI, or the related methylation sensitive 
restriction enzyme DpnII, to cleave either fully or unmethylated molecular break light 
probes (149, 170). Neither of these assays allows for continuous real-time monitoring 
of DNA methylation, with the DpnII assay relying on end-point measurements, and the 
alternative DpnI assay utilising an unmethylated probe requiring two methylation steps 
which  cannot  be  easily  differentiated.  The  real-time  break  light  Dam  activity  assay 
overcomes these limitations by using a hemimethylated oligonucleotide substrate and 
an  excess  of  DpnI  to  enable  real-time,  continuous  monitoring  of  Dam  catalysed 
methylation. 
 
All  three  assays  require  the  addition  of  a  secondary  enzyme  in  order  to  obtain  an 
observable  change  in  fluorescence  upon  methylation,  and  as  such  are  classified  as J C McKelvie      Chapter 2   
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coupled enzyme assays.  Problems frequently encountered in coupled assay systems 
include  an  observed  lag  phase  in  the  time  course  of  product  formation  where  the 
target enzyme is not completely rate limiting, and the identification of false positives 
with activity against the coupling enzyme in HTS (203, 204). 
 
For  the  primary  enzyme  to  be  rate  limiting,  and  to  minimise  the  effect  of  coupled 
enzyme inhibition, it is common for the secondary enzyme to be added in excess. This 
in itself can induce further problems, as increasing coupling enzyme concentration can 
lead to increased non-specific background activity. When optimising such assays it is 
therefore  necessary  to  carefully  balance  assay  conditions  to  ensure  the  greatest 
possible signal:noise ratio is achieved. Furthermore, it is essential that the appropriate 
controls  are  employed,  enabling  activity  data  to  be  corrected  for  the  effects  of 
background noise (207). 
 
The  following  chapter  describes  the  initial  optimisation  of  the  real-time  break  light 
Dam activity assay and subsequent optimisation of this assay for use in HTS.  
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2.2 Protein expression and purification 
 
The aim of this project was to identify inhibitors of Y. pestis Dam, which has been 
validated as a target for the treatment of plague (40). Previous attempts at identifying 
Dam  inhibitors  have  employed  the  E.  coli  Dam  enzyme  (147,  149-151),  which  is 
available commercially (New England Biolabs, UK) and has been expressed and purified 
by various groups (99, 105, 208). Both wild-type and N-terminal six-histidine tagged E. 
coli  Dam  have  been  kinetically  characterised,  with  minimal  difference  observed 
between the two (105). It therefore seems probable that the Six-histidine tag has close 
to no effect on the kinetics of Dam, and as the tagged Y. pestis enzyme can be purified 
much more readily it was used throughout this project. 
 
Although Y. pestis Dam shares a considerable sequence similarity (70.5% identity over 
271 amino acids) with E. coli Dam (Figure 2.4) it is preferable to use the target enzyme 
for  the  identification  of  inhibitors,  consequently  N-terminal  six-histidine  tagged  Y. 
pestis Dam has been expressed, purified and kinetically characterised previously in the 
research group (171). 
 
 
Figure 2.4 Pairwise alignment of Y. pestis and E. coli Dam 
Calculated by percentage identity using the program Jalview  (95, 96). 100% identity 
shown in blue. 
 
The coupling enzyme, DpnI, from Streptococcus pneumoniae (previously Diplococcus 
pneumoniae)  has  been  expressed  and  purified  in  E.  coli  (209)  and  is  also  available 
commercially (New England Biolabs, UK). Even though potentially suitable Dam (E. coli) 
and  DpnI  enzymes  were  available  commercially,  both  Y.  pestis  Dam  and  DpnI  were 
purified in the research group to afford tighter control over purity and minimise costs.  
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2.2.1 Expression and purification of DpnI 
An expression system for DpnI was previously prepared by M.D. Maynard-Smith (210). 
Briefly, N-terminal six-histidine tagged DpnI expression vector pMMS/4958/59, under 
the  control  of  the  arabinose-inducible  pBAD  expression  system,  was  prepared  and 
transformed into E. coli GM43. The optimal growth conditions for protein expression 
were then determined by small scale expression study. 
 
2.2.1.1  Large scale growth and purification 
A  large  scale  growth  of  E.  coli  GM48  harbouring  the  DpnI  expression  vector, 
pMMS/4958/59, under optimised conditions yielded 5.2 g of cell paste per litre of 
culture. After cell lysis by sonication purification of the cleared lysate by nickel affinity 
column chromatography was monitored by Bradford Assay (211) and fractions with a 
protein  concentration  of  greater  than  0.75  mg  ml
-1  were  pooled  and  dialysed.  The 
purification yielded 9.8 mg of purified DpnI from 7 g of cell paste (1.4 mg g
-1); however 
SDS-PAGE  analysis  of  the  individual  and  pooled  fractions  (Figure  2.5)  showed  the 
sample to be contaminated by two lower molecular weight proteins. 
 
The  molecular  weight  of  DpnI  (~30  kDa)  is  approximately  equal  to  the  sum  of  the 
molecular weights of the contaminants (~12 and 17 kDa), suggesting that DpnI had 
undergone  proteolytic  cleavage  during  expression  and  purification  (Figure  2.5).  To 
circumvent this process, growth time was reduced and protease inhibitor tablets and 
phenylmethylsulfonyl  fluoride  (PMSF  (212))  were  added  to  the  cell  lysis  buffer  and 
purification column wash buffers. 
 
 
Figure 2.5 DpnI purification 
SDS-PAGE gel (left) and graph of protein concentration versus fraction number (right) 
of initial DpnI purification. 
(M): marker, (1): DpnI standard
1, (2): pooled fractions 8-14, (3-9): fractions 8-14. 
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A second large scale growth of E. coli GM48 harbouring the DpnI expression vector, 
pMMS/4958/59, was carried out, with the time between induction and cell harvest 
reduced  from  4  to  3  hours.  A  yield  of  4.7  g  of  cell  paste  per  litre  of  culture  was 
obtained  from  the  second  growth,  comparable  to  the  yield  obtained  from  the  first 
growth  (Table  2.1).  The  cleared  lysate  was  purified  by  nickel  affinity  column 
chromatography,  using  cell  lysis  and  wash  buffers  supplemented  with  protease 
inhibitor tablets and PMSF. The protein concentration was monitored by Bradford Assay 
(211) and  fractions  with a  protein  concentration  of  greater than 0.25  mg  ml
-1  were 
analysed by SDS-PAGE, pooled and dialysed. The purification yielded a total of 27 mg 
of protein from 10 g of cell paste (2.7 mg g
-1), with SDS-PAGE analysis (Figure 2.6) 
showing a reduction in the proteolysis of DpnI compared with the initial purification. 
 
 
Figure 2.6 DpnI purification II 
SDS-PAGE gel (left) and graph of protein concentration versus fraction number (right) 
of DpnI purification II. 
(M):  marker,  (1):  DpnI  standard
1,  (2):  supernatant,  (3):  flow-through,  (4):  pooled 
fractions 2-16, (5-12): fractions 2-16. 
 
Table 2.1 Protein yields from DpnI purifications 
Growth time 
hrs 
Source  [Protein] 
mg ml-1 
Volume 
ml 
Total  Protein 
mg 
4  Lysate (from 7 g of cell paste)  22  30  660 
Purified protein  0.96  10  9.6 
3  Lysate (from 10 g of cell paste)  26  30  780 
Purified protein  1.4  20  27 
Data given to 2 significant figures 
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The specific (cleavage of a fully methylated oligonucleotide substrate) and non-specific 
(cleavage of a hemimethylated oligonucleotide substrate) activities of DpnI from both 
purifications (DpnI
A and DpnI
B) and a DpnI standard
2 (DpnI
std) were assessed by real-time 
break light DpnI activity assay (Table 2.2). Both DpnI
A and DpnI
B were found to have 
similar specific and non-specific activities, whilst the specific and non-specific activities 
of DpnI
std were considerably higher, possibly due to small differences in purification 
method. Although little difference in specific:non-specific activity ratio was observed 
for the freshly prepared samples, DpnI
B was shown by SDS-PAGE to be of higher purity 
than DpnI
A, having undergone less proteolytic cleavage.  DpnI
B (referred to from this 
point forward as DpnI) was therefore used in all subsequent activity assays. 
 
Table 2.2 Activity of purified DpnI samples 
Sample  Specific  Activity*† 
pmol s-1 µg-1 
Non-specific 
Activity#† pmol s-1 µg-
1 
Ratio  Specific:Non-
specific Activity‡ 
DpnI
A  6.77 ± 0.47  1.03 ± 0.07  6.6   
DpnI
B  4.58 ± 0.09  0.650 ± 0.024  7.0 
DpnI
std  24.0 ± 1.0  2.19 ± 0.03  11 
* Fully methylated substrate, 0.08 nM DpnI. 
# Hemimethylated substrate, 0.8 nM DpnI. 
† Average of triplicate measurements ± standard deviation. 
‡ Given to 2 significant figures. 
Assay  conditions:  0.08  nM  or  0.8  nM  DpnI,  300  nM  fully  methylated  (ODN2)  or 
hemimethylated (ODN1) oligonucleotide, 25 µM AdoMet, 20 mM Tris, 50 mM KOAc, 10 
mM Mg(OAc)
2, 20 mM NaCl, 0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 
100 µl, in 96 well plate, gain 100, temperature 30 °C. 
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2.2.2 Expression and purification of Y. pestis Dam 
2.2.2.1  Selection of an expression system 
The overexpression of Dam has been shown to affect the virulence of a number of 
different pathogens (87-89) and may prove toxic to host cells. To minimise the effects 
of  high  Dam  concentrations  on  host  cells,  dam  mutant  strains  (lacking  the 
chromosomal copy of dam) of E. coli were selected for the overexpression of Y. pestis 
Dam.  N-terminal  six-histidine  tagged  Y.  pestis  Dam  was  expressed  from  the 
pBAD/HisA derivative pRJW/4213/07, originally prepared by Dr R.J. Wood (171). The 
plasmid was transformed into the E. coli dam knockout strains GM2929 and ER2925. 
Negative  controls  of  pBAD/HisA  transformed  into  both  E.  coli  strains  were  also 
prepared.  
 
To  confirm  that  no  Dam  was  being  expressed  prior  to  induction  of  the  arabinose-
regulated  pBAD  expression  system  plasmids  were  isolated  from  cultures  of 
transformed E. coli and digested with the restriction enzymes NcoI, DpnI and MboI to 
confirm  their  mwthylation  state.  The  results  were  analysed  by  1%  agarose  gel 
electrophoresis (Figure 2.7). 
 
 
Figure 2.7 pRJW4213/07 and pBAD/HisA analytical digests 
1% agarose gel electrophoresis of plasmids isolated from GM2929 (A) and ER2925 (B) 
E. coli and digested with NcoI, DpnI or MboI.  
(L):  Ladder,  (1-4):  pBad/HisA,  (5-12):  pRJW4213/07,  (1,  5  and  9):  unlinearised 
plasmid, (2, 6 and 10): NcoI digested plasmid, (3, 7 and 11): DpnI digested plasmid, (4, 
8 and 12): MboI digested plasmid. 
   
The control samples showed no DpnI digestion, confirming that no Dam methylation 
occurs  in  either  E.  coli  GM2929  or  ER2925  in  the  absence  of  the  Y.  pestis  Dam 
expression plasmid pRJW/4213/07. Samples of pRJW/4213/07 isolated from E. coli 
GM2929 were digested by MboI, but not DpnI, indicative of an unmethylated plasmid. J C McKelvie      Chapter 2   
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However samples of  pRJW/4213/07 isolated from  E. coli ER2925  were digested by 
DpnI,  but  not  MboI,  indicating  that  the  plasmid  was  fully  methylated.  This  result 
suggests that in E. coli ER2925, Y. pestis Dam was expressed prior to the induction of 
the  arabinose-regulated  pBAD  expression  system.  Both  ER2925  and  GM2929  were 
derived from the same original strain (GM2163) and differ only slightly in genotype
3. It 
is therefore surprising that uninduced expression was  only observed for ER2925.  To 
investigate the effects of uninduced expression on the final yield of Y. pestis Dam from 
an  induced  system,  both  transformed  strains  were  carried  forward  for  large  scale 
growth and purification. 
 
2.2.2.2  Large scale growth and purification 
Small scale expression studies of E. coli strains ER2925 and GM2929 harbouring the Y. 
pestis Dam expression vector pRJW/4213/07, showed very low levels of Y. pestis Dam 
expression and could not be used to  determine optimal growth conditions prior to 
large scale expression. The optical density at 600 nm (OD
600) was therefore used to 
determine when a stationary phase in E. coli growth had been reached, at which point 
cells  were  harvested  (Figure  2.8).  GM2929  cells  were  harvested  at  290  minutes, 
yielding 5.14 g of cell paste per litre of culture, and ER2925 cells were harvested at 
320 minutes, yielding 7.84 g of cell paste per litre of culture. 
 
 
Figure 2.8 Growth curves for E. coli GM2929 and ER2925 harbouring pRJW/4213/07 
Data were fitted to a sigmoidal curve of the form  f = a/(1+exp(-(x-x0)/b)). GM2929 
growth (filled circles, solid line), ER2925 growth (open circles, dotted line), induction at 
OD
600 = 0.6 (dashed red line), cells harvested at circled data point. 
 
Cells  were  lysed  by  sonication  and  the  protein  purified  from  the  cleared  lysate  by 
nickel  affinity  column  chromatography  and  the  protein  content  of  eluted  fractions 
determined by Bradford Assay (211). Fractions with a protein concentration of at least 
                                                
3 ER2925 carries the endA1 mutation which abolishes the activity of nonspecific endonuclease I, 
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0.15 mg ml
-1 were analysed by SDS-PAGE (Figure 2.9), pooled, dialysed into storage 
buffer and stored at -80 °C until required. The yields of purified protein obtained from 
each expression strain are tabulated overleaf (Table 2.3). 
 
 
Figure 2.9 Y. pestis Dam purification 
SDS-PAGE gels (left) and graphs of protein concentration versus fraction number (right) 
for GM2929 (A) and ER2925 (B) purifications. 
(M):  marker,  (1):  Y.  pestis  Dam  standard
4, (2): supernatant, (3): flow -through, (4A): 
pooled GM2929 fractions 3-8, (4B): pooled ER2925 fractions 3-6, (5-10A): fractions 3-8, 
(5-9B): fractions 3-6.  
 
Table 2.3 Protein yields from Y. pestis Dam purifications 
Expression 
Strain 
Source  [Protein] 
mg ml-1 
Volume 
ml 
Total  Protein 
mg 
E. coli 
GM2929 
Lysate (from 10 g of cell paste)  25  30  750 
Purified protein  0.27  10  2.7 
E. coli 
ER2925 
Lysate (from 10 g of cell paste)  20  30  600 
Purified protein  0.15  6.5  0.98 
Data given to 2 significant figures 
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A higher yield of protein was obtained from the GM2929 expression and purification, 
however the protein isolated from ER2925 cells was shown to be of higher purity. The 
activity of the Y. pestis Dam protein obtained from both purifications (Dam
GM2929 and 
Dam
ER2925) was assessed alongside a Y. pestis Dam reference sample
4 (Dam
std). A short 
lag phase was observed in the assay time courses, most likely due to the addition of an 
insufficient  concentration  of  the  coupled  enzyme,  DpnI.  As  this  issue  would  be 
resolved  during  assay  optimisation  the  lag  phase  was  discounted  and  activity 
determined  from  the  data  obtained  immediately  after  it.  Total  and  non-specific  (as 
determined for negative controls lacking DpnI) activities for each protein sample are 
tabulated below (Table 2.4). 
 
Table 2.4 Activity of purified Y. pestis Dam samples 
Sample  Total  Activity* 
pmol s-1 µg-1 
Non-specific  Activity# 
pmol s-1 µg-1 
Ratio  Total:Non-specific 
Activity† 
Dam
GM2929   0.0216 ± 0.0028  0.0171  1.3 
Dam
ER2925  0.0729 ± 0.0036  0.0128  5.7 
Dam
std  0.189 ± 0.033  ND  - 
* Average of triplicate measurements ± standard deviation. 
# Single measurement. 
† Given to 2 significant figures. 
ND – not detectable. 
Assay  conditions:  2  nM  Dam,  0.8  nM  DpnI,  30  nM  hemimethylated  oligonucleotide 
(ODN1), 25 µM AdoMet, 20 mM Tris, 50 mM KOAc, 10 mM Mg(OAc)
2, 20 mM NaCl, 0.1 
mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 130, 
temperature 30 °C. 
 
The similar total and non-specific activities observed for Dam
GM2929 imply that minimal 
active  Y. pestis Dam  was purified from the GM2929 expression system.  The higher 
total:non-specific activity ratio observed for Dam
ER2925 compared to Dam
GM2929 suggests 
that  Y.  pestis  Dam  of  higher activity  and  specificity  was  obtained  from  the  ER2925 
expression  system,  however  a  significant  level  of  non-specific  activity  was  also 
observed  for  this  sample.  Y.  pestis  Dam  isolated  from  ER2925  cells  was  therefore 
carried forward for further optimisation. 
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2.2.2.3  Improving Y. pestis Dam specific activity 
A second purification was investigated to improve the specific activity of Dam
ER2925. The 
detergent Triton X-100 was added to cell lysis and column wash buffers, in order to 
disrupt protein:protein interactions and increase the proportion of impurities removed 
prior to elution. Fractions with a protein concentration of at least 0.08 mg ml
-1 were 
analysed by SDS-PAGE (Figure 2.10), pooled fractions were then dialysed and stored at 
-80 °C until required. The second ER2925 purification yielded 0.72 mg of protein from 
8.5 g of cell paste (0.084 mg g
-1), comparable with the yield of 0.098 mg g
-1 obtained 
for the initial purification.  
 
 
Figure 2.10 ER2925 Y. pestis Dam purification II 
SDS-PAGE gel (left) and graph of protein concentration versus fraction number (right) 
of ER2925 purification II. 
(M):  marker,  (1):  Y.  pestis  Dam
std,  (2):  Dam
ER2925,  (3):  pooled  fractions  3-7,  (4): 
supernatant, (5): flow-through, (6-10): fractions 3-7.  
 
Comparison  of  Y.  pestis  Dam  from  the  first  and  second  purification  (Dam
ER2925  and 
Dam
ER2925/2) by SDS-PAGE showed Dam
ER2925/2 to contain fewer contaminating proteins. No 
non-specific activity was detected for Dam
ER2925/2 (under assay conditions as for Table 
2.4) and the total activity of Dam
ER2925/2 was found to be 0.0942 ± 0.0118 pmol s
-1 µg
-1, 
compared with 0.0729 ± 0.0036 pmol s
-1 µg
-1 for the initial purification. The addition of 
detergent  to  cell  lysis  and  column  wash  buffers  during  purification  therefore 
significantly  improved  the  ratio  of  total:non-specific  activity  whilst  not  significantly 
decreasing purification yield. Dam
ER2925/2 (referred to from this point forward as Y. pestis 
Dam) was therefore used in all subsequent activity assays. 
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2.3 Optimisation 
 
Specific  assay  parameters  to  be  optimised  included:  buffer  conditions,  substrate 
concentrations, enzyme concentrations, temperature, enzyme stability, assay volume, 
and  the  effect  of  compound  library  solvent  on  enzyme  activity.  Conditions  were 
carefully balanced to obtain the optimal screening window by maximising the specific 
activities of the target and coupling enzyme, whilst minimising non-specific activity. 
Validation of conditions included assessment of signal:noise ratios (Equation 2.3), size 
of screening window (Z-value, Equation 2.2), and reproducibility (CV, Equation 2.1). 
 
- T BG
BG
Signal:Noise Ratio = 
vv
v
 
Equation 2.3 Signal:noise ratio 
Where 
T = initial rate of full assay and 
BG = initial rate of negative controls. 
 
As parameters must be varied separately in order to ascertain their individual affects 
on assay quality, optimisation can be a complex process. It is therefore helpful to have 
an initial set of conditions from which to start, with parameters optimised one-by-one 
until the final assay conditions are determined. Table 2.5, below, lists initial conditions 
for the real-time break light Dam activity assay, as employed previously for the kinetic 
characterisation of Y. pestis Dam (171). 
 
Table 2.5 Initial conditions for real-time break light Dam activity assay 
Parameter  Initial Conditions 
Buffer  NEBuffer 4: [20 mM Tris-acetate, 50 mM potassium acetate, 10 mM 
magnesium acetate, 1 mM dithiothreitol, 0.1 mg ml
-1 bovine serum 
albumin, pH 7.9] 
Substrate 
concentrations 
K
M
AdoMet = 11.3 ± 0.63 µM 
K
M
DNA = 3.43 ± 1.68 nM 
Enzyme 
concentrations 
Y. pestis Dam = 2 nM 
DpnI = 3 U (~0.8 nM) 
Volume  100 µl (96 well plate) 
Temperature  30 °C J C McKelvie      Chapter 2   
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2.3.1 Buffer conditions 
Assay buffers generally contain a buffering agent, mono- and di- valent cations, and a 
range of additives. Previously the general buffer NEBuffer 4 (New England Biolabs, UK, 
Table 2.4) was used in the real-time break light Dam activity assay, demonstrating the 
effectiveness of a Tris-based buffer system. To assess the effects of other components 
on overall assay quality a buffer comprising of Tris-HCl at pH 7.9, the reducing agent 
dithiothreitol (DTT), and the non-specific blocking agent bovine serum albumin (BSA), 
was  employed,  whilst  mono-  and  di-valent  salt  concentrations  were  varied 
independently. 
 
2.3.1.1  Sodium chloride concentration 
High concentrations of sodium ions (above 50 mM) have been shown to increase the 
specificity  of  DpnI  for  the  fully  methylated  product  of  Dam  methylation,  over  the 
hemimethylated  substrate  (213).  Whilst  concentrations  below  100  mM  have  been 
shown to have minimal effect on Dam activity (208).  
 
   
Figure 2.11 Sodium chloride concentration optimisation 
A: Specific initial rate of cleavage of fully methylated product (filled circles) and non-
specific initial rate of cleavage of hemimethylated substrate (open circles) by DpnI, and 
ratio of specific:non-specific activity (red circles). 
Assay  conditions:  0.8  nM  DpnI,  30  nM  fully  methylated  (ODN2)  or  hemimethylated 
(ODN1) oligonucleotide, 25 µM AdoMet, 0-150 mM NaCl, 20 mM Tris, 10 mM MgCl
2, 
0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 
130, temperature 30 °C. 
B:  Background  subtracted  initial  rate  of  methylation  by  Y.  pestis  Dam  (black)  and 
signal:noise ratio (red). 
Assay  conditions:  2  or  0  nM  Y.  pestis  Dam,  0.8  nM  DpnI,  30  nM  hemimethylated 
oligonucleotide (ODN1), 25 µM AdoMet, 0-150 mM NaCl, 20 mM Tris, 10 mM MgCl
2, 
0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 
130, temperature 30 °C. 
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The effect of varying sodium chloride concentration on Y. pestis Dam and DpnI activity 
was assessed (Figure 2.11) and both specific and non-specific DpnI activity were found 
to  be  reduced  by  the  addition  of  sodium  chloride  (Figure  2.11A).  In  the  full  assay 
(Figure 2.11B) concentrations of up to 100 mM sodium chloride appeared to improve 
both  specific  activity  and  signal:noise  ratio.  The  maximum  initial  activity  and 
signal:noise  ratio  were  observed  between  75  and  125  mM  sodium  chloride,  with  a 
more  rapid  reduction  in  activity  observed  after  100  mM  than  before.  To  preserve 
enzyme activity and maximise signal:noise ratio, a sodium chloride concentration of 80 
mM was selected, at which small variations in concentration would have minimal effect 
on activity. 
 
2.3.1.2  Magnesium chloride concentration 
As  a  type  II  restriction  enzyme  DpnI  requires  divalent  metal  ions,  most  commonly 
magnesium ions, to catalyse the cleavage of DNA (214). The effect of magnesium ions 
on Dam activity has not been reported.  
 
   
Figure 2.12 Magnesium chloride concentration optimisation 
A: Specific initial rate of cleavage of fully methylated product (filled circles) and non-
specific initial rate of cleavage of hemimethylated substrate (open circles) by DpnI, and 
ratio of specific:non-specific activity (red circles). 
Assay  conditions:  0.8  nM  DpnI,  30  nM  fully  methylated  (ODN2)  or  hemimethylated 
(ODN1) oligonucleotide, 25 µM AdoMet, 0-30 mM MgCl
2, 20 mM Tris, 80 mM NaCl, 0.1 
mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 130, 
temperature 30 °C. 
B:  Background  subtracted  initial  rate  of  methylation  by  Y.  pestis  Dam  (black)  and 
signal:noise ratio (red). 
Assay  conditions:  2  or  0  nM  Y.  pestis  Dam,  0.8  nM  DpnI,  30  nM  hemimethylated 
oligonucleotide (ODN1), 25 µM AdoMet, 0-30 mM MgCl
2, 20 mM Tris, 80 mM NaCl, 0.1 
mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 130, 
temperature 30 °C. 
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Y. pestis Dam and DpnI activity assays carried out at a range of magnesium chloride 
concentrations  (Figure  2.12)  showed  DpnI  activity  to  be  dependent  on  a  low 
concentration  (~2-6  mM)  of  magnesium  chloride,  with  concentrations  up  to  15  mM 
increasing the ratio of specific:non-specific cleavage. In the full assay maximum signal 
was  obtained  between  6  and  10  mM  magnesium  chloride,  whilst  the  optimum 
signal:noise ratio was achieved between 8 and 15 mM. A final assay concentration of 8 
mM  magnesium  chloride  was  therefore  selected  to  ensure  optimal  enzyme  activity 
whilst maintaining a good signal:noise ratio. 
 
2.3.1.3  Additives 
Dam activity assays were routinely supplemented with two additives: BSA was added to 
reduce non-specific binding interactions, and DTT was added to ensure thiols remained 
reduced (215). Additionally, glycerol is often added to buffers to help stabilise proteins 
in  solution  (216,  217);  however  glycerol  is  also  known  to  affect  the  specificity  of 
restriction enzymes,  with high concentrations inducing non-specific or „star‟ activity 
(218). To achieve the stabilisation effect of glycerol whilst minimising the risk of „star‟ 
activity, a small quantity of glycerol (5%) was also added to the real-time break light 
Dam activity assay buffer. 
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2.3.2 Assay temperature 
The temperature at which an assay is incubated affects enzyme and substrate stability, 
as well as reaction rates. The achievement of the maximum initial rate may require the 
application of incubation temperatures at which the enzyme(s) and/or substrate(s) are 
unstable, making the assessment of initial rate data potentially difficult. To determine 
the  optimum  assay  temperature  for  the  real-time  break  light  Dam  activity  assay  a 
series of assays were carried out at a range of temperatures (Figure 2.13). 
 
   
Figure 2.13 Temperature optimisation 
A: Activity assay time course 
B:  Background  subtracted  initial  rate  of  methylation  by  Y.  pestis  Dam  (black)  and 
signal:noise ratio (red). 
Assay  conditions:  1  or  0  nM  Y.  pestis  Dam,  0.8  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 µM AdoMet, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM 
DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 100 µl, in 96 well plate, 
gain 130. 
Temperature (°C): 28 (black solid line), 30 (red solid line), 32 (black long dash line), 34 
(black dotted line), 38 (black short dash line), or 40 (black dash and dotted line). 
 
An increase in initial activity and signal:noise ratio was observed between 28 and 30 
°C,  and  a  decrease  was  observed  between  30  and  40  °C  (Figure  2.13B).  The  time 
courses show the fluorescence reached after 380 seconds to be greatest for the assay 
carried out at 30 °C, with assays carried out at 32  °C and above showing a loss of 
enzyme  activity  over  time  (Figure  2.13A).  To  maintain  enzyme  activity  whilst 
maximising initial rate an assay temperature of 30 °C was selected, which correlates 
well with the optimal temperature for the growth of Y. pestis bacteria (30 °C (23)). 
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2.3.3 Enzyme concentration and stability 
2.3.3.1  Coupling enzyme concentration 
In  general,  an  insufficient  quantity  of  coupling  enzyme  will  lead  to  an  increasingly 
significant lag phase during a coupled assay (219). This was observed for the DpnI 
coupled  Dam  activity  assay  (Sections  2.2.1,  2.2.2  and  2.3.2).  Lag  phases  generally 
make the determination of initial rate data more challenging, and in some cases, where 
the lag phase exceeds the initial rate phase, impossible.  
 
Evaluation  of  the  effect  of  coupled  enzyme  concentration  on  overall  rate  (Figure 
2.14A)  shows  that  at  2  nM  DpnI  initial  rate  reaches  99.8%  of  the  maximum  (as 
determined by fitting the data to an exponential rise to a maximum). Furthermore, 50% 
inhibition  of  DpnI  at  this  concentration  (equivalent  to  1  nM)  would  lead  to  only  a 
minimal drop in initial rate, with 95.8% of the maximum rate still reached. Increasing 
DpnI concentration leads to a decrease in signal:noise ratio (Figure 2.14B), due to an 
increase  in  non-specific  cleavage  of  the  hemimethylated  substrate  oligonucleotide. 
There  is  therefore  a  delicate  balance  to  be  struck  between  adding  too  much  DpnI 
(resulting in excessive non-specific cleavage) and too little (resulting in a significant lag 
phase). The selected compromise concentration (2 nM) was selected to minimise the 
effects of non-specific cleavage on signal:noise ratio. 
 
          
Figure 2.14 DpnI concentration optimisation 
A: Background subtracted initial rate of methylation by Y. pestis Dam. Data fitted to an 
exponential rise to a maximum of the form f=a*(1-exp(-b*x)). 
B:  Background  subtracted  initial  rate  of  methylation  by  Y.  pestis  Dam  (black)  and 
signal:noise ratio (red). 
Assay  conditions:  1  nM  Y.  pestis  Dam,  0-4  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 
mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, in 384 well 
plate, gain 170, temperature 30 °C. 
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2.3.3.2  Primary enzyme concentration 
The classical kinetic model for enzyme catalysis requires that the enzyme is present at 
very low concentrations relative to the substrate. Addition of insufficient substrate or 
excess  enzyme  can  lead  to  significant  deviation  from  this  condition,  substantially 
complicating the kinetic analysis. By monitoring the effect of increasing Y. pestis Dam 
concentration on initial rate the effective range of the real-time break light Dam activity 
assay was established (Figure 2.15).  
 
Initial rate was plotted against Y. pestis Dam concentration (Figure 2.15) and a line of 
best  fit  was  plotted  through  data  points  correlating  to  0.25  nM  Y.  pestis  Dam  and 
above.  A  negative  y-axis  intercept  was  observed,  indicating  a  lower  Y.  pestis  Dam 
concentration limit at the x-axis intercept (~0.276 nM). At higher concentrations of Y. 
pestis  Dam  a  linear  plot  was  observed,  suggesting  an  upper  concentration  limit  of 
greater than 4 nM. The non-linear reduction in rate observed for lower Y. pestis Dam 
concentrations could be caused by a number of factors, including the signal detection 
limit being reached, and the loss of a small amount of enzyme through non-specific 
binding or denaturation. 
 
 
Figure 2.15 Effective assay range 
Background subtracted initial rate of methylation by  Y. pestis Dam. Data fitted to a 
linear equation of the form f=y
0+a*x. 
Assay  conditions:  0-4  nM  Y.  pestis  Dam,  2  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, 
in 384 well plate, gain 170, temperature 30 °C. 
 
Whilst  Y.  pestis  Dam  concentrations  of  up  to  4  nM  were  accommodated  under  the 
conditions  of  this  experiment  (Figure  2.15  legend)  it  is  common  practise  to  use  a 
minimum of a 10-fold excess of substrate(s) to enzyme (205, 219). In this case 10 nM 
DNA  and  25  µM  AdoMet  were  used,  suggesting  an  optimum  Y.  pestis  Dam J C McKelvie      Chapter 2   
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concentration of 1 nM, which falls within the effective assay range as shown in Figure 
2.15.  A  Y.  pestis  Dam  concentration  of  at  most  one-tenth  the  lowest  substrate 
concentration was therefore selected for all subsequent assays. 
 
2.3.3.3  Stability 
Temperature optimisation assays (Section 2.3.2, Figure 2.13A) showed a temperature 
dependant loss of enzyme activity over time. As Y. pestis has a lower optimal growth 
temperature  than  S.  pneumoniae  (30  versus  37  °C  (23,  220))  and  the  suggested 
reaction temperature for commercially available DpnI is 37 °C, it was hypothesised that 
the loss in activity observed was due to the inactivation of Y. pestis Dam. To test this 
theory  Y.  pestis  Dam  was  incubated  with  and  without  substrates  and  the  effect  on 
initial rate assessed over a range of time points. 
 
 
Figure 2.16 Inactivation of Y. pestis Dam 
Initial rate of methylation by Y. pestis Dam incubated with DNA (filled circles), AdoMet 
(open circles) or no substrates (filled triangles) at 30 °C for 0-1600 s prior to assay 
initiation. Data fitted to an exponential decay curve of the form f = a*exp(-b*x). 
Assay  conditions:  1  nM  Y.  pestis  Dam,  2  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, 
in 384 well plate, gain 170, temperature 30 °C. 
 
A plot of initial rate against incubation time (Figure 2.16) showed inactivation of Y. 
pestis Dam to occur at 30 °C. The rate of Y. pestis Dam decay, determined by fitting 
data to an exponential decay curve, was found to be slowest for samples incubated in 
the presence of DNA (b = 0.0021 ± 0.0001 s
-1), and fastest for samples incubated with 
no substrate (b = 0.0231 ± 0.0030 s
-1). The inactivation of Y. pestis Dam has previously 
been reported by Wood et al. (171), however inactivation has not been reported for 
other Dam proteins. 
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Whilst the preparation of Y. pestis Dam samples for addition to assays in the presence 
of DNA should help to reduce the effects of inactivation, these findings demonstrate 
that rapid collection of early data points is required for the determination of accurate 
initial rates. 
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2.3.4 Effect of compound library solvent 
The high solubility of a wide range of chemical functionalities in DMSO has made it the 
solvent of choice for the majority of compound libraries. Although tolerance of low 
concentrations of DMSO by enzymes is generally good, this is not always the case, and 
as such the effect of DMSO on enzyme activity should be assessed (204). The DMSO 
tolerance of the real-time break light Dam activity assay system was determined by 
monitoring  the  effect  of  increasing  concentrations  of  DMSO  on  initial  rate  (Figure 
2.17). 
 
 
Figure 2.17 DMSO titration 
Background  subtracted  initial  rate  of  methylation  by  Y.  pestis  Dam  (black)  and 
signal:noise ratio (red). 
Assay  conditions:  1  nM  Y.  pestis  Dam,  2  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 0-10% DMSO, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, 
in 384 well plate, gain 170, temperature 30 °C. 
 
Addition of 10% DMSO led to a significant loss of both activity and signal:noise ratio, 
raising two possibilities, the first, that DMSO has a greater effect on the activity of Dam 
than  DpnI,  and  the  second,  that  DMSO  has  an  effect  on  the  specificity  of  DpnI. 
Although high concentrations of DMSO are clearly detrimental to assay quality, lower 
concentrations induce smaller reductions in activity and  signal:noise ratios, with 5% 
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2.3.5 Assay volume 
The  large  number  of  compounds  available  for  HTS  campaigns  has  led  to  the 
miniaturisation of assay technologies, with many companies now choosing to screen in 
384, 1536 and even 3456 well plates. Although the reduction of assay volume appears 
to  be  an  attractive  concept  due  to  the  potential  for  decreased  reagent  cost  and 
increased throughput, the set-up cost, and potential effect of low assay volumes on 
reagent absorption and stability, has led to many companies choosing to remain with 
the 384 well format, as these plates can accommodate assay volumes as low as 10-20 
µl whilst using well spacing compliant with liquid handling technology designed for 96 
well plates (178).  
 
To assess the effect of reducing assay volume from 100 µl (in 96 well plates) to 20 µl 
(in 384 well plates) CV (Equation 2.1) and Z‟-values (Equation 2.2) were calculated 
from a series of positive (full) and negative (lacking AdoMet) control assays in each 
plate format (Table 2.6, experiment 1). Assays from the 96 well plate showed a good 
level  of reproducibility  (CV  =  10.6  and  18.5%),  and  a good  screening  window  (Z‟  = 
0.65). Assays from the 384 well plate however showed poor reproducibility (CV = 28.7 
and 54.3), with no screening window observed (Z‟ = 0). 
 
Table 2.6 CV and Z‟-value for 96 and 384 well plates 
Plate  Experiment  Positive Control*  CV  Negative Control*  CV  Z'-
value 
96 well  1
#  0.588 ± 0.062  10.6  0.021 ± 0.004  18.5  0.65 
384 well  1
†  0.116 ± 0.033  28.7  0.006 ± 0.003  54.3  0.00 
2
‡  0.227 ± 0.021  9.05  0.003 ± 0.001  33.1  0.71 
* Average of the positive or negative (lacking AdoMet) control assays ± standard 
deviation, given to 3 decimal places. 
# 72 assays total, 36 positive, 36 negative (lacking AdoMet). 
† 80 assays total, 40 positive, 40 negative (lacking AdoMet). 
‡ 96 assays total, 48 positive, 48 negative (lacking AdoMet). 
CV and Z‟-value calculated using Equation 2.1 and Equation 2.2 respectively. 
Assay conditions as Figure 2.18. Total assay volume 100 µl and gain 120 for 96 well 
plate. Total assay volume 20 µl and gain 170 for 384 well plate. 
 
Analysis of initial rate data from the 1
st 384 well plate experiment (Figure 2.18A  and 
B) showed rates to decrease across the plate, a trend which correlates with the order in 
which  assays  were  initiated  by  the  addition  of  Y.  pestis  Dam  and  DpnI.  Previous 
experiments  (Sections  2.3.2  and  2.3.3)  have  shown  Y.  pestis  Dam  to  become J C McKelvie      Chapter 2   
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inactivated  over  time  at  30  °C,  therefore  the  temperature  at  which  enzymes  were 
incubated  during  plate  addition  was  reduced  from  25  to  4  °C  and  the  experiment 
repeated (Figure 2.18C and D, and Table 2.6 experiment 2). Initial rate plots showed 
no decrease in enzyme activity across the plate and calculated values for CV and Z‟-
value showed the assay to be highly reproducible, with an excellent screening window. 
These experiments validate the transfer of the real-time Dam activity assay from 96 to 
384 well plate formats, with a slight modification of the assay initiation step to reduce 
Y. pestis Dam inactivation. 
 
   
   
 
Figure 2.18 Variation in assay signal across a 384 well plate 
A: Experiment 1 – initial rate versus well number (top to bottom, left to right of plate). 
B: Experiment 1 – initial rate versus column number. 
C: Experiment 2 – initial rate versus well number (top to bottom, left to right of plate). 
D: Experiment 2 – initial rate versus column number. 
Positive and negative control averages and ± 3 standard deviations shown as red lines. 
Assay  conditions:  1  nM  Y.  pestis  Dam,  2  nM  DpnI,  10  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, 
in 384 well plate, gain 170, 30 °C. Enzyme stock maintatined at ambient temperature 
(~25 °C) for experiment 1, and at 4 °C for experiment 2. 
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2.3.6 Substrate concentrations 
The optimisation of assay conditions for the non-biased identification of competitive, 
uncompetitive, and noncompetitive reversible inhibitors requires the determination of 
substrate K
M values, as discussed in Section 2. For a single substrate system (Equation 
2.4A) this process is relatively simple, requiring the evaluation of initial rate at a range 
of substrate concentrations. The kinetic constants K
M and V
max can then be determined 
by directly fitting a plot of initial rate against substrate concentration to the Michaelis-
Menten equation (Equation 2.4B), or by fitting a double reciprocal plot of initial rate 
against substrate concentration to a rearranged form of the Michaelis-Menten equation 
known as the Lineweaver-Burk equation (Equation 2.4C).  
 
A: 
on cat
off
k k
k E + S   ES   E + P 
 
B:  max
M
V [S]
 = 
[S] K
 
 
C: 
1 M
max max
K 11
 = 
V [S] V v
 
Equation 2.4 Single substrate enzymatic reaction mechanism (A), the Michaelis-Menten 
equation (B), and the Lineweaver-Burk equation (C) 
Where E = enzyme, S = substrate, P = product, k
on = rate of substrate binding, k
off = rate 
of  substrate  dissociation,  k
cat  =  rate  of  product  formation,    =  initial  rate,  V
max  = 
maximum rate, [S] = concentration of substrate, K
M = substrate concentration at half 
V
max (the Michaelis-Menten constant). 
For derivation of A-C see Appendix Section 0. 
 
Methods for the determination of kinetic constants for bi-substrate enzyme systems 
can be challenging (219), however pseudo-first order kinetics can be achieved by the 
addition of a large excess of the second substrate. It is then possible to assess  K
M 
using  the  methods  described  in  the  previous  paragraph.  Although  this  method 
represents a good approximation to K
M care should be taken to ensure that the second 
substrate is present at saturating concentrations, and that results are not affected by 
substrate inhibition. 
 J C McKelvie      Chapter 2   
  61   
2.3.6.1  AdoMet 
To determine K
M
AdoMet a series of assays were prepared containing an excess of DNA 
(relative  to  K
M
DNA  as  calculated  previously,  Table  2.5,  (171))  and  a  range  of  AdoMet 
concentrations. A plot of initial rate against substrate concentration was fitted to a 
hyperbola of the form f=a*x/(b+x), and V
max (a) and K
M (b) were determined as 0.091 ± 
0.004 fmol s
-1 and 16.4 ± 2.29 µM respectively (Figure 2.19). K
M
AdoMet is slightly higher 
than  the  value  of  11.3  ±  0.63  µM  determined  previously  for  Y.  pestis  Dam  (171), 
possibly  due to  variations  in assay  conditions  between  the two  experiments.  Lower 
values for K
M
AdoMet have also been reported for E. coli and T4 Dam (approximately 6 and 
0.4 µM respectively (104, 105, 108, 109)).  
 
The calculated k
cat for Y. pestis Dam determined from this experiment is 0.273 ± 0.012 
min
-1, which is again high in comparison with reported values of k
cat for the E. coli and 
T4 enzymes (0.6-1.2 min
-1) (104, 105, 108, 109). Whilst these results may represent a 
true difference in the kinetics of Y. pestis, T4 and E. coli Dam it is perhaps more likely 
that the difference observed is due to variations in experimental method, specifically 
the type of assay used (fluorescence-based for Y. pestis Dam versus radiation-based for 
T4 and E. coli Dam).  
 
 
Figure 2.19 Graphical determination of Y. pestis Dam K
M
AdoMet 
Initial rate versus concentration of AdoMet. Data fitted to Equation 2.4B. 
Assay  conditions:  1  nM  Y.  pestis  Dam,  2  nM  DpnI,  30  nM  hemimethylated 
oligonucleotide (ODN1), 0-200 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM 
MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, in 
384 well plate, gain 170, 30 °C. 
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2.3.6.2  DNA 
A  similar  process  was  used  to  determine  K
M
DNA,  with  a  series  of  assays  prepared 
containing a range of hemimethylated oligonucleotide concentrations and an excess of 
AdoMet.  A  plot  of  initial  rate  against  substrate  concentration  showed  an  apparent 
inhibitory effect at higher concentrations of DNA, a further series of experiments were 
therefore prepared containing both higher and lower fixed concentrations of AdoMet 
(Figure  2.20).  A  reduction  in  the  concentration  of  AdoMet  led  to  a  decrease  in 
maximum rate, whilst having no effect on the apparent inhibition, whereas an increase 
in the concentration of AdoMet had little effect on either maximum rate or inhibition. 
 
   
Figure 2.20 Graphical determination of Y. pestis Dam K
M
DNA 
A:  Background  subtracted  initial  rate  versus  concentration  of  ODN1  at  25  (open 
circles), 50 (filled circles) and 100 (open triangles) µM AdoMet. 
B: Data from (A) fitted globally to Equation 2.5, with K
i fixed. 
Assay  conditions:  0.3  nM  Y.  pestis  Dam,  2  nM  DpnI,  3-30.5  nM  hemimethylated 
oligonucleotide (ODN1), 0, 25, 50 or 100 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM 
NaCl,  8  mM  MgCl
2,  1  mM  DTT,  0.1  mg  ml
-1  BSA,  5%  glycerol,  pH  7.9.  Total  assay 
volume 20 µl, in 384 well plate, gain 170, 30 °C. 
 
max
is
M
V [S]
 = 
[S]
1 [S]
v
K
K
 
Equation 2.5 Competitive substrate inhibition 
Where   = initial rate, V
max = maximum rate, [S] = concentration of substrate, K
M = the 
Michaelis-Menten constant and K
is = the substrate inhibition dissociation constant. 
For derivation see Appendix Section 0. 
 
It is unusual to observe substrate inhibition at concentrations close to K
M, as in this 
case, suggesting that the effect observed may be more complicated. However, in the 
interest of obtaining estimates for kinetic parameters, data were fitted to an equation 
describing competitive substrate inhibition (Equation 2.5). As concentration of AdoMet 
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was shown to have little or no effect on apparent substrate inhibition, each data set 
were  fitted  globally  to  the  substrate  inhibition  equation  with  the  value  of  K
i  fixed, 
allowing for a more accurate approximation of K
M and V
max. The values and associated 
coefficients of determination (R
2) obtained are listed in Table 2.7 below. 
 
Table 2.7 Kinetic parameters derived from the graphical determination of K
M
DNA 
[AdoMet] 
µM 
Vmax 
fmol s-1 
kcat 
min-1 
KM 
nM 
R2 
25  0.140 ± 0.042  1.40 ± 0.42   2.35 ± 1.65  0.944 
50  0.172 ± 0.051  1.72 ± 0.51   2.28 ± 1.57  0.979 
100  0.200 ± 0.061  2.00 ± 0.61   4.15 ± 2.24  0.894 
AVERAGE  0.171 ± 0.051  1.71 ± 0.51   2.93 ± 1.88  0.939 ± 0.043 
Where errors shown are the standard error of fit or an average of the standard error of 
fit. K
is = 5.49 ± 2.20 for all experiments. 
 
The  values  of  K
M
DNA,  k
cat  and  V
max  obtained  for  each  concentration  of  AdoMet  were 
averaged, giving V
max as 0.171 ± 0.051 fmol s
-1, k
cat as 1.71 ± 0.51 min
-1 and K
M
DNA as 
2.93 ± 2.20 nM. At 100 µM AdoMet k
cat is comparable to that determined in the K
M
AdoMet 
experiment,  as  would  be  expected,  and  K
M
DNA  is  within  error  of  that  determined 
previously for Y. pestis Dam (3.43 ± 1.68 nM (171)). Reported values of K
M
DNA for both E. 
coli  and  T4  Dam  are  higher  (18-81  and 6-8  µM  respectively  (104, 105, 108, 109)), 
however this may again be due to differences in experimental method, as discussed 
previously. 
 
Inhibition by AdoMet has been ruled out, and the inhibition of Dam by concentrations 
of  hemimethylated  oligonucleotide  substrate  only  slightly  higher  than  the  apparent 
K
M
DNA is unlikely. The most probable explanation for the observed effects therefore lies 
within the coupled nature of the assay, and more specifically with the coupling enzyme 
DpnI.  Kinetic  characterisation  of  DpnI  has  shown  the  enzyme  to  display  Michaelis-
Menten  kinetics  with  respect  to  the  fully  methylated  oligonucleotide,  with  K
M
DNA 
determined  as  14.1  ±  2.3  nM  (Figure  2.21A).  However  for  the  hemimethylated 
oligonucleotide sigmoidal kinetics, indicative of cooperative binding, were observed, 
with a Hill parameter of 2.26 ± 0.09 suggesting positive cooperative binding (Figure 
2.21B). The apparent substrate inhibition observed in the full assay and the kinetics of 
DpnI with respect to the fully and hemimethylated DNA substrates will be discussed 
further in Chapter 3, Section 3.5.3.  J C McKelvie      Chapter 2   
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Figure 2.21 Graphical determination of DpnI K
M
DNA 
A:  Background  subtracted  initial  rate  versus  concentration  of  fully  methylated 
oligonucleotide ODN2. Data fitted to a hyperbola of the form f=a*x/(b+x), where a = 
V
max and b = K
M. 
B:  Background  subtracted  initial  rate  versus  concentration  of  hemimethylated 
oligonucleotide  ODN1.  Data  fitted  to  a  sigmoidal  Hill  equation  of  the  form 
f=a*x^b/(c^b+x^b), where a = V
max, b = the Hill parameter and c = K
M. 
Assay  conditions:  0  (background),  2  nM  (A)  or  12.5  pM  (B)  DpnI,  0-250  nM  fully 
methylated  oligonucleotide  (ODN2)  or  0-1000  nM  hemimethylated  oligonucleotide 
(ODN1), 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 
5% glycerol, pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 140 (A) or 150 
(B), 30 °C. 
 
Whilst the apparent substrate  inhibition effect observed at  higher concentrations of 
DNA may affect the kinetic constants obtained for Y. pestis Dam with respect to DNA 
concentration, the assay can still be applied to the identification of inhibitors of all 
modalities,  providing  DNA  concentration  (and  consequently  substrate  inhibition)  is 
kept  to  a  minimum.  In  addition,  kinetic  characterisation  of  inhibitors  can  also  be 
achieved,  although  K
i  values  determined  with  respect  to  varying  DNA  concentration 
may be affected and should be carefully assessed.  
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2.3.6.3  Optimisation of substrate concentrations for HTS 
Ideally substrate concentrations for HTS should be held at K
M for the target enzyme. 
However this can seriously impair the observed screening window, reducing the overall 
quality of the assay. To ensure a suitable screening window whilst keeping substrate 
concentrations close to K
M, AdoMet concentration was held constant and the effect of 
increasing DNA concentration on Z‟-value monitored.  
 
   
Figure 2.22 Optimisation of substrate concentrations for HTS 
A: Z‟-value for 12.5 µM AdoMet and varying DNA. 
B: Z‟-value for 25 µM AdoMet and varying DNA. 
Z‟-value calculated using Equation 2.2, from 8 positive and 8 negative (lacking Dam) 
assays. Z‟ = 0.5 (good) and 0.7 (excellent) shown as dashed red lines. 
Assay  conditions:  1  nM  Y.  pestis  Dam,  0.8  nM  DpnI,  3-34  nM  hemimethylated 
oligonucleotide (ODN1), 0 (A  and  B), 12.5 (A) or 25 (B) µM AdoMet, 20 mM Tris, 80 
mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay 
volume 100 µl, in 96 well plate, gain 130, 30 °C. 
 
At concentrations of AdoMet slightly lower than K
M the screening window was generally 
poor  (Figure  2.22A),  however  increasing  the  concentration  of  AdoMet  to  slightly 
higher than K
M increased the Z‟-value to at least 0.5, with the optimum at 10 nM DNA 
(Figure  2.22B).  Under  the  optimum  conditions  (25  µM  AdoMet,  10  nM  DNA)  the 
screening window was maximised and substrates were present in at least a 10-fold 
excess over the target enzyme. 
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2.3.7 Assay optimisation for the kinetic characterisation of Dam inhibitors 
2.3.7.1  Half maximal inhibitory concentration 
The  half  maximal  inhibitory  concentration,  known  as  the  IC
50,  relates  to  the 
concentration of an inhibitor which elicits a 50% reduction in the activity of a target 
enzyme in vitro. IC
50 values can be determined by fitting a plot of fractional activity 
against inhibitor concentration to a logistic sigmoid (Equation 2.6A and B). 
 
A:  i
0
Fractional Activity = 
v
v
 
 
B: 
- max min
min
50
FA FA
Fractional Activity = FA
[I]
1
IC
h  
Equation 2.6 Fractional activity (A) and determination of IC
50 (B) 
Where 
i = inhibited rate, 
0 = uninhibited rate, FA
min = minimum fractional activity, FA
max 
= maximum fractional activity, IC
50 = concentration of inhibitor at a fractional activity of 
0.5, [I] = inhibitor concentration and h = the Hill coefficient. 
For derivation of B see Appendix Section 0. 
 
Unlike  the  inhibition  constant  K
i,  IC
50  values  are  dependent  on  both  the  mode  of 
inhibition and substrate concentration. This relationship is described by the Cheng-
Prusoff equations (Equation 2.7), which express the relationship between IC
50 and K
i 
for  competitive,  noncompetitive  and  uncompetitive  reversible  inhibition  (221).  
Application  of  the  Cheng-Prusoff  equations  for  the  determination  of  K
i  from  IC
50 
requires  prior  knowledge  of  inhibitor  modality.  Where  substrate  concentrations  are 
held  at  K
M,  the  Cheng-Prusoff  equations  can  be  simplified  to  give  IC
50  =  2K
i,  IC
50  = 
2 K
i/( +1),  and  IC
50  =  2 K
i  for  competitive,  noncompetitive  and  uncompetitive 
reversible  inhibition  respectively.  By  preparing  IC
50  experiments  with  substrate 
concentrations held equal to K
M it is therefore possible to make an approximation to K
i 
of IC
50/2. Inhibitor IC
50 values determined for different targets can then be compared to 
determine selectivity in addition to assessing potency. 
 
A:  50 i
M
[S]
IC  =  1 K
K
 
 
B:  M
50
M
ii
[S]
IC  = 
[S]
K
K
KK
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C:  M
50 i IC  =  1
[S]
K
K  
Equation 2.7 The Cheng-Prusoff equations 
For  competitive  (A),  noncompetitive  (B)  and  uncompetitive  (C)  reversible  inhibition 
(221). 
Where IC
50 = half maximal inhibitory constant, K
i = the inhibitory dissociation constant, 
K
M  =  the  Michaelis-Menten  constant,    =  constant  describing  the  degree  to  which 
inhibitor  binding  affects  the  affinity  of  the  enzyme  for  substrate,  S  =  substrate 
concentration. 
For derivation of A-C see Appendix Section 0. 
 
Validation with AdoHcy 
Validation of the real-time break light Dam activity assay for the determination of IC
50 
values was achieved by preparing a dose-response curve for the known Dam inhibitor 
AdoHcy,  under  conditions  where  substrate  concentrations  were  equal  to  K
M  (Figure 
2.23). Values obtained for IC
50
AdoHcy from two separate experiments (each with triplicate 
data points) were 8.5 ± 2.1 and 15.3 ± 8.1 µM respectively. These values compare well 
with a previously determined value for K
i
AdoHcy, with an average of the two (11.9 ± 4.2 
µM) being within error double K
i
AdoHcy for Y. pestis Dam (6.93 ± 2.01 µM) as determined 
by Wood et al. (171). 
 
   
Figure 2.23 IC
50
AdoHcy determination 
Fractional activity, calculated using Equation 2.6A versus concentration of AdoHcy for 
experiment 1 (A) and 2 (B). Data fitted to Equation 2.6B. 
Assay  conditions:  0.3  nM  Y.  pestis  Dam,  2  nM  DpnI,  3.5  nM  hemimethylated 
oligonucleotide (ODN1), 0 or 16 µM AdoMet, 0-1000 µM AdoHcy, 5% DMSO, 20 mM 
Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total 
assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
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2.3.7.2  Inhibition constant 
The inhibition constant (K
i) is the dissociation constant for the binding of a reversible 
inhibitor  to  an  enzyme.  To  determine  K
i,  plots  of  1/rate  against  1/substrate 
concentration at various concentrations of inhibitor are fitted to the Lineweaver-Burk 
equation  (Equation  2.8A).  Re-plots  of  gradient  (K
M
app/V
max
app)  and  y-axis  intercept 
(1/V
max
app)  against  inhibitor  concentration  are  then  used  to  determine  K
i  and  K
i 
respectively from the negative of the re-plot x-axis intercepts (Equation 2.8B and C). 
 
A: 
max max
1 1 1 M  = 
[S] VV
app
app app
K
v
 
i
i
max
max
i
1
1
1
M
M
[I]
 = 
[I]
V
V  = 
[I]
app
app
K
K
K
K
K
 
 
B: 
max i max max
M M M  =  [I]
VV V
app
app
K K K
K
 
 
C: 
max i max max
1 1 1
 =  [I]
VV V
app K
 
Equation 2.8 The Lineweaver-Burk equation for reversible inhibition (A) and re-plots of 
gradient (B) and y-axis intercept (C) against inhibitor concentration 
Where    =  initial  rate,  K
M
app  =  apparent  substrate  concentration  at  half  V
max  (the 
Michaelis-Menten  constant), V
max
app =  apparent maximum rate, [S] =  concentration  of 
substrate,  S  =  substrate,  I  =  inhibitor,  K
M  =  the  Michaelis-Menten  constant,  V
max  = 
maximum rate, K
i = the inhibition dissociation constant. 
For derivation of A-C see Appendix Section 0. 
 
For inhibitors displaying a competitive mode of  inhibition,  K
i will be much greater 
than K
i, with Lineweaver-Burk y-axis intercepts being approximately equal for different 
concentrations of inhibitor. Inhibitors displaying an uncompetitive mode of inhibition 
will have Lineweaver-Burk gradients of approximately equal value for different inhibitor 
concentrations due to K
i being much greater than  K
i. For noncompetitive inhibitors 
both y-axis intercepts and gradients will vary with inhibitor concentration giving values 
for  both  K
i  and  K
i.  A  schematic  representation  of  how  mode  of  inhibition  affects 
Lineweaver-Burk plots is shown in Figure 2.24. 
 J C McKelvie      Chapter 2   
  69   
 
Figure 2.24 Effect of inhibition mode on Lineweaver-Burk plots 
For  competitive  inhibitors  (left)  plots  of  1/   against  1/[S]  for  increasing  inhibitor 
concentrations  intersect  on  the  y-axis.  For  noncompetitive  inhibitors  where    =  1 
(centre) plots intersect on the x-axis, where     1 plots intersect to the left of the y-
axis. For uncompetitive inhibitors (right) plots do not intersect. 
 
For  inhibitors  of  bi-substrate  enzymes  such  as  Dam,  a  pseudo-first  order 
approximation can again be made by having a fixed excess of one substrate, whilst 
varying  the  concentration  of  the  second.  This  method  has  previously  been  used  to 
determine K
i
AdoHcy with the real-time break light Dam activity assay, giving a competitive 
mode of inhibition with respect to AdoMet and a K
i
AdoHcy of 6.93 ± 2.01 µM (171). The 
observed  competitive  mode  of  inhibition  of  AdoMet  by  AdoHcy  is  as  expected, 
validating  this  method  as  a  means  of  establishing  inhibitory  mode  for  AdoMet 
competitive inhibitors. However, as mentioned previously care will have to be taken 
when assessing mode of inhibition and K
i with respect to DNA concentration, due to 
the effect of apparent substrate inhibition at concentrations of DNA above K
M. J C McKelvie      Chapter 2   
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2.4 Summary 
 
The expression and purification of active recombinant Y. pestis Dam and DpnI for use 
in the real-time break light activity assay has been achieved through the optimisation 
of expression systems, growth conditions, and purification buffers. Initial optimisation 
experiments have found the optimum buffer system for the maximisation of Y. pestis 
Dam activity and the minimisation of non-specific activity, to consist of 20 mM Tris (pH 
7.9), 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA and 5% glycerol, and 
validation of the assay under HTS conditions has shown the addition of up to 5% DMSO 
to be well tolerated. Experiments to determine the optimum assay temperature found 
the maximum initial rate to be achieved and maintained at 30 °C, with a loss in the 
activity  of  Y.  pestis  Dam  over  time  observed  at  higher  temperatures.  This  loss  in 
activity  was  minimised  by  incubating  the  stock  solution  of  Y.  pestis  Dam  in  the 
presence of DNA at 4 °C prior to assay initiation. 
 
To ensure that Dam catalysed methylation is the rate limiting step, and eliminate any 
lag  phase,  the  coupling  enzyme  concentration  was  optimised,  with  99.8%  of  the 
maximum  initial  rate  achieved  upon  addition  of  2  nM  DpnI  to  activity  assays. 
Furthermore, the inhibition of up to 50% of the coupling enzyme led to a decrease in 
initial rate of only 4%, minimising the observable effect of any DpnI inhibition on the 
overall assay. The optimal concentration of the primary enzyme was determined by 
assessing the effective assay range, with a Y. pestis Dam concentration of 10% of the 
minimum  DNA  concentration  found  to  fall  within  the  upper  (>40%  of  the  DNA 
concentration added) and lower (<3% of the DNA concentration added) assay limits. 
 
The  optimal  substrate  concentrations  for  the  identification  and  characterisation  of 
inhibitors were established by determining K
M values for each substrate, with K
M
AdoMet 
found to be 16.4 ± 2.29 µM, and K
M
DNA found to be 2.93 ± 2.20 nM. Whilst simple 
Michaelis-Menten  kinetics  were  observed  for  experiments  in  which  AdoMet 
concentration was varied, experiments in which DNA concentration was varied showed 
an apparent substrate inhibition effect. This effect has been identified as an artefact of 
the coupled enzyme assay system, and will be discussed further in Chapter 3, Section 
3.5.3. Since the coupled enzyme DpnI, and not Y. pestis Dam, is inhibited the effect of 
inhibitors on the primary enzyme can still be readily assessed with the real-time break 
light Dam activity assay. However experiments in which DNA concentration is varied 
should be carefully interpreted as the true concentration of DNA available for reaction 
may be limited by the apparent substrate inhibition observed. 
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Validation  of  HTS  conditions  for  the  identification  of  inhibitors  was  achieved  by 
assessing CV and Z-values for assays prepared in both 96 and 384 well microplates, 
with substrate concentrations varied around K
M. The reduction of total assay volume 
from 100 µl (96 well) to 20 µl (384 well) was found to severely reduce CV and Z-value 
when Y. pestis Dam was not incubated at 4 °C prior to assay initiation, however when Y. 
pestis Dam was cooled prior to assay initiation a good level of reproducibility (CV) and 
excellent screening window (Z-value) were observed. Although an unbiased HTS assay 
should be carried out at substrate concentrations equal to K
M to allow for all inhibitor 
modalities  to  be  identified,  in  the  case  of  the  real-time  Dam  activity  assay  a  poor 
screening window was achieved under such conditions. Substrate concentrations were 
therefore  increased  until  an  appropriate  screening  window  was  achieved,  with  the 
optimum concentrations identified as 25 µM AdoMet and 10 nM DNA. 
 
Finally, validation of IC
50 and K
i assay conditions for the characterisation of inhibitors 
was achieved by assessing a known Dam inhibitor, the methyl donor product AdoHcy. 
Use of the real-time break light Dam activity assay for the determination of K
i
AdoHcy was 
previously  achieved  by  Wood  et  al.  (171)  who  identified  a  competitive  mode  of 
inhibition  for AdoHcy  with respect to  AdoMet and a  K
i
AdoHcy  of  6.93 ±  2.01  µM.  The 
validation of the assay for the determination of IC
50 values was achieved by calculating 
IC
50
AdoHcy from two separate experiments, each consisting of triplicate data points. The 
average IC
50
AdoHcy was determined as 11.9 ± 4.2 µM, approximately double the reported 
K
i
AdoHcy  for  Y.  pestis  Dam,  as  would  be  expected  for  a  competitive  inhibitor,  thus 
validating the measurement.  
  72   
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3  Secondary Assay Development 
 
3.1 Introduction 
 
In HTS, primary assays are used to screen compound libraries, establish initial hits, and 
in some cases, to kinetically characterise compounds. Secondary assays are required 
for the validation of primary screening results, and the assessment of lead potency and 
selectivity.  The  hit  validation  process  includes  hit  confirmation  in  which  the 
reproducibility and purity of an inhibitor are assessed and hit verification in which false 
positives are identified (204). 
 
Hit verification can be achieved through counter-screening and/or the application of an 
alternative  assay  format,  with  both  methods  designed  to  validate  hits  through  the 
identification  and  elimination  of  false  positives.  Whilst  hit  confirmation  generally 
involves the re-testing of identified hits sourced from both original and fresh stocks, 
and the assessment of compound purity via chromatographic techniques such as high-
pressure liquid chromatography (HPLC) or thin layer chromatography (TLC) (204). 
 
The  following  chapter  describes  the  development  activity  and  binding  assays  in  a 
number of formats. These assays have been used to validate in vitro and in cell activity 
and to provide detailed kinetic and thermodynamic data for validated hits. 
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3.2 Counter-screening 
 
3.2.1 DpnI activity assay 
A  limitation  of  the  coupled  enzyme  assay  format  is  that  inhibition  of  the  coupling 
enzyme could lead to the identification of false positives. Due to careful optimisation 
of  the  real-time  break  light  Dam  activity  assay,  the  coupled  enzyme  DpnI  can  be 
inhibited by up to 50% with minimal effect on the overall  assay (Chapter 2, Section 
2.3.3.1). However, potent inhibitors may inhibit DpnI by greater than 50%, causing a 
significant decrease in the overall observed assay rate and the identification of false 
positives.  To  identify  and  eliminate  such  compounds  a  DpnI  activity  assay  was 
developed, in which a fully methylated break light probe (ODN2) is cleaved by DpnI, 
leading to an increase in fluorescence (Figure 3.1).  
 
 
Figure 3.1 Real-time break light DpnI activity assay 
A  fully  methylated  break  light  oligonucleotide  substrate  (ODN2)  containing  a  GATC 
recognition site is cleaved by the restriction enzyme DpnI, resulting in the separation 
of  fluorophore  (fluorescein)  and  quencher  (dabcyl)  and  a  subsequent  proportional 
increase in fluorescence. 
 
For  the  results  of  the  DpnI  counter-screen  to  be  directly  comparable  with  the  HTS 
results,  conditions  were  kept  constant,  with  the  exception  of  the  enzyme 
concentration. This was optimised to ensure the assay was carried out within the valid 
detection range. A plot of initial rate against  DpnI concentration  showed the upper 
assay limit to be at approximately 25 pM DpnI, with concentrations greater than this 
showing saturation (Figure 3.2). To ensure the accurate determination of initial rate a 
DpnI concentration of 12.5 pM was selected for the DpnI counter-screen. J C McKelvie    Chapter 3   
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Figure 3.2 DpnI counter-screen effective assay range 
Background subtracted initial rate of cleavage by DpnI. Data points from 0-12.5 pM 
DpnI fitted to a linear equation of the form f=y
0+a*x. 
Assay conditions: 0-100 pM DpnI, 10 nM fullymethylated oligonucleotide (ODN2), 5% 
DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, 
pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 170, temperature 30 °C. 
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3.2.2 Fluorescent intercalator displacement assay 
Another potential source of false positives is through assay signal interference, which 
can  occur  directly,  or  via  the  modification  of  assay  components.  Measuring  the 
fluorescence and absorbance properties of compounds can determine if their spectra 
overlap with the wavelength used for the assay signal, however compounds affecting 
assay  components  can  be  more  difficult  to  detect.  The  real-time  break  light  Dam 
activity assay utilises a hairpin oligonucleotide probe for the detection of methylation; 
in this type of assay compounds which intercalate DNA may prevent either methylation 
or  cleavage  occurring  by  inducing  a  conformational  change  in  the  oligonucleotide 
probe. Although DNA intercalators have been successfully employed in the treatment 
of cancer (222), the Dam recognition sequence is unlikely to provide a unique enough 
intercalation site to eliminate the potential mutagenic effect of such compounds. 
 
The identification of DNA intercalation can be achieved through the application of a 
fluorescent intercalator displacement (FID) assay. Originally developed as a method for 
establishing  DNA  binding  selectivity  and  affinity  (223,  224),  FID  assays  utilise  the 
fluorescence decrease associated with the displacement of a fluorescent intercalator, 
such as thiazole orange (225), from DNA to establish the DNA binding properties of a 
secondary  compound.  Adaptation  of  this  assay  for  the  identification  of  DNA 
intercalators  was  previously  reported  by  Mashhoon  et  al.  who  used  the  relative 
fluorescence  decrease  upon  displacement  of  thiazole  orange  by  a  compound  as  a 
measure of DNA intercalation (149). We have employed a similar method to assess the 
ability  of  HTS  hits  to  displace  thiazole  orange  from  an  unlabelled  oligonucleotide 
substrate (Figure 3.3), with compounds showing significant displacement of thiazole 
orange being discarded from further investigation. 
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Figure 3.3 Fluorescent intercalator displacement assay 
Intercalation by thiazole orange of an unmethylated oligonucleotide substrate (ODN3) 
containing a GATC recognition site produces a fluorescence signal, which is decreased 
when thiazole orange is displaced by a DNA intercalating test compound. J C McKelvie    Chapter 3   
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3.3 Gel-based Dam methylation assay 
 
It is common for HTS hits to be validated using a secondary assay to confirm inhibition 
of activity in more than one assay format. This increases confidence in the ability of a 
ligand  to  inhibit  the  target  and  reduces  the  possibility  of  false  positives  being 
identified by eliminating artefacts associated with a single assay format. The real-time 
break light Dam activity assay is a coupled, fluorescence-based assay which utilises a 
short,  hairpin,  oligonucleotide  probe  as  a  substrate.  To  maximise  its  value  an 
alternative assay format should therefore employ a non-fluorescence-based detection 
method, a different/no coupling enzyme, and a different oligonucleotide substrate. 
 
Whilst the adaptation of the primary assay to a high-throughput format is essential for 
HTS, a secondary assay need not be readily adaptable as the number of compounds to 
be  screened  is  generally  greatly  reduced.  A  low-throughput  gel-based  methylation 
assay  was  therefore  appropriate  for  hit  confirmation.  The  gel-based  assay  is  a 
protection-based,  stopped  assay,  in  which  Dam  methylation  protects  a  plasmid 
substrate  from  cleavage  by  the  methylation-sensitive  restriction  enzyme  BclI,  with 
results  visualised  by  agarose  gel electrophoresis  (Figure  3.4).  False  positives  which 
inhibit  the  coupling  enzyme  DpnI,  or  interfere  with  either  the  assay  signal  or 
oligonucleotide substrate would not be expected to affect the secondary assay in the 
same way and would therefore not be confirmed as hits. 
 
 
Figure 3.4 Gel-based Dam methylation assay 
Methylation  of  a  plasmid  substrate  by  Dam  protects  it  from  BclI  cleavage.  In  the 
presence  of  an  inhibitor,  methylation  is  prevented  allowing  BclI  cleavage  to  occur. 
Results are visualised by agarose gel electrophoresis, with a single band representing 
an  unmethylated  plasmid,  three  bands  representing  a  partially  methylated  plasmid, 
and two bands representing an unmethylated plasmid. J C McKelvie    Chapter 3   
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3.3.1 Optimisation 
The commercially available restriction enzymes BclI and XhoI show optimal activity in 
two out of four supplied buffers, one of which (NEBuffer 3
5) is comparable to the real-
time break light Dam activity assay buffer
6 and was therefore selected for use in the 
gel-based assay. For ease of quantification a plasmid  containing a single XhoI site for 
linearisation and a non-equidistant single BclI site for methylation-sensitive restriction 
was selected (Figure 3.5). Unmethylated plasmid was obtained by isolating pRL821 
(226) from the E. coli dam knockout strain ER2925. 
 
 
Figure 3.5 Gel-based Dam activity assay plasmid 
Plasmid pRL821 was originally constructed by Dr R. Leonardi (226) and contains 46 
Dam recognition sites (GATC), 1 XhoI recognition site (CTCGAG), and 1 BclI recognition 
site (TGATCA). Cleavage by XhoI and BclI results in the formation of two fragments of 
4084 and 6580 base pairs in length. 
 
3.3.1.1  Enzymes 
Dam 
Initial experiments with Y. pestis Dam showed incomplete digestion of plasmid DNA at 
various enzyme concentrations. Previous experiments (Chapter 2, Section 2.3.3.3) have 
shown Y. pestis Dam to rapidly lose activity at 30 °C, suggesting that it is not ideal for 
use  in  extended  assays.  The  closely  related  E.  coli  Dam  has  been  expressed  and 
purified by J.E Harmer, and may represent a more stable alternative due to the higher 
                                                
5 NEBuffer3: [50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl
2, 1 mM DTT, pH 7.9]. 
6 Real-time break light Dam activity assay buffer:  [20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM 
DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9]. J C McKelvie    Chapter 3   
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optimal growth temperature of the E. coli bacterium (37 °C (220), compared with 30 °C 
for Y. pestis (23)). To test this theory the activity of E. coli Dam was assessed after 
incubation at  30  °C  with  or  without  substrates  using the  real-time  break  light Dam 
activity assay (see Appendix Section 9.5 for optimisation of the real-time break light 
Dam  activity  assay  for  E.  coli  Dam),  and  compared to a  previous  experiment  which 
measured the activity of Y. pestis Dam (Section 2.3.3.3, Figure 3.6).  
 
   
Figure 3.6 Comparison of the inactivation of Y. pestis (A) and E. coli (B) Dam 
Initial rate of methylation by Y. pestis Dam (A) or E. coli Dam (B) incubated with DNA 
(filled circles), AdoMet (open circles), or no substrates (filled triangles) at 30 °C for 0-
1600 s prior to determination of initial rate. Data fitted to an exponential decay curve 
of the form f = a*exp(-b*x). 
Assay conditions: 1 nM Y. pestis Dam (A) or E. coli Dam (B), 2 (A) or 10 (B) nM DpnI, 10 
(A) or 25 (B) nM hemimethylated oligonucleotide (ODN1), 25 (A), 12 (B) or 0 (A and B) 
µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 
BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 170 (A) or 
150 (B), temperature 30 °C. 
 
Table 3.1 Comparison of the inactivation of Y. pestis and E. coli Dam at 30 °C 
Incubated With  Enzyme  Rate of Decay 
min-1 
R2 
DNA  Y. pestis Dam  0.128 ± 0.007  0.995 
E. coli Dam  0.059 ± 0.010  0.817 
AdoMet  Y. pestis Dam  0.214 ± 0.012  0.996 
E. coli Dam  0.137 ± 0.010  0.942 
No substrates  Y. pestis Dam  1.385 ± 0.178  0.974 
E. coli Dam  0.679 ± 0.270  0.978 
Assay conditions as for Figure 3.6. 
Data given to 3 decimal places. 
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Plots of initial rate against incubation time were fitted to first order exponential decay 
curves  and  the  rate  constant  for  decay  tabulated  for  each  enzyme  and  incubation 
condition (Table 3.1). E. coli Dam was found to be approximately twice as stable as Y. 
pestis  Dam  at  30  °C  with  or  without  substrates  present.  The  E.  coli  enzyme  was 
therefore selected for the gel-based Dam activity assays due to its increased stability. 
The concentration of E. coli Dam to be used in the gel-based assay was optimised by 
assessing the fraction of plasmid DNA methylated (Equation 3.1) at a range of E. coli 
Dam concentrations (Figure 3.7). 
 
1
13
I
Fraction of methylated DNA = 
SUM(I )
 
Equation 3.1 Fraction of methylated DNA 
Where I
1 = the intensity of the 10664 base pair band and I
1-3 = the intensities of the 
10664, 6580 and 4084 base pair bands. 
 
 
Figure 3.7 Gel-based Dam activity assay E. coli Dam concentration optimisation 
0.8% agarose gel electrophoresis of E. coli Dam concentration optimisation assay (left) 
and fraction of methylated DNA, quantified from gel band intensity using  Equation 
3.1, for varying E. coli Dam concentration (right). 
(L): ladder, (1-3): 250-62.5 nM E. coli Dam. 
Assay conditions: 62.5-250 nM E. coli Dam, 6 nM plasmid (pRL821), 10 U µl
-1 XhoI, 7.5 
U µl
-1 BclI, 60 µM AdoMet, 5% DMSO, 50 mM Tris, 100 mM NaCl, 10 mM MgCl
2, 1 mM 
DTT, pH 7.9. Step 1 (methylation) – total assay volume 20 µl, temperature 30 °C, 1 hr; 
Step 2 (denaturation) – total assay volume 20 µl, temperature 95  °C, 5 min; Step 3 
(cleavage)  –  restriction  enzymes  XhoI  and  BclI  added,  total  assay  volume  22  µl, 
temperature 37 °C, 1 hr and 50 °C, 1 hr. Digested plasmid analysed by 0.8% agarose 
gel electrophoresis, bands quantified using the program ImageJ (227). J C McKelvie    Chapter 3   
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Complete methylation of 6 nM plasmid (equivalent to ~276 nM GATC sites) required 
the addition of 250 nM E. coli Dam. This concentration of E. coli Dam was therefore 
selected for all subsequent gel-based Dam methylation assays. 
 
Restriction enzymes 
An  excess  of  BclI  and  XhoI  were  added  to  assays  after  the  completion  of  the  Dam 
methylation and denaturation steps, to ensure complete digestion of all plasmid DNA. 
 
3.3.1.2  Substrate concentration 
The  optimum  concentration  of  AdoMet  was  determined  by  assessing  the  effect  of 
varying AdoMet concentrations on the fraction of DNA methylated (Figure 3.8). Full 
methylation of the plasmid was observed for AdoMet concentrations of 0.61 µM and 
above. This lower AdoMet concentration limit is approximately one tenth the  E. coli 
Dam K
M
AdoMet (5.6 µM, Appendix Section 9.5.2) which is unsurprising due to the large 
excess of E. coli Dam (~80 times plasmid concentration) added to the assay. 
 
 
Figure 3.8 Gel-based Dam activity assay AdoMet concentration optimisation 
0.8% agarose gel electrophoresis of AdoMet concentration optimisation assay (left) and 
fraction of methylated DNA, quantified from gel band intensity using Equation 3.1, for 
varying AdoMet concentration (right). 
(L): ladder, (1-8): 60-0 µM AdoMet. 
Assay conditions: 250 nM E. coli Dam, 3 nM plasmid (pRL821), 10 U µl
-1 XhoI, 7.5 U µl
-1 
BclI, 0-60 µM AdoMet, 5% DMSO, 50 mM Tris, 100 mM NaCl, 10 mM MgCl
2, 1 mM DTT, 
pH 7.9. Step 1 (methylation) – total assay volume 20 µl, temperature 30 °C, 1 hr; Step 2 
(denaturation) – total assay volume 20 µl, temperature 95 °C, 5 min; Step 3 (cleavage) – 
restriction enzymes XhoI and BclI added, total assay volume 22 µl, temperature 37 °C, 
1 hr and 50 °C, 1 hr. Digested plasmid analysed by 0.8% agarose gel electrophoresis, 
bands quantified using the program ImageJ (227). J C McKelvie    Chapter 3   
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Ideally substrate concentrations at or close to K
M should be employed in assays for the 
identification of inhibitors (as discussed in Chapter 1), however in a secondary assay 
this  is  less  important,  as  the  goal  of  the  assay  is  the  confirmation  and  not  initial 
identification of hit compounds. In the case of the gel-based methylation assay, DNA 
concentration is limited by the detection mode and availability of reagent and as such 
a  concentration  of  3  nM  (~  one tenth  K
M
DNA  of  28  nM,  Appendix  Section  9.5.2)  was 
selected to minimise reagent usage whilst maximising signal.  
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3.3.2 Validation 
To validate the gel-based assay for the identification of Dam inhibitors and establish an 
optimal  concentration  of  AdoMet  for  inhibition  assays,  a  series  of  assays  were 
prepared  containing  fixed  concentrations  of  AdoMet  and  a  range  of  AdoHcy 
concentrations (Figure 3.9). 
 
 
Figure 3.9 Gel-based Dam activity assay validation 
A-C: 0.8% agarose gel electrophoresis of varying AdoHcy concentration with 6 (A), 24 
(B) and 60 (C) µM AdoMet. 
(L):  ladder,  (1):  negative  control  (lacking  AdoMet  and  AdoHcy),  (2-7):  5-0.05  mM 
AdoHcy, (8): positive control (lacking AdoHcy). 
D:  Fractional  activity,  quantified  from  gel  band  intensity  with  Equation  2.6A,  for  6 
(filled  circles),  24  (open  circles)  and  60  (triangles)  µM  AdoMet  versus  AdoHcy 
concentration. Data fitted to Equation 2.6B. 
Assay conditions: 250 nM E. coli Dam, 3 nM plasmid (pRL821), 10 U µl
-1 XhoI, 7.5 U µl
-1 
BclI, 0, 6, 24 or 60 µM AdoMet, 0-5 mM AdoHcy, 5% DMSO, 50 mM Tris, 100 mM NaCl, 
10 mM MgCl
2, 1 mM DTT, pH 7.9. Step 1 (methylation) – total assay volume 20 µl, 
temperature 30 °C, 1 hr; Step 2 (denaturation) – total assay volume 20 µl, temperature 
95 °C, 5 min; Step 3 (cleavage) – restriction enzymes XhoI and BclI added, total assay 
volume 22 µl, temperature 37 °C, 1 hr and 50 °C, 1 hr. Digested plasmid analysed by 
0.8% agarose gel electrophoresis, bands quantified using the program ImageJ (227). 
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Increasing  AdoMet  concentration  from  6  to  60  µM  had  little  effect  on  the  positive 
control assays (lacking AdoHcy), as  would be expected based on the results of the 
AdoMet  concentration  optimisation.  An  effect  on  the  inhibition  of  Dam  by  AdoHcy, 
however, was observed, with increased concentrations of AdoMet leading to a decrease 
in  inhibition,  as  would  be  expected  for  an  AdoMet-competitive  inhibitor  such  as 
AdoHcy. An AdoMet concentration of 6 µM (~ equal to E. coli Dam K
M
AdoMet) was therefore 
selected for inhibition assays. 
 
It  should  be  noted  however  that  at  an  AdoMet  concentration  of  6  µM,  IC
50
AdoHcy  was 
determined as 267 µM, much higher than the reported K
i
AdoHcy for E. coli Dam of 41.6 ± 
10.4 (105). This is most likely due to the low concentration of DNA used in the gel-
based  assay  and  care  should  therefore  be  taken  when  interpreting  results,  which 
should ideally be used purely for the confirmation of inhibitory activity, and not for the 
determination of kinetic parameters. 
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3.4 Real-time  break  light  cytosine  methyltransferase 
activity assay 
 
Off-target effects can induce unacceptable levels of toxicity, often leading to the failure 
of potential drug candidates. It is therefore important that the selectivity of HTS hits is 
established at an early stage, reducing the potential for attrition in the latter stages of 
the  drug  development  process  and  thus  minimising  costs  (228).  The  lack  of  a 
functionally similar DNA adenine-N6 methyltransferase enzyme in humans makes Dam 
an attractive target for the development of selective antimicrobials (42). However the 
abundance  of  other  AdoMet-dependant  methyltransferases  in  humans  gives  rise  to 
other possible sources of toxic off-target effects.  
 
The human DNA cytosine-C5 methyltransferases are functionally similar to Dam. The 
methyltransferases have two common substrates (DNA and AdoMet) but different DNA 
recognition  sites  and  nucleotide  targets.  To  assess  the  selectivity  of  compounds 
identified as Dam inhibitors through HTS, the principles of the real-time break light 
Dam activity assay have been utilised for the development of an activity assay for the 
human cytosine-C5 methyltransferase DNMT1 (Figure 3.10 (172)).  
 
 
Figure 3.10 Real-time break light DNMT1 activity assay 
A partially methylated break light oligonucleotide substrate (ODN4/6/8) containing a 
CG methylation site is fully methylated by DNMT1 (ODN5/7/9), making it a substrate 
for  the  restriction  enzyme  GlaI.  Cleavage  by  GlaI  results  in  the  separation  of 
fluorophore  (Cy3/fluorescein)  and  quencher  (dabcyl)  and  a  subsequent  proportional 
increase in fluorescence. 
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3.4.1 Optimisation 
3.4.1.1  Buffer 
Previous  optimisation  of  the  real-time  break  light  DNMT1  activity  assay  has  been 
completed by Dr R.J. Wood (172), with the optimum buffer conditions determined as 
[100 mM Tris, 5 mM magnesium chloride, 1 mM DTT, 0.1 mg ml
-1 BSA, pH 7.5]. Sodium 
chloride concentration was not previously optimised for DNMT1 and so the effect of 
increasing sodium chloride concentration on DNMT1 activity was determined (Figure 
3.11), with the optimum concentration identified as 12.5 mM. 
 
 
Figure 3.11 DNMT1 activity assay sodium chloride concentration optimisation 
Background subtracted initial rate of methylation by DNMT1 (black) and signal:noise 
ratio (red). 
Assay  conditions:  25  nM  DNMT1,  0.0125  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide (ODN8),  0 or 20 µM AdoMet, 0-200 mM  NaCl,  100 mM  Tris,  5 mM 
MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 
384 well plate, gain 100, temperature 37 °C. 
 
3.4.1.2  Oligonucleotide substrate design 
Initial DNMT1 activity assays were carried out using break light oligonucleotide probes 
labelled with the fluorophore Cy3 and the quencher dabcyl. To minimise reagent costs 
Cy3 was replaced with the more economically viable fluorophore fluorescein (Figure 
3.12).  
 
 
Figure 3.12 Structures of the fluorophores Cy3 and fluorescein J C McKelvie    Chapter 3   
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In  addition  to  altering  the  fluorophore,  oligonucleotides  with  CG-rich  and  CG-poor 
recognition  site  flanking  sequences  were  investigated  to  determine  the  optimal 
substrate for DNMT1 (Table 3.2). 
 
Table 3.2 DNMT1 activity assay oligonucleotides 
Oligonucleotide*  Fluorophore  Stem Length#  %CG Character† 
Recognition  site 
and    flanking 
bases‡ 
ODN4/5  Cy3  14 bp  57%  TATGCGCA 
ODN6/7  Fluorescein  14 bp  57%  TATGCGCA 
ODN8/9  Fluorescein  14 bp  57%  TAGGCGCC 
* Partially methylated/fully methylated.  
# Length of the hairpin stem duplex (i.e. a 20 base hairpin with a 4 base loop would 
have an 8 base pair (bp) stem). 
† Number of C or G bases in the hairpin stem/total bases in the hairpin stem. 
‡ DNMT1 GC recognition site in bold red. 
 
Initial  GlaI  activity  assays  carried  out  with  the  fully  methylated  fluorescein  labelled 
oligonucleotide  ODN7,  showed  a  change  in  the  product  formation  time  course 
compared to experiments where the equivalent Cy3 oligonucleotide (ODN5) was used 
(Figure 3.13A). A “bi-phasic” change in fluorescence over time was observed for the 
fluorescein labelled oligonucleotide, whereas a steady decrease in rate over time was 
observed for the Cy3 labelled oligonucleotide.  
 
Further analysis of the oligonucleotide equilibration period prior to the addition of GlaI 
showed  the  fluorescein  labelled  oligonucleotide  to  undergo  two  equilibration 
processes,  the  first  over  approximately  fifteen  minutes,  and  the  second  over 
approximately  thirty  minutes  (Figure  3.13B).  The  drop  in  fluorescence  observed 
between  equilibration  points  1  and  2  appeared  to  correlate  with  the  bi-phasic 
behaviour  observed  in  the  assay  time  course  for  the  fluorescein  labelled 
oligonucleotide, raising the possibility that the two phenomena are connected. 
 
Oligonucleotide melting profiles were obtained for the partially methylated fluorescein 
labelled  oligonucleotide  (ODN6),  which  showed  the  hairpin  to  have  two  different 
melting temperatures (T
m‟s), at 80 and 50 °C (Figure 3.14). This result suggests that 
the oligonucleotide has at least two stable forms at assay temperature (37 °C), with the 
effect observed in Figure 3.13B possibly due to equilibration between these forms.  J C McKelvie    Chapter 3   
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Figure 3.13 Comparison of GlaI assay time courses for Cy3 and fluorescein labelled 
fully methylated oligonucleotide substrates 
A:  Normalised  fluorescence  against  time  plots  for  Cy3  (solid  line)  and  fluorescein 
(dashed line) labelled oligonucleotide substrates.  
B: Normalised fluorescence against time plots for fluorescein labelled oligonucleotide 
extended  equilibration  (solid  line)  and  assay  time  course  after  standard  15  minute 
equilibration (dashed line). 
Assay conditions: 0.05 U µl
-1 GlaI, 250 nM fully methylated oligonucleotide (ODN5 – 
solid line or ODN7 – dashed line), 20 µM AdoMet, 12.5 mM NaCl, 100 mM Tris, 5 mM 
MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 
384 well plate, gain 133 or 110, temperature 37 °C. 
 
 
Figure 3.14 Fluorescein labelled oligonucleotide melting profile 
Fluorescence versus temperature melting profile, and first derivative of melting profile 
showing melting temperatures at 80 and 50 °C. 
Assay conditions: 250 nM partially methylated oligonucleotide (ODN6), 12.5 mM NaCl, 
100 mM Tris, 5 mM MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.5. Total assay volume 20 
µl. 
 
The  reason  for  the  difference  in  the  behaviour  of  the  Cy3  (ODN5)  and  fluorescein 
(ODN7) labelled oligonucleotides is unclear.  Both substrates are of the same length 
and sequence, making the only variation the fluorescent label located at the 5‟ end of 
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the oligonucleotide. This may suggest that the Cy3 fluorescent dye is stabilising the 
hairpin  form,  thus  reducing  the  time  for  equilibration  to  occur.  However,  another 
possible  explanation  is  that  a  similar  effect  does  occur  for  the  Cy3  labelled 
oligonucleotide, but that the change in fluorescence observed is much smaller than for 
the fluorescein labelled oligonucleotide and thus not as readily detected. The latter of 
these two theories is supported by the low quantum yield of Cy3 (0.09 in Tris buffer 
(229)) compared  to  fluorescein  (0.92  in  water  (230)).  The reinstatement  of the  Cy3 
labelled oligonucleotide to circumvent this issue was therefore not implemented due to 
cost and the potential risk of experiencing a similar, unobservable, equilibration effect. 
 
Whilst the bi-phasic behaviour observed for the fluorescein labelled oligonucleotide is 
not ideal, the overall effect on assay quality can be minimised by the application of an 
extended  equilibration  step  prior  to  assay  initiation.  To  limit  the  evaporation  of 
reagents  over  the  duration  of  the  assay  this  equilibration  step  was  set  at  thirty 
minutes, approximately equal to the second equilibration phase (Figure 3.13B). 
 
The effect of DNA recognition site flanking sequence on enzyme activity was assessed 
by monitoring the assay time courses for partially methylated oligonucleotides ODN6 
and  ODN8  (Figure  3.15A  and  B).  Whilst  the  signal  obtained  for  the  full  assay  was 
similar for the two substrates, ODN6 showed a much lower negative signal (for assays 
lacking AdoMet), as reflected by the signal:noise ratios (Figure 3.15A and B, red line). 
 
        
Figure 3.15 Comparison of DNMT1 assay time courses for fluorescein labelled partially 
methylated oligonucleotide substrates 
Fluorescence against time plots for positive (solid line) and negative (lacking AdoMet, 
dashed  line)  DNMT1  activity  assays  for  ODN6  (A)  and  ODN8  (B).  Signal:noise  ratio 
shown in red.  
Assay  conditions:  25  nM  DNMT1,  0.0125  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide  (A: ODN6 or B: ODN8), 0 or 20 µM AdoMet, 12.5 mM NaCl, 100 mM 
Tris, 5 mM MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 
20 µl, in 384 well plate, gain 110, temperature 37 °C. 
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The results of the DNMT1 assays show that a better signal:noise ratio was obtained for 
the oligonucleotide with the less CG-rich flanking sequences (ODN6). In addition, GlaI 
activity  assays  conducted  with  the  partially  and  fully  methylated  oligonucleotides 
(ODN6/7  and  8/9)  showed  that  non-specific  cleavage  of  the  partially  methylated 
substrate was higher for ODN8 than ODN6, suggesting that in this instance, increasing 
the CG-richness of the flanking sequences decreases GlaI specificity (Figure 3.16). As 
such, ODN6 was selected as the optimum substrate for the DNMT1 activity assay. 
 
            
Figure 3.16 Comparison of GlaI assay time courses for fluorescein labelled partially 
and fully methylated oligonucleotide substrates 
Fluorescence  against  time  plots  for  fully  (solid  line)  and  partially  (dashed  line) 
methylated oligonucleotides ODN6/7 (A) and ODN8/9 (B). Signal:noise ratio shown in 
red.  
Assay conditions: 0.05 U µl
-1 GlaI, 250 nM partially or fully methylated oligonucleotide  
(A: ODN6/7 or B: ODN8/9), 12.5 mM NaCl, 100 mM Tris, 5 mM MgCl
2, 0.1 mg ml
-1 BSA, 
1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 384 well plate, gain 110, 
temperature 37 °C. 
 
3.4.1.3  Plate reader 
Detection of fluorescence for the real-time break light DNMT1 activity assay could be 
carried out using a Tecan Safire
II or a BMG  Polarstar Omega microplate reader. The 
variation  in  assay  signal  across  and  down  a  384  well  plate  was  assessed  for  both 
readers, with 16 positive and 8 negative (lacking AdoMet) control assays placed on 
either side of the plate. The initial rate of the positive controls divided by the average 
of the positive controls was plotted against row position for the first and last column 
of the plate (Figure 3.17), and showed minimal difference between the two readers. 
Assays read in the BMG reader had a CV of 10.5% for the positive controls compared 
with 14.5% for the Tecan reader, and the Z‟-value across the plate was 0.40 for the 
BMG reader compared with 0.34 for the Tecan. The BMG reader was therefore selected 
for  subsequent  DNMT1  activity  assays  due  to  the  observed  production  of  more 
reproducible and accurate results. 
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Figure 3.17 Comparison of DNMT1 assay reproducibility for different plate readers 
Fractional rate relative to the average initial rate of assays placed in column 1 (black) 
and 24 (red) of a 384 well plate. Plate read in Tecan Safire
II (A) or BMG Polarstar Omega 
(B) plate reader. 
Assay  conditions:  25  nM  DNMT1,  0.05  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide  (ODN6),  0  or  20  µM  AdoMet,  12.5  mM  NaCl,  100  mM  Tris,  5  mM 
MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 
384 well plate, gain 110 (A) or 1550 (B), temperature 37 °C. 
 
3.4.1.4  Enzyme concentrations 
The optimum concentration of the restriction enzyme GlaI to be added to the DNMT1 
activity assay was determined by monitoring the apparent initial rate over a range of 
GlaI concentrations (Figure 2.14).  
 
       
Figure 3.18 DNMT1 activity assay GlaI concentration optimisation 
A:  Background  subtracted  initial  rate  of  methylation  by  DNMT1.  Data  fitted  to  an 
exponential rise to a maximum of the form f=a*(1-exp(-b*x)), where a = maximum rate. 
B: Background subtracted initial rate of methylation by DNMT1 (black) and signal:noise 
ratio (red). 
Assay  conditions:  25  nM  DNMT1,  0-0.2  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide  (ODN6),  0  or  20  µM  AdoMet,  12.5  mM  NaCl,  100  mM  Tris,  5  mM 
MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 
384 well plate, gain 1550, temperature 37 °C. 
A  B 
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Maximum  rate  was  obtained  at  approximately  0.15  U  µl
-1  GlaI,  however  a  rapid 
decrease  in  signal:noise  was  observed  from  0.025  U  µl
-1  GlaI.  To  maintain  a  viable 
screening  window  a  slightly  lower  concentration  of  0.05  U  µl
-1  GlaI  was  therefore 
selected, at which approximately 87% of the maximum rate and a signal:noise ratio of 
4.8 were achieved. 
 
The effective assay range was established by assessing the effect of increasing DNMT1 
concentration on initial rate of methylation (Figure 2.15). A line of best fit of the form 
f=y
0+a*x fitted through data points from 0 to 25 nM showed the upper assay limit to 
be approximately 25 nM DNMT1, approximately one-tenth of the DNA concentration 
added to the assay. 
 
 
Figure 3.19 DNMT1 activity assay effective assay range 
Background subtracted initial rate of methylation by DNMT1. Data fitted to a linear 
equation of the form f=y
0+a*x, where y
0 = the y-axis intercept and a = the line gradient. 
Assay  conditions:  0-200  nM  DNMT1,  0.05  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide  (ODN6),  0  or  20  µM  AdoMet,  12.5  mM  NaCl,  100  mM  Tris,  5  mM 
MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 
384 well plate, gain 1550, temperature 37 °C. 
 
3.4.1.5  Substrate concentrations 
Reported values for DNMT1 K
M
DNA range from 4.6 µM for unmethylated DNA to 10.8 µM 
for hemimethylated DNA (231). Attempts at determining K
M
DNA using the real-time break 
light DNMT1 activity assay were inconclusive due to the equilibration effect observed 
previously (Section 3.4.1.2). Whilst a thirty minute equilibration was adequate for lower 
concentrations  of  DNA  (up  to  250  nM),  increasing  the  DNA  concentration  further 
extends the  required  equilibration  time,  leading to  a  re-emergence  of  the  bi-phasic 
time  courses  at  higher  DNA  concentrations,  and  a  decrease  in  the  observed  rates. 
Increasing  equilibration  time  led  to  problems  with  reagent  evaporation,  and  the 
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the available technology. It was therefore not possible to determine K
M
DNA for DNMT1 
using the real-time break light assay and a maximum DNA concentration of 250 nM 
was applied to all subsequent DNMT1 activity assays. 
 
The K
M
AdoMet was investigated under conditions where DNA concentration was potentially 
limiting in order to avoid the effects of oligonucleotide equilibration seen at higher 
concentrations  of  DNA.  Initial  rates  of  methylation  were  determined  for  a  range  of 
AdoMet concentrations and data were fitted to a hyperbola of the form f=a*x/(b+x). 
Values  for  V
max  (a)  and  K
M  (b)  were  0.565  ±  0.007  fmol  s
-1  and  3.25  ±  0.12  µM 
respectively. The value of  K
M
AdoMet determined using the real-time break light DNMT1 
activity  assay  compares  well  with  the  previously  reported  value  of  3.4  µM  (231), 
suggesting that the low concentration of DNA used in the assay does not affect the 
affinity of DNMT1 for AdoMet. 
 
 
Figure 3.20 Graphical determination of DNMT1 K
M
AdoMet 
Initial rate versus concentration of AdoMet. Data fitted to Equation 2.4B. 
Assay  conditions:  25  nM  DNMT1,  0.05  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide  (ODN6), 0-20 µM AdoMet, 12.5 mM NaCl, 100 mM Tris, 5 mM MgCl
2, 
0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 384 well 
plate, gain 1550, temperature 37 °C. 
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3.4.2 Validation 
The screening window of the real-time break light DNMT1 activity assay was assessed 
over a series of four positive and four negative (lacking AdoMet) control assays. The 
limited  availability  of  both  enzymes  required  for  the  assay  made  a  more  valid 
assessment over more data points unfeasible. The results of this limited test showed 
the assay screening window to be acceptable, with a Z‟-value of 0.51 obtained. 
 
Validation of the assay for the identification of inhibitors and the determination of IC
50 
values was achieved by assessing the affect of the known inhibitor AdoHcy on enzyme 
activity. Two separate experiments, in which AdoMet concentration was held equal to 
K
M
AdoMet,  found  IC
50
AdoHcy  to  be  0.941  ±  0.076  µM,  and  0.419  ±  0.076  µM,  giving  an 
average of 0.680 ± 0.369 µM, which compares well with IC
50 values reported in the 
literature (131, 232). Experiments to determine K
i
AdoHcy were not carried out due to the 
limited availability of both DNMT1 and GlaI. 
 
   
Figure 3.21 DNMT1 activity assay AdoHcy IC
50 determination 
Fractional activity, calculated using Equation 2.6A versus concentration of AdoHcy for 
experiment 1 (A) and 2 (B). Data fitted to Equation 2.6B. 
25 nM DNMT1, 0.05 U µl
-1 GlaI, 250 nM partially methylated oligonucleotide  (ODN6), 0 
or 3 µM AdoMet, 0-2 mM AdoHcy, 5% DMSO, 12.5 mM NaCl, 100 mM Tris, 5 mM MgCl
2, 
0.1 mg ml
-1 BSA, 1 mM DTT, 5% glycerol, pH 7.5. Total assay volume 20 µl, in 384 well 
plate, gain 1250, temperature 37 °C. 
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3.5 Fluorescence anisotropy assay 
 
The substrate inhibition effect observed when increasing  DNA concentrations above 
the apparent K
M
DNA for Dam makes the analysis of DNA concentration dependant effects 
with the real-time break light Dam activity assay difficult. In light of these issues an 
alternative assay format was developed to probe the binding interaction between Dam 
and DNA using fluorescence anisotropy (Figure 3.22). 
 
 
Figure 3.22 Fluorescence anisotropy assay 
A hemimethylated oligonucleotide substrate (ODN10) containing a GATC methylation 
site is bound by Dam resulting in an increase in the observed fluorescence anisotropy 
of the fluorophore (fluorescein). 
 
Excitement of a fluorophore by polarised light results in the emission of light polarised 
as a function of fluorescence lifetime and rotational diffusion, with the intensity of the 
fluorescence emitted typically measured parallel and perpendicular to the plane of the 
excited  light.  The  degree  to  which  the  parallel  and  perpendicular  fluorescence 
intensities vary from each other gives a measure of how  quickly the fluorophore is 
tumbling  in  solution,  and  is  generally  measured  as  fluorescence  polarisation  or  
fluorescence  anisotropy,  which  can  be  calculated  with  Equation  3.2A  and  B 
respectively (233, 234). 
 
A:   = 
II
P
II
 
 
B:   = 
2
II
A
II
 
Equation 3.2 Fluorescence polarisation (A) and anisotropy (B) 
Where  P =  polarisation,  A  = anisotropy,  I
||  =  parallel  fluorescence  intensity  and  I   = 
perpendicular fluorescence intensity. 
 J C McKelvie    Chapter 3   
  97   
Fluorophores covalently attached to small ligands, such as short oligonucleotides or 
peptides, rotate rapidly in solution, emitting mostly depolarised light when excited by 
a polarised light source. Binding of a small labelled ligand to a larger receptor, such as 
an enzyme, significantly reduces the rotational speed of the fluorophore, leading to 
the  emission  of  a  greater  proportion  of  polarised  light  (234).  The  degree  of 
polarisation  can  be  measured  as  anisotropy,  which  can  be  used  to  calculate  the 
fraction  of  a  labelled  ligand  bound  by  an  unlabelled  receptor  using  Equation  3.3A 
(233).  The  anisotropy  of  the  labelled  ligand  in  the  free  and  bound  states  are 
determined by fitting a plot of anisotropy against receptor concentration to a ligand 
binding  calibration  curve  (Equation  3.3B)  (235).  Finally,  dissociation  constants  for 
ligand:receptor binding interactions can be determined by fitting a plot of fraction of 
substrate bound versus receptor concentration to Equation 3.3C (233). 
 
A: 
-
--
obs F
B
B obs obs F
AA
F  = 
A A Q A A
 
 
B: 
- FB
obs F
0
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A  = A
[R]
1
x
h  
 
C: 
--
2
D T d T T
B
T
K [L] [R] K [L] [R] [L] [R]
F  = 
2[L]
 
Equation 3.3 Fraction of substrate bound in a fluorescence anisotropy experiment (A), 
ligand  binding  calibration  curve  (B)  and  determination  of  equilibrium  dissociation 
constant (C) 
Where  F
B  =  fraction  of  labelled  substrate  bound,  A
obs  =  observed  anisotropy  of  the 
solution, A
F and A
B = anisotropy of the free and bound labelled substrate (as calculated 
by Equation 3.1B), Q = the ratio of the fluorescence intensities of the free and bound 
labelled substrates, [R] = receptor concentration, x
0 = receptor concentration at F
B = 
0.5,  h  =  the  Hill  coefficient,  K
D  =  the  equilibrium  dissociation  constant  for  the 
ligand:receptor  complex,  [L]
T  =  total  ligand  concentration  and  [R]
T  =  total  receptor 
concentration. 
 
Fluorescence anisotropy  can  also  be  used to  study  the  inhibition  of  ligand:receptor 
binding through competition binding experiments, in which increasing concentrations 
of  inhibitor  are  added  to  a  fixed  concentration  of  labelled  ligand  and  unlabelled 
receptor. If the inhibitor competes with the labelled ligand for the receptor a decrease 
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the equilibrium dissociation constant (K
D) is known and a ligand binding calibration 
curve has been plotted, competition binding constants can be determined by fitting a 
plot of the fraction of substrate bound versus inhibitor concentration to Equation 3.4 
(233). 
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Equation 3.4 Determination of competition binding constant 
Where F
B = fraction of labelled substrate bound (calculated from Equation 3.3A and B), 
K
D  =  the  dissociation  constant  for  the  substrate:receptor  complex,  K
Dc  =  the 
competition  binding  constant  for  the  inhibitor:receptor  complex,  [L]
T  =  total  ligand 
concentration and [R]
T = total receptor concentration. J C McKelvie    Chapter 3   
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3.5.1 Optimisation 
3.5.1.1  Non-specific binding 
Non-specific binding and aggregation of the labelled substrate can severely impede 
fluorescence anisotropy readings, with labelled ligand concentration showing a non-
linear  relationship  to  fluorescence  anisotropy.  Reduction  of  these  effects  can  be 
achieved  through  the  addition  of  additives  such  as  BSA  and  detergent  (236,  237). 
Decreasing  the  surface:volume  ratio  can  also  help  reduce  non-specific  binding,  by 
minimising interactions between the labelled ligand and the reaction vessel.  
 
Initial  experiments  examined  the  effects  of  buffer  system  and  assay  volume  on 
fluorescence  anisotropy  over  a  range  of  fluorescently  labelled  DNA  (substrate) 
concentrations, as shown in  
Figure 3.23. 
 
   
Figure 3.23 Optimisation of the fluorescence anisotropy assay buffer system and assay 
volume 
Background corrected anisotropy versus labelled oligonucleotide concentration in 96 
(A)  and  384  (B)  well  plates.  Anisotropy  measured  in  H
2O  (filled  circles)  or  real-time 
break light Dam activity assay buffer
7 (open circles). 
Assay conditions: 0-200 nM hemimethylated oligonucleotide (ODN10), buffer as stated 
above. Total assay volume 100 (A) or 2 0 (B) µl, in 96 (A) or 384 (B) well plate, gain 
1450/1445 (A) or 1519/1518 (B), 25 °C. 
 
                                                
7 Real-time break light Dam activity assay buffer: [20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM 
DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9]. 
A  B J C McKelvie    Chapter 3   
  100   
Addition  of  the  detergent  Tween-20 to  assays  prepared in the  real-time  break  light 
Dam activity assay buffer in 96 well plates led to little change in non-specific binding, 
with  a  linear  relationship  between  labelled  ligand  concentration  and  fluorescence 
anisotropy  observed  down  to  10  nM  oligonucleotide  with  and  without  Tween-20 
(Figure 2.24). Although a slight increase in anisotropy was observed below 10 nM on 
the addition of Tween-20, the detergent was included in further assays to reduce the 
potential for increased aggregation and non-specific binding on enzyme addition. 
 
 
Figure 3.24 Fluorescence anisotropy assay optimisation of buffer additives 
Background  corrected  normalised  anisotropy  versus  labelled  oligonucleotide 
concentration  with  (filled  circles)  and  without  (open  circles)  Tween-20.  Anisotropy 
values normalised to minimum anisotropy = 0. 
Assay conditions: 0-200 nM hemimethylated oligonucleotide (ODN10), 0.1% Tween-20, 
20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 
7.9. Total assay volume 100 µl, in 96 well plate, gain 1450/1445, 25 °C. 
 
3.5.1.2  Enzyme stability 
Stability experiments carried out with Y. pestis and E. coli Dam (Section 3.3.1.1 and 
Chapter 2, Section 2.3.3.3) show both enzymes to undergo inactivation over extended 
assay time courses at 30 °C, with E. coli Dam stability approximately double that of Y. 
pestis  Dam.  Assessment  of  the  effect  of  this  inactivation  process  on  fluorescence 
anisotropy signal was achieved by monitoring assays containing Y. pestis Dam and E. 
coli Dam over time. A control experiment was also prepared containing a thermally 
stable Dam from the thermophile Pyrococcus horikoshii (expressed and purified by J.E. 
Harmer). 
 
For the thermally stable P. horikoshii Dam anisotropy remained relatively constant over 
time, however for both E. coli and Y. pestis Dam anisotropy decreased over time, with a 
faster rate of decay observed for Y. pestis Dam (Figure 3.25A). The addition of AdoHcy 
resulted  in  the  stabilisation  of  initial  anisotropy  signals  over  the  lifetime  of  the 
experiment  (Figure  3.25B),  suggesting  that  AdoHcy  has  a  stabilising  effect  on  the 
Dam:DNA complex. J C McKelvie    Chapter 3   
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Figure 3.25 Effect of enzyme stability on anisotropy 
Background subtracted anisotropy over time for Y. pestis (blue line) E. coli (black line) 
and P. horikoshii (red line) Dam in the absence (A) and presence (B) of AdoHcy. 
Assay  conditions:  0  or  500  nM  Dam,  0  or  50  nM  hemimethylated  oligonucleotide 
(ODN10), 0 (A) or 2 (B) mM AdoHcy, 5% DMSO, 0.1% Tween-20, 20 mM Tris, 80 mM 
NaCl,  8  mM  MgCl
2,  1  mM  DTT,  0.1  mg  ml
-1  BSA,  5%  glycerol,  pH  7.9.  Total  assay 
volume 100 µl, in 96 well plate, gain 2181/2212, 30 °C. 
 
The loss of anisotropy observed for E. coli and Y. pestis Dam in the absence of AdoHcy 
suggest  that  the  Dam:DNA  complex  is  dissociating  over  time,  possibly  due  to 
inactivation  of  the  enzyme.  The  rates  of  complex  dissociation  and  inactivation  are 
faster for Y. pestis Dam, consistent with a model in which enzyme inactivation leads to 
complex dissociation. These findings imply that Dam:DNA binding is regulated by the 
presence of the methyl donor AdoMet (in this case an AdoMet mimic, AdoHcy), which is 
in agreement with literature reports that AdoMet facilitates the formation of a specific 
Dam:DNA complex (99, 101, 105).   
 
Although P. horikoshii Dam shows better stability in the absence of AdoHcy than E. coli 
Dam,  the  latter  shares  a  much  higher  percentage  sequence  identity  (70.5%  versus 
31.4%) with Y. pestis Dam. E. coli Dam was therefore selected for use in fluorescence 
anisotropy assays due to its increased similarity to Y. pestis Dam. 
 
3.5.1.3  Substrate concentrations 
A fixed concentration of the fluorescently labelled ligand at a concentration close to K
D 
for the ligand:receptor complex (if known) is typically used for fluorescence anisotropy 
and  polarisation  experiments  (234).  Coffin  et  al.  have  reported  a  fluorescence 
polarisation method for assessing the binding of E. coli Dam in which they employed 
20 nM labelled substrate, with K
D
DNA values of 84 and 101 nM obtained in the presence 
of 50 µM sinefungin (103, 104). The use of a similar concentration of DNA in this case 
would therefore be valid, as K
M
DNA for E. coli Dam was determined as 28 nM with the 
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real-time  break  light  Dam  activity  assay  (Appendix  Section  9.5.2),  and  non-specific 
binding  has  been  shown  to  be  minimised  at  ODN10  concentrations  of  10  nM  and 
above (Section 3.5.1.1). 
 
Formation of a stable substrate:receptor complex for the determination of fluorescence 
anisotropy often requires the removal of a secondary substrate or co-factor to prevent 
turnover of substrate and subsequent product release. For a bi-substrate mechanism 
this process is relatively simple, with the unlabelled substrate removed from solution. 
As Dam has been shown to follow an ordered bi-bi mechanism in which AdoMet binds 
prior to the formation of a specific Dam:DNA complex (99, 101, 105), the removal of 
AdoMet could affect the observed K
D values. In addition, investigations into the affect 
of enzyme inactivation on anisotropy have shown that the addition of AdoHcy induces 
stabilisation  (Figure  3.25B).  Experiments  were  therefore  prepared  with  and  without 
AdoHcy, in order to assess the effect on both K
D and enzyme stability. 
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3.5.2 Validation 
Validation of the fluorescence anisotropy experiment was achieved by comparison of 
K
D
DNA values for E. coli Dam binding the hemimethylated hairpin ODN10 to K
D
DNA values 
reported in the literature. Anisotropy was monitored for assays containing a range of E. 
coli Dam concentrations, a fixed concentration of fluorescently labelled oligonucleotide 
(ODN10) and either 0 or 200 µM AdoHcy. Data were analysed using Equation 3.3A-C 
and K
D
DNA was determined as 141.5 ± 13.3 nM in the absence of AdoHcy, and 77.2 ± 
7.5 nM in the presence of AdoHcy. R
2 values for the fitting of data to Equation 3.3C 
were 0.997 and 0.977 respectively. 
 
 
Figure 3.26 Determination of E. coli Dam K
D
DNA from fluorescence anisotropy 
Fraction of substrate bound calculated using Equation 3.3A and B versus E. coli Dam 
concentration  in  the  absence  (filled  circles,  solid  line)  and  presence  (open  circles, 
dotted line) of AdoHcy. Data fitted to Equation 3.3C to determine K
D. 
Assay  conditions:  0-1000  nM  Dam,  0  or  20  nM  hemimethylated  oligonucleotide 
(ODN10), 0 or 200 µM AdoHcy, 5% DMSO, 0.1% Tween-20, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 100 µl, 
in 96 well plate, gain 2315/2366, 25 °C. 
 
The values of K
D
DNA compare well with those determined previously (84 and 101 nM 
(103,  104)),  and  the  addition  of  AdoHcy  appears  to  increase  binding  affinity 
approximately 2-fold. The fluorescence anisotropy assay therefore represents a viable 
method  for  studying  Dam:DNA  interactions  and  the  effect  of  inhibitors  on  these 
interactions. J C McKelvie    Chapter 3   
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3.5.3 DpnI fluorescence anisotropy assay 
To further investigate the substrate inhibition effects observed in the real-time break 
light Dam activity assay (Chapter 2, Section 2.3.6.2) the fluorescence anisotropy was 
adapted for monitoring the binding of the coupled restriction enzyme DpnI to hemi- 
and fully methylated DNA substrates. As a type II restriction enzyme,  DpnI requires 
magnesium  ions  for  catalytic  activity,  the  trapping  of  the  DNA:DpnI  complex  can 
therefore be achieved by omitting magnesium chloride from the assay buffer. It should 
however be noted that some type II restriction enzymes require magnesium ions to 
facilitate specific binding, and results should therefore be interpreted carefully (214, 
238). 
 
Initial experiments were carried out to determine K
D
DNA for both the hemi- (ODN10) and 
fully (ODN11) methylated substrates, with DpnI shown to have a higher affinity for fully 
methylated DNA over hemimethylated DNA, even in the absence of magnesium ions 
(Figure  3.27).  Comparisons  of  K
M
DNA  and  K
D
DNA  show  that  whilst  the  values  for  fully 
methylated  DNA  are  approximately  the  same,  the  values  for  hemimethylated  DNA 
differ greatly, with K
M
DNA approximately 8 times K
D
DNA (Table 3.3). 
 
 
Figure 3.27 Determination of DpnI K
D
DNA from fluorescence anisotropy 
Fraction  of  substrate  bound  calculated  using  Equation  3.3A  and  B  versus  DpnI 
concentration for hemimethylated (filled circles, solid line) and fully methylated (open 
circles, dotted line) DNA. Data fitted to Equation 3.3C to determine K
D. 
Assay  conditions:  0-1000  nM  DpnI,  0  or  20  nM  hemimethylated  (ODN10)  or  fully 
methylated (ODN11) oligonucleotide, 0.1% Tween-20, 20 mM Tris, 80 mM NaCl, 1 mM 
DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 100 µl, in 96 well plate, 
gain 2120/2145, 25 °C. 
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Table 3.3 DpnI kinetic parameters for hemimethylated and fully methylated DNA 
Kinetic Parameter  Hemimethylated DNA  Fully methylated DNA 
K
M/nM  653 ± 27  14.1 ± 2.3 
k
cat/s
-1  0.0228 ± 0.0009  0.668 ± 0.028 
K
D/nM  77.8 ± 3.6  9.02 ± 0.63 
As determined from Figure 2.21 and Figure 3.27. 
 
To  probe  the  substrate  binding  effect  observed  for  the  real-time  break  light  Dam 
activity assay, a competition binding experiment was prepared to determine the effects 
of increasing concentrations of unlabelled hemimethylated substrate on the binding of 
DpnI  to  the  labelled  fully  methylated  substrate.  Fraction  of  substrate  bound  was 
calculated using the ligand binding calibration curve constructed for Figure 3.27 (fully 
methylated  DNA)  and  a  plot  of  fraction  of  substrate  bound  against  unlabelled 
hemimethylated  DNA  concentration  was  fitted  to  Equation  3.4A  to  determine  the 
competition binding constant. 
 
Figure 3.28 Hemimethylated DNA competition binding curve for DpnI  
Fraction  of  substrate  bound  calculated  using  Equation  3.3A  and  B  (ligand  binding 
curve  as  for  Figure  3.27,  fully  methylated  DNA)  versus  ODN12  concentration.  Data 
fitted to Equation 3.4 to determine competition binding constant. 
Assay conditions: 500 nM DpnI, 0-1000 nM unlabelled hemimethylated oligonucleotide 
(ODN12),  0 or 20 nM labelled fully methylated oligonucleotide (ODN11), 0.1% Tween-
20, 20 mM Tris, 80 mM NaCl, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total 
assay volume 100 µl, in 96 well plate, gain 2120/2145, 25 °C. 
 
Addition of an excess of hemimethylated DNA to a fully methylated DNA:DpnI complex 
resulted  in  partial  displacement  of  the  fully  methylated  DNA  from  DpnI,  with  a 
competition binding constant of 49.4 ± 5.3 nM (Figure 3.28). In the real-time break 
light  Dam  activity  assay,  high  concentrations  of  hemimethylated  DNA  are  therefore 
likely  to  lead  to  the  preferential  binding  of  DpnI  to  the  hemi-  rather  than  the  fully J C McKelvie    Chapter 3   
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methylated  substrate,  with  the  low  k
cat  of  DpnI  for  the  hemimethylated  substrate 
resulting in the formation of a pseudo-dead-end complex. DpnI is then released only by 
the relatively slow non-specific cleavage of the hemi-methylated substrate (Table 3.3, 
Figure 3.29). 
 
 
Figure 3.29 Sequestration of DpnI by hemimethylated DNA 
Where E = DpnI, D
m = fully methylated DNA, ED
m = DpnI:fully methylated DNA complex, 
ED
mc = DpnI:cleaved fully methylated DNA complex, D
mc = cleaved fully methylated DNA, 
D = hemimethylated DNA, ED = DpnI:hemimethylated DNA complex, ED
c = DpnI:cleaved 
hemimethylated DNA complex, D
c = cleaved hemimethylated DNA. Pseudo-dead-end ED 
complex boxed. 
 
The apparent substrate inhibition observed in the real-time break light Dam activity 
assay is therefore probably due to the sequestration of the coupling enzyme (DpnI) by 
the  substrate  for  the  primary  enzyme  (hemimethylated  DNA).  Whilst  increasing  the 
concentration of DpnI added to the assay would alleviate this problem, the associated 
increase  in  non-specific  cleavage  would  severely  reduce  the  screening  window  by 
decreasing the signal:noise ratio. Limiting DNA concentrations in the real-time break 
light Dam activity assay to concentrations close to K
M
DNA for Dam is therefore the best 
way to alleviate this effect. 
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3.6 In culture Dam activity assays 
 
A major factor in the success of drug candidates is compound bioavailability, i.e. the 
rate  and  extent  to  which  the  active  ingredient  or  moiety  is  absorbed  and  becomes 
available  at  the  site  of  action.  Efforts  within  the  pharmaceutical  industry  to  better 
assess and understand the pharmacokinetic properties of lead compounds, has led to 
a significant reduction in the rate of attrition due to poor bioavailability in recent years 
(239).  Cell  permeability  is  a  significant  contributor  to  the  bioavailability  of  a 
compound, and can be assessed in simple culture based assays. 
 
For a bacterial target such as Dam, the ability of a compound to permeate the bacterial 
cell and reach the target of interest unhindered by efflux pumps or degradation can be 
assessed by monitoring the effect of the compound on the intrecellular activity of the 
biological  target.  The  viability  of  dam  knockout  E.  coli  strains  and  the  wide-spread 
availability of non-pathogenic laboratory strains of E. coli make the bacterium ideal for 
use as a model system.  
 
The methylation state of E. coli cells grown in media supplemented with an in vitro 
inhibitor  can  be  compared  with  control  assays  prepared  with  no  inhibitor,  with  the 
percentage of methylated adenine providing a measure of Dam activity. Both genomic 
and plasmid DNA can be assessed, with N6-methyladenine concentration quantified by 
gel-based  methods  using  methylation  sensitive  restriction-digest,  or  by  HPLC-based 
analysis of individual nucleotide concentrations. In addition to measuring the effect of 
in vitro inhibitors on the in cell methylation of adenine, off-target toxicity can also be 
assessed by monitoring E. coli growth curves. 
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3.6.1 In culture gel-based plasmid methylation activity assay 
An in culture activity assay was designed utilising the previously discussed gel-based 
methylation  assay  format  (Section  3.3).  E.  coli  were  transformed  with  a  plasmid 
containing a methylation sensitive restriction site and cultured in media supplemented 
with  or  without  an  in  vitro  inhibitor.  The  degree  of  plasmid  methylation  was  then 
measured  by  restriction  digest  analysis,  with  results  visualised  by  agarose  gel 
electrophoresis (Figure 3.30). 
 
 
Figure 3.30 In culture gel-based plasmid methylation assay 
A  plasmid  harboured  by  E.  coli  cells  is  methylated  and  isolated  plasmid  DNA  is 
protected  from  Dam  cleavage.  In  the  presence  of  a  cell-permeable  Dam  inhibitor 
methylation is blocked and isolated plasmid is cleaved by both XhoI and BclI. Results 
are  detectable  by  agarose  gel  electrophoresis,  where  a  single  band  represents  an 
unmethylated plasmid, three bands represent a partially methylated plasmid, and two 
bands represent an unmethylated plasmid. 
 
3.6.1.1  Optimisation of assay volume 
Minimisation of compound quantity required per assay was achieved by minimising cell 
culture volume. Assays containing the dam knockout E. coli strain ER2925 transformed 
with plasmid pRL821 (Figure 3.5) were prepared in 12 well microplates containing 1-4 
ml of culture medium and the amount of plasmid isolated after 15 hrs was quantified 
by agarose gel electrophoresis after digestion with the methylation sensitive restriction 
enzyme BclI.  
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Plots of OD
600 and plasmid DNA concentration after 15 hrs against cell culture volume 
(Figure 3.31A and B) showed both to decrease with increasing volume. This is most 
likely due to a decrease in culture aeration with increasing volume. An assay volume of 
1  ml  was  therefore  selected as optimal  for  methylation  assays to  minimise  reagent 
costs and maximise plasmid yield. 
 
     
Figure 3.31 In culture gel-based plasmid methylation assay volume optimisation 
A: OD
600 at 15 hrs for pRL821 transformed ER2925 cultures of 1-4 ml volume. 
B:  Plasmid  DNA  concentration  for  plasmid  isolated  from  cultures  of  1-4  ml  volume 
grown for 15 hrs. 
Assay conditions: 1, 2, 3 or 4 ml 2YT media, 100 µg ml
-1 ampicillin, 1% innoculum of 
ER2925  harbouring  pRL821.  Total  assay  volume  1-4  ml, temperature 37  °C,  orbital 
shaking  at  200  rpm  for  5  out  of  every  10  min.  Plasmid  isolated  after  15  hrs  and 
digested with 7.5 U µl
-1 BclI, 1 hr, 50 °C. Digested plasmid analysed by 0.8% agarose gel 
electrophoresis, bands quantified using the program ImageJ (227). 
 
3.6.1.2  Optimisation of assay end-point 
The  optimal  time  for  plasmid  isolation  was  identified  by  monitoring  the  growth  of 
pRL821 transformed E. coli TOP10 and ER2925. Stationary growth was reached after 
approximately 10 hrs, with ER2925 cells growing to a lower final OD
600 than TOP10 
cells (Figure 3.32). Plasmid was isolated after 5 hrs and digested with the restriction 
enzymes XhoI and BclI. Plasmid isolated from the Dam
+ strain (TOP10) gave a single 
band on the agarose gel, consistent with complete methylation of pRL821, whereas 
plasmid isolated from the Dam
- strain (ER2925) gave two bands, consistent with no 
methylation of pRL821. 
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To ensure plasmid isolation was timed to occur during the exponential growth phase, 
an assay end-point of 5 hrs was selected. This corresponded to approximately half way 
through exponential growth. Plasmid DNA isolated after 5 hrs was of a high enough 
concentration  to  be  readily  analysed  by  restriction  digest  and  agarose  gel 
electrophoresis,  with  the  assessment  of  plasmids  grown  in  Dam
+  and  Dam
-  E.  coli 
strains validating the assay as a method for identifying Dam inhibition. 
 
 
Figure 3.32 In culture gel-based plasmid methylation assay end-point optimisation 
0.8% agarose gel electrophoresis of analytical digests of plasmids isolated from TOP10 
(1-4) and ER2925 (5-8) E. coli after 5 hrs (left) and OD
600 versus time for TOP10 (black) 
and ER2925 (red) E. coli monitored over 5 (solid lines) or 10 (dotted line) hours. 
(L): ladder, (1-4): E. coli TOP10, (5-8): E. coli ER2925. 
Assay conditions: 1 ml 2YT media, 100 µg ml
-1 ampicillin, 5% DMSO, ER2925 or TOP10 
harbouring pRL821 to a final OD
600 of 0.05. Total assay volume 1 ml, temperature 37 
°C, orbital shaking at 400 rpm for 5 out of every 10 min. Plasmid isolated after 5 hrs 
and digested with 10 U µl
-1 XhoI, 1 hr, 37 °C and 7.5 U µl
-1 BclI, 1 hr, 50 °C. Digested 
plasmid  analysed  by  0.8%  agarose  gel  electrophoresis,  bands  quantified  using  the 
program ImageJ (227). 
 
3.6.1.3  Growth curve analysis 
A possible limitation of this assay is that a small proportion remains active but is stil 
sufficient  to  catalyse  the  total  methylation  of  the  plasmid  substrate,  and  so  partial 
inhibition  may  not  be  detectable  by  this  method.  However,  growth  curves  for  an 
isogenic pair of Dam
+ and Dam
- E. coli (BW25113 and JW3350-2) show that a lack of 
Dam depresses cell growth (Figure 3.33). A decrease in E. coli growth in the presence 
of  an  inhibitor  may  therefore  be  a  useful  indicator  of  Dam  inhibition,  and  by 
association, cell permeability. 
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Figure 3.33 Growth curves for isogenic Dam
+ and Dam
- E. coli strains 
OD
600 normalised to a start OD
600 of 0.05 against time for BW25113 (black) and JW3350-
2 (red) E. coli monitored over 5 hours. 
Assay conditions: 1 ml 2YT media, 0 (BW25113) and 10 (JW3350-2) µg ml
-1 kanamycin, 
5% DMSO, E. coli BW25113 or JW3350-2 to a final OD
600 of 0.05. Total assay volume 1 
ml, temperature 37 °C, orbital shaking at 180 rpm for 5 out of every 10 min. 
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3.6.2 In culture HPLC-based genomic DNA methylation assay 
A second in culture methylation assay was developed to assess the methylation state 
of genomic DNA, again using E. coli as a model system. Genomic DNA isolated from E. 
coli cells cultured in media supplemented with an in vitro inhibitor is digested with 
Nuclease P1, isolated from Penicillium citrinum. The resulting 2‟-deoxyribonucleotide 
monophosphates (dNMPs) can then be quantified by HPLC analysis (Figure 3.34). 
 
 
Figure 3.34 In culture HPLC-based genomic DNA methylation assay 
Genomic DNA is isolated from E. coli cells cultured in media supplemented with an in 
vitro  Dam  inhibitor.  Genomic  DNA  is  isolated  and  digested  with  Nuclease  P1,  the 
concentrations of the resulting dNMPs are determined by HPLC. 
 
Digestion  of  genomic  DNA  into  dNMPs  can  be  easily  achieved  with  the  addition  of 
Nuclease P1 to denatured genomic DNA samples. The subsequent application of an 
ion-pairing methodology allows the dNMPs to be separated with good resolution on a 
reverse-phase  HPLC  column,  through  the  addition  of  an  ion-pairing  reagent,  N,N-
dimethylhexylamine (DMHA), to column chromatography wash buffers (Figure 3.35) 
(240). 
 
 
Figure 3.35 Ion-pairing interaction between DMHA and a dNMP 
 
3.6.2.1  Optimisation of genomic DNA isolation and HPLC buffer gradient 
E.  coli  genomic  DNA  was  isolated  from  overnight  cultures  of  BW25113  (Dam
+)  and 
JW3350-2  (Dam
-)  with  a  Qiagen  Gentra  Puregene  Yeast/Bacteria  kit  as  per  the 
manufacturer‟s instructions. Heat denatured DNA was then digested with nuclease P1 
and  analysed  by  HPLC.  Initial  results  showed  impurities  in  the  HPLC  trace  of  the 
genomic  DNA  samples  relative  to  a  set  of  standards  (Figure  3.36A).  Further 
optimisation showed these impurities to be removed by modifying the genomic DNA 
isolation procedure. Inclusion of an extended RNA digestion step, in which an excess 
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purity,  suggesting  that  the  impurities  observed  were  nucleotide  monophosphates 
(Figure 3.36B). 
 
         
 
Figure 3.36 Genomic DNA isolation and HPLC buffer gradient optimisation 
A and B: HPLC trace of genomic DNA digests following isolation as per manufacturer‟s 
instructions (A) and with extended RNase digest (B). dNMP standards (black line): 2'-
deoxycytidine-5'-monophosphate  (10.4  min),  2'-deoxyguanosine-5'-monophosphate 
(14.2  min),  2'-thymidine-5'-monophosphate  (15.5  min),  2'-deoxyadenosine-5'-
monophosphate (33.4). Genomic DNA isolated from E. coli BW25113 (Dam
+) (blue line) 
and E. coli JW3350-2 (Dam
-) (red line). MeOH gradient 1 (A) and 2 (B) shown as dotted 
black line. Signal normalised to maximum = 1 for each trace. 
C:  HPLC  trace  of  dNMP  standards  2‟-deoxyadenosine-5'-monophosphate  (black  line) 
and 2‟-deoxy-N6-methyladenosine-5'-monophosphate (red line). 
Assay conditions: A – gradient 1, 12.5-42.5% MeOH over 26 min, 80 µl injection, 100 
µM  dNMP  standards.  B  and  C  –  gradient  2,  8.75-42.5%  MeOH  over  38  min,  80  µl 
injection, 100 µM dNMP standards. 
 
The  HPLC  buffer  gradient  was  optimised  to  improve  resolution  between  individual 
dNMP peaks, with an increase in the length of the gradient from 12.5-42.5% MeOH over 
26 minutes (gradient 1, Figure 3.36A) to 8.75-42.5% MeOH over 38 min (gradient 2, 
Figure  3.36B)  resulting  in  enhanced  resolution.  The  resolution  between  the  2'-
deoxyadenosine-5'-monophosphate  (dAMP)  and  the  2‟-deoxy-N6-methyladenosine-5'-
monophosphate  (dmAMP)  peaks  was  also  assessed  to  confirm  that  the  two  dNMPs 
could be completely resolved (Figure 3.36C).  
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3.6.2.2  Determination of detection limits 
A  dmAMP  standard  was  serial  diluted  and  analysed  by  HPLC.  Peak  areas  were 
integrated  to  determine  area,  and  background  subtracted  peak  areas  were  plotted 
against dmAMP concentration to determine the detection limit for the assay (Figure 
3.37).  Fitting  a  straight  line  of  the  form  f=y
0+a*x  to  the  data  showed  the  x-axis 
intercept to be at 0.317 µM, correlating to a dmAMP detection limit of 25.4 pmoles. 
This  plot  can  also  be  used  as  a  calibration  curve,  with  the  gradient  (772851  area 
units/µM) linking integrated peak area and dmAMP concentration. 
 
 
Figure 3.37 Determination of in culture HPLC-based genomic DNA methylation assay 
detection limit 
Background  subtracted  peak  areas  against  dmAMP  concentration.  Data  fitted  to  a 
linear equation of the form f=y
0+a*x, where y
0 = the y-axis intercept and a = the line 
gradient. 
Assay conditions: HPLC gradient of 8.75-42.5% MeOH over 38 min, 80 µl injection, 0-
100 µM dmAMP standard. 
 
An estimated 2% of adenine bases are methylated in E. coli (241), therefore, assuming 
an equal ratio of the four unmethylated bases and an average dNMP molecular weight 
of 325 g mol
-1, the minimum amount of genomic DNA required for the detection of 
dmAMP is 1.65 µg. Approximately 15 times this amount of DNA (25 µg) is purified on 
average  from  0.5  ml  of  gram-negative  bacteria  culture  using  the  Qiagen  Gentra 
Puregene Yeast/Bacteria kit.  This experiment therefore suggests that in principle, it 
should be possible to quantify the extent of N6-adenine methylation in cultures of E. 
coli grown in media supplemented with or without an in vitro inhibitor. 
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3.7 Summary 
 
Counter-screening  and  hit  confirmation  assays  have  been  developed  to  permit  the 
elimination  of  false  positives  which  inhibit  DpnI,  intercalate  DNA,  or  interfere  with 
assay signal. A selectivity assay has also been developed for the human cytosine DNA 
methyltransferase DNMT1 to eliminate relatively non-specific hits with potentially toxic 
off-target effects due to non-selective modes of inhibition. The introduction of assays 
employing plasmid and genomic DNA substrates has enabled the effect of inhibitors 
on Dam to be assessed with substrate closer to those naturally methylated by Dam, 
whilst in culture assays have been developed to determine the ability of compounds to 
permeate cells and inhibit intracellular Dam. 
 
The development of a fluorescence anisotropy assay for the investigation of enzyme-
DNA binding interactions has ensured that investigation of the effect of inhibitors on 
such  interactions  is  unhindered  by  the  apparent  substrate  inhibition  observed  at 
concentrations of DNA above K
M in the real-time break light Dam activity assay. The 
fluorescence anisotropy assay has also provided further insight into the mechanism of 
this effect, with the sequestration of the coupling enzyme DpnI by the substrate for the 
primary enzyme being identified as the likely mechanism of the inhibition observed.   
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4  High-throughput Screening 
 
4.1 Introduction 
 
Previous HTS campaigns for the identification of Dam inhibitors have included an in 
silico  screen  of  the  NCI/DTP  open  access  library  (151),  a  50,000-compound  small 
molecule library screen (149), and a genetic selection screen of a cyclic peptide library 
(150).  Dam  inhibitors  were  identified  from  all  three  screens,  with  the  50,000-
compound small molecule library yielding the most potent compounds (57 compounds 
with IC
50 values of 25 µM or less). 
 
The majority of pharmaceutical companies involved in drug discovery have their own in 
house compound libraries. Academic research facilities however are generally reliant 
on  external  resources,  which  can  be  both  time-consuming  and  costly.  Open  access 
repositories,  such  as  the  NCI/DTP  open  chemical  repository  (http://dtp.cancer.gov), 
represent  a  rich  source  of  compounds  available  at  minimal  cost  to  the  researcher, 
making HTS accessible to the wider scientific community. 
 
A  random  library  approach  to  HTS  was  initially  adopted  for  this  project,  with  the 
specific aim of identifying lead compounds which could later be incorporated into a 
rational  design  approach.  The  development  of  a  real-time  break  light  Dam  activity 
assay and its subsequent optimisation for HTS enabled compounds to be screened in a 
high-throughput format, with secondary assays available for hit confirmation and the 
assessment  of  selectivity,  potency  and  mode  of  action.  The  calculation  of  Z‟-values 
throughout HTS allowed assay quality to be monitored, whilst defining the screening 
window for the identification of hits. 
 
The  following  chapter  describes  the  HTS  of  two  compound  libraries,  and  the 
subsequent biochemical characterisation of hits identified from each screen. 
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4.2 The Developmental Therapeutics Program library 
 
A 3,082-compound library was obtained from the NCI/DTP open chemical repository in 
plated form for screening. Of the compounds selected: 221 originated from a natural 
product  derived  set,  and  were  selected  based  on  their  structural  diversity  and 
availability; 1,974 were selected based on the identification of diverse pharmacophores 
using the Chem-X program (Chemical Design, Oxford); 827 were selected to represent 
a broad range of human tumour cell growth inhibition patterns; and 60 were selected 
from compounds inducing unusual patterns of cell line sensitivity and resistance in the 
DTP human tumour cell line assay (242). 
 
Screening conditions were selected based on the optimisation of the real-time break 
light Dam activity assay, as discussed in Chapter 2, and are presented in Table 4.1, 
below. Further information on HTS set-up can be found in Appendix Section 9.7. 
 
Table 4.1 DTP library screening conditions 
Parameter  Screening Conditions 
Buffer  [20 mM Tris, 80 mM sodium chloride, 8 mM magnesium 
chloride, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9] 
Substrate concentrations  Hemimethylated oligonucleotide ODN1 = 10 nM 
AdoMet = 25 µM 
Enzyme concentrations  Y. pestis Dam = 1 nM 
DpnI = 2 nM 
Compound concentration  25 µM 
Final DMSO concentration  5% 
Volume  20 µl (384 well plate) 
Assays/set*  96 (80 compounds, 16 controls
#) 
Temperature  30 °C 
* Assays/set refers to the total number of assays to be run at one time. 
# 8 positive (lacking library compound) and 8 negative (lacking library compound and 
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4.2.1 Dam Screen 
The 3,082-compound DTP library was screened in duplicate against Y. pestis Dam with 
the real-time break light Dam activity assay. Hits were identified as compounds with 
initial rates falling outside three standard deviations from the positive control average 
in  both  the  initial and  duplicate  screens.  Compounds  identified as  hits  in  only  one 
screen, with a CV in initial rate over both screens of 5% or less, were classed as weak 
borderline hits and discarded. Compounds identified as hits in only one screen, with 
an initial rate CV over both screens of greater than 5% were re-tested. 
 
A total of 242 potential hits  were identified in the initial and duplicate screens. Of 
these,  33  were  classed  as  borderline  hits  and  a  further  63  were  eliminated  by  a 
triplicate screen, giving a final total of 146 screening hits and a hit rate of 4.7%. Assay 
reproducibility and quality during screening was assessed by measuring the activity of 
over 300 control assays, with the results showing the assay to be highly reproducible 
(CV ~10%) with a good to excellent screening window (Z‟-value ~0.65) and low non-
specific activity (Table 4.2). 
 
Table 4.2 Statistical analysis of assay reproducibility and quality during HTS 
  CV*  Non-specific Activity#  Z’-value† 
Initial Screen
‡  10.5 ± 3.5%  5.46 ± 1.93%  0.63 ± 0.12 
Duplicate Screen
‡  9.07 ± 2.43%  3.85 ± 1.12%  0.69 ± 0.08 
* Calculated from the average  and standard deviation of the positive controls using 
Equation 2.1. 
# Calculated from the average of the positive and negative controls using Equation 4.1. 
†  Calculated  from  the  average  and  standard  deviation  of  the  positive  and  negative 
controls using Equation 2.2, given to 2 decimal places. 
‡ Data from 39 sets of 8 positive and 8 negative controls. 
 
100
c
c+
 
Equation 4.1 Non-specific activity 
Where µ
c- = the average of the negative controls and µ
c+ = the average of the positive 
controls. 
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4.2.2 Counter-screening 
4.2.2.1  DpnI 
Elimination  of  false  positives  and  non-selective  inhibitors,  with  activity  against  the 
coupling enzyme DpnI, was achieved by screening the 146 hits identified from the real-
time break light Dam activity assay in triplicate against  DpnI. Compounds found to 
inhibit DpnI by greater than three standard deviations from the average of the positive 
controls in two or more screens were eliminated, leaving a total of 26 compounds. 
 
4.2.2.2  FID 
The remaining 26 compounds were screened in an FID assay to assess their ability to 
displace thiazole orange  from  DNA.  Compounds  found  to  decrease  fluorescence by 
greater than three standard deviations from the average of the positive controls in a 
single  concentration  point  assay  were  eliminated,  leaving  a  total  of  six  viable  hits 
(Figure 4.1). 
 
 
Figure 4.1 Structures of the DTP library hits 
Structures of viable hits from screening and counter-screening. Number in bold = DTP 
NSC identifier. J C McKelvie    Chapter 4 
  121   
4.2.3 Hit Validation 
4.2.3.1  Extended FID assays 
FID assays were prepared at a range of compound concentrations to identify any partial 
or weak DNA intercalation activity. The closely related compounds 10460 and 93739 
were shown to displace thiazole orange at higher concentrations than employed in the 
FID counter-screen and were discarded (Figure 4.2). In addition, compound 109268 
was found to be poorly soluble under assay conditions, with precipitate visible to the 
naked  eye  when  assays  were  prepared  in  colourless  reaction  vessels,  109268  was 
therefore also discarded as an unsuitable lead.  
 
   
Figure 4.2 Fluorescent intercalator displacement by compounds 10460 and 93739 
Increasing  concentration  of  compounds  10460  (A)  and  93739  (B)  plotted  against 
percentage  fluorescence  decrease  relative  to  a  positive  control.  Data  fitted  to  a 
hyperbola of the form f=a*x/(b+x). 
Assay conditions: 100 nM unlabelled unmethylated oligonucleotide (ODN3), 500 nM 
thiazole orange, 0-1000 µM compound, 10% DMSO, 100 mM Tris, 100 mM NaCl, pH 
7.9. Total assay volume 20 µl, in 384 well plate, gain 255, 25 °C. 
 
4.2.3.2  Purity 
FID  assays  of  compound  88915  were  inconclusive  due  to  interference  from 
background  fluorescence  in  the  sample.  The  chemical  structure  of  88915  is  not 
consistent  with  the  observed  spectral  properties;  the  purity  of  the  sample  was 
therefore investigated by TLC. Separation of four different compounds was achieved in 
100%  methanol,  suggesting  the  presence  of  at  least  three  impurities  in  compound 
88915. Whilst the separation of the various components may be possible, the limited 
availability  (milligram  quantities)  of  88915  makes  the  identification  of  the  active 
component extremely difficult, consequently the compound was discarded. 
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4.2.3.3  Compound 166687 
Compound  166687  (bis(8-hydroxyquinoline-5-sulfonic  acid)  zinc(II))  is  comprised  of 
two  molar  equivalents  of  8-hydroxy-quinoline-5-sulphonic  acid  (HQSA)  bound  to  a 
central zinc ion. Each component of the complex was assayed alongside 166687, at a 
range of concentrations against  Y. pestis Dam  and  DpnI, in  order to determine IC
50 
values. The IC
50 of 166687 was determined as 25.9 ± 5.0 µM for Dam and 96.4 ± 23.3 
µM for DpnI, however HQSA was found to have no inhibitory effect on either enzyme, 
whilst the IC
50 of zinc chloride was determined as 9.79 ± 1.52 µM for Dam and 17.5 ± 
3.21 µM for DpnI (Figure 4.3). 
 
   
Figure 4.3 IC
50 Dam and DpnI determinations for 166687, HQSA and zinc chloride 
Fractional  activity,  calculated  using  Equation  2.6A  versus  concentration  of  166687 
(filled circles), HQSA (open circles) and zinc chloride (filled triangles) for Dam (A) and 
DpnI (B). Data fitted to Equation 2.6B for 166687 (solid line), HQSA (dotted line) and 
zinc chloride (dashed line). 
Assay  conditions:  0.3  or  0  nM  Y.  pestis  Dam,  2  nM  or  12.5  pM  DpnI,  3.5  nM 
hemimethylated  oligonucleotide  (ODN1)  or  15  nM  fully  methylated  oligonucleotide 
(ODN2), 0 or 16 µM AdoMet, 0-1000 µM compound, 5% DMSO, 20 mM Tris, 80 mM 
NaCl,  8  mM  MgCl
2,  1  mM  DTT,  0.1  mg  ml
-1  BSA,  5%  glycerol,  pH  7.9.  Total  assay 
volume 20 µl, in 384 well plate, gain 190 or 170, 30 °C. 
 
The decrease in IC
50 for zinc chloride over 166687 and the lack of inhibition by HQSA 
suggests that the inhibition observed for 166687 was due to the release of zinc ions in 
solution,  and  not  to  the  overall  complex.  Divalent  zinc  ions  have  a  radius  of 
approximately 0.74 Å, similar to that of divalent magnesium ions (0.71 Å) (243), which 
are required for the catalytic activity of DpnI (244). The inhibition of DpnI by zinc ions 
may therefore be due to competitive binding at the catalytic site, blocking the binding 
of magnesium ions and preventing DNA cleavage. The important role of zinc in many 
cellular processes (245) and the inhibitory effect on DpnI suggest that 166687 would 
be a poor lead, and as such the compound was excluded from further investigations. 
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4.2.4 Compound 13776 
The  potency  of  the  remaining  compound,  (4-(N-(2-hydroxyethyl)sulfamoyl)phenyl) 
stibonic acid (13776) was determined for both Y. pestis Dam and DpnI. The IC
50 value 
for Y. pestis Dam was found to be 3.26 ± 1.14 µM and for DpnI the value was greater 
than the detection limit of the experiment (10 µM) (Figure 4.4). Although an IC
50 was 
not  determined  for  DpnI,  some  inhibition  is  observed  (Figure  4.4);  however,  the 
potency  of  the  compound  for  Y.  pestis  Dam  is  clearly  higher,  suggesting  some 
selectivity for Dam over DpnI. 
 
 
Figure 4.4 IC
50
13776 determination for Dam and DpnI 
Fractional activity, calculated using Equation 2.6A, versus concentration of 13776 for 
Dam (filled circles) and DpnI (open circles). Data fitted to Equation 2.6B for Dam. 
Assay  conditions:  0.3  or  0  nM  Y.  pestis  Dam,  2  nM  or  12.5  pM  DpnI,  3.5  nM 
hemimethylated  oligonucleotide  (ODN1)  or  15  nM  fully  methylated  oligonucleotide 
(ODN2), 0 or 16 µM AdoMet, 0-1000 µM compound, 5% DMSO, 20 mM Tris, 80 mM 
NaCl,  8  mM  MgCl
2,  1  mM  DTT,  0.1  mg  ml
-1  BSA,  5%  glycerol,  pH  7.9.  Total  assay 
volume 20 µl, in 384 well plate, gain 190 or 170, 30 °C. J C McKelvie    Chapter 4 
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4.3 The University of Cincinnati library 
 
An  alternative  approach  to  minimising  cost  whilst  maximising  the  potential  for 
identifying  a  suitable  lead,  is  to  use  in  silico  screening  methods  to  reduce  large 
compound  libraries  to  small  focussed  sets.  By  employing  a  pharmacophore-based 
screening approach Dr M. Bodkin (Lilly, UK) was able to “cherry-pick” 3,193 compounds 
with structural similarities to AdoMet and adenine from the University of Cincinnati‟s 
drug discovery library (>250,000 compounds). Due to availability a total of 2,445 of 
these  compounds  were  obtained  and  employed  in  a  second  HTS  campaign  for  the 
identification of Y. pestis Dam inhibitors. 
 
HTS  conditions  were  re-assessed  following  the  DTP  library  screen  and  substrate 
concentrations were reduced by 20% in order to conduct screening at concentrations 
closer to K
M whilst maintaining an acceptable screening window. In addition, compound 
concentration was increased from 25 to 50 µM to increase hit rates and improve the 
possibility of identifying a viable lead. A Z‟-value of 0.68 was determined under the re-
optimised assay conditions (Table 4.3), close to the value of 0.71 determined under 
the previous HTS conditions.  
 
Table 4.3 University of Cincinnati library screening conditions 
Parameter  Screening Conditions 
Buffer  [20 mM Tris, 80 mM sodium chloride, 8 mM magnesium 
chloride, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9] 
Substrate concentrations  Hemimethylated oligonucleotide ODN1 = 8 nM 
AdoMet = 20 µM 
Enzyme concentrations  Y. pestis Dam = 1 nM 
DpnI = 2 nM 
Compound concentration  50 µM 
Final DMSO concentration  5% 
Volume  20 µl (384 well plate) 
Assays/set*  96 (80 compounds, 16 controls
#) 
Temperature  30 °C 
* Assays/set refers to the total number of assays to be run at one time. 
# 8 positive (lacking library compound) and 8 negative (lacking library compound and 
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4.3.1 Dam screen 
The in silico enriched University of Cincinnati library was screened in duplicate against 
Y. pestis Dam and hits were identified as described in Section 4.2.1. Hits identified in 
either the initial or duplicate screen were carried through for counter-screening and 
validation,  giving  a  total  of  102  potential  hits  (69  of  which  were  identified  in  both 
screens), and a hit rate of 4.2%, comparable to that of the DTP library screen.  
 
The  reproducibility  and  quality  of  the  assay  were  assessed  by  monitoring  control 
assays, with an average CV, Z‟-value and non-specific activity of 12.4%, 0.59 and 2.44% 
determined respectively (Table 4.4). Compared with the DTP library the CV is slightly 
higher and the non-specific activity and Z‟-value are both slightly lower, as would be 
expected  due  to  the  decrease  in  substrate  concentrations.  However,  the  values 
obtained are still indicative of a highly reproducible assay with a low background and 
good screening window. 
 
Table 4.4 Statistical analysis of assay reproducibility and quality during HTS II 
  CV*  Non-specific Activity#  Z’-value† 
Initial Screen
‡  11.8 ± 3.6%  2.51 ± 0.46%  0.60 ± 0.11 
Duplicate Screen
‡  12.9 ± 4.2%  2.37 ± 0.61%  0.57 ± 0.13 
* Calculated from the average and standard deviation of the positive controls using 
Equation 2.1. 
# Calculated from the average of the positive and negative controls using Equation 4.1. 
†  Calculated  from  the  average  and  standard  deviation  of  the  positive  and  negative 
controls using Equation 2.2 given to 2 decimal places. 
‡ Data from 31 sets of 8 positive and 8 negative controls. 
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4.3.2 Counter-screening 
4.3.2.1  DpnI 
Due to the decreased concentration of DNA employed in the Dam screen a second DpnI 
concentration optimisation was completed (Figure 4.5). An upper DpnI concentration 
limit of 25 pM was identified, as with the previous optimisation (Chapter 3, Section 
3.2.1). However, to maximise assay signal, DpnI concentration was increased to this 
upper limit (25 pM) for the University of Cincinnati library coupling enzyme counter-
screen. 
 
 
Figure 4.5 DpnI counter-screen effective assay range II 
Background subtracted initial rate of cleavage by DpnI. Data points from 0-12.5 pM 
DpnI fitted to a linear equation of the form f=y
0+a*x. 
Assay conditions: 0-100 pM  DpnI,  8 nM fullymethylated oligonucleotide (ODN2),  5% 
DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, 
pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 170, temperature 30 °C. 
 
The 102 hits identified in the Dam screen were counter-screened in duplicate against 
DpnI, identifying a total of 69 compounds which inhibited the coupling enzyme by 50% 
or  more  in  either  screen.  These  false  positives  and  non-selective  inhibitors  were 
eliminated, leaving a total of 33 compounds. 
 
4.3.2.2  FID 
An  FID  screen  of  the  remaining  33  compounds  found  13  to  significantly  decrease 
thiazole orange fluorescence relative to a positive control (i.e. by greater than three 
standard  deviations  from  the  average  of  the  positive  controls),  suggesting  DNA 
intercalation activity. The DNA intercalators were discarded, leaving a total of 20 viable 
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4.3.3 Hit validation 
Of the 20 viable hits remaining after counter-screening, 9 were available to purchase 
commercially. Due to the limited quantities of library compounds available from the 
University of Cincinnati, and to ensure that compounds were pure and of the correct 
structure, only those available commercially were selected for further analysis (Figure 
4.6). 
 
 
Figure 4.6 Structures of the University of Cincinnati library hits 
Structures of the commercially available viable hits from the University of Cincinnati 
library  screen.  Compound  UC2  was  purchased  in  both  the  hydrated  (UC2)  and 
unsaturated (UC2-2) forms. 
 
4.3.3.1  Confirmation of activity 
Confirmation of the activity of the 11 purchased University of Cincinnati library hits 
(UC1-10 and UC2-2) was achieved by assessing their activity against E. coli Dam in the 
gel-based Dam methylation assay. Plasmid pRL821 was incubated with E. coli Dam and 
2 mM of each compound, the effects on methylation were then assessed by restriction 
digest and visualised by agarose gel electrophoresis. Controls containing no AdoMet 
(negative), 2 mM AdoHcy (inhibition), and no compound (positive) were also prepared.  J C McKelvie    Chapter 4 
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The results (Figure 3.9) showed compounds UC2, UC2-2, UC3, UC4, UC5 and UC10 
to strongly inhibit  E. coli Dam at 2 mM, compounds  UC1, UC7 and UC8 to  weakly 
inhibit E. coli Dam at 2 mM, and compounds UC6 and UC9 to have no effect on E. coli 
Dam methylation. 
 
 
 
Figure 4.7 Gel-based Dam activity assay of the University of Cincinnati library hits 
A and B: 0.8% agarose gel electrophoresis of Dam activity assay restriction digest for 
UC1-9 and UC2-2 (A) and UC10 (B). 
(L):  ladder,  (1):  negative  control  (lacking  AdoMet),  (2):  positive  control  (lacking 
compound), (3): inhibition control (with AdoHcy), (4-12 A): UC1-9, (13 A): UC2-2, (4 B): 
UC10. 
C: Fractional activity quantified from gel band intensity with Equation 2.6A. 
Assay conditions: 250 nM E. coli Dam, 3 nM plasmid (pRL821), 10 U µl
-1 XhoI, 7.5 U µl
-1 
BclI, 0 or 6 µM AdoMet, 0 or 2 mM compound, 5% DMSO, 50 mM Tris, 100 mM NaCl, 
10 mM MgCl
2, 1 mM DTT, pH 7.9. Step 1 (methylation) – total assay volume 20 µl, 
temperature 30 °C, 1 hr; Step 2 (denaturation) – total assay volume 20 µl, temperature 
95 °C, 5 min; Step 3 (cleavage) – restriction enzymes XhoI and BclI added, total assay 
volume 22 µl, temperature 37 °C, 1 hr and 50 °C, 1 hr. Digested plasmid analysed by 
0.8% agarose gel electrophoresis, bands quantified using the program ImageJ (227). 
A  B 
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The complete lack of inhibition observed for compounds UC6 and UC9 suggest that 
they  are  inactive  against  Dam,  whereas  all  other  compounds  tested  showed  some 
inhibitory activity. Also of interest is the result of the restriction digest for the assay 
containing UC3, which showed a number of bands correlating to molecular weights 
greater than that of the linearised plasmid (10 664 base pairs). The reason for this is 
not  clear  at  present,  however  it  may  suggest  some  covalent  or  non-covalent 
crosslinking of DNA strands in the presence of UC3, resulting in DNA fragments of 
greater molecular weight. 
 
4.3.3.2  Potency and selectivity 
The  IC
50  values  for  University  of  Cincinnati  library  hits  UC1-10  and  UC2-2  were 
determined  against  Dam  and  DpnI  to  assess  potency  and  selectivity.  Although 
compounds  UC6  and  UC9  showed  no  inhibition  in  the  gel-based  Dam  methylation 
assay, they were included in potency and selectivity assays to confirm the previous 
negative  result.  Dam  and  DpnI  activity  was  evaluated  over  a  range  of  compound 
concentrations and fractional activity versus compound concentration plots were fitted 
to Equation 2.6B to determine IC
50 (Table 4.5).  
 
Table 4.5 Potency and selectivity of University of Cincinnati library hits UC1-10 and 
UC2-2 
Compound  Dam IC50* 
µM 
DpnI IC50* 
µM 
Selectivity# 
UC1  1840 ± 41  >2000  - 
UC2  74.1 ± 0.7  183 ± 26  2.5 
UC2-2  61.2 ± 20.0  116 ± 19  1.9 
UC3  150 ± 26  562 ± 95  3.8 
UC4  80.5 ± 1.5  221 ± 3  2.7 
UC5  306 ± 38  673 ± 11  2.2 
UC6  >2000   >2000  - 
UC7  >2000   >2000  - 
UC8  159 ± 9  107 ± 23  0.67 
UC9  >2000  >2000  - 
UC10  -  -  - 
Assay conditions and data handling as stated for Figure 4.4. 
* Average of fitting to two sets of triplicate data, error stated is the standard deviation. 
# Calculated as DpnI IC
50/Dam IC
50 and given to 2 significant figures 
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The potency of UC10 could not be established for either Dam or DpnI due to the high 
background  fluorescence  of the compound  at the  wavelengths  used  for the activity 
assays.  However  the  close  structural  similarities  between  3-hydrazinylpyrimido[4,5-
e][1,2,4]triazine-6,8(5H,7H)-dione  (UC10)  and  the  bacterial  toxin  toxoflavin  (Figure 
4.8), which forms the basis for a range of antibiotic compounds (246, 247), suggests 
that  further  development  of  UC10  would  be  highly  unlikely  to  result  in  the 
identification of a selective Dam inhibitor. 
 
 
Figure 4.8 Structures of UC10 and toxoflavin 
 
With the exception of UC8, compounds which showed little or no activity in the gel-
based assay were found to have high IC
50 values, confirming minimal inhibition of Dam 
by compounds UC1, UC6, UC7 and UC9. Compound UC8 was poorly soluble under the 
conditions  of  the  gel-based  Dam  activity  assay,  affecting  the  concentration  of  DNA 
loaded onto the gel, and making the accurate assessment of band intensities difficult. 
The most potent Dam inhibitors, compounds UC2 and UC2-2 have similar IC
50 values 
of  74  and  61  µM  respectively,  suggesting  that  both  compounds  are  behaving  in  a 
similar way in solution, as would be expected in aqueous media
8. Other IC
50 values for 
Dam range from 81 µM for UC4 to 306 µM for UC5, with selectivity ratios ranging from 
1.9 for UC2-2 to 3.8 for UC3.  
 
These  results  show  that  all  of  the  University  of  Cincinnati  library  hits  tested  are 
relatively weak Dam inhibitors with limited selectivity and as such are unlikely to be 
good  leads.  In  addition  the  imine  compounds  UC4  and  UC5  have  been  shown  to 
undergo hydrolysis to their respective aldehyde and amine components in solution, 
with the active component in both cases identified as the aldehyde. Such compounds 
would  therefore  make  poor  leads  for  drug  development,  regardless of  potency  and 
selectivity. 
                                                
8  From  this  point  forwards  the  more  potent  of  the  two  compounds,  UC2-2,  was  used  for 
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4.3.4 In culture activity of hits 
4.3.4.1  Restriction digest analysis of genomic DNA from Yersinia culture 
In parallel with hit validation the activity of the University of Cincinnati compounds in 
bacterial  cell  culture  was  assessed  by  Dr  M.I.  Richards  (dstl,  Porton  Down,  UK).  Y. 
pseudotuberculosis, a close relative of Y. pestis which can be handled at a lower level of 
containment, was used to assess the ability of the compounds to penetrate Yersinia 
spp. cells. Genomic DNA isolated from Y. pseudotuberculosis cell cultures grown in the 
presence  of  each  inhibitor
9  was  analysed  by  restriction  digest ,  and  the  results 
visualised by agarose gel electrophoresis. Restriction by  Sau3AI, which cleaves both 
methylated  and  unmethylated  GATC  sites,  was  used  as  a  control  to  confirm  the 
presence of GATC sites in the genomic DNA, whilst restriction by MboI indicated the 
presence of unmethylated DNA, and restriction by DpnI indicated by the presence of 
fully methylated DNA. 
 
All  genomic  DNA  samples  were  degraded  by  both  Sau3AI  and  DpnI,  indicating  the 
presence of methylated DNA. In addition, five samples, those grown in the presence of 
UC1,  UC2-2,  UC6,  UC9  and  UC10,  were  also  restricted  by  MboI,  indicating  the 
presence of unmethylated DNA. These results suggest that compounds UC1, UC2-2, 
UC6, UC9 and UC10 penetrate Y. pseudotuberculosis cells and partially inhibit Dam, 
leading to the formation of both unmethylated and fully methylated DNA. 
 
The weak potencies observed for compounds UC1, UC6 and UC9 against Y. pestis Dam 
would seem to suggest that the decrease in methylation observed in cell culture is due 
to off-target effects, or that the compounds are metabolised to a more active form in 
the cell. 
 
4.3.4.2  Gel-based plasmid methylation assay 
The in culture activity of compounds UC1-UC910 against Dam was assessed using the 
gel-based plasmid methylation assay. The results showed none of the compounds to 
inhibit the methylation of plasmid pRL821 in E. coli TOP10 at a concentration of 500 
µM. OD
600 was used to monitor E. coli growth during the experiment and the average of 
two  growth  curves  obtained  in  the  presence  of  each  compound  and  a  control 
containing no compound, are shown in Figure 4.9. 
 
 
                                                
9 Compounds UC7 and UC8 had not been tested by restriction digest analysis of genomic DNA 
isolated from Yersinia culture at the time of writing this thesis. 
10 Compound UC10 was not available for testing at the time the gel-based plasmid methylation 
assay was conducted. J C McKelvie    Chapter 4 
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Figure 4.9 E. coli growth curves in the presence of UC1-9 
OD
600 normalised to a start OD
600 of 0.05 against time for E. coli TOP10 grown in the 
presence of UC1-5 (A) and UC6-9 (B). Positive control (lacking compound) shown as 
dotted black line (A and B). UC1 (A, red line), UC2-2 (A, green line), UC3 (A, cyan line), 
UC4 (A, blue line), UC5 (A, pink line), UC6 (B, red line), UC7 (B, green line), UC8 (B, 
cyan line), UC9 (B, blue line). 
Assay conditions: 1 ml 2YT media, E. coli TOP10 to a final OD
600 of 0.05. Total assay 
volume 1 ml, temperature 37 °C, orbital shaking at 180 rpm for 5 out of every 10 min. 
 
Experiments  with  isogenic  Dam
+  and  Dam
-  strains  have  shown  a  lack  of  Dam 
methylation in E. coli to lead to a decrease in the rate of bacterial cell growth (Chapter 
3, Section 3.6.1.3). As dam knockout mutants of E. coli are still viable a significant 
decrease in growth rate in the presence of an inhibitor is likely to be indicative of an 
off-target  toxic  effect.  Compounds  UC1,  UC4,  UC5  and  UC9,  which  significantly 
decreased the rate of E. coli TOP10 growth relative to a positive control, are therefore 
likely to be affecting cellular processes in addition to/other than Dam methylation. The 
lack  of  a  decrease  in  growth  rate  for  E.  coli  TOP10  grown  in  the  presence  of 
compounds UC2-2, UC6 and UC7 relative to the positive control sample suggests that 
these compounds have little or no effect on Dam methylation in the cell, either due to 
a lack of cellular penetration, compound breakdown within the cell, or poor potency. 
 
The slight decrease in the growth rate of E. coli TOP10 in the presence of compounds 
UC3 and UC8 compared to the positive control implies that these compounds may be 
penetrating the cell and inhibiting Dam methylation. However a poorly resolved growth 
curve  was  obtained  for  UC8  (Figure  4.9B)  due  to  insufficient  compound  solubility, 
which may also account for the observed effect. 
 
4.3.4.3  HPLC-based genomic DNA methylation assay 
Compounds found to  penetrate  Y. pseudotuberculosis and affect the methylation of 
genomic DNA whilst showing no toxicity in E. coli TOP10 were also assessed using the 
HPLC-based genomic DNA methylation assay. Within error no decrease in the ratio of 
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dmAMP:dAMP  was  observed  for  E.  coli  BW25113  grown  in  the  presence  of  500  µM 
UC2-2,  UC6  or  UC10,  relative  to  a  positive  control  (lacking  compound)  (Figure 
4.10A). In addition, plots of OD
600 over time show no decrease in the rate of E. coli 
BW25113 growth in the presence of any of the compounds (Figure 4.10B), suggesting 
little if any Dam inhibition. 
 
   
Figure 4.10 Ratio of methylated to unmethylated adenine (A) and E. coli growth curves 
in the presence of UC2-2, UC6 and UC10 (A). 
A: Average ratio of dmAMP:dAMP peaks calculated from the peak areas of an HPLC 
trace of digested genomic DNA isolated from one culture of E. coli  BW25113 (Dam
+) or 
JW3350-2 (Dam
-) (Dam
+ and Dam
- controls) or two separate cultures of E. coli  BW25113 
(Dam
+) grown in the presence of UC2-2, UC6 or UC10. 
B: OD
600 normalised to a start OD
600 of 0.05 against time for E. coli BW25113 (Dam
+) 
grown in the presence of UC2-2 (green line), UC6 (cyan line) and UC10 (blue line), 
positive  control  (lacking  compound,  dotted  black  line)  and  negative  control  (E.  coli 
JW3350-2 (Dam
-), dotted red line).  
Assay conditions: 1 ml 2YT media, 0 (BW25113) and 10 (JW3350-2) µg ml
-1 kanamycin, 
5% DMSO, 0 or 500 µM compound, E. coli BW25113 (Dam
+) or JW3350-2 (Dam
-) to a 
final OD
600 of 0.05. Total assay volume 1 ml, temperature 37 °C, orbital shaking at 180 
rpm for 5 out of every 10 min, cells harvested by centrifugation at 5 hrs, genomic DNA 
isolated and digested to dNMPs for HPLC analysis. HPLC gradient 8.75-42.5% MeOH 
over 38 min, 80 µl sample injection. 
 
The HPLC-based genomic DNA methylation assay displays a low level of sensitivity for 
changes in methylation, with only complete inhibition of Dam methylation, as observed 
for the Dam
- control sample, clearly distinguishable from the fully methylated Dam
+ 
control sample. Therefore, although the results of this assay suggest that at 500 µM 
compounds UC2-2, UC6 and UC10 do not fully inhibit Dam methylation in  E. coli, 
partial inhibition cannot be ruled out. 
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4.4 Summary 
 
Of the 146 compounds identified as hits in the DTP library screen, 140 were eliminated 
by counter-screening against DpnI inhibition and DNA intercalation, leaving a total of 
six viable hits, and a hit rate after counter-screening of 0.2%. A further five compounds 
were discarded during purity and potency analysis, leaving one viable hit, the stibonic 
acid 13776.  
 
The University of Cincinnati library screen yielded 102 potential hits, with 82 of these 
eliminated during counter-screening, leaving a total of 20 compounds and giving a hit 
rate of 0.8%. Of the 20 remaining compounds only half were investigated further due 
to limited compound availability, with none of the tested compounds showing high 
levels of either potency or selectivity.  
 
Due to differences in the concentration of library compounds screened and the cut-off 
limits  used  to  select  hits,  the  two  screens  cannot  be  directly  compared.  However, 
trends apparent across both screens include the identification of a high percentage of 
false positives (96% of the initial DTP library hits and 80% of the initial University of 
Cincinnati library hits) eliminated during counter-screening, resulting in low final hit 
rates (0.2% and 0.8%).  
 
A  low  hit  rate  is  not  unexpected  for  a  random  library  screen,  with  a  previous  HTS 
campaign  to  identify  Dam  inhibitors  from  a  random  library  of  50,000  compounds 
yielding a 0.7% hit rate (149). The lack of a significant increase in hit rate for the in 
silico enriched library however is disappointing, and would appear to suggest that in 
this case there is little difference in the chance of identifying an inhibitor from an in 
silico enriched library or a random library of a similar size. There are relatively few 
examples  in  the  literature  where  high-throughput  and  in  silico  screens  have  been 
directly compared, however in the few studies that have been reported a significantly 
higher hit rate has been achieved through virtual screening than through traditional 
HTS methods (248). The failure of in silico screening to identify a greater number of 
hits  than  HTS  in  this  case  could  be  due  to  a  wide  range  of  reasons  including  the 
specific in silico method used, the quality of the crystal structure used to inform  in 
silico screening, and the size and chemical diversity of the library sampled.  
 
The high false positive rate observed for both libraries is most likely an artefact of the 
in vitro screening assay methodology. The most common false positives identified in 
HTS  are  compounds  which  form  aggregates  under  HTS  conditions  (promiscuous 
binders),  compounds  which  interfere  with  the  assay  or  detection  method,  and J C McKelvie    Chapter 4 
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compounds  with  reactive  functionalities  (249).  Fortunately  the  majority  of  such 
compounds can be eliminated at an early stage with the application of counter-screens 
and validation assays, as implemented in this case. 
 
Of the hits identified from both screens the most potent, the stibonic acid 13776, was 
identified from the DTP library. None of the hits identified showed high selectivity for 
Dam over DpnI, however 13776 exhibited a greater potency for Dam than DpnI under 
IC
50 assay conditions. Compound 13776 was therefore selected for further analysis, 
which will be discussed in detail in the following chapter.  
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5  Stibonic Acids 
 
5.1 Introduction 
 
The use of antimony is widespread: as an alloy in the manufacturing of solder, lead 
storage batteries, sheet and pipe metal, and castings; as an oxide in the formulation of 
fire-retardant  plastics,  rubbers,  textiles,  paper,  and  paints;  as  a  trisulfide  in  the 
production  of  explosives,  pigments  and  glass;  and  as  a  therapeutic  agent  for  the 
treatment  of  the  parasitic  diseases  leishmaniasis  and  schistosomiasis.  Antimony 
toxicity,  arising  from  therapeutic  or  occupational  exposure,  can  induce  severe 
respiratory, gastrointestinal and cardiovascular effects, and both antimony trioxide and 
antimony  trisulfide  have  been  implicated  as  carcinogens  (250).  Despite  this, 
pentavalent antimonials such as sodium stibogluconate and meglumine antimoniate 
(Figure  5.1),  which  generally  elicit  less  severe  side  effects  than  their  trivalent 
counterparts,  remain  the  drugs  of  choice  for  the  treatment  of  both  visceral  and 
cutaneous leishmaniasis (251, 252). 
 
 
Figure 5.1 Proposed structures of meglumine antimoniate and stibogluconate 
As  determined  by  negative  electrospray  ionisation  mass  spectrometry  in  aqueous 
solution. 
Source – reference (253). 
 
Although pentavalent antimony (Sb
V) has been used in the treatment of leishmaniasis 
for  over  50  years,  its mechanism  of  action  is  still  poorly  understood.  Amongst the 
models  proposed  for  the  mechanism  of  action  of  pentavalent  antimonials  are  a 
prodrug model, in which Sb
V is reduced to the active trivalent form (Sb
III) intracellularly, 
and an intrinsic activity model, in which Sb
V has intrinsic antileishmanial activity, with 
DNA topoisomerases suggested as potential sites of action (253, 254).  
 
Topoisomerase inhibition has been observed for the pentavalent animonial arylstibonic 
acids,  with  the  Stivers  group  reporting  the  inhibition  of  both  human  and  poxvirus 
topoisomerase I by a series of arylstibonic acids obtained from the DTP open access 
repository (255, 256). Arylstibonic acids have also been identified as inhibitors of other J C McKelvie    Chapter 5 
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DNA binding proteins, including human apurinic/apyrimidinic endonuclease (257) and 
CCAAT-enhancer-binding protein (258), as well exhibiting potent anti-HIV activity by 
inhibiting the interaction between human immunodeficiency virus type 1 gp120 and 
CD4 cells (259). 
 
The identification of arylstibonic acids as inhibitors of additional protein targets and 
the toxicity associated with antimonial therapeutics raises serious questions regarding 
the selectivity and suitability of such compounds as drug candidates. The likelihood of 
the arylstibonic acid identified from the DTP library screen (compound 13776) proving 
to be a successful lead compound for drug development is therefore relatively small. 
However, further assessment of the inhibitory effect observed for Dam in the presence 
of  the  stibonic  acid  13776  may  prove  highly  informative,  helping  to  improve 
understanding of both the mode of action of pentavalent antimonials, and the effect of 
Dam inhibition on cellular processes. 
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5.2 Structure activity relationships 
 
5.2.1 Sublibrary screening 
5.2.1.1  Stibonic acid sublibrary 
To investigate the role of the stibonic acid group in the activity of 13776 a sublibrary 
of arylstibonic acids and other antimonial compounds (Figure 5.2) was obtained from 
the  DTP  open  access  repository  and  screened  against  Y.  pestis  Dam.  Of  the  38 
additional  compounds  screened  17  were  found  to  inhibit  Dam  by  more  than  three 
standard deviations from the average of the positive controls at a concentration of 25 
µM. No inhibition was observed for the non-stibonic acid antimonials. 
 
 
Figure 5.2 Arylstibonic acid sublibrary 
Individual  structures  of  the  arylstibonic  acid  sublibrary  and  additional  antimonial 
compounds are included in Appendix Section 9.7.2.1. 
 
5.2.1.2  Phosphonic acid sublibrary 
In  discussing  the  inhibition  of  human  apurinic/apyrimidinic  endonuclease  by 
arylstibonic  acids  Seiple  et  al.  suggested  that  arylstibonic  acids  may  act  as  DNA 
phosphate  backbone  mimics  (257).  A  similar  inhibitory  effect  might  therefore  be 
expected  for  phosphonic  acids.  To  test  this  hypothesis  an  arylphosphonic  acid 
sublibrary was obtained from the DTP open access repository and screened against Y. 
pestis Dam.  
 
 
Figure 5.3 Analogous arylstibonic and arylphosphonic acids 
Individual structures of the arylphosphonic sublibrary are included in Appendix Section 
9.7.2.2. 
 
No inhibition of Y. pestis Dam was observed for the 41 arylphosphonic acids at 25 µM, 
and testing of three arylphosphonic  acids  with analogous structures to three active J C McKelvie    Chapter 5 
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arylstibonic acids (Figure 5.3) over an extended concentration range (0.001 to 1000 
µM) revealed no effect on Dam activity up to a concentration of 1 mM. Whilst these 
results do not rule out the possibility of stibonic acids acting as phosphate backbone 
mimics they do show that replacement of the stibonic acid moiety with an isostere of 
similar size and chemical composition results in a total loss of activity, suggesting that 
inhibitory activity is dependent on the stibonic acid.  
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5.2.2 Potency 
The  Y.  pestis  Dam  IC
50  values  for  the  18  arylstibonic  acid  Dam  inhibitors  were 
determined over a compound concentration range of 0.001 to 1000 µM (Table 5.1, 
Figure 5.2). The highest ranking compounds were found to be those with a carbonyl or 
sulfonyl  functional  group  in  the  meta  or  para  positions,  with  the  meta-substituted 
compounds showing a slightly greater potency than their para- or ortho-substituted 
analogues  where  available.  Of  the  arylstibonic  acid  compounds  tested,  substituent 
groups were ranked in the following order of potency: sulfonic acid > carboxylic acid ≈ 
ester > amide. The increase in potency in this series is relatively small and unlikely to 
be due purely to an ionic effect. However, the trends observed are consistent with the 
carbonyl/sulfonyl oxygen atom acting as a hydrogen-bond acceptor. The increase in 
potency  observed  for  meta-substituted  compounds  over  their  para-  and  ortho-
substituted analogues  may  indicate a  more  favourable  positioning  of  this  hydrogen 
bond acceptor. 
 
Table 5.1 Potency of the stibonic acid hits against Y. pestis Dam 
Compound 
ID* 
R1  R2  R3  Y. pestis Dam IC50 
nM# 
13746  H  H  SO
3H  16.4 ± 4.5 
15578  H  H  CH
2SO
3H  43.1 ± 15.9 
13771  H  CO
2CH
3  H  65.5 ± 22.2 
13759  H  CO
2H  H  75.9 ± 11.8 
15584  H  CO
2C
2H
5  H  87.8 ± 9.2 
13755  H  NO
2  CO
2H  119 ± 20 
13760  H  H  CO
2H  125 ± 20 
15583  H  H  CO
2C
2H
5  214 ± 75 
13778  H  C
2H
4CO
2H  H  247 ± 72 
13765  H  CONH
2  H  288 ± 126 
13793  H  H  C
3H
6CO
2C
2H
5  488 ± 75 
13782  H  CONHC
2H
4OH  H  742 ± 83 
15575  H  H  CONH
2  1,020 ± 140 
15577  H  H  CH
3  1,320 ± 700 
13758  CO
2H  H  H  2,850 ± 890 
13776  H  H  SO
2NHC
2H
4OH  3,260 ± 1,140 
13745  H  H  OH  7,250 ± 1,150 
25176  H  H  NH
2  >10,000
‡ 
* DTP NSC identifier. Compounds ranked by Y. pestis Dam IC
50. 
# Error is the standard error of measurement from a triplicate IC
50 determination. 
‡ IC
50 was greater than the detection limit of the experiment (10,000 nM). J C McKelvie    Chapter 5 
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5.2.3 Selectivity 
5.2.3.1  Against DpnI 
The selectivity of the arylstibonic acid Dam inhibitors against DpnI was assessed by 
comparing  IC
50  values  determined  for  Y.  pestis  Dam  and  DpnI.  Experiments  were 
carried out under conditions where substrate concentrations were held approximately 
equal to K
M, allowing a rough approximation to be made to K
i and IC
50 values for the 
two separate enzymes to be compared. The selectivity of each compound for Y. pestis 
Dam over DpnI is tabulated as a selectivity ratio in Table 5.2, below.  
 
Table 5.2 Selectivity of the stibonic acid hits for Y. pestis Dam over DpnI 
Compound 
ID* 
R1  R2  R3  Selectivity Ratio# 
13746  H  H  SO
3H  22 ± 10 
15578  H  H  CH
2SO
3H  2.9 ± 1.1 
13771  H  CO
2CH
3  H  26 ± 12 
13759  H  CO
2H  H  25 ± 14 
15584  H  CO
2C
2H
5  H  30 ± 11 
13755  H  NO
2  CO
2H  7.8 ± 2.8 
13760  H  H  CO
2H  3.1 ± 0.9 
15583  H  H  CO
2C
2H
5  12 ± 6 
13778  H  C
2H
4CO
2H  H  5.4 ± 1.9 
13765  H  CONH
2  H  24 ± 11 
13793  H  H  C
3H
6CO
2C
2H
5  3.5 ± 0.9 
13782  H  CONHC
2H
4OH  H  0.16 ± 0.03 
15575  H  H  CONH
2 
‡ 
15577  H  H  CH
3  2.4 ± 1.4 
13758  CO
2H  H  H 
‡ 
13776  H  H  SO
2NHC
2H
4OH 
‡ 
13745  H  H  OH 
‡ 
25176  H  H  NH
2 
† 
* DTP NSC identifier. Compounds ranked by Y. pestis Dam IC
50. 
#  DpnI  IC
50/Y.  pestis  Dam  IC
50  given  to  2  significant  figures,  error  is  the  combined 
standard error of measurement from each triplicate IC
50 determination. 
‡ DpnI IC
50 was greater than the detection limit of the experiment (10,000 nM). 
† DpnI and Y. pestis Dam IC
50 was greater than the detection limit of the experiment 
(10,000 nM). 
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A single compound, 13782, was found to be selective for DpnI over Y. pestis Dam, with 
the  remaining  compounds  showing  selectivity  ratios  of  between  2.4  and  30  (where 
calculation of a ratio was possible). These results show that, in addition to being more 
potent  than  their  para-  or  ortho-  substituted  counterparts,  the  meta-substituted 
compounds have a greater selectivity for Y. pestis Dam. Also of interest is the apparent 
decrease  in  selectivity  observed  when  the  distance  between  a  carbonyl  or  sulfonyl 
substituent and the benzene ring is increased.  
 
5.2.3.2  Against DNMT1 
The  selectivity  of  15
11  of the arylstibonic acid  Dam  inhibitors was also assessed by 
screening each compound against the human cytosine methyltransferase DNMT1. The 
results showed all bu t three compounds to inhibit DNMT1 by greater than 50% at a 
concentration of 25  µM. The three compounds showing less than 50% inhibition of 
DNMT1 were also weak Y. pestis Dam inhibitors, ranked 13
th, 16
th and 17
th out of 18 in 
order of potency. These findings strongly suggest that the arylstibonic acids are non-
selective, inhibiting DNA binding proteins in an indiscriminate manner. 
 
                                                
11 Compounds 13758, 15577, 15578 were unavailable for testing at this time. J C McKelvie    Chapter 5 
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5.3 Mode of Inhibition Characterisation  
 
5.3.1 Inhibitory constants 
To  improve  our  understanding  of  the  non-selective  inhibition  displayed  by  the 
arylstibonic acids, their mode of action was assessed. The apparent K
i values of the 
original  DTP  libray  hit,  13776,  and  the  most  potent  arylstibonic  acid,  4-
stibonobenzenesulfonic  acid  (13746)  were  determined  with  respect  to  DNA  and 
AdoMet. Lineweaver-Burk plots revealed a competitive mode of action for both 13776 
and 13746 with  respect to the hemimethylated oligonucleotide ODN1  (Figure  5.5A 
and C), and noncompetitive modes of action with respect to AdoMet (Figure 5.5B and 
D). 
 
 
Figure 5.4 Structures of the original HTS hit 13776 and the most potent sublibrary hit 
13746 
 
K
i  and  K
i  values  were  calculated  by  fitting  replots  of  y-axis  intercept  and  gradient 
against inhibitor concentration to Equation 2.8B and C respectively (Table 5.3). The 
determined  modes  of  inhibition  are  in  agreement  with  those  revealed  by  the 
Lineweaver-Burk  plots,  and  in  both  cases  K
i  values  determined  for  varying  AdoMet 
concentration are higher than those determined for varying DNA concentration. The 
variation in K
i is likely due to the addition of insufficient DNA for pseudo-first order 
kinetics to be observed. Due to the substrate inhibition effects observed at higher DNA 
concentrations  further  experiments  at  higher  concentrations  of  DNA  were  not 
attempted. 
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Figure 5.5 Lineweaver-Burk plots for compounds 13776 and 13746  
A  and  B:  Plots  of  1/initial  rate  at  0  (filled  circles),  0.77  (open  circles),  1.92  (filled 
triangles), 4.80 (open triangles), and 12.00 (filled squares) µM 13776 against 1/DNA 
concentration (A) or 1/AdoMet concentration (B). 
C and D: Plots of 1/initial rate at 0 (filled circles), 6.14 (open circles), 15.36 (filled 
triangles), 38.40 (open triangles), and 96.00 (filled squares) nM 13746 against 1/DNA 
concentration (C) or 1/AdoMet concentration (D). 
Data fitted globally to Equation 2.8A. 
Assay conditions: 0.3 (A and C) or 1 (B and D) nM Y. pestis Dam, 2 nM DpnI, 3.1-12 (A 
and C) or 10 (B and D) nM hemimethylated oligonucleotide (ODN1), 0, 160 (A and C) or 
5.4-70 (B and D) µM AdoMet, 0-12 µM 13776 or 0-96 nM 13746, 5% DMSO, 20 mM 
Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total 
assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
 
Table 5.3 Inhibition constants for compounds 13776 and 13746 
Compound  Variable 
substrate 
Ki  Ki  Mode  of 
inhibition 
13776  DNA  0.960 ± 0.036 µM  179 ± 119 µM  Competitive 
AdoMet  2.59 ± 0.07 µM  22.7 ± 3.2 µM  Noncompetitive 
13746  DNA  6.46 ± 0.07 nM  234 ± 31 nM  Competitive 
AdoMet  25.1 ± 2.3 nM  58.8 ± 0.3 nM  Noncompetitive 
Errors given are the standard errors of fit. 
A  B 
C  D J C McKelvie    Chapter 5 
  146   
5.3.2 Fluorescence anisotropy competition binding 
Further  probing  of  the  DNA  competitive  mode  of  action  observed  was  achieved  by 
monitoring the effect of compounds 13776 and 13746 on the binding of E. coli Dam 
to  DNA.  Competition  binding  constants  (K
Dc)  were  determined  by  fitting  plots  of 
fraction  of  compound  bound  versus  substrate  concentration  to  Equation  3.4  for 
experiments prepared with and without AdoHcy (Figure 3.28, Table 5.4). 
 
   
Figure 5.6 Competition binding curves for compounds 13776 and 13746 
Fraction  of  substrate  bound  calculated  using  Equation  3.3A  and  B  (ligand  binding 
curves as for Figure 3.26) versus 13776 (A) or 13746 (B) concentration in the absence 
(open circles, dotted line) and presence (filled circles, solid line) of AdoHcy. Data fitted 
to Equation 3.4. 
Assay conditions: 200 nM E. coli Dam, 0-1000 µM compound 13776 (A) or 13746 (B), 
0 or 100 µM AdoHcy, 0 or 20 nM labelled hemimethylated oligonucleotide (ODN10), 
0.1% Tween-20, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% 
glycerol, pH 7.9. Total assay volume 100 µl, in 96 well plate, gain 2315/2366, 25 °C. 
 
Table 5.4 Competition binding constants for compounds 13776 and 13746 
Compound  Second Ligand  KDc* 
µM  
R2 
13776  None  43.9 ± 32.2  0.899 
AdoHcy  64.8 ± 4.7  0.989 
13746  None  0.859 ± 0.352  0.979 
AdoHcy  1.04 ± 0.01  0.998 
* Competition binding constant calculated using Equation 3.4. 
Errors shown are the standard errors of fit. 
 
Compounds 13776 and 13746 were found to fully displace DNA from E. coli Dam in 
solution, both in the absence and presence of AdoHcy, confirming a DNA competitive 
mode  of  inhibition.  Addition  of  AdoHcy  had  little  effect  on  K
Dc,  with  the  slightly 
A  B J C McKelvie    Chapter 5 
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increased R
2 values for these experiments possibly reflecting the collection of more 
accurate data due to the stabilisation of Dam induced by AdoHcy. Competition binding 
constants were higher than the values of K
i determined for each inhibitor, although the 
order of potency remains the same, with 13746 showing a greater affinity for Dam 
than 13776. 
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5.3.3 Oligonucleotide melting curves 
The identification of arylstibonic acids as inhibitors of multiple DNA binding proteins 
(255-258)  raises  question  about  both  their  selectivity  and  mode  of  action.  To 
investigate complex formation between DNA and arylstibonic acids as a potential cause 
of enzyme inhibition, DNA duplex melting profiles were assessed in the absence and 
presence of compounds 13776 and 13746. Melting temperature (T
m) was calculated as 
the  maximum  of  the  first  derivatives  of  fluorescence  versus  temperature  plots  for 
varying concentrations of 13776 and 13746 (Table 5.5). 
 
Table 5.5 DNA melting temperatures for varying arylstibonic acid concentration 
Compound  Compound Concentration 
µM 
Tm 
°C 
None  -  78.4 ± 0.2 
13776  25  78.5 ± 0.2 
10  78.5 ± 0.2 
1  78.4 ± 0.2 
13746  25  78.4 ± 0.2 
10  78.2 ± 0.1 
1  78.5 ± 0.0 
T
m‟s  determined  as  the  average  maximum  of  the  first  derivatives  of  triplicate 
fluorescence  versus  temperature  plots  for  hemimethylated  oligonucleotide  ODN1. 
Errors are the standard deviation of triplicate measurements. 
Assay conditions: 100 nM hemimethylated oligonucleotide (ODN1), 0, 1, 10 or 25 µM 
13776 or 13746, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg 
ml
-1 BSA, pH 7.9. Total assay volume 20 µl, in LightCycler capillaries, 30-90 °C. 
 
No significant difference in T
m was observed on addition of either 13776 or 13746 to 
solutions  containing  the  hemimethylated  hairpin  oligonucleotide  ODN1.  Whilst  not 
conclusive proof, the lack of a change in T
m combined with the lack of intercalation 
observed  in  the  FID  assay  would  suggest  that  no  complex  is  formed  between  the 
arylstibonic acids and DNA. This fits well with literature reports, which have found Sb
V 
to  form  complexes  in  solution  with  ribonucleotides,  but  not  deoxyribonucleotides 
(260). 
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5.3.4 Aggregation 
An alternative possible cause of non-selective inhibition is the formation of arylstibonic 
aggregates which may act as promiscuous binders (199). The addition of detergent to 
HTS assays has been suggested as a method by which to identify and eliminate such 
compounds (237, 261). The addition of Tween-20 (0.1%) to fluorescence anisotropy 
competition  binding  experiments  did  not  lead  to  a  loss  of  inhibitory  action  by 
compounds  13776  or  13746  (Section  5.3.2).  However  in  order  to  fully  assess  the 
effect  of  detergent  on  the  potency  of  the  arylstibonic  acids  the  IC
50  of  13746  was 
determined  in  the  presence  of  0.1%  Tween-20  and  compared  to  an  experiment 
containing no detergent was added. 
 
 
Figure 5.7 Comparison of IC
50
13746 with and without detergent 
Fractional activity, calculated using Equation 2.6A versus concentration of 13746 with 
(open circles) and without (filled circles) detergent. Data fitted to Equation 2.6B. 
Assay  conditions:  0.3  or  0  nM  Y.  pestis  Dam,  2  nM  DpnI,  3.5  nM  hemimethylated 
oligonucleotide (ODN1), 0 or 16 µM AdoMet, 0-100 µM 13746, 5% DMSO, 0 or 0.1% 
Tween-20, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% 
glycerol, pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
IC
50  was determined as 44.5 ± 13.7 nM  when assays  were supplemented with 0.1% 
Tween-20, compared to 16.4 ± 4.5 nM in a separate experiment where no detergent 
was  added.  Ryan  et  al.  Suggest  that  the  addition  of  36%  of  the  critical  micellular 
concentration (CMC) of Tween-20 (approximately 0.025% v/v) is sufficient to eliminate 
the  effects  of  promiscuous  inhibition  (237).  The  small  change  in  IC
50  observed  on 
addition  of  0.1%  Tween-20  is  therefore  unlikely  to  be  indicative  of  promiscuous 
binding,  implying  that  the  arylstibonic  acids  do  not  cause  inhibition  through 
aggregation. 
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5.4 In culture activity 
 
The activity of the arylstibonic acids in Y. pseudotuberculosis cell culture was assessed 
by Dr M.I. Richards (dstl, Porton Down, UK). Genomic DNA was isolated from cultures 
of Y. pseudotuberculosis grown in the presence of each of the arylstibonic acid Dam 
inhibitors and a selection of inactive arylstibonic acids. Isolated DNA was then analysed 
by  restriction  digest  with  Sau3AI  (to  confirm  the  presence  of  GATC  sites),  MboI  (to 
identify unmethylated DNA), and DpnI (to identify methylated DNA). The results of the 
restriction  digests  were  visualised  by  agarose  gel  electrophoresis  and  a  single 
compound, (3-((2-hydroxyethyl)carbamoyl)phenyl)stibonic acid (13782), was found to 
cause the partial inhibition of DNA methylation in bacterial cell culture, as evidenced 
by the degradation of genomic DNA by both MboI and DpnI (Figure 5.8). 
 
   
Figure 5.8 Restriction digest of Y. pseudotuberculosis genomic DNA grown in the 
presence of compound 13782 
1% agarose gel electrophoresis of Y. pseudotuberculosis genomic DNA digest (left) and 
the structure of compound 13782 (right). 
(L):  ladder,  (1-4):  genomic  DNA  isolated  from  Y.  pseudotuberculosis  grown  in  the 
presence  of  an  inactive  control  compound,  (5-8):  genomic  DNA  isolated  from  Y. 
pseudotuberculosis grown in the presence of 13782, (1 and 5): uncut genomic DNA, (2 
and 6): DpnI digested genomic DNA, (3 and 7): MboI digested genomic DNA, (4 and 8): 
Sau3AI digested genomic DNA. J C McKelvie    Chapter 5 
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5.4.1 Compound 13782 
Assessment  of  the  methylation  state  of  genomic  DNA  isolated  from  Y. 
pseudotuberculosis cell culture showed arylstibonic acid 13782 to be able to penetrate 
cells and partially inhibit DNA methylation. Compound 13782 has been identified as a 
potent inhibitor of both Dam and the restriction enzyme DpnI in vitro, with a Dam:DpnI 
selectivity  ratio  of  0.7,  suggesting  that  13782  would  make  a  poor  drug  candidate. 
However the mechanism by which 13782 is able to penetrate Yersinia cells and inhibit 
DNA  methylation  and  the  effect  of  this  inhibition  on  other  cellular  processes  is  of 
interest and may help to direct further drug discovery efforts. 
 
5.4.1.1  Toxicity 
Dam is not essential for the viability of Y. pestis (40), and so the inhibition of Dam by 
should not have a detrimental effect on the growth of Y. pestis cells. To assess the 
toxicity of 13782, Y. pestis cells were cultured in the presence of 13782 by Dr M.I. 
Richards (dstl, Porton Down, UK) and their growth monitored by OD
600. Comparison of 
growth curves for inhibited and control cultures of Y. pestis showed 13782 to have 
little effect on Y. pestis growth (Figure 5.9), suggesting that the compound does not 
elicit  off-target  toxicity.  Further  evidence  of  the  lack  of  toxicity  displayed  by  the 
arylstibonic acids can be found in the publicly available DTP AIDS antiviral screening 
data (available online at http://dtp.nci.nih.gov), which tested eleven of the arylstibonic 
acid Dam inhibitors (including 13782) for toxicity against human CEM cells and found 
all to have EC
50 values of greater than 30 µM (the detection limit of the experiment). 
 
 
Figure 5.9 Y. pestis growth curves in the presence of 13782 
OD
600  against  time  for  Y.  pestis  grown  in  the  presence  of  13782  (filled  triangles, 
dashed line), DMSO (filled circles, solid line), or no additives (open circles, dotted line). 
Data fitted to a sigmod of the form y = a/(1+exp(-(x-x
0)/b)). 
 
5.4.1.2  mRNA profiling 
The effect of 13782 on gene expression was assessed by Dr T.S. Milne (dstl, Porton 
Down, UK) via microarray mRNA profiling of duplicate RNA samples isolated from Y. J C McKelvie    Chapter 5 
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pestis  cultures grown  in the  presence of  13782,  and control cultures  grown  in the 
absence of 13782. Statistical analysis of profiling data showed a total of 91 Y. pestis 
open reading frames (ORFs) to have undergone statistically significant (greater than 
1.3-fold) up- or down-regulation in the presence of 13782 (see Appendix Section 9.8 
for further details). Down-regulated Y. pestis genes included ORFs encoding proteins 
involved in iron acquisition, type III secretion, DNA repair and response to universal 
stress. Among the genes affected by 13782 mediated inhibition are those involved in 
the Yersiniabactin (Ybt) iron uptake system and the type III secretion system encoded 
by the Yop virulon. These results are encouraging as they correlate well with reports in 
the  literature,  which  have  shown  both  the  Ybt  and type  III  secretion systems  to  be 
involved in the pathogenicity of Yersinia spp. (262, 263). 
 
5.4.1.3  Activity of re-synthesised compound 13782 
Due to the promising activity shown by compound 13782 in Y. pestis, the compound 
was synthesised by Dr G. Hobley using the method of Englert and Sweeting (264). HPLC 
analysis of both resynthesised compound 13782 (GH13782) and 13782 showed the 
latter to contain a mixture of two components, only one of which was present in the re-
synthesised sample, and Y. pestis Dam IC
50 determinations showed GH13782 to have a 
significantly lower potency than 13782 (Figure 5.10). 
 
 
Figure 5.10 IC
50
13782 and IC
50
GH13782 for Y. pestis Dam 
Fractional  activity,  calculated  using  Equation  2.6A  versus  concentration  of  13782 
(filled circles, solid line) and GH13782 (open circles). Data fitted to Equation 2.6B for 
13782. Assay conditions: 0.3 nM Y. pestis Dam, 2 nM DpnI, 3.5 nM hemimethylated 
oligonucleotide  (ODN1),  0  or  16  µM  AdoMet,  0-100  or  0-1000  µM  compound,  5% 
DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, 
pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
 
The minimal potency displayed by GH13782 suggested that the activity of 13782 may 
be due to the second component visible by HPLC, and that the presence of a small 
amount of this contaminant or break-down product in the re-synthesised sample may J C McKelvie    Chapter 5 
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be responsible for the inhibition of Y. pestis Dam observed at 1 mM GH13782. The 
components  of  13782  were  separated  by  reverse  phase  chromatography,  fractions 
collected, concentrated, and tested for activity against Y. pestis Dam. 
 
 
Figure 5.11 HPLC trace of 13782 and activity of concentrated fractions 
HPLC  trace of  13782  (black  line) and  activity  of  concentrated  HPLC  fractions  (filled 
circles).  Positive  and  negative  control  averages  and  plus/minus  three  standard 
deviations shown as red lines. 
Assay  conditions:  HPLC  gradient  0-100%  0.1  M  ammonium  acetate  over  20  min 
followed  by  100%  ammonium  acetate  over  40  min,  2  ml  fractions  collected  every 
minute. Freeze-dried fractions were resuspended in 20 µl H
2O and assayed under the 
following  conditions  0.3  nM  Y.  pestis  Dam,  2  nM  DpnI,  3.5  nM  hemimethylated 
oligonucleotide  (ODN1),  0  or  16  µM  AdoMet,  25%  compound,  20  mM  Tris,  80  mM 
NaCl,  8  mM  MgCl
2,  1  mM  DTT,  0.1  mg  ml
-1  BSA,  5%  glycerol,  pH  7.9.  Total  assay 
volume 20 µl, in 384 well plate, gain 190, 30 °C. 
 
Complete  inhibition  was  observed  from  18  minutes,  corresponding  to  the  point  at 
which ammonium acetate concentration reaches 100%. Subsequent assays showed Y. 
pestis  Dam  to  be  fully  inhibited  by  0.1  M  ammonium  acetate,  rendering  the  HPLC 
method  used  inadequate  for  this  purpose.  Further  attempts  at  isolating  the  active 
component of 13782 have to date proved futile. 
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5.5 Summary 
 
Basic  SARs  for  compounds  related  to  HTS  hit  13776  have  been  investigated  by 
screening sublibraries of arylstibonic and arylphosphonic acids. A total of 17 additional 
arylstibonic  acid,  and  no  arylphosphonic  acid,  Dam  inhibitors  were  identified, 
suggesting that the stibonic acid group is required for activity. Some minor SAR trends 
were observed for the arylstibonic acids, with meta-substituted compounds showing 
both increased selectivity for Dam over DpnI and increased potency compared to their 
ortho- and para-substituted analogues. Compounds with a carbonyl or sulfonyl group 
located  directly  adjacent  to  the  aromatic  ring  also  showed  improved  selectivity  for 
Dam. 
 
None of the arylstibonic acids tested showed high levels of selectivity for Dam over 
DpnI, and all but the weakest Dam inhibitors were also shown to inhibit the human 
DNA methyltransferase DNMT1 by greater than 50% at a concentration of 25 µM. This 
lack of selectivity is perhaps unsurprising in light of the identification of arylstibonic 
acids as inhibitors of other DNA-binding proteins. However, further experiments have 
shown  a  promiscuous  mode  of  inhibition  by  aggregation  or  binding  to  DNA  to  be 
unlikely,  suggesting  a  common  mode  of  action  for  the  inhibition  of  DNA-binding 
proteins which is yet to be determined. 
 
The identification of a compound with in cell activity (13782) has allowed us to study 
the effect of the arylstibonic acids on gene expression, with the results of an mRNA 
profiling study showing genes involved in pathogenesis to be down-regulated. Whether 
this effect is purely due to the inhibition of Dam or a combination of effects is unclear, 
however no effects on Y. pestis growth were observed, suggesting that 13782 exhibits 
little or no bacterial toxicity. 
 
Resynthesis of 13782 and HPLC analysis of both 13782 and resynthesised compound 
GH13782 have shown the original compound to comprise of two components, only 
one of which  is present in  GH13782. Further analysis showed  GH13782 to exhibit 
weak activity against Y. pestis Dam in both in vitro and preliminary in culture assays. 
These  findings  suggest  that  an  active  component  is  common  to  both  samples,  but 
present at much higher concentrations in 13782. Whether this active component is a 
break-down product or a contaminant is yet to be elucidated, and the development of 
an HPLC method compatible with the in vitro testing of Dam activity could prove to be 
a key step in this process. 
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6  Bisubstrate Analogues 
 
6.1 Introduction 
 
Analogues  of  the  methyl  donor  AdoMet  have  been  widely  explored  as 
methyltransferase  inhibitors  (114-121),  however  poor  levels  of  selectivity  have  been 
observed  for  such  compounds  due  to  the  extensive  use  of  AdoMet  in  enzymatic 
reactions  (265).  To  improve  the  selectivity  of  AdoMet  analogue  methyltransferase 
inhibitors a bisubstrate approach has been applied in which the structural features of 
AdoMet  are  combined  with  those  of  the  methylation  target.  Examples  of 
methyltransferases targeted using this approach include COMTs (136, 137), bacterial 
DNA methyltransferases (142), HMTs (134), mycolic acid methyltransferases (141), and 
PRMTs  (135).  A  range  of  synthetic  methodologies  have  been  applied  to  the 
development  of  bisubstrate  methyltransferase  inhibitors,  with  AdoMet  modified  at 
various positions, as shown in Figure 6.1.  
 
 
Figure  6.1  Modification  of  AdoMet  for  the  development  of  bisubstrate 
methyltransferase inhibitors 
 
A reductive amination strategy has been applied as a means of synthesising a series of 
bisubstrate Dam inhibitors from an amine AdoMet analogue scaffold and an aldehyde 
adenine analogue, based on the methods of Wahhab et al. (266). A similar technique 
has been successfully applied to the development of bisubstrate PRMT inhibitors (135), 
demonstrating the validity of such an approach. Inhibitors were designed to mimic the 
methylation  transition  state  by  linking  an  adenine  analogue  to  the  sulfonyl  (or 
equivalent) moiety of an AdoMet analogue (Figure 6.2). J C McKelvie    Chapter 6 
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Figure 6.2 Design of bisubstrate Dam inhibitors 
Structure of T4 Dam in complex with sinefungin (red) and DNA (blue) and combination 
of AdoMet (red) and adenine (blue) to form a bisubstrate inhibitor. 
Protein image created using pdb file 1YFL molecule E with the program UCSF Chimera 
(77). 
 
 
Figure 6.3 The bisubstrate Dam inhibitor library 
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A small library of 9 bisubstrate Dam inhibitors (Figure 6.3) were prepared by Dr G. 
Hobley as described in reference (267). The following chapter describes the in vitro 
evaluation of the potency, selectivity and mode of action of these compounds. 
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6.2 Hit Validation 
 
6.2.1 Potency 
Y. pestis Dam IC
50 values were determined for the 9-compound bisubstrate inhibitor 
library and AdoHcy over a concentration range of 0 to 2000 µM and ranked in terms of 
potency  (Table  5.1).  Substitution  of  the  amine  AdoMet  analogue  scaffold  with  a 
pyridine  ring  led  to  a  loss  of  activity  compared  to  control  analogues  SA1  and  2. 
Whereas substitution by an indole, benzofuran or benzothiophene ring system led to 
an increase in activity over the control compounds, with the analogues substituted with 
an indole ring at the C3-position showing IC
50 values comparable to that of AdoHcy. 
 
Table 6.1 Potency of the bisubstrate inhibitors against Y. pestis Dam 
Compound ID*  Adenine  Analogue 
Substituent 
Y. pestis Dam IC50 
µM# 
AdoHcy  -  11.9 ± 4.8 
SA5  CH
2CH
2C
7H
5NH  12.3 ± 0.8 
SA6  CH
2CH
2CH
2C
7H
5NH  13.1 ± 2.7 
SA8  CH
2CH
2C
7H
5S  28.9 ± 8.9 
SA9  CH
2CH
2C
7H
5NH  31.3 ± 13.0 
SA7  CH
2CH
2C
7H
5O  39.2 ± 2.6 
SA1  H  84.0 ± 20.9 
SA2  CH
3  237 ± 68.0 
SA3  CH
2C
5H
4N  > 250
‡ 
SA4  CH
2CH
2CH
2C
5H
4N  > 250
‡ 
* Compounds ranked by Y. pestis Dam IC
50. 
# Average ± standard deviation of two independent triplicate assay sets. 
‡ IC
50 was greater than the detection limit of the experiment (250 µM). 
 J C McKelvie    Chapter 6 
  161   
6.2.2 Confirmation of activity 
The activity of the bisubstrate analogues with Y. pestis Dam IC
50 values of less than 250 
µM  was  confirmed  by  assessing  their  activity  against  E.  coli  Dam  in  the  gel-based 
methylation  assay.  Plasmid  pRL821  was  incubated  with  E.  coli  Dam  and  2  mM  of 
compounds  SA1,  2  and  5-9,  and  restriction  digest  was  used  to  determine  the 
methylation state of the plasmid after incubation. The results were then visualised by 
agarose gel electrophoresis (Figure 3.9). Control assays were also prepared containing 
no  AdoMet  (negative),  2  mM  AdoHcy  (inhibition),  and  no  compound  (positive). 
Inhibition  of  E.  coli  Dam  was  observed  for  all  of  the  bisubstrate  analogues  tested, 
confirming SA1, 2 and 5-9 as Dam inhibitors. 
 
 
Figure 6.4 Gel-based Dam activity assay of the active bisubstrate inhibitors 
A: 0.8% agarose gel electrophoresis of Dam activity assay restriction digest for SA1, 2 
and 5-9. 
(L): ladder, (1): negative control (lacking AdoMet), (2): inhibition control (with AdoHcy), 
(3): positive control (lacking compound), (4): SA1, (5): SA2, (6): SA7, (7): SA8, (8): SA9, 
(9): SA5, (10): SA6. 
C: Fractional activity, quantified from gel band intensity with Equation 2.6A. 
Assay conditions: 250 nM E. coli Dam, 3 nM plasmid (pRL821), 10 U µl
-1 XhoI, 7.5 U µl
-1 
BclI, 0 or 6 µM AdoMet, 0 or 2 mM compound, 5% DMSO, 50 mM Tris, 100 mM NaCl, 
10 mM MgCl
2, 1 mM DTT, pH 7.9. Step 1 (methylation) – total assay volume 20 µl, 
temperature 30 °C, 1 hr; Step 2 (denaturation) – total assay volume 20 µl, temperature 
95 °C, 5 min; Step 3 (cleavage) – restriction enzymes XhoI and BclI added, total assay 
volume 22 µl, temperature 37 °C, 1 hr and 50 °C, 1 hr. Digested plasmid analysed by 
0.8% agarose gel electrophoresis, bands quantified using the program ImageJ (227). 
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6.3 Selectivity 
 
6.3.1 Against DpnI 
IC
50 values were determined for each compound against DpnI, and compared to the 
previously determined Y. pestis Dam IC
50 values. Substrate concentrations for all IC
50 
experiments were held in the region of K
M, allowing IC
50 to be roughly approximated to 
K
i and IC
50 values for the two different enzymes to be compared. The selectivity ratio 
(DpnI IC
50/Y. pestis Dam IC
50) for each of the active inhibitors is tabulated below (Table 
6.2). 
 
Table 6.2 Selectivity of the bisubstrate inhibitors for Y. pestis Dam over DpnI 
Compound ID*  Adenine  Analogue 
Substituent 
Selectivity Ratio# 
AdoHcy  - 
‡ 
SA5  CH
2CH
2C
7H
5NH  3.8 ± 1.0 
SA6  CH
2CH
2CH
2C
7H
5NH  4.1 ± 2.5 
SA8  CH
2CH
2C
7H
5S  4.5 ± 1.3 
SA9  CH
2CH
2C
7H
5NH  2.1 ± 1.3 
SA7  CH
2CH
2C
7H
5O  6.3 ± 3.4 
SA1  H 
‡ 
SA2  CH
3 
‡ 
* Compounds ranked by Y. pestis Dam IC
50. 
#  DpnI  IC
50/Y.  pestis  Dam  IC
50  given  to  2  significant  figures,  error  is  the  combined 
standard deviation from each pair of triplicate IC
50 determinations. 
‡ DpnI IC
50 was greater than the detection limit of the experiment (250 nM). 
 
Whilst control analogues SA1 and 2 show no affinity for DpnI at the concentrations 
tested the more potent compounds, SA5-9, were all identified as DpnI inhibitors with 
minimal selectivity shown for Y. pestis Dam. The lack of DpnI inhibition displayed by 
the control compounds suggests that this lack of selectivity is caused by the addition 
of the adenine analogue substituent to the amine AdoMet analogue scaffold.  
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6.3.2 Against DNMT1 
The bicyclic, heteroaromatic ring substituted analogues SA5-9 display similar levels of 
potency for Y. pestis Dam, and similar levels of selectivity for Y. pestis Dam over DpnI, 
a  single  analogue,  the  benzothiophene  substituted  SA8,  was  therefore  selected  for 
further  analysis.  Assessment  of  the  effect  of  adding  an  adenine-like  moiety  to  an 
AdoMet analogue  on  Y.  pestis  Dam  and  DNMT1  IC
50  was  assessed  for  SA8 and the 
methylated control SA2 (Figure 6.5, Table 6.3).  
 
   
Figure 6.5 Comparison of IC
50
SA2 and IC
50
SA8 for Y. pestis Dam and DNMT1 
Fractional activity, calculated using Equation 2.6A versus concentration of SA2 (filled 
circles, solid line) and SA8 (open circles, dotted line) for Dam (A) and DNMT1 (B). Data 
fitted to Equation 2.6B. 
Assay  conditions  (A):  0.3  nM  Y.  pestis  Dam,  2  nM  DpnI,  3.5  nM  hemimethylated 
oligonucleotide (ODN1), 0 or 3 µM AdoMet, 0-2000 µM compound, 5% DMSO, 20 mM 
Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total 
assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
Assay  conditions  (B):  25  nM  DNMT1,  0.05  U  µl
-1  GlaI,  250  nM  partially  methylated 
oligonucleotide (ODN6), 0 or 16 µM AdoMet, 0-2000 µM compound, 5% DMSO, 100 
mM Tris, 12.5 mM NaCl, 5 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. 
Total assay volume 20 µl, in 384 well plate, gain 1250, 37 °C. 
 
Table 6.3  Comparison of IC
50
SA2 and IC
50
SA8 for Y. pestis Dam and DNMT1 
Compound ID  Adenine Analogue 
Substituent 
Y. pestis Dam IC50 
µM 
DNMT1 IC50 
µM* 
SA2  CH
3  237 ± 68  302 ± 29 
SA8  CH
2CH
2C
7H
5NH
  28.9 ± 8.9  132 ± 9 
Potency Ratio#    8.2 ± 3.5  2.3 ± 0.3 
* IC
50
SA2/IC
50
SA8 given to 2 significant figures, error is the combined standard error of 
measurement from each triplicate IC
50 determination. 
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An increase in potency was observed for both Y. pestis Dam and DNMT1 upon addition 
of  the  benzothiophene  group;  however  the  increase  for  Y.  pestis  Dam  was 
approximately four times that for DNMT1. This result implies that the incorporation of 
an adenine analogue moiety into bisubstrate Dam inhibitors increases their selectivity 
for Dam over cytosine-specific methyltransferases such as DNMT1.  
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6.4 Mode of Inhibition Characterisation  
 
6.4.1 Inhibitory constants 
The  apparent  K
i  values  of  the  benzothiophene  analogue  (SA8)  were  determined  by 
assessing  the  effect  of  varying  substrate  and  SA8  concentration  on  Y.  pestis  Dam 
activity. Lineweaver-Burk plots were used to determine mode of action with respect to 
each substrate (Figure 6.6), and K
i values were calculated by fitting replots of y-axis 
intercept  and  gradient  against  inhibitor  concentration  to  Equation  2.8B  and  C 
respectively (Table 6.4). 
 
   
Figure 6.6 Lineweaver-Burk plots for compound SA8 
A  and  B:  Plots  of  1/initial  rate  at  0  (filled  circles),  11.7  (open  circles),  19.4  (filled 
triangles),  32.4  (open  triangles),  and  54.0  (filled  squares)  µM  SA8  against  1/DNA 
concentration (A) or 1/AdoMet concentration (B). 
Data fitted globally to Equation 2.8A. 
Assay conditions: 0.3 (A) or 1 (B) nM Y. pestis Dam, 2 nM DpnI, 3.1-12 (A) or 10 (B) nM 
hemimethylated oligonucleotide (ODN1), 0, 160 (A) or 5.4-70 (B) µM AdoMet, 0-54 µM 
SA8, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% 
glycerol, pH 7.9. Total assay volume 20 µl, in 384 well plate, gain 190, 30 °C. 
 
Table 6.4 Inhibition constants for compound SA8 
Compound  Variable 
substrate 
Ki 
µM 
Ki 
µM 
Mode  of 
inhibition 
SA8  DNA  65.0 ± 33.4  572 ± 966  Noncompetitive 
AdoMet  57.6 ± 12.2  > 10,000  Competitive 
Errors given are the standard errors of fit. 
 
The Lineweaver-Burk plots showed SA8 to have a competitive mode of inhibition with 
respect  to  AdoMet,  and  a  noncompetitive  mode  of  inhibition  with  respect  to  DNA. 
However the variable DNA concentration plot is ill-defined, with large standard errors 
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of fit associated with K
i and  K
i values calculated from gradient and y-axis intercept 
replots, possibly due to the substrate inhibition effect observed at concentrations of 
DNA above Y. pestis Dam K
M. The K
i calculated with respect to AdoMet, 57.6 ± 12.2 µM, 
is therefore likely to represent a more realistic value. 
 
As an AdoMet analogue compound SA2 is also likely to possess an AdoMet competitive 
mode of inhibition. However the determination an inhibitory constant using the real-
time Dam activity assay was not possible for this compound due to its relatively weak 
affinity for Y. pestis Dam. 
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6.4.2 Fluorescence anisotropy 
6.4.2.1  Fluorescence anisotropy competition binding 
The effect of the bisubstrate analogue inhibitors on the interaction between Y. pestis 
Dam  and  DNA  was  assessed  through  fluorescence  anisotropy  competition  binding 
experiments. The addition of up to 2 mM of the benzothiophene (SA8) or methyl (SA2) 
substituted analogues to assays containing 200 nM E. coli Dam and 20 nM DNA had 
little effect on fluorescence anisotropy. Whilst this results implies that neither SA8 or 
SA2 affect the overall binding affinity of Dam for DNA, the affect of the bisubstrate 
inhibitors on the binding of the flipped adenine base to the active site pocket has not 
been established. 
 
6.4.2.2  Stabilisation of the Dam:DNA complex 
Previous experiments (Chapter 3, Section 3.5.1.2) have shown the AdoMet analogue 
AdoHcy to  have a  stabilising effect  on  the  E. coli  Dam:DNA  complex.  The effect  of 
bisubstrate inhibitor (SA8) and the methylated AdoMet analogue control (SA 2) on the 
lifetime of the E. coli Dam:DNA complex was therefore assessed to determine whether 
this  stabilisation  also  occurs  in  the  presence  of  an  amine  AdoMet  analogue  or  a 
bisubstrate amine AdoMet analogue. The results (Figure 6.7) showed compound SA2 
to induce partial stabilisation of the enzyme:DNA complex compared to the controls 
(with  AdoHcy  and  lacking  compound),  and  compound  SA8  to  induce  minimal 
stabilisation. Suggesting that SA2, SA8 and AdoHcy have different Dam binding modes 
resulting in different levels of stabilisation of the enzyme:DNA complex. 
 
 
Figure 6.7 Effect of AdoHcy, SA2 and SA8 on Dam:DNA complex stability 
Background  subtracted  averaged  anisotropy  over  time  for  Y.  pestis  Dam:DNA 
supplemented with AdoHcy (black line), SA2 (red line), SA8 (blue line) and a control 
(black dotted line) lacking compound. 
Assay  conditions:  0  or  500  nM  Dam,  0  or  50  nM  hemimethylated  oligonucleotide 
(ODN10), 0 or 2 mM compound, 5% DMSO, 0.1% Tween-20, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 100 µl, 
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6.5 Summary 
 
The activity of the AdoMet amine analogue SA2 against Y. pestis Dam demonstrates 
the  validity  of  a  nitrogen  centred  scaffold  as  a  starting  point  for  developing  Dam 
inhibitors. However comparison of the IC
50 values of the AdoHcy amine analogue SA1 
and  AdoHcy,  shows  that  the  substitution  of  sulfur  for  nitrogen  results  in  an  8-fold 
decrease  in  potency,  highlighting  the  need  for  the  continued  development  of 
alternative AdoMet analogue scaffolds. 
 
Replacement  of  the  amino  methyl  substituent  with  a  hydrogen  substituent,  as  in 
compound  SA1,  resulted  in  a  3-fold  increase  in  potency,  whilst  replacement  by  a 
substituent containing a single heteroaromatic ring (SA3 and 4) resulted in a loss of 
potency,  suggesting  that  the  inhibitor  is  bound  to  a  confined  pocket.  However, 
substitution of the nitrogen centred scaffold by a bicyclic heteroaromatic ring (SA5-9) 
led  to  an  increase  in  potency  over  both  the  methyl-  and  hydrogen-substituted 
analogues,  implying  that  compounds  SA5-9  employ  an  alternative  binding 
conformation to compounds SA1-4. 
 
Increasing the length of the linker between the bicyclic heteroaromatic substituent and 
the  nitrogen  of  the  AdoMet  analogue  scaffold  from  two  to  three  carbons  had  little 
effect  on  potency,  suggesting  a  certain  degree  of  flexibility  within  the  binding  site 
accommodating the adenine mimic. Attempts at probing this binding interaction by 
varying  the  heteroatom  have  shown  a  slight  decrease  in  potency  when  nitrogen  is 
substituted for oxygen or sulfur, and a minor decrease in potency when the point of 
attachment is moved from the C3 to the C4 position.  
 
The  selectivity  of  the  bisubstrate  inhibitors  for  Y.  pestis  Dam  over  DpnI  was 
surprisingly poor considering the total lack of affinity shown by DpnI for the AdoMet 
analogue AdoHcy. Activity against DpnI has therefore been attributed to the adenine 
analogue substituent. Selectivity for Y. pestis Dam over DNMT1 is also poor, however in 
this case the addition of an adenine analogue substituent led to an increase in potency 
for Dam compared to a control compound containing a methyl substituent (SA2). The 
bisubstrate nature of these inhibitors suggests that the development of analogues with 
a greater degree of selectivity for Dam over both DpnI and DNMT1 can be achieved by 
modifying both the AdoMet and adenine analogue portions of the inhibitors. 
 
Mode  of  inhibition  characterisation  showed  bisubstrate  inhibitor  SA8  to  have  a 
competitive mode of action with respect to AdoMet and a K
i of 57.6 ± 12.2 µM. Mode 
of  inhibition  with  respect  to  DNA  was  not  fully  resolved,  however  fluorescence J C McKelvie    Chapter 6 
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anisotropy competition binding studies revealed no displacement of E. coli Dam from 
DNA by either SA2 or SA8. Extended fluorescence anisotropy assays revealed that SA2 
partially  stabilised  the  Dam:DNA  complex,  whereas  no  stabilisation  effect  was 
observed in the presence of compound SA8.  
 
The interaction between the bisubstrate inhibitors and Dam has been probed further 
by  the  crystallisation  of  E.  coli  Dam  in  complex  with  AdoHcy  and  compound  SA8 
(carried out by J.E. Harmer). Resolution of these crystal structures has shown binding 
of analogues containing the bicyclic heteroaromatic substituent to be accommodated 
by a conformational change in the protein backbone involving tryptophan 10 (Figure 
6.8). 
 
       
Figure 6.8 AdoHcy and SA8 in complex with E. coli Dam 
Structure of  E. coli Dam in complex  with AdoHcy (red) or bisubstrate inhibitor  SA8 
(purple). Tryptophan 10 shown in black. 
Protein image created with the program UCSF Chimera (77). 
 
Accommodation  of  the  adenine-like  moiety  of  bisubstrate  inhibitor  SA8  requires  a 
conformational shift in the protein backbone of E. coli Dam. No such change occurs on 
binding  AdoHcy  or  the  amine  AdoMet  analogue  SA2,  indicating  that  the  lack  of 
stabilisation induced by bisubstrate inhibitor SA8 in fluorescence anisotropy assays is 
a direct result of this shift. The lack of displacement observed in competition binding 
studies implies that binding SA8 does not decrease the affinity of E. coli Dam for DNA. 
The  lack  of  stabilisation  induced  by  SA8  therefore  suggests  that  E.  coli  Dam  is 
destabilised  by  the  conformational  change  in  the  protein  backbone,  resulting  in 
enzyme denaturation and the subsequent release of DNA. 
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7  Conclusions and Further Work 
 
7.1 Conclusions 
 
A  real-time  coupled  enzyme  assay  for  monitoring  the  activity  of  the  bacterial  N6-
adenine  methyltransferase  Dam  has  been  developed  and  optimised  for  HTS,  to 
facilitate  the  identification  of  Y.  pestis  Dam  inhibitors.  Careful  optimisation  has 
resulted in a robust and highly reproducible assay, capable of tolerating up to 50% 
inhibition  of  the  coupling  enzyme  DpnI,  and  identifying  all  modalities  of  reversible 
inhibition with minimal bias. 
 
Assays  for  the  validation  and  characterisation  of  screening  hits  have  also  been 
developed including: DpnI activity and FID counter-screens designed to eliminate false 
positives and non-selective compounds which inhibit the coupling enzyme, intercalate 
DNA,  or  interfere  with  assay  signal;  an  alternative  Dam  activity  assay,  in  which  the 
methylation state of a plasmid incubated with E. coli Dam is determined by restriction 
digest  and  agarose  gel  electrophoresis  visualisation,  designed  to  validate  hits  not 
eliminated  through  counter-screening;  an  activity  assay  for  the  human  cytosine 
methyltransferase DNMT1, designed to assess the selectivity of validated hits; gel- and 
HPLC-based  in  culture  assays  designed  to  determine  the  ability  of  compounds  to 
permeate bacterial cells and reach the target of interest, unhindered by efflux pumps 
or  degradation;  IC
50  and  K
i assays  designed to  determine the  potency  and  mode of 
inhibition of viable leads; and fluorescence anisotropy assays designed to probe the 
effect of compounds on the Dam-DNA binding interaction. 
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7.1.1 HTS 
Two  libraries  were  selected  for  HTS,  the  first,  a  3,082  compound  library  from  the 
NCI/DTP open access repository, and the second, a 2,445 compound in silico enriched 
library selected from the University of Cincinnati‟s drug discovery compound collection 
(>250,000 compounds) based on structural similarities to AdoMet and adenine. Both 
libraries were screened in duplicate, with control assays used to monitor assay quality 
and consistency. The average CV, non-specific activity and Z‟-value for each screen is 
tabulated  below  (Table  4.2)  with  overall  averages  calculated  over  140  data  sets 
illustrating the high levels of reproducibility and robustness achieved with the real-time 
break light Dam activity assay during HTS.  
 
Table 7.1 Statistical analysis of assay reproducibility and quality during HTS 
Library  Screen
‡  CV*  Non-specific 
Activity# 
Z’-value† 
DTP  Initial
‡  10.5 ± 3.5%  5.46 ± 1.93%  0.63 ± 0.12 
Duplicate
‡  9.07 ± 2.43%  3.85 ± 1.12%  0.69 ± 0.08 
University  of 
Cincinnati 
Initial
§  11.8 ± 3.6%  2.51 ± 0.46%  0.60 ± 0.11 
Duplicate
§  12.9 ± 4.2%  2.37 ± 0.61%  0.57 ± 0.13 
  AVERAGE§  11.1 ± 1.7%  3.55 ± 1.44%  0.63 ± 0.05 
* Calculated from the average and standard deviation of the positive controls using 
Equation 2.1. 
# Calculated from the average of the positive and negative controls using Equation 4.1. 
†  Calculated  from  the  average  and  standard  deviation  of  the  positive  and  negative 
controls using Equation 2.2, given to 2 decimal places. 
‡ DTP library screen data calculated from 39 sets of 8 positive and 8 negative controls, 
University of Cincinnati library screen data calculated from 39 sets of 8 positive and 8 
negative controls. 
§ Average of each screen ± standard deviation.  
 
Whilst a significant number of hits were initially identified from both screens, a high 
percentage  of  these  (96  and  80%  for  the  DTP  and  University  of  Cincinnati  libraries 
respectively)  were eliminated as  false  positives  during  counter-screening,  with  post-
counter-screening  hit  rates  similar  for  both  HTS  campaigns.  The  failure  of  in  silico 
screening to improve HTS results in this case is inconsistent with reported examples, 
in which the benefits of in silico enrichment have been documented (248) with possible 
causes  including  the  specific  in  silico  screening  method  applied,  the  quality  of  the 
crystal structure used to inform in silico screening, and the size and chemical diversity 
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Of  the  six  DTP  library  hits  and  10  University  of  Cincinnati  library  hits  investigated 
further, only one compound, the stibonic acid 13776, was found to exhibit modest 
(low micromolar) potency against Y. pestis Dam, whilst displaying some selectivity for 
Y. pestis Dam over the coupling enzyme DpnI. Although an additional 10 compounds 
identified as hits in the University of Cincinnati library screen were not investigated 
further, the likelihood of identifying a viable lead from these compounds is minimal as 
none  inhibited  Y.  pestis  Dam  by  greater  than  50%  at  50  µM,  and  all  showed  some 
activity against the coupling enzyme DpnI. 
 
Examples  of  hit  rates  from  other  fluorescence-based  HTS  campaigns  range  from 
around 0.1 to 1% (268-270), at least 500-times the rate observed in this study (a single 
lead from a total of 5,527 compounds represents a final hit rate of 0.0002%). Possible 
reasons  for  this  low  hit  rate  include  poor  sampling  of  chemical  diversity  in  library 
selection, a high  false-negative rate, or the application of a more rigorous  counter-
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7.1.2 Stibonic acids 
Sublibrary screening of compounds analogous to HTS hit 13776 identified a further 17 
arylstibonic  acids  with  activity  against  Y.  pestis  Dam.  Investigation  of  basic  SARs 
revealed that replacement of the stibonic acid moiety with an isosteric phosphonic acid 
group led to a total loss of activity. Of the compounds tested substituent groups were 
ranked  in  the  following  order  of  potency:  sulfonic  acid  >  carboxylic  acid  ≈  ester  > 
amide, with the meta-substituted compounds showing a slightly greater potency than 
their para- and ortho-substituted analogues where available. The minimal increases in 
potency observed are consistent with the carbonyl/sulfonyl oxygen atom acting as a 
hydrogen-bond acceptor which is positioned more favourably in the meta- substituted 
compounds. 
 
Poor  levels  of  selectivity  were  observed  for  the  arylstibonic  acids  against  both  the 
coupling enzyme DpnI and the human cytosine methyltransferase DNMT1, which, in 
light  of  the  identification  of  arylstibonic  acids  as  inhibitors  of  other  DNA  binding 
proteins  (255-258),  suggests  that  the  arylstibonic  acids  have  a  non-selective,  DNA-
competitive mode of action. However, the disruption of protein-protein interactions by 
arylstibonic acids has also been reported (259), raising the possibility that inhibition 
arises from nonspecific compound-protein interactions. 
 
Kinetic  characterisation  of  the  initial  DTP  library  hit  (13776)  and  the  most  potent 
inhibitor  (13746)  against  Dam  revealed  a  DNA-competitive  mode  of  action,  with  K
i 
values calculated as 960 ± 36 and 6.46 ± 0.07 nM for 13776 and 13746 respectively. 
Whilst  fluorescence  anisotropy  experiments  showed  both  compounds  to  completely 
displace a hemimethylated hairpin oligonucleotide substrate from E. coli Dam. These 
findings,  combined  with  the  negative  results  of  compound  aggregation  and 
oligonucleotide melting temperature experiments, suggest that the arylstibonic acids 
are binding to the surface of the protein and blocking the formation of a Dam:DNA 
complex. A similar phenomenon has been reported for Sb
III species, which have been 
shown to form stable complexes with intracellular thiols (271). 
 
Of the 17 arylstibonic acids found to be active against Dam in vitro a single compound, 
13782, was found to be active in Yersinia spp. cell culture. Cell growth and restriction 
digest  experiments  showed  13782  to  be  capable  of  penetrating  Yersinia  cells  and 
partially  inhibiting  methylation,  whilst  having  no  toxic  effect  on  cell  growth.  In 
addition,  mRNA  profiling  experiments  have  shown  13782  to  induce  a  statistically 
significant  change  in  a  total  of  91  Y.  pestis  ORFs,  including  the  Ybt  and  type  III 
secretion  systems,  both  of  which  are  involved in the  pathogenicity  of  Yersinia  spp. 
(262, 263). Unfortunately attempts at resynthesising 13782 have resulted in minimal J C McKelvie      Chapter 7 
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success,  with  re-synthesised  compound  GH13782  displaying  only  weak  potency 
against Y. pestis Dam (IC
50
GH13782 > 100 µM, compared with IC
50
13782 = 742 ± 83 nM). 
HPLC  analysis  of  both  13782  and  GH13782  have  identified  a  second  component 
present  only  in  the  original  sample,  whilst  the  activity  of  GH13782  in  cell  culture 
suggests that this secondary component may be a break-down product, the formation 
of which is catalysed more readily in vivo. J C McKelvie      Chapter 7 
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7.1.3 Bisubstrate analogues 
The in vitro evaluation of a series of bisubstrate compounds designed to mimic both 
the methyl donor AdoMet, and the methyl acceptor adenine, has established that the 
size  of  the  adenine  analogue  substituent  directly  affects  compound  potency. 
Comparison  of  the  inhibitor  AdoHcy  and  the  analogous  bisubstrate  inhibitor  (SA1) 
revealed that substitution of sulfur for nitrogen results in a significant but not total 
loss of activity, demonstrating the viability of an amine AdoMet analogue scaffold for 
the development of bisubstrate inhibitors. Substitution of the hydrogen atom of SA1 
with a methyl group led to a 3-fold decrease in potency, whilst substitution by a more 
bulky substituent, containing a single heteroaromatic ring, led to an even greater loss 
of potency.  
 
In contrast, substitution by a bicyclic heteroaromatic ring led to an increase in potency, 
with  the  indole  substituted  analogues  SA5  and  SA6  exhibiting  similar  levels  of 
potencies to that of AdoHcy. Examination of the crystal structure of E. coli Dam bound 
to both AdoHcy and the benzothiophene substituted analogue SA8 revealed that the 
bulky bicyclic heteroaromatic ring was accommodated by a conformational change in 
the protein backbone. Fluorescence anisotropy analysis of E. coli Dam and DNA in the 
presence  of  SA8  and  AdoHcy  showed  that  the  methyl  donor  product  stabilised  the 
enzyme-DNA  complex,  whilst  SA8  did  not.  This  result  suggests  that  either  the 
conformational change induced by SA8 is destabilising to the protein:DNA complex, or 
that  AdoHcy  (and  AdoMet)  induces  a  conformational  change  that  stabilises  the 
complex. 
  
Selectivity analysis showed the addition of a bicyclic heteroaromatic ring substituent to 
decrease the affinity of the analogues for DNMT1, whilst increasing their affinity for 
DpnI.  In  addition,  kinetic  characterisation  of  the  benzothiophene  analogue  (SA8) 
identified  an  AdoMet-competitive  mode  of  action.  These  findings  imply  that  both 
selectivity  and  potency  can  be  improved  by  modifying  the  AdoMet  and  adenine 
analogues independently, with the AdoMet analogue substituent controlling selectivity 
against  other  adenine  binding  proteins,  and  the  adenine  analogue  substituent 
controlling selectivity against other AdoMet binding proteins. J C McKelvie      Chapter 7 
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7.2 Further Work 
 
7.2.1 Identification of inhibitors 
The low hit rate observed for both HTS campaigns suggests that the identification of a 
viable lead would require the screening of a significantly larger number of compounds. 
Whilst  in  silico  screening  would  enable  large  libraries  to  be  screened  quickly  and 
relatively inexpensively, this methodology has to date proved unsuccessful as a means 
of  identifying  potent  and  selective  Dam  inhibitors.  A  fragment-based  screening 
approach  would  allow  a  diverse  range  of  chemical  space  to  be  sampled  without 
screening large numbers of compounds, thus minimising both cost and development 
time. In addition a fragment-based approach is ideal for probing targets with multiple 
binding  pockets,  such  as  Dam,  with  the  development  of  an  efficient  and  reliable 
crystallisation system for E. coli Dam facilitating the location of binding sites for active 
compounds. 
 
An initial fragment-based screening campaign has been implemented by J.E. Harmer, 
with  the  Maybridge  1,000-compound  RO3  fragment  library  screened  at  high 
concentration  (~1  mM)  to  identify  weak  binders.  Crystallisation  of  E.  coli  Dam  with 
screening  hits  is  currently  being  undertaken  to  establish  binding  sites,  with  future 
work hopefully involving the linking of weak  inhibitors binding different pockets to 
form a more potent amalgamated compound. 
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7.2.2 Characterisation of inhibitors 
The  real-time  break  light  Dam  activity  assay  has  proved  efficient  at  identifying  and 
ranking Dam inhibitors, however some issues have arisen due to the coupled nature of 
the assay. Specifically the inhibition of the coupled enzyme by  the primary enzyme 
substrate has led to difficulties in establishing mode of inhibition with respect to DNA 
concentration. To overcome this issue a fluorescence anisotropy DNA binding assay 
was developed to monitor Dam-DNA binding interactions. Whilst this assay has enabled 
the  direct  assessment  of  DNA-competitive  inhibition,  AdoMet-,  and  flipped  adenine-
competitive inhibition cannot probed so readily. 
 
A fluorescence anisotropy AdoMet binding assay could be applicable not only to the 
identification and characterisation of Dam inhibitors, but also to the identification and 
characterisation of inhibitors of other AdoMet-dependant methyltransferases. As such, 
a fluorescent AdoMet analogue (SA10) has been synthesised by Dr G. Hobley (Figure 
7.1). Initial experiments have shown SA10 to inhibit Y. pestis Dam with an IC
50 of 77.6 
± 32.6 µM, implying that the compound binds Dam, despite the addition of the bulky 
coumarin group. Further work is now required to determine whether SA10 could be 
used as a fluorescent probe for monitoring Dam-AdoMet binding interactions. 
 
    
Figure 7.1 Structure and fluorescence spectra of AdoMet analogue SA10 
Where 
EX
max  =  maximum  excitation  wavelength  and 
EM
max  =  maximum  emission 
wavelength. 
 
Probing  the  flipped  adenine  binding  pocket  has  previously  been  achieved  by 
monitoring the fluorescence of the adenine analogue 2AP in stopped flow fluorescence 
experiments  (93).  Adaptation  of  this  method  could  provide  a  third  direct  binding 
interaction assessment, with the effect of inhibitors on the binding of flipped adenine 
to the active site pocket monitored by changes in the fluorescence of 2AP. J C McKelvie      Chapter 7 
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7.2.3 Hit-to-lead progression  
7.2.3.1  Stibonic acids  
Further investigation of the stibonic acid Dam inhibitors requires identification of the 
active component of the in cell inhibitor 13782. Initially this may be achieved through 
the development of alternative HPLC methods compatible with Dam activity assays. In 
parallel with this other antimonial compounds, such as the anti-leishmaniasis drugs 
meglumine antimoniate and stibogluconate, could be tested both in vitro and in cell 
culture  and  their  effects  compared  with  those  of  the  stibonic  acid  Dam  inhibitors. 
Attempts at elucidating binding mode by crystallising E. coli Dam in the presence of 
the stibonic acids have to date been unsuccessful, however structural analysis of the 
protein in the presence of inhibitor could prove invaluable, with alternative methods 
such as circular dichroism (CD) spectroscopy providing insight into both the mode of 
action and binding site of these compounds. 
 
7.2.3.2  Bisubstrate analogues 
Analysis  of  the  bisubstrate  analogue  series  showed  the  addition  of  an  adenine-like 
moiety to increase selectivity for Dam over DNMT1, but reduce selectivity for Dam over 
DpnI.  Further  bisubstrate  analogue  libraries  should  therefore  focus  on  both  the 
AdoMet and the adenine moieties. To achieve this, a fragment-based approach could 
be  used  to  screen  separate  libraries  of  adenine  and  AdoMet  analogues,  with 
crystallisation used to identify the most efficient way of linking the two components. 
The identification of a more appropriate sulfur atom substitute is also required, and 
could potentially be achieved using an in silico approach to model the properties of 
potential  replacement  groups,  with  the  ease  of  synthesising  such  compounds  also 
carefully considered. J C McKelvie      Chapter 7 
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7.2.4 Investigating the stability of Dam 
Experiments have shown Y. pestis Dam to be thermally less stable than E. coli Dam, 
which is in turn less stable than the thermophillic P. horikoshii Dam. A similar result 
has  been  observed  for  wild-type  S.  typhimurium  Dam  and  a  C-terminal  deletion 
mutant, suggesting that temperature sensitivity is related to the C-terminus of the Dam 
protein  (272).  Alignment  of  all  four  sequences  (Figure  2.4)  shows  the  longest  and 
shortest C-terminals to correlate respectively to the most (P. horikoshii) and least (Y. 
pestis) thermally stable Dams. 
 
 
Figure 7.2 Alignment of Y. pestis, E. coli, S. typhimurium and P. horikoshii Dam 
Calculated  with  the  ClustalW  algorithm  using  the  program  Jalview  (95,  96).  100% 
identity shown in blue. 
 
Additionally fluorescence anisotropy experiments revealed that DNA was released over 
time from the Dam:DNA complex in the absence of AdoHcy for both Y. pestis and E. 
coli Dam. This result suggests that the protein undergoes a time-dependant change 
which leads to the release of DNA. A possible reason for this behaviour is that the 
binding  of  Dam  to  DNA  must  be  tightly  regulated  to  prevent  the  blocking  of 
methylated  GATC  sites  by  Dam.  The  specific  binding  of  the  protein  to  DNA  would 
therefore  occur  only  in  the  presence  of  the  methyl  donor  AdoMet,  as  previously 
observed  in  crystallographic  studies  of  both  E.  coli  and  T4  Dam  (91,  97,  98). 
Additionally, in the absence of DNA the protein may unfold, with the rate of unfolding J C McKelvie      Chapter 7 
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mediated  by  both  temperature  and  the  C-terminus.  Such  temperature-dependant 
denaturation may have a role in controlling the concentration of Dam within the cell, 
thus circumventing the potentially toxic effects of Dam overexpression. 
 
Investigation of this effect could be achieved through the study of further C-terminal 
deletion mutants, and the crystallisation of Dams with C-terminals of differing lengths, 
with  and  without  substrates.  Although  the  lack  of  a  published  substrate-free  Dam 
structure suggests that the crystallisation of the enzyme without substrates is difficult, 
giving  further  weight  to  the  theory  that  the  protein  unfolds  in  the  absence  of 
substrates.  Probing  of  this  unfolding  interaction  may  be  possible  through  a  more 
dynamic technique such as CD spectroscopy.   
  182   J C McKelvie    Chapter 8 
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8  Experimental 
 
8.1 Materials 
 
Chemicals 
AdoMet hydrochloride, AdoHcy, thiazole orange and standard dNMPs were purchased 
from Sigma Aldrich (Dorset, UK); dmAMP was purchased from AtdBio (Hampshire, UK); 
DTT,  BSA  and  antibiotics  were  purchased  from  Melford  Laboratories  (Suffolk,  UK); 
polyacrylamide-bis polyacrylamide (30% w/v, 37:5:1) and Bacto agar were purchased 
from Fisher Scientific (Leicestershire, UK); Bacto tryptone and yeast extract for culture 
media were purchased from Oxoid (Hampshire, UK); Chelating Fast Flow resins were 
purchased from GE Healthcare (Buckinghamshire, UK). 
 
All other chemicals were of the highest quality available and purchased from Sigma 
Aldrich or Fisher Scientific. 
 
Compound libraries 
The  DTP  library,  stibonic  acid  sublibrary  and  phosphonic  sublibrary  were  obtained 
from the NCI/DTP open chemical repository (http://dtp.cancer.gov); the University of 
Cincinnati library was obtained from the University of Cincinnati; Compounds UC1- 10 
were  re-sourced  from  Acros  Organics  (Fisher  Scientific),  Ambinter  (Orléans,  France), 
ChemBridge  (San  Diego,  USA),  Maybridge  (Fisher  Scientific)  and  Sigma  Aldrich;  the 
bisubstrate  analogue  library  was  synthesised  by  Dr  G.  Hobley  at  the  University  of 
Southampton. 
 
Consumables 
12 well clear sterile suspension plates with lids, 96 well half area black microplates and 
384 well low volume black HiBase microplates were purchased from Greiner Bio-One 
(Gloucestershire, UK); Biomek P20 and P250 robotic tips were purchased from Beckman 
Coulter  (Buckinghamshire,  UK);  LightCycler  capillaries  were  purchased  from  Roche 
(West  Sussex,  UK);  sterile  filters  were  purchased  from  Millipore  (Hertfordshire,  UK); 
Wizard  Plus  SV  Minipreps  Plasmid  DNA  Purification  System  was  purchased  from 
Promega  (Hampshire,  UK);  Gentra  Puregene  Yeast/Bacteria  kit  was  purchased  from 
Qiagen (West Sussex, UK). 
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E. coli Strains 
E.  coli  strains  GM43  (CGSC#  5127,  Marinus  M.G.),  GM2929  (CGSC#  7080,  Marinus 
M.G.), BW25113 (CGSC# 7636, Wanner, B.L.) and JW3350-2 (CGSC# 11675, the Keio 
collection) were obtained from the Yale E. coli genetic stock centre; E. coli ER2925 was 
purchased from New England Biolabs (Hertfordshire, UK); E. coli TOP10 was purchased 
from Invitrogen (Paisley, UK). 
 
Enzymes 
Restriction enzymes BclI, DpnI, MboI, NcoI and XhoI were purchased from New England 
Biolabs; His-tagged DpnI and Y. pestis Dam were prepared by M.D. Maynard-Smith and 
J.C. McKelvie and kept in frozen stocks at the University of Southampton; His-tagged P. 
horikoshii and E. coli Dam were prepared by J.E. Harmer and kept in frozen stocks at 
the  University  of  Southampton;  DNMT1  was  a  kind  gift  from  Cancer  Research 
Technologies  (London,  UK);  GlaI  was  purchased  from  SibEnzyme  (Siberia,  Russia); 
Nuclease P1 was purchased from Sigma-Aldrich; RNaseA and T1 were purchased from 
Roche. 
 
Oligonucleotides 
Oligonucleotides ODN1-12 were purchased from AtdBio. 
 
Plasmids 
E.  coli  GM43  harbouring  plasmid  pMMS/4958/59  was  prepared  by  M.D.  Maynard-
Smith  and  kept  in  frozen  stocks  at  the  University  of  Southampton;  plasmids 
pRJW/4213/07  and  pRL821  were  prepared  by  Dr  R.J.  Wood  and  Dr  R.  Leonardi 
respectively  and  kept  in  frozen  stocks  at  the  University  of  Southampton;  plasmid 
pBAD/HisA was purchased from Invitrogen. 
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8.2 Equipment 
 
Automated assay preparation 
Assays were prepared in 96 or 384 well plates using a Beckman Coulter Biomek 3000 
laboratory automation workstation at room temperature. 
 
Centrifugation 
Samples were centrifuged at 4 °C in a Sorval Evolution RC centrifuge fitted with an SLC-
6000 or an SLA-1500 rotor or a Heraeus Multifuge 1-R fitted with a Highconic rotor. 
Small volumes (< 1.5  ml)  were centrifuged in a bench top  microcentrifuge at room 
temperature.  
 
Computer software 
Data analysis was carried out using Microsoft Excel and MathWorks MATLAB; Graphs 
were plotted using Systat SigmaPlot 11; Protein structures were visualised with UCSF 
Chimera (77); Gel bands were quantified using ImageJ (227); Alignments, percentage 
identity and neighbour joining trees were calculated with Jalview  (95, 96); Chemical 
structures were drawn with CambridgeSoft ChemDraw Ultra 12. 
 
DNA melting profile analysis 
A  carousel-based  Roche  LightCycler  1.5  system  was  used  to  measure  DNA  melting 
profiles over temperature ranges of 30-95 °C. 
 
Fluorescence spectroscopy 
Fluorescence  measurements  were  recorded  in  a  Tecan  Safire
2  or  BMG  POLARstar 
Omega microplate reader and fluorescence anisotropy experiments were carried out in 
a BMG POLARstar Omega microplate reader. The following measurement parameters 
were applied unless otherwise stated: 
Tecan Safire
2 microplate reader – Z-Position of 9,300 µm for 96 well plates or 12 000 
µm for 384 well plates, integration time of 20 µs, 0 s between each movement and 
reading, no shaking between data collections. 
BMG POLARstar Omega microplate reader – Integration time of 20 µs, 0 s between 
each movement and reading, no shaking between data collections. 
 
Excitation and emission wavelengths, bandwidths, gain and temperature are stated for 
each experimental method. 
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FPLC 
A GE Healthcare FPLC System maintained at 4 °C was used for all protein purifications. 
 
HPLC analysis 
A  Gilson  system  workcenter  including  321  pumps  and  234  Gilson  autoinjector  was 
connected to a Shimadzu RF-10Axl fluorimeter and a Gilson UV/Vis-155 detector, and 
used for HPLC analysis at room temperature.   
 
Incubations 
Bacterial plate cultures were grown in a Gallenkamp Economy Incubator Size 2 (37 °C, 
overnight).  Bacterial  liquid  cultures  were  incubated  in  a  New  Brunswick  Scientific 
Innova 4400 Incubator Shaker (37 °C, 180 rpm), or a BMG POLARstar Omega microplate 
reader (37 °C, with double orbital shaking). 
 
pH determination 
A  Mettler  Delta  340  pH  meter  in  conjunction  with  a  Mettler  Toledo  Inlab  413 
Combination Electrode was used for pH measurements. This equipment was calibrated 
at pH 4.0–7.0 or pH 7.0–10.0 before use and stored in 3 M potassium chloride. 
 
UV-Vis spectroscopy 
UV  absorbance  measurements  were  recorded  with  a  Thermo  Electron  Biomate  3 
spectrophotometer  and  UV  spectra  were  recorded  with  BMG  POLARstar  Omega 
microplate reader. 
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8.3 General Methods 
 
8.3.1 Microbiological Methods 
Standard  sterile  techniques  were  used  during  all  microbiological  experiments. 
Sterilisation of growth media and heat stable solutions was achieved with a PriorClave 
autoclave  (121  °C,  25  min).  Heat  labile  solutions  (antibiotics  and  arabinose)  were 
sterilised by filtration through 0.22 µm filters. 
 
Growth media were supplemented with antibiotics (dependant on specific cell strain 
antibiotic resistance) of the following concentrations: 
ampicillin, 100 µg ml
-1 
kanamycin, 10 µg ml
-1 
chloramphenicol 30 µg ml
-1 
 
8.3.1.1  The rubidium chloride method for making competent cells 
2YT  media  (100  ml)  was  inoculated  with  overnight  cultures  of  E.  coli  (1  ml).  The 
resulting culture was incubated with shaking (37 °C, 180 rpm) until an OD
600 of ~0.6 
was reached. Cultures were then cooled on ice (<4 °C, 10 min) and cells harvested by 
centrifugation (2 x 50 ml, 4 °C, 4000 rpm, 10 min). The supernatant was decanted and 
the centrifuge tubes inverted to remove excess liquid (4 °C, 1 min). Cell pellets were 
resuspended in TBFI (10 ml, 4 °C) and recovered by centrifugation (2 x 10 ml, 4 °C, 
4000 rpm, 10 min). The supernatant was decanted and the centrifuge tubes inverted to 
remove excess liquid (4 °C, 2 min). Cell pellets were resuspended in TBFII (1.5 ml, 4 °C) 
and aliquots (100 µl) flash frozen on dry ice and stored at -80 °C until required. 
 
8.3.1.2  Transformation 
Plasmid solution (1 µl, <4 °C) was added with gentle mixing to an aliquot of thawed (<4 
°C) competent cells and the cells incubated on ice (<4 °C, 30-40 min). Cells were then 
heat shocked (42 °C, 45 s) before being returned to the ice (<4 °C, 2 min). SOC media 
(250 µl, 37 °C) was added to the heat shocked cells which were then incubated with 
shaking  (37  °C,  180  rpm,  1  hr).  Antibiotic  (dependant  on  the  cell  strain  used) 
supplemented  2YT  media  plates  (37  °C)  were  spread  with  transformed  cell  solution 
(100 µl) and incubated (37 °C, overnight). Plates were sealed and stored at 4 °C for up 
to 8 weeks. 
 
8.3.1.3  Preparation of glycerol freezes 
Overnight culture of E. coli, prepared by inoculation of 2YT media with a single colony 
picked from an agar plate, was mixed with sterile glycerol (70%) in a 4:1 ratio and 
aliquots were stored at -80 °C until required. J C McKelvie    Chapter 8 
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8.3.1.4  Isolation of plasmid DNA 
E. coli cells were harvested from cultures by centrifugation (1-10 ml, 4 °C, 4000 rpm, 
10 min) and plasmid DNA was isolated using the Promega Wizard Plus SV Minipreps 
Plasmid DNA Purification System, as per the manufacturer‟s instructions. Plasmid DNA 
was eluted from the purification column with sterile water (50-100 µl) and stored at -20 
°C until required. 
 
8.3.1.5  Isolation of genomic DNA 
E. coli cells were harvested from cultures by centrifugation (1 ml, 13,200 rpm, 5 min) 
and genomic DNA was isolated using the Qiagen Gentra Puregene Yeast/Bacteria Kit, 
as per the manufacturer‟s instructions, with the exception of the RNase digestion step 
which was modified to digestion (37 °C, 30 min) with RNase A/T1 solution (0.5 µg µl
-1 
/50 U µl
-1, 20 µl). Genomic DNA was eluted from the purification column with sterile 
water (100 µl) and stored at -20 °C until required. 
 
8.3.1.6  Analytical digests 
The analytical digest solution described below (Table 8.1) was prepared and incubated 
at the optimal temperature
12 (typically 37 °C, 1 hr). The results were analysed by 0.8 or 
1% agarose gel electrophoresis with ethidium bromide staining. 
 
Table 8.1 Analytical digest solution 
Component  Final Concentration  Quantity 
Plasmid DNA (100-500 ng µl
-1)  50-250 ng µl
-1  5 µl 
NEBuffer1-4
12 (10x)  1x  1 µl 
BSA
13 (1 mg µl
-1)  0.1 mg µl
-1  1 µl 
Restriction enzyme(s) (5-20 U µl
-1)  0.25-1 U µl
-1  0.5 µl (per enzyme)
 
Sterile Water    To a final volume of 10 µl 
 
8.3.1.7  Determination of protein concentration by Bradford Assay 
Protein  concentration  was  assayed  using  the  method  of  Bradford  (211).  Bradford 
reagent  (1  ml)  was  added  to  a  protein  sample  (20  µl)  and  incubated  (5  min,  room 
temperature). Absorbance at 595 nm (OD
595) was measured, and the sample diluted if 
OD
595 exceeded 1.0. Calibration curves were prepared from BSA standards and used to 
convert OD
595 to protein concentration.  
                                                
12 Optimal buffer and temperature conditions for each restriction enzyme were selected using the 
NEBuffer Activity Chart (available online at http://www.neb.com). 
13 BSA was only added when recommended by the manufacturer. J C McKelvie    Chapter 8 
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8.3.1.8  SDS-PAGE 
15% SDS-PAGE gels were prepared by mixing the components described in Table 8.2 
and Table 8.3 respectively, with the resolving gel (~4 ml) poured first and allowed to 
set (~45 min) before pouring of the stacking gel (~1.5 ml). 
 
Table 8.2 15% SDS-PAGE resolving gel 
Component  Final Concentration  Quantity 
Acrylamide/bis acrylamide (30%)  15%  2.5 ml 
Tris (pH 8.8, 1.5 M)  0.4 M  1.3 ml 
SDS (10%)  0.1%  50 µl 
Ammonium persulfate (10%)  0.1%  50 µl 
TEMED  0.04%  2 µl 
Deionised Water    1.1 ml 
Total Volume    5 ml 
 
Table 8.3 5% SDS-PAGE stacking gel 
Component  Final Concentration  Quantity 
Acrylamide/bis acrylamide (30%)  5%  333 µl 
Tris (pH 6.8, 1 M)  0.2  400 µl 
SDS (10%)  0.1%  20 µl 
Ammonium persulfate (10%)  0.1%  20 µl 
TEMED  0.1%  2 µl 
Deionised Water    1.23 ml 
Total Volume    2 ml 
 
Samples were prepared by mixing protein solution in a 1:1 ratio  with 2x SDS-PAGE 
loading buffer and denaturing (95 °C, 5 min). Samples (15 µl) were then loaded onto 
the gel and electrophoresis was carried out (200 V, in 1x SDS-PAGE running buffer). 
Gels were stained with coomassie brilliant blue and destained in destain solution (12-
48 hrs) before imaging. 
 
8.3.1.9   Small scale protein expression studies 
An overnight E. coli starter culture (1 ml) was used to inoculate 2YT media (100 ml) 
supplemented  with  antibiotic  (dependant  on  cell  strain).  The  culture  was  incubated 
with  shaking  (37  °C,  180  rpm)  and  OD
600  monitored.  At  an  OD
600  of  0.6  cells  were 
induced by the addition of sterile arabinose solution (20% w/v, 1 ml). Cells were then J C McKelvie    Chapter 8 
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incubated with shaking (37 °C, 180 rpm), with a samples (1 ml) removed every hour for 
analysis.  Cells  from  samples  were  immediately  harvested  by  centrifugation  (10,000 
rpm, 10 min) and the supernatant discarded. Cell pellets were then analysed by SDS-
PAGE (Section 8.3.1.8). 
 
8.3.1.10 Large scale protein expression 
An overnight E. coli starter culture (12.5 ml) was used to inoculate 2YT media (1.25 L) 
supplemented  with  antibiotic  (dependant  on  cell  strain).  The  culture  was  incubated 
with  shaking  (37  °C,  180  rpm)  and  OD
600  monitored.  At  an  OD
600  of  0.6  cells  were 
induced by the addition of sterile arabinose solution (20% w/v, 1.25 ml) and cultures 
were incubated with shaking (37 °C, 180 rpm). Cells were harvested by centrifugation 
(4 °C, 7000 rpm, 30 min) and stored at -80 °C until required. Time of harvesting was 
dependant on expression studies and growth monitoring, and is stated for each large 
scale growth described. 
 
8.3.1.11 Purification of His-tagged protein 
Frozen cell pellet (10 g) was resuspended in ice cold low imidazole buffer (30 ml, <4 
°C, 10 min). Lysozyme (5-15 mg) was added and the resuspension mixture stirred on 
ice (<4 °C, 15 min). The solution was then sonicated on ice (<4 °C, 20 x 10 s with 10 s 
rest). Protein concentration was determined by Bradford Assay, as described in Section 
0,  and  if  a  concentration  of  <20  mg  ml
-1  was  observed  sonication  was  repeated  as 
before. The lysate was then centrifuged (4 °C, 14000 rpm, 30 min) to precipitate cell 
debris,  and  the  resulting  supernatant  loaded  (4  ml  min
-1)  onto  a  Ni-NTA  sepharose 
column with a bed volume of 10 ml. The column was then washed
 with low imidazole 
buffer (4 ml min
-1, 150 ml). Elution of His-tagged protein was achieved with a 0-100% 
step  to  high  imidazole  buffer.  Eluted  fractions  containing  protein  (determined  by 
Bradford assay as before) were pooled and desalted by dialysis (2 x 500 ml, 30 min) 
into storage buffer and stored at -80 °C until required. J C McKelvie    Chapter 8 
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8.3.2 Real-time break light enzyme activity assay methods 
8.3.2.1  Real-time break light Dam activity assay 
The activity of Y. pestis or E. coli Dam was measured in triplicate (unless otherwise 
stated) in Greiner 96 well half area black microplates with a total assay volume of 100 
μl, or Greiner 384 well low volume black HiBase microplates with a total assay volume 
of 20 μl, maintained at 30 °C. Assays were prepared as described below using a Biomek 
3000  laboratory  automation  workstation  (unless  otherwise  stated)  and  fluorescence 
changes were recorded in a Tecan Safire
2 microplate reader with 10 readings per well 
(each measurement), measurement parameters were as described previously (Section 
8.2). Excitation was set at 486 nm (5 nm bandwidth) and emission at 518 nm (10 nm 
bandwidth). Microplate reader gain was as stated per experiment. 
 
Assays  containing  buffer  A  or  B  supplemented  with  AdoMet  and  hemimethylated 
oligonucleotide  ODN1  were  equilibrated  in  a  Tecan  Safire
2  (30  °C,  10  min)  prior  to 
initiation with ice-cold Y. pestis Dam and DpnI in buffer A or B. An average background 
fluorescence was determined over 5 readings prior to initiation and subtracted from 
the  fluorescence  of  initiated  assays,  monitored  over  2000-4000  s.  Initial  rate  of 
fluorescence  change  was  determined  as  the  gradient  of  the  first  ten  background 
subtracted data points or as the maximum differential of a moving average taken over 
5 background subtracted data points. Rate of change of fluorescence was converted to 
initial  rate  of  reaction  using  calibration  plots,  prepared  as  described  in  Appendix 
Section 9.4.1, and non-specific background changes in fluorescence were accounted 
for by subtracting a negative control (lacking AdoMet) where appropriate. 
 
8.3.2.2  Real-time break light DpnI activity assay 
The activity of DpnI was measured in triplicate (unless otherwise stated) in Greiner 96 
well half area black microplates with a total assay volume of 100 μl, or Greiner 384 
well  low  volume  black  HiBase  microplates  with  a  total  assay  volume  of  20  μl, 
maintained at 30 °C. Assays were prepared as described below using a Biomek 3000 
laboratory automation workstation (unless otherwise stated) and fluorescence changes 
were recorded  in a Tecan Safire
2 microplate reader with 10 readings per well (each 
measurement), measurement parameters were as described previously (Section 8.2). 
Excitation  was  set  at  486  nm  (5  nm  bandwidth)  and  emission  at  518  nm  (10  nm 
bandwidth). Microplate reader gain was as stated per experiment. 
 
Assays containing buffer A or B supplemented with hemimethylated oligonucleotide 
ODN1 or fully methylated oligonucleotide ODN2 were equilibrated in a Tecan Safire
2 
(30  °C,  10  min)  prior  to  initiation  with  ice-cold  DpnI  in  buffer  A  or  B.  An  average 
background  fluorescence  was  determined  over  5  readings  prior  to  initiation  and 
subtracted  from  the  fluorescence  of  initiated  assays,  monitored  over  2000-4000  s. J C McKelvie    Chapter 8 
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Initial  rate  of  fluorescence  change  was  determined  as  the  gradient  of  the  first  ten 
background  subtracted  data  points  or  as  the  maximum  differential  of  a  moving 
average  taken  over  5  background  subtracted  data  points.  Rate  of  change  of 
fluorescence was converted to initial rate of reaction using calibration plots, prepared 
as  described  in  Appendix  Section  9.4.1,  and  non-specific  background  changes  in 
fluorescence were accounted for by subtracting a negative control (lacking DpnI) where 
appropriate. 
 
8.3.2.3  Real-time break light cytosine methyltransferase activity assay 
The activity of DNMT1 was measured in triplicate (unless otherwise stated) in Greiner 
384  well  low  volume  black  HiBase  microplates,  with  a total assay  volume  of  20  μl, 
maintained at 37 °C. Assays were prepared as described below using a Biomek 3000 
laboratory automation workstation and fluorescence changes were recorded in a Tecan 
Safire
2 or BMG POLARstar Omega microplate reader with 10 readings per well (each 
measurement), measurement parameters were as described previously (Section 8.2). 
For the Tecan Safire
2 excitation was set at 486 nm (5 nm bandwidth) and emission at 
518 nm (10 nm bandwidth), and for the BMG POLARstar Omega excitation was set at 
490  nm  (5  nm  bandwidth)  and  emission  at  520  nm  (5  nm  bandwidth).  Microplate 
reader gain was as stated per experiment. 
 
Assays  containing  buffer  C  supplemented  with  AdoMet  and  partially  methylated 
oligonucleotide  ODN4/6/8  were  equilibrated  in  a  Tecan  Safire
2  or  BMG  POLARstar 
Omega  (37  °C,  10-30  min)  prior  to  initiation  with  DNMT1  and  GlaI  in  buffer  D.  An 
average background fluorescence was determined over 5 readings prior to initiation 
and subtracted from the fluorescence of initiated assays, monitored over 2000-6000 s. 
Initial  rate  of  fluorescence  change  was  determined  as  the  gradient  of  background 
subtracted data collected between 500 and 1000 s (allowing for a slight lag phase). 
Rate  of  change  of  fluorescence  was  converted  to  initial  rate  of  reaction  using 
calibration plots, prepared as described in Appendix Section 9.4.2, and non-specific 
background  changes  in  fluorescence  were  accounted  for  by  subtracting  a  negative 
control (lacking AdoMet) where appropriate. 
 
8.3.2.4  Real-time break light GlaI activity assay 
The activity of GlaI was measured in triplicate (unless otherwise stated) in Greiner 384 
well  low  volume  black  HiBase  microplates,  with  a  total  assay  volume  of  20  μl, 
maintained at 37 °C. Assays were prepared as described below using a Biomek 3000 
laboratory automation workstation and fluorescence changes were recorded in a Tecan 
Safire
2 or BMG POLARstar Omega microplate reader with 10 readings per well (each 
measurement), measurement parameters were as described previously (Section 8.2). J C McKelvie    Chapter 8 
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For the Tecan Safire
2 excitation was set at 486 nm (5 nm bandwidth) and emission at 
518 nm (10 nm bandwidth), and for the BMG POLARstar Omega excitation was set at 
490  nm  (5  nm  bandwidth)  and  emission  at  520  nm  (5  nm  bandwidth).  Microplate 
reader gain was as stated per experiment. 
 
Assays  containing  buffer  C  supplemented  with  partially  methylated  oligonucleotide 
ODN4/6/8 or fully methylated oligonucleotide ODN5/7/9 were equilibrated in a Tecan 
Safire
2  or  BMG  POLARstar  Omega  (37  °C,  10-30  min)  prior  to  initiation  with  GlaI  in 
buffer D. An average background fluorescence was determined over 5 readings prior to 
initiation  and  subtracted  from  the  fluorescence  of  initiated  assays,  monitored  over 
2000-6000 s. Initial rate of fluorescence change was determined as the gradient of 
background subtracted data collected between 500 and 1000 s (allowing for a slight 
lag  phase). Rate of change of fluorescence was converted to  initial rate of reaction 
using  calibration  plots,  prepared  as  described  in  Appendix  Section  9.4.2,  and  non-
specific  background  changes  in  fluorescence  were  accounted  for  by  subtracting  a 
negative control (lacking GlaI) where appropriate. 
 
8.3.2.5  Determination of KM from real-time break light activity assays 
Enzyme activity was determined as described in Sections 8.3.2.1, 8.3.2.2 and 8.3.2.3 
for assays supplemented with substrates at a range of concentrations (one fixed, one 
variable). Control assays lacking AdoMet (negative) were also prepared. Plots of initial 
rate versus substrate concentration were fitted to Equation 2.4B to determine K
M. 
 
8.3.2.6  High-throughput screening 
Sets of 96 assays were prepared as described in Sections 8.3.2.1 and 8.3.2.3 in Greiner 
384  well  low  volume  black  HiBase  microplates,  with  a total assay  volume  of  20  μl. 
Assays were supplemented with library compounds dissolved in DMSO or ammonium 
carbonate, and control assays lacking library compound, but supplemented with DMSO 
or  ammonium  carbonate  (positive)  or  lacking  library  compound  and  AdoMet,  but 
supplemented with DMSO or ammonium carbonate (negative) were also prepared. The 
Z‟-value  for  each  assay  set  (80  compounds  and  16  controls)  was  calculated  using 
Equation 2.2 and hits were classified as those compounds falling outside 3 standard 
deviations from the average of the positive control. 
 
8.3.2.7  Determination of IC50 from real-time break light activity assays 
Enzyme activity was determined as described in Sections 8.3.2.1, 8.3.2.2 and 8.3.2.3 
for assays supplemented with inhibitor at a range of concentrations. Control assays 
lacking  library  compound,  but  supplemented  with  DMSO  or  ammonium  carbonate 
(positive) or lacking library compound and AdoMet, but supplemented with DMSO or 
ammonium carbonate (negative) were also prepared. Fractional activity was calculated J C McKelvie    Chapter 8 
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using Equation 2.6A and a plot of fractional activity against inhibitor concentration 
was fitted to Equation 2.6B to determine IC
50. 
 
8.3.2.8  Determination of Ki from real-time break light activity assays 
Enzyme  activity  was  determined  in  duplicate  as  described  in  Sections  8.3.2.1  and 
8.3.2.3  for  assays  supplemented  with  inhibitor  at  a  range  of  concentrations  and 
substrates  at  a  range  of  concentrations  (one  fixed,  one  variable).  Control  assays 
lacking  inhibitor,  but  supplemented  with  DMSO  (positive)  or  lacking  inhibitor  and 
AdoMet, but supplemented with DMSO (negative) were also prepared. Lineweaver-Burk 
plots  of  reciprocal  rate  and  substrate  concentration  data  for  each  inhibitor 
concentration were globally fitted to Equation 2.8A to determine K
M
app and V
max
app. Re-
plots of y-axis intercept and gradient against inhibitor concentration were then fitted 
to Equation 2.8B and C to determine K
i and αK
i respectively from the negative of the x-
axis intercepts. J C McKelvie    Chapter 8 
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8.3.3 Counter-screening assay methods 
8.3.3.1  DpnI counter-screen 
Sets of 96 assays were prepared as described in Section 8.3.2.2 in Greiner 384 well low 
volume  black  HiBase  microplates,  with  a  total  assay  volume  of  20  μl.  Assays  were 
supplemented with library compounds dissolved in DMSO and control assays lacking 
library compound, but supplemented with DMSO (positive) or lacking library compound 
and DpnI, but supplemented with DMSO (negative) were also prepared. The Z‟-value for 
each assay set (80 compounds and 16 controls) was calculated using Equation 2.2 and 
hits (non-DpnI inhibitors) were classified as those compounds falling within 3 standard 
deviations from the average of the positive control or those compounds inhibiting DpnI 
by less than 50% compared to the average of the positive controls. 
 
8.3.3.2  Fluorescent intercalator displacement (FID) counter-screen 
The  relative  percentage  of  fluorescent  intercalator  displacement  was  measured  in 
triplicate  (unless  otherwise  stated)  in  Greiner  384  well  low  volume  black  HiBase 
microplates, with a total assay volume of 20 μl, maintained at room temperature (~25 
°C).  Assays  were  prepared  as  described  below  using  a  Biomek  3000  laboratory 
automation  workstation  and  fluorescence  changes  were  recorded  in  a  Tecan  Safire
2 
microplate  reader  with  10  readings  per  well  (each  measurement)  and  measurement 
parameters were as described previously (Section 8.2). Excitation was set at 504 nm (5 
nm bandwidth) and emission at 527 nm (5 nm bandwidth). Microplate reader gain was 
as stated per experiment. 
 
Assays  containing  buffer  D  supplemented  with  hemimethylated  unlabelled 
oligonucleotide ODN3, thiazole orange and DMSO (5%) were equilibrated in a Tecan 
Safire
2 (~25 °C, 5 min). Library compound and DMSO (5%) were then added and assays 
were  equilibrated  in  a  Tecan  Safire
2  (~25  °C,  30  min).  An  average  of  10  end-point 
fluorescence  readings  were  then  taken  and  percentage  fluorescence  decrease  was 
calculated relative to an average of three positive controls (lacking library compound) 
using Equation 8.1. 
 
Percentage fluorescence decrease =  100
s
c
 
Equation 8.1 Percentage fluorescence decrease 
Where µ
s = assay fluorescence signal and µ
c+ = average of the positive control assay 
fluorescence signals. 
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8.3.4 Additional assay and characterisation methods 
8.3.4.1  Fluorescence anisotropy assay 
Fluorescence anisotropy was measured in triplicate (unless otherwise stated) in Greiner 
96 well half area black microplates, with a total assay volume of 100 μl, maintained at 
25-30 °C. Assays were prepared as described below using a Biomek 3000 laboratory 
automation workstation and fluorescence changes were recorded in a BMG POLARstar 
Omega microplate reader with 10 readings per well (each measurement), measurement 
parameters were as described previously (Section 8.2). Excitation was set at 490 nm (5 
nm bandwidth) and dual emission at 520 nm (5 nm bandwidth). Microplate reader gain 
for emission channels A and B was as stated per experiment. 
 
Assays  containing  buffer  B  or  E  supplemented  with  hemimethylated  oligonucleotide 
ODN10  or  fully  methylated  oligonucleotide  ODN11  were  equilibrated  in  a  BMG 
POLARstar Omega (25 °C, 10 min) prior to initiation with ice-cold enzyme in buffer B or 
E.  The  parallel  and  perpendicular  fluorescein  emission  of  initiated  assays  was 
monitored  over  2000-14000  s.  Control  assay  containing  no  enzyme  or  DNA 
(background) and no enzyme (negative) were also prepared. Fluorescence anisotropy 
was  calculated  from  background  subtracted  parallel  and  perpendicular  fluorescence 
using Equation 3.2B. 
 
Determination of KD from fluorescence anisotropy assays 
Assays  were  prepared  as  described  above  and  supplemented  with  Tween-20  and  a 
range of enzyme concentrations. Fluorescence anisotropy was plotted against enzyme 
concentration  and  fitted  to  a  ligand  binding  calibration  curve  (Equation  3.3B)  to 
determine the anisotropy of the bound and free labelled ligand. This data was then 
used to convert fluorescence anisotropy to fraction of substrate bound using Equation 
3.3A, and fraction of substrate bound was plotted against enzyme concentration and 
fitted to Equation 3.3C to determine K
D. 
 
Determination  of  competition  binding  constants  from  fluorescence  anisotropy 
assays 
Assays  were  prepared  as  described  above  and  supplemented  with  Tween-20  and  a 
range of inhibitor concentrations. Fluorescence anisotropy was converted to fraction of 
substrate  bound  using  Equation  3.3A  and  the  anisotropy  of  the  bound  and  free 
labelled ligand determined from a ligand binding calibration curve (as above). A plot of 
fraction of substrate bound against inhibitor concentration was then fitted to Equation 
3.4 to determine K
Dc. 
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8.3.4.2  Determination of oligonucleotide melting profiles 
Oligonucleotide melting profiles were measured in triplicate (unless otherwise stated) 
in Roche LightCycler capillaries, with a total assay volume of 20 μl, over a temperature 
range of 30-95 °C. Fluorescence changes at an emission wavelength of 530 nm were 
recorded in a Roche LightCycler with using the following program: 
 
Step  Temperature 
°C 
Rate of change 
°C s-1 
Step Time 
min 
Denature  30-95  1  5 
Anneal  95-30  0.017  65 
Hold  30  -  10 
Melt  30-95  0.017  65 
Cool  95-30  1  10 
 
Fluorescence versus time data was differentiated, with T
m calculated from the maxima 
of annealing data or the minima of melting data. 
 
8.3.4.3  Gel-based Dam methylation assay 
Unmethylated plasmid pRL821 was prepared by transforming methylated pRL821 into 
competent cells of the Dam
- E. coli strain ER2925 (prepared as described in Section 
8.3.1.1) following the protocol described in Section 8.3.1.2. Unmethylated plasmid was 
then  isolated  from  overnight  cultures  of  ER2925  harbouring  plasmid  pRL821  as 
described in Section 8.3.1.4. 
 
Methylation  assays  were  prepared  by  supplementing  NEBuffer  3  with  unmethylated 
plasmid pRL821, E. coli Dam, AdoMet, DMSO and library compound in a final volume 
of 20 µl. Control assays containing no compound (positive) and no AdoMet (negative) 
were also prepared in some cases. Assays were incubated in an Eppendorf Mastercycler 
Gradient thermal cycler (30 °C, 1 hr), the restriction enzymes BclI (15 U ul
-1, 1 µl) and 
XhoI (20 U ul
-1, 1 µl) were then added and assays incubated (37 °C, 1 hr followed by 50 
°C, 1 hr). The results were analysed by 0.8% agarose gel electrophoresis with ethidium 
bromide staining, and quantified with the program ImageJ (227). 
8.3.4.4  In culture gel-based plasmid methylation assay 
Plasmid  pRL821  was  transformed  into  competent  E.  coli  TOP10  cells  (prepared  as 
described  in  Section  8.3.1.1)  following  the  protocol  described  in  Section  8.3.1.2. 
Overnight cultures of TOP10 harbouring plasmid pRL821 were used to inoculate 2YT 
media (1 ml) supplemented with inhibitor and DMSO to an initial OD
600 of 0.05. Positive 
control assays containing no compound were also prepared. Assays were prepared in J C McKelvie    Chapter 8 
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Greiner  12  well  clear  sterile  suspension  plates  with  lids  and  maintained  in  a  BMG 
POLARstar Omega (37 °C, with double orbital shaking). OD
600 was monitored and cells 
were  harvested  after  5  hours.  Plasmid  DNA  was  isolated  from  harvested  cells  as 
described  in  Section  8.3.1.4  and  the  plasmid  methylation  state  was  analysed  as 
described in Section 8.3.4.3. 
 
8.3.4.5  In culture HPLC-based genomic DNA methylation assay 
Overnight  cultures  of  E.  coli  BW25113  were  used  to  inoculate  2YT  media  (1  ml) 
supplemented  with  inhibitor  and  DMSO  to  an  initial  OD
600  of  0.05.  Control  assays 
containing DMSO  were  also  prepared  and  inoculated  with  E.  coli  BW25113  (positive 
control) or JW3350-2 (negative inhibition control). Assays were prepared in Greiner 12 
well  clear  sterile  suspension  plates  with  lids  and  maintained  in  a  BMG  POLARstar 
Omega (37 °C, with double orbital). OD
600 was monitored and cells were harvested after 
5 hours. Genomic DNA was isolated as described in Section 8.3.1.5 and dNMPs were 
excised by heat denaturation (90 °C, 10 min) followed by rapid cooling (4 °C, 1 min) 
and digestion (50 °C, 4 hrs) with nuclease P1 solution (3 µg µl
-1, 4 µl). Nuclease P1 was 
inactivated  by  heat  denaturation  (90  °C,  10  min)  followed  by  centrifugation  (5  min, 
13,200  rpm)  to  remove  debris.  dNMP  solution  (80  µl)  or  dNMP  standard  solution 
(prepared by dissolving dNMP standards in water) was injected onto a Gemini 5u C18 
110A column, washed with HPLC buffer A [pH 7, 5 mM DMHA, 5% MeOH] (4 min, 0.8 
ml min
-1) and eluted with a gradient of HPLC buffer B [pH 7, 5 mM DMHA, 80% MeOH] 
as described for each experiment. 
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8.4 Experimental for Chapter 2 
 
8.4.1 Large scale growth and purification of His-tagged DpnI 
8.4.1.1  Large scale DpnI growth 
Large  scale  growths  of  E.  coli  GM43  harbouring  the  DpnI  expression  plasmid 
pMMS/4958/59 were carried out as described in Section 8.3.1.10, with cells harvested 
after 4 or 3 hours. 
 
8.4.1.2  DpnI purification 
Purification of His-tagged DpnI was carried out as described in Section 8.3.1.11, with 
the  low  imidazole  buffer  supplemented  with  PMSF  (1  mM)  and  a  Roche  protease 
inhibitor tablet. 
 
8.4.1.3  Determination of DpnI activity 
The  activity  of  purified  DpnI  was  determined  using  the  real-time  break  light  DpnI 
activity assay, as described in Section 8.3.2.2. Assays were prepared by hand in 96 well 
plates in a total volume of 100 µl using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  100 
Buffer  A 
Substrate(s)  300 nM ODN1 or 2 
25 µM AdoMet 
Enzyme(s)  0.8 (ODN1) or 0.08 (ODN2) nM DpnI 
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8.4.2 Large scale growth and purification of His-tagged Y. pestis Dam 
8.4.2.1  Large scale Y. pestis Dam growth 
Large  scale  growths  of  E.  coli  ER2925  and  GM2929  harbouring  the  Y.  pestis  Dam 
expression plasmid pRJW/4958/59 were carried out as described in Section 8.3.1.10, 
with cells harvested once growth had reached the stationary phase (290 minutes for 
GM2929 cells and 320 minutes for ER2925 cells). 
 
8.4.2.2  Y. pestis Dam purifications 
Purification  of  His-tagged  Y.  pestis  Dam  was  carried  out  as  described  in  Section 
8.3.1.11,  with  the  low  imidazole  buffer  supplemented  with  Triton-X  (0.05%)  for  the 
second purification. 
 
8.4.2.3  Determination of Y. pestis Dam activity 
The activity of purified Y. pestis Dam was determined using the real-time break light 
Dam activity assay, as described in Section 8.3.2.1. Assays were prepared by hand in 
96 well plates in a total volume of 100 µl using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  130 
Buffer  A 
Substrate(s)  30 nM ODN1 
25 µM AdoMet 
Enzyme(s)  2 nM Y. pestis Dam 
0.8 nM DpnI 
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8.4.3 Optimisation of the real-time break light Dam activity assay 
8.4.3.1  Buffer conditions 
Dam and DpnI activity assays were prepared by hand in 96 well plates in a total volume 
of 100 µl, as described in Sections 8.3.2.1 and 8.3.2.2, with the components of assay 
buffer B varied to determine the optimal buffer conditions. Assay conditions were as 
described below for each assay format: 
 
DpnI activity assay 
Component/Parameter  Amount/Value 
Gain setting  130 
Buffer  B 
Varied buffer components  NaCl (0-150 mM) 
MgCl
2 (0-30 mM) 
Substrate(s)  30 nM ODN1 or 2 
25 µM AdoMet 
Enzyme(s)  0.8 nM DpnI 
 
Dam activity assay 
Component/Parameter  Amount/Value 
Gain setting  130 
Buffer  B 
Varied buffer components  NaCl (0-150 mM) 
MgCl
2 (0-30 mM) 
Substrate(s)  30 nM ODN1 
25 µM AdoMet 
Enzyme(s)  2 nM Y. pestis Dam 
0.8 nM DpnI 
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8.4.3.2  Assay temperature 
Dam activity assays were prepared by hand in 96 well plates in a total volume of 100 
µl, as described in Section 8.3.2.1 with enzyme and assay solutions incubated at 28, 
30, 32, 34, 38 and 40 °C prior to initiation and during the assay. Conditions were as 
described below: 
 
Component/Parameter  Amount/Value 
Gain setting  130 
Buffer  A 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
0.8 nM DpnI 
 
8.4.3.3  Enzyme concentration 
Dam activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.1. With DpnI concentration varied to determine the optimal 
amount of coupled enzyme, and Y. pestis Dam concentration varied to determine the 
linear range of the assay. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 or 0-4 nM Y. pestis Dam 
0-4 or 2 nM DpnI 
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8.4.3.4  Enzyme stability 
Y. pestis Dam was incubated with oligonucleotide ODN1, AdoMet or no substrates in 
an Eppendorf Mastercycler Gradient thermal cycler (30 °C,  0-1600 s), the remaining 
assay components were then added and Y. pestis Dam activity determined as described 
in Section 8.3.2.1. Assays were prepared in 384 well plates in a total volume of 20 µl 
using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
8.4.3.5  Effect of compound library solvent 
Dam activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in  Section 8.3.2.1 and supplemented  with 0-10% DMSO.  Assay conditions 
were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  0-10% 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
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8.4.3.6  Assay volume 
Dam activity assays were prepared in 96 or 384 well plates in a total volume of 20 or 
100 µl, as described in Section 8.3.2.1. A total of 36-48 positive and 36-48 negative 
control  assays  were  prepared  for  each  experiment  and  used  to  calculate  Z‟-values 
(Equation 2.2). Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  120 (96 well) or 170 (384 well) 
Buffer  B 
DMSO  5% 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
8.4.3.7  Substrate concentrations 
Experiments to determine Y. pestis Dam K
M
AdoMet and K
M
DNA, and DpnI K
M
DNA were prepared 
in 384 well plates in a total volume of 20 µl as described in Section 8.3.2.5. Assay 
conditions were as described below for each experiment: 
 
Y. pestis Dam K
M
AdoMet 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  10 nM ODN1 
0-200 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
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Y. pestis Dam K
M
DNA 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  3-30.5 nM ODN1 
25, 50 or 100 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
 
DpnI K
M
DNA 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  0-1000 nM ODN1 or 0-250 nM ODN2 
Enzyme(s)  2 nM (ODN1) or 12.5 pM (ODN2) DpnI 
 
Substrate concentrations for HTS 
Dam activity assays were prepared in 96 well plates in a total volume of 100 µl, as 
described in Section 8.3.2.1. A total of 8 positive and 8 negative control assays were 
prepared at a range of DNA and AdoMet concentrations and used to calculate Z‟-values 
(Equation 2.2). Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  130 
Buffer  B 
Substrate(s)  3-34 nM ODN1 
12.5 or 25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
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8.4.3.8  Y. pestis Dam IC50AdoHcy 
Assays were prepared in 384 well plates in a total volume of 20 µl as described in 
Section 8.3.2.7. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  190 
Buffer  B 
DMSO  5% 
Inhibitor  0-1000 µM AdoHcy 
Substrate(s)  3.5 nM ODN1 
16 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
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8.5 Experimental for Chapter 3 
 
8.5.1 Optimisation of the real-time break light DpnI activity assay 
8.5.1.1  Enzyme concentration 
DpnI activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.2. With DpnI concentration varied to determine the linear 
range of the assay. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  10 nM ODN2 
Enzyme(s)  0-100 pM DpnI 
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8.5.2 Optimisation of the gel-based Dam methylation assay 
8.5.2.1  Enzymes 
Stability 
E.  coli  Dam  stability  was  determined  as  described  in  Section  8.4.3.4.  Assays  were 
prepared in 384 well plates in a total volume of 20 µl using conditions as described 
below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Substrate(s)  25 nM ODN1 
12 µM AdoMet 
Enzyme(s)  1 nM E. coli Dam 
10 nM DpnI 
 
Concentration 
Gel-based Dam methylation assays were prepared in a total assay volume of 20 µl as 
described in Section 8.3.4.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
DMSO  5% 
Substrate(s)  6 nM unmethylated pRL821 
60 µM AdoMet 
Enzyme(s)  62.5-250 nM E. coli Dam 
 
8.5.2.2  Substrate concentration 
Gel-based Dam methylation assays were prepared in a total assay volume of 20 µl as 
described in Section 8.3.4.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
DMSO  5% 
Substrate(s)  3 nM unmethylated pRL821 
0-60 µM AdoMet 
Enzyme(s)  250 nM E. coli Dam 
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8.5.2.3  Inhibition with AdoHcy 
Gel-based Dam methylation assays were prepared in a total assay volume of 20 µl as 
described in Section 8.3.4.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
DMSO  5% 
Inhibitor  0-5 mM AdoHcy 
Substrate(s)  3 nM unmethylated pRL821 
0, 6, 24 or 60 µM AdoMet 
Enzyme(s)  250 nM E. coli Dam 
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8.5.3 Optimisation of the real-time break light cytosine methyltransferase activity 
assay 
8.5.3.1  Buffer conditions 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Sections 8.3.2.3 and 8.3.2.4, with sodium chloride concentration varied to 
determine the optimal buffer conditions. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Microplate reader  Tecan Safire
2 
Gain setting  100 
Varied buffer component  NaCl (0-200 mM) 
Substrate(s)  250 nM ODN8 
20 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.0125 U µl
-1 GlaI 
 
8.5.3.2  Oligonucleotide substrate 
GlaI activity I 
GlaI activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.4, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
Microplate reader  Tecan Safire
2 
Gain setting  100 
Substrate(s)  250 nM ODN5 or ODN7 
20 µM AdoMet 
Enzyme(s)  0.05 U µl
-1 GlaI 
 
Melting profiles 
Assays were prepared in assay buffer C and supplemented with partially methylated 
oligonucleotide ODN6 (250 nM), melting profiles were then determined as described in 
Section 8.3.4.2. 
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DNMT1 activity 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
Microplate reader  Tecan Safire
2 
Gain setting  110 
Substrate(s)  250 nM ODN6 or ODN8 
20 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.0125 U µl
-1 GlaI 
 
GlaI activity II 
GlaI activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.4, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
Microplate reader  Tecan Safire
2 
Gain setting  110 
Substrate(s)  250 nM ODN6, ODN7, ODN8 or ODN9 
20 µM AdoMet 
Enzyme(s)  0.05 U µl
-1 GlaI 
 
8.5.3.3  Plate reader 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described  in  Section  8.3.2.3.  Fluorescence  measurements  were recorded  in  a  Tecan 
Safire
2 at a gain setting of 110 or a BMG POLARstar Omega at a gain setting of 1550, 
with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
Substrate(s)  250 nM ODN6 
20 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.05 U µl
-1 GlaI 
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8.5.3.4  Enzyme concentration 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.3, and fluorescence measurements were recorded in a BMG 
POLARstar Omega. GlaI concentration was varied to determine the optimal amount of 
coupled enzyme, and DNMT1 concentration was varied to determine the linear range 
of the assay. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  1550 
Substrate(s)  250 nM ODN6 
20 µM AdoMet 
Enzyme(s)  25 or 0-200 nM DNMT1 
0-0.2 or 0.05 U µl
-1 GlaI 
 
8.5.3.5  DNMT1 KMAdoMet 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described in Section 8.3.2.3, and fluorescence measurements were recorded in a BMG 
POLARstar Omega. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  1550 
Substrate(s)  250 nM ODN6 
0-20 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.05 U µl
-1 GlaI 
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8.5.3.6  DNMT1 IC50AdoMet 
DNMT1 activity assays were prepared in 384 well plates in a total volume of 20 µl, as 
described  in  Section  8.3.2.3,  fluorescence  measurements  were  recorded  in  a  BMG 
POLARstar Omega. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  1250 
DMSO  5% 
Inhibitor  0-2 mM AdoHcy 
Substrate(s)  250 nM ODN6 
0-20 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.05 U µl
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8.5.4 Optimisation of the fluorescence anisotropy assay 
8.5.4.1  Non-specific binding 
Buffer 
Assays were prepared in 96 or 384 well plates in a total volume of 100 or 20 µl, as 
described in Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  1450/1445 (96 well) or 1519/1518 (384 
well) 
Buffer  Water or B 
Substrate(s)  0-200 nM ODN10 
Enzyme(s)  none 
 
Detergent 
Assays  were  prepared  in  96  well  plates  in  a  total  volume  of  100,  as  described  in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  1450/1445 
Buffer  B 
Detergent  0 or 0.1% Tween-20 
Substrate(s)  0-200 nM ODN10 
Enzyme(s)  none 
 
8.5.4.2  Enzyme stability 
Assays  were  prepared  in  96  well  plates  in  a  total  volume  of  100,  as  described  in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  1450/1445 
Temperature  30 °C 
Buffer  B supplemented with 0.1% Tween-20 
Substrate(s)  50 nM ODN10 
Enzyme(s)  500 nM Y. pestis, E. coli or P. horikoshii 
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8.5.4.3  E. coli Dam KDDNA 
Assays were prepared in 96 well plates in a total volume of 100 µl, as described in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  1450/1445 
Buffer  B supplemented with 0.1% Tween-20 
Substrate(s)  20 nM ODN10 
0 or 200 µM AdoHcy 
Enzyme(s)  0-1000 nM E. coli Dam 
 
8.5.4.4  DpnI KDDNA 
Assays were prepared in 96 well plates in a total volume of 100 µl, as described in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  2120/2145 
Buffer  E supplemented with 0.1% Tween-20 
Substrate(s)  20 nM ODN10 or ODN11 
Enzyme(s)  0-1000 nM DpnI 
 
8.5.4.5  DpnI hemimethylated DNA competition binding constant 
Assays were prepared in 96 well plates in a total volume of 100 µl, as described in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  2120/2145 
Buffer  E supplemented with 0.1% Tween-20 
DMSO  5% 
Inhibitor  0-1000 ODN12 
Substrate(s)  20 nM ODN11 
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8.5.5 Optimisation of the in culture gel-based plasmid methylation assay 
8.5.5.1  Assay volume 
Cultures of ER2925  harbouring  pRL821  were prepared  in  1,  2,  3  and  4  ml  of  2YT 
media as described in Section 8.3.4.4 and supplemented with DMSO (5%). Plasmid DNA 
was isolated after 15 hrs and digested with BclI (7.5 U µl
-1, 1 hr, 50 °C) the results were 
analysed  by  0.8%  agarose  gel  electrophoresis  and  concentration  determined  by 
quantification of bands with the program ImageJ (227). 
 
8.5.5.2  Assay end-point 
Cultures of ER2925 harbouring pRL821 supplemented with DMSO (5%) were prepared 
as described in Section 8.3.4.4. 
 
8.5.5.3  Growth curve analysis 
2YT media (1 ml) was inoculated with E. coli BW25113 and JW3350-2 from overnight 
cultures to a start OD
600 of 0.05. Assays were prepared in Greiner 12 well clear sterile 
suspension plates with lids, maintained in a BMG POLARstar OMEGA (37 °C, with double 
orbital shaking), and OD
600 was monitored. 
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8.5.6 Optimisation of the in culture HPLC-based genomic DNA methylation assay 
8.5.6.1  Genomic DNA isolation 
Genomic DNA was isolated from overnight cultures of E. coli BW25113 and JW3350-2 
as described in Section 8.3.1.5 with the RNase digestion step as per manufacturer‟s 
instructions (RNase A, 4 U µl
-1, 1.5 µl) or as described in Section 8.3.1.5 (RNase A/T1 
solution, 0.5 µg µl
-1 /50 U µl
-1, 20 µl).  
 
8.5.6.2  HPLC buffer gradient 
Genomic DNA (Section 8.5.6.1) was then digested and analysed as described in Section 
8.3.4.5, with an HPLC gradient of 10-50% HPLC buffer B over 26 min or 5-50% HPLC 
buffer B over 38 min. 
 
8.5.6.3  Detection limits 
A serial dilution of dmAMP was prepared in water and analysed by HPLC as described 
in Section 8.3.4.5, with an HPLC gradient of 5-50% HPLC buffer B over 38 min. HPLC 
peak areas were integrated to determine area and plotted against dAMP concentration 
to determine the upper and lower assay detection limits. 
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8.6 Experimental for Chapter 4 
 
8.6.1 High-throughput screen of the DTP library 
8.6.1.1  Dam screen 
The  DTP  library  was  diluted  in  DMSO  (100%)  to  a  concentration  of  500  µM  and 
screened  against  Y.  pestis  Dam  as  described  in  Section  8.3.2.6  using  the  assay 
conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Library compound concentration  25 µM 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
8.6.1.2  Counter-screening 
DpnI 
Hits from the DTP library screen were screened against DpnI as described in Section 
8.3.3.1 using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Library compound concentration  25 µM 
Substrate(s)  10 nM ODN2 
Enzyme(s)  12.5 pM DpnI 
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FID 
Compounds inhibiting DpnI by less than three standard deviations from the average of 
the  positive  controls  were  screened  for  DNA  intercalation  activity  as  described  in 
Section 8.3.3.2 using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  255 
Temperature  25 °C 
Buffer  D 
DMSO  10% 
Thiazole orange concentration  500 nM 
Library compound concentration   5 µM 
Substrate(s)  100 nM ODN3 
 
8.6.1.3  Extended FID assays 
Assays were prepared as described in Section 8.3.3.2 using the assay conditions listed 
below: 
 
Component/Parameter  Amount/Value 
Gain setting  255 
Temperature  25 °C 
Buffer  D 
DMSO  10% 
Thiazole orange concentration  2.5 µM 
Library compound concentration   0-1000 µM 
Substrate(s)  500 nM ODN3 
 
8.6.1.4  Purity analysis 
TLC analysis of compound 88915 was achieved with using following solvent systems: 
100%  hexane;  75%  hexane,  25%  ethylacetate;  50%  hexane,  50%  ethylacetate;  50% 
ethylacetate, 50% methanol; 100% methanol; and 70% DCM, 30% methanol. 
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8.6.1.5  Potency 
Y. pestis Dam and DpnI IC
50 were determined in duplicate from assays prepared in 384 
well plates in a total volume of 20 µl as described in Section  8.3.2.7. Assays  were 
carried out in duplicate using conditions as described below for each enzyme: 
 
Y. pestis Dam 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
University of Cincinnati library hit  0-2000 µM 
Substrate(s)  3.5 nM ODN1 
16 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
 
DpnI 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
University of Cincinnati library hit  0-2000 µM 
Substrate(s)  14 nM ODN2 
Enzyme(s)  12.5 pM DpnI 
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8.6.2 High-throughput screen of the University of Cincinnati library 
8.6.2.1  Dam screen 
The University of Cincinnati library was diluted in DMSO (100%) to a concentration of 1 
mM and screened against Y. pestis Dam as described in Section 8.3.2.6 using the assay 
conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Library compound concentration  50 µM 
Substrate(s)  8 nM ODN1 
20 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
8.6.2.2  Counter-screening 
DpnI 
Hits  from  the  University  of  Cincinnati  library  screen  were  screened  against  DpnI  as 
described in Section 8.3.3.1 using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Library compound concentration  50 µM 
Substrate(s)  8 nM ODN2 
Enzyme(s)  25 pM DpnI 
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FID 
Compounds inhibiting DpnI by less than 50% compared to the average of the positive 
controls were screened for DNA intercalation activity as described in Section 8.3.3.2 
using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  255 
Temperature  25 °C 
Buffer  D 
DMSO  10% 
Thiazole orange concentration  500 nM 
Library compound concentration   5 µM 
Substrate(s)  100 nM ODN3 
 
8.6.2.3  Hit validation 
Gel-based Dam methylation assays were prepared in a total assay volume of 20 µl as 
described in Section 8.3.4.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
DMSO  5% 
University of Cincinnati library hits  2 mM 
Substrate(s)  3 nM unmethylated pRL821 
6 µM AdoMet 
Enzyme(s)  250 nM E. coli Dam 
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8.6.2.4  Potency 
Y. pestis Dam and DpnI IC
50 were determined in duplicate from assays prepared in 384 
well plates in a total volume of 20 µl as described in Section  8.3.2.7. Assays  were 
carried out in duplicate using conditions as described below for each enzyme: 
 
Y. pestis Dam 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
University of Cincinnati library hit  0-2000 µM 
Substrate(s)  3.5 nM ODN1 
16 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
 
DpnI 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
University of Cincinnati library hit  0-2000 µM 
Substrate(s)  14 nM ODN2 
Enzyme(s)  12.5 pM DpnI 
 
8.6.2.5  In culture activity 
Restriction digest analysis of genomic DNA from Yersinia culture 
Experiments  were  carried  out  at  dstl  Porton  Down  under  containment  level  2. 
Overnight cultures of Y. pseudotuberculosis were used to inoculate LB broth (10 ml) 
supplemented with University of Cincinnati library hit (20 µg ml
-1) and DMSO (0.025%). 
Cultures were incubated with shaking (28 °C, overnight) and genomic DNA was isolated 
as described in Section 8.3.1.5 as per the manufacturer‟s instructions only. Isolated 
genomic DNA was then analysed by restriction with MboI, Sau3AI or DpnI (4 hrs, 37 °C) 
and results were analysed by 0.7% agarose gel electrophoresis with ethidium bromide 
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In culture gel-based plasmid methylation assay 
Assays supplemented with University of Cincinnati library hit (500 µM) were prepared 
and analysed as described in Section 8.3.4.4. 
 
In culture HPLC-based genomic DNA methylation assay 
Assays supplemented with University of Cincinnati library hit (500 µM) were prepared 
and analysed as described in Section 8.3.4.5, using an HPLC gradient of 5-50% HPLC 
buffer B over 38 min. J C McKelvie    Chapter 8 
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8.7 Experimental for Chapter 5 
 
8.7.1 Sublibrary screening 
8.7.1.1  Stibonic acid sublibrary 
The stibonic acid sublibrary was diluted in DMSO (100%) to a concentration of 500 µM 
and screened against Y. pestis Dam as described in Section 8.3.2.6 using the assay 
conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Sublibrary compound concentration  25 µM 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
8.7.1.2  Phosphonic acid sublibrary 
The  phosphonic  acid  sublibrary  was  diluted  in  ammonium  carbonate  (25  mM)  to  a 
concentration of 500 µM and screened against Y. pestis Dam as described in Section 
8.3.2.6 using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Temperature  30 °C 
Buffer  B 
Ammonium carbonate  1.25 mM 
Sublibrary compound concentration  25 µM 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
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8.7.2 Potency 
Y. pestis Dam IC
50 determination assays were prepared in 384 well plates in a total 
volume of 20 µl as described in Section 8.3.2.7, using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Arylstibonic acid  0-100 µM 
Substrate(s)  3.5 nM ODN1 
16 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
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8.7.3 Selectivity 
8.7.3.1  Against DpnI 
DpnI IC
50 determination assays were prepared in 384 well plates in a total volume of 20 
µl as described in Section 8.3.2.7, using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Arylstibonic acid  0-100 µM 
Substrate(s)  14 nM ODN2 
Enzyme(s)  12.5 pM DpnI 
 
8.7.3.2  Against DNMT1 
The  diluted  stibonic  acid  sublibrary  (500  µM  in  100%  DMSO)  was  screened  against 
DNMT1 as described in Section 8.3.2.6 using the assay conditions listed below: 
 
Component/Parameter  Amount/Value 
Gain setting  1250 
Temperature  37 °C 
Buffer  B 
DMSO  5% 
Sublibrary compound concentration  25 µM 
Substrate(s)  250 nM ODN6 
3 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.05 U µl
-1 GlaI 
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8.7.4 Mode of inhibition Characterisation 
8.7.4.1  Determination of Ki13776 and Ki13746 
Assays were prepared in 384 well plates in a total volume of 20 µl as described in 
Section 8.3.2.8. Assay conditions were as described below for each substrate: 
 
Variable AdoMet 
Component/Parameter  Amount/Value 
Gain setting  190 
Buffer  B 
DMSO  5% 
Inhibitor  0-12 µM 13776 or 0-96 nM 13746 
Substrate(s)  10 nM ODN1 
5.4-70 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
Variable DNA 
Component/Parameter  Amount/Value 
Gain setting  190 
Buffer  B 
DMSO  5% 
Inhibitor  0-12 µM 13776 or 0-96 nM 13746 
Substrate(s)  3.1-12 nM ODN1 
160 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
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8.7.4.2  Determination of Competition binding constants 
Assays were prepared in 96 well plates in a total volume of 100 µl, as described in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  2315/2366 
Buffer  E supplemented with 0.1% Tween-20 
DMSO  5% 
Inhibitor  0-1000 µM 13776 or 13746 
Substrate(s)  20 nM ODN10 
Enzyme(s)  500 nM E. coli Dam 
 
8.7.4.3  Oligonucleotide melting profiles 
Assays  were  prepared  in  assay  buffer  B  and  supplemented  with  hemimethylated 
oligonucleotide ODN1 (100 nM), DMSO (5%) and 13776 or 13746 (0, 1, 10 or 25 µM). 
Melting profiles were then determined as described in Section 8.3.4.2. 
 
8.7.4.4  Aggregation 
Y. pestis Dam IC
50 determination assays were prepared as described in Section 8.7.2 
and supplemented with Tween-20 (0.1%). 
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8.7.5 In culture activity 
8.7.5.1  Restriction digest analysis of genomic DNA from Yersinia culture 
Assays were prepared and analysed as described in Section 8.7.5.1 and supplemented 
with arylstibonic acid (20 µg ml
-1) 
 
8.7.5.2  Toxicity of compound 13782 against Y. pestis GB 
Experiments  were  carried  out  at  dstl  Porton  Down  under  containment  level  3. 
Overnight  cultures  of  Y.  pestis  GB  were  used  to  inoculate  BAB  media  (10  ml) 
supplemented with CaCl
2 (2.5 mM), 13782 (20 µg ml
-1) and DMSO (0.025%). Cultures 
were incubated with shaking (37 °C) and samples removed periodically for assessment 
of OD
600 for the construction of growth curves. 
 
8.7.5.3  Determination of the activity of re-synthesised 13782 
IC5013782 
Y. pestis Dam IC
50 determination assays were prepared as described in Section 8.7.2 
and supplemented with re-synthesised 13782. 
 
HPLC analysis 
Compound 13782 (~1 mg) was dissolved in sodium carbonate solution (1%, 50 µl) and 
injected onto a Hamilton pRP-X100 anion exchange column, washed with water and 
eluted with a gradient of HPLC buffer C [pH 9, 0.1 M ammonium acetate] (0-100%, 20 
min) and washed with HPLC buffer C (40 min). Collected fractions (60 x 2 ml) were 
freeze-dried  and  resuspended  in  water  (20  µl).  Y.  pestis  Dam  activity  was  then 
determined as described in Section 8.3.2.1, with assays prepared in 384 well plates 
and  supplemented  with  freeze-dried/resuspended  HPLC  fraction.  Assay  conditions 
were as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  170 
Buffer  B 
DMSO  5% 
Freeze-dried/resuspended HPLC fraction  5 µl 
Substrate(s)  10 nM ODN1 
25 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
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8.8 Experimental for Chapter 6 
 
8.8.1 Validation 
8.8.1.1  Potency 
Y. pestis Dam IC
50 determination assays were prepared in 384 well plates in a total 
volume of 20 µl as described in Section 8.3.2.7, using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Bisubstrate analogue  0-2000 µM 
Substrate(s)  3.5 nM ODN1 
16 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
 
8.8.1.2  Confirmation of activity 
Gel-based Dam methylation assays were prepared in a total assay volume of 20 µl as 
described in Section 8.3.4.3, with assay conditions as described below: 
 
Component/Parameter  Amount/Value 
DMSO  5% 
Bisubstrate analogue  2 mM 
Substrate(s)  3 nM unmethylated pRL821 
6 µM AdoMet 
Enzyme(s)  250 nM E. coli Dam 
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8.8.2 Selectivity 
8.8.2.1  Against DpnI 
DpnI IC
50 determination assays were prepared in 384 well plates in a total volume of 20 
µl as described in Section 8.3.2.7, using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  190 
Temperature  30 °C 
Buffer  B 
DMSO  5% 
Bisubstrate analogue  0-2000 µM 
Substrate(s)  14 nM ODN2 
Enzyme(s)  12.5 pM DpnI 
 
8.8.2.2  Against DNMT1 
DNMT1 IC
50 determination assays were prepared in 384 well plates in a total volume of 
20 µl as described in Section 8.3.2.7, using conditions as described below: 
 
Component/Parameter  Amount/Value 
Gain setting  1250 
Temperature  37 °C 
Buffer  C 
DMSO  5% 
Bisubstrate analogue  0-2000 µM 
Substrate(s)  250 nM ODN6 
3 µM AdoMet 
Enzyme(s)  25 nM DNMT1 
0.05 U µl
-1 GlaI 
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8.8.3 Mode of inhibition 
8.8.3.1  Determination of KiSA8 
Assays were prepared in 384 well plates in a total volume of 20 µl as described in 
Section 8.3.2.8. Assay conditions were as described below for each substrate: 
 
Variable AdoMet 
Component/Parameter  Amount/Value 
Gain setting  190 
Buffer  B 
DMSO  5% 
Inhibitor  0-54 µM SA8 
Substrate(s)  10 nM ODN1 
5.4-70 µM AdoMet 
Enzyme(s)  1 nM Y. pestis Dam 
2 nM DpnI 
 
Variable DNA 
Component/Parameter  Amount/Value 
Gain setting  190 
Buffer  B 
DMSO  5% 
Inhibitor  0-54 µM SA8 
Substrate(s)  3.1-12 nM ODN1 
160 µM AdoMet 
Enzyme(s)  0.3 nM Y. pestis Dam 
2 nM DpnI 
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8.8.3.2  Determination of Competition binding constants 
Assays were prepared in 96 well plates in a total volume of 100 µl, as described in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  2315/2366 
Buffer  E supplemented with 0.1% Tween-20 
DMSO  5% 
Inhibitor  0-2000 µM SA8 or SA2 
Substrate(s)  20 nM ODN10 
Enzyme(s)  500 nM E. coli Dam 
 
8.8.3.3  Stabilisation of the Dam:DNA complex 
Assays  were  prepared  in  96  well  plates  in  a  total  volume  of  100,  as  described  in 
Section 8.3.4.1. Assay conditions were as described below: 
 
Component/Parameter  Amount/Value 
Gain settings (A/B)  2478/2624 
Temperature  30 °C 
Buffer  B supplemented with 0.1% Tween-20 
DMSO  5% 
Inhibitor  2 mM SA8 or SA2 
Substrate(s)  50 nM ODN10 
Enzyme(s)  500 nM E. coli Dam 
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8.9 Media and buffers 
 
8.9.1 Competent cell buffers 
TBFI (pH 5.8) 
Reagent  Final Concentration  Quantity 
Potassium acetate  30 mM  0.588 g 
Rubidium Chloride  100 mM  2.42 g 
Calcium Chloride  10 mM  0.294 g 
Manganese Chloride  50 mM  2.0 g 
Glycerol  15% (v/v)  30 ml 
Sterile Water    To a final volume of 200 ml 
 
TBFII (pH 6.5) 
Reagent  Final Concentration  Quantity 
MOPS  10 mM  0.21 g 
Rubidium Chloride  10 mM  0.121 g 
Calcium Chloride  75 mM  1.1 g 
Glycerol  15% (v/v)  15 ml 
Sterile Water    To a final volume of 100 ml 
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8.9.2 SDS-PAGE buffers, stains and destains 
1x SDS-PAGE loading buffer 
Reagent  Final Concentration  Quantity 
Tris.HCl (pH 6.8, 0.2 M)  50 mM  2.5 ml 
DTT  0.1 mM  15.4 mg 
SDS  2% (w/v)  200 mg 
Bromophenol Blue  0.1% (w/v)  10 mg 
Glycerol  10% (v/v)  1 ml 
Deionised Water    To a final volume of 10 ml 
 
1x Tris-Glycine electrophoresis buffer 
Reagent  Final Concentration  Quantity 
Tris Base  25 mM  3.02 g 
Glycine  250 mM  18.8 g 
SDS   0.1% (w/v)  1 g 
Deionised Water    To a final volume of 1 L 
 
SDS-PAGE gel stain 
Reagent  Final Concentration  Quantity 
Coomassie Brilliant Blue    0.25 g 
Methanol  45% (v/v)  45 ml 
Glacial Acetic Acid  10% (v/v)  10 ml 
Deionised Water    To a final volume of 10 ml 
 
SDS-PAGE gel destain 
Reagent  Final Concentration  Quantity 
Methanol  5% (v/v)  50 ml 
Glacial Acetic Acid  7.5% (v/v)  75 ml 
Deionised Water    To a final volume of 1 L 
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8.9.3 Purification buffers 
8.9.3.1  DpnI purification buffers 
Low imidazole DpnI purification buffer (pH 7.4) 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 6.61 g 
Base: 0.97 g 
Sodium chloride  400 mM  23.4 g 
Imidazole  50 mM  3.40 g 
β-mercaptoethanol  5 mM  350 µl 
Glycerol  10% (w/v)  100 g 
Deionised Water    To a final volume of 1 L 
 
High imidazole DpnI purification buffer (pH 7.4) 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 6.61 g 
Base: 0.97 g 
Sodium chloride  400 mM  23.4 g 
Imidazole  500 mM  34.0 g 
β-mercaptoethanol  5 mM  350 µl 
Glycerol  10% (w/v)  100 g 
Deionised Water    To a final volume of 1 L 
 
DpnI storage buffer (pH 7.4) 
Reagent  Final Concentration  Quantity 
Tris  10 mM  Acid: 1.32 g 
Base: 0.19 g 
Sodium chloride  400 mM  23.4 g 
EDTA  0.1 mM  29 mg 
DTT  1 mM  154 mg 
Glycerol  50% (w/v)  500 g 
Deionised Water    To a final volume of 1 L 
 J C McKelvie    Chapter 8 
  238   
8.9.3.2  Y. pestis Dam purification buffers 
Low imidazole Y. pestis Dam purification buffer (pH 9) 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 0.76 g 
Base: 5.47 g 
Sodium chloride  300 mM  17.5 g 
Imidazole  50 mM  3.40 g 
β-mercaptoethanol  5 mM  350 µl 
Glycerol  10% (w/v)  100 g 
Deionised Water    To a final volume of 1 L 
 
High imidazole Y. pestis Dam purification buffer (pH 9) 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 0.76 g 
Base: 5.47 g 
Sodium chloride  300 mM  17.5 g 
Imidazole  500 mM  34.0 g 
β-mercaptoethanol  5 mM  350 µl 
Glycerol  10% (w/v)  100 g 
Deionised Water    To a final volume of 1 L 
 
Y. pestis Dam storage buffer (pH 7.5) 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 6.35 g 
Base: 1.18 g 
Sodium chloride  200 mM  11.7 g 
EDTA  0.2 mM  58 mg 
DTT  2 mM  308 mg 
Glycerol  20% (w/v)  200 g 
Deionised Water    To a final volume of 1 L 
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8.9.4 Assay buffers 
Assay buffer A (pH 7.9) 
Reagent  Final Concentration  Quantity 
Tris  20 mM  Acid: 1.95 g 
Base: 0.92 g 
Potassium acetate  50 mM  4.91 g 
Magnesium acetate  10 mM  1.42 g 
Sodium chloride  20 mM  1.17 g 
BSA  0.1 mg ml
-1  100 mg 
DTT  1 mM  154 mg 
Deionised Water    To a final volume of 1 L 
 
Assay buffer B (pH 7.9) 
Reagent  Final Concentration  Quantity 
Tris  20 mM  Acid: 1.95 g 
Base: 0.92 g 
Magnesium chloride.6H
2O  8 mM  1.63 g 
Sodium chloride  80 mM  4.68 g 
BSA  0.1 mg ml
-1  100 mg 
DTT  1 mM  154 mg 
Glycerol  5% (w/v)  50 g 
Deionised Water    To a final volume of 1 L 
 
Assay buffer C (pH 7.5) 
Reagent  Final Concentration  Quantity 
Tris  100 mM  Acid: 9.75 g 
Base: 4.60 g 
Magnesium chloride.6H
2O  5 mM  1.02 g 
Sodium chloride  12.5 mM  0.73 g 
BSA  0.1 mg ml
-1  100 mg 
DTT  1 mM  154 mg 
Glycerol  5% (w/v)  50 g 
Deionised Water    To a final volume of 1 L 
 J C McKelvie    Chapter 8 
  240   
Assay buffer D (pH 7.9) 
Reagent  Final Concentration  Quantity 
Tris  100 mM  Acid: 9.75 g 
Base: 4.60 g 
Sodium chloride  100 mM  5.85 g 
Deionised Water    To a final volume of 1 L 
 
Assay buffer E (pH 7.9) 
Reagent  Final Concentration  Quantity 
Tris  20 mM  Acid: 1.95 g 
Base: 0.92 g 
Sodium chloride  80 mM  4.68 g 
BSA  0.1 mg ml
-1  100 mg 
DTT  1 mM  154 mg 
Glycerol  5% (w/v)  50 g 
Deionised Water    To a final volume of 1 L 
 
NEBuffer 3 
Reagent  Final Concentration  Quantity 
Tris  50 mM  Acid: 0.76 g 
Base: 5.47 g 
Sodium chloride  100 mM  5.85 g 
Magnesium chloride  10 mM  952 mg 
DTT  1 mM  154 mg 
Deionised Water    To a final volume of 1 L 
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8.9.5 HPLC buffers 
HPLC buffer A (pH 7) 
Reagent  Final Concentration  Quantity 
DMHA  5 mM  869 µl 
Methanol  5%  50 ml 
Deionised Water    To a final volume of 1 L 
 
HPLC buffer B (pH 7) 
Reagent  Final Concentration  Quantity 
DMHA  5 mM  869 µl 
Methanol  80%  800 ml 
Deionised Water    To a final volume of 1 L 
 
HPLC buffer C (pH 9) 
Reagent  Final Concentration  Quantity 
Ammonium acetate  0.1 M  7.71 g 
Deionised Water    To a final volume of 1 L  
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9  Appendix 
 
9.1 Derivation of equations 
 
9.1.1 Enzyme kinetics 
9.1.1.1  The Michaelis-Menten equation 
 
 
Figure 9.1 Enzyme catalysed reaction 
Where E = enzyme, S = substrate, ES = enzyme-substrate complex, P = product, k
1 and 
k
2  =  association  rate  constants,  k
-1  =  dissociation  rate  constant  (k
-2  can  be  ignored 
under initial rate conditions). 
 
The rate of change of enzyme-substrate complex concentration is given as: 
9.1 
1 1 2
1 1 2
d[ES]
 = k [E][S]-k [ES]-k [ES]
dt
= k [E][S]- k +k [ES]
 
 
Under steady-state approximation the rate of enzyme-substrate complex formation is 
equal to the rate of enzyme-substrate complex decay hence: 
9.2 
d[ES] d[ES]
 = -  = 0
dt dt
 
 
Substituting 9.2 into 9.1 gives: 
9.3 
1 -1 2
1 -1 2
k [E][S]- k +k [ES] = 0
k [E][S] =  k +k [ES]
 
 
Rearranging 9.3 to group the rate constants gives: 
9.4 
-1 2
1
k +k
[E][S] =  [ES]
k
 
 
Where (k
-1+k
2)/k
1 is defined as the Michaelis-Menten constant (K
M) 9.4 becomes: 
9.5  [E][S] =  [ES] M K  
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Total enzyme concentration ([E]
T) can be written as: 
9.6  T0 [E]  = [E]  = [E]+[ES] 
(where [E]
0 = initial enzyme concentration) 
 
Rearranging 9.6 gives: 
9.7  0 [E] = [E] -[ES] 
 
Substituting 9.6 into 9.5 gives: 
9.8 
0
0
0
0
0
[E] -[ES] [S] =  [ES]
[E] [S]-[ES][S] =  [ES]
[E] [S] =  [ES]+[ES][S]
[E] [S] = [ES] +[S]
[E] [S]
[ES] = 
+[S]
M
M
M
M
M
K
K
K
K
K
 
 
Initial velocity ( ) is dependent on rate of product formation and can be defined as: 
9.9  2  = k [ES] 
 
And maximum velocity (V
max) is the rate of product formation when all the enzyme is 
substrate-bound, defined as: 
9.10 
2 total
20
V  = k [E]
= k [E]
max  
 
Substituting 9.9 and 9.10 into 9.8 gives: 
9.11 
22
V [S]
 = 
k k +[S]
max
M K
 
 
The  rate  constant  k
2  can  then  be  cancelled  from  both  sides  of  9.11  to  give  the 
Michaelis-Menten equation: 
9.12 
V [S]
 = 
+[S]
max
M K
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9.1.1.2  Competitive substrate inhibition 
 
 
Figure 9.2 Enzyme catalysed reaction with competitive substrate inhibition 
Where E = enzyme, S = substrate, ES = enzyme-substrate complex, P = product, ES* = 
inactive  enzyme-substrate  complex,  k
1-k
3  =  association  rate  constants,  k
-1  and  k
-3  = 
dissociation rate constants (k
-2 can be ignored under initial rate conditions). 
 
Where substrate binds the free enzyme to form active and inactive enzyme-substrate 
complexes (Figure 9.2) the rate of reaction can be equated to the rate of reaction in 
the presence of a competitive inhibitor. 
 
The rate of change of inactive enzyme-substrate complex concentration is given as: 
9.13  33
d[ES*]
 = k [E][S]-k [ES*]
dt
 
 
Under steady-state approximation the rate of enzyme-substrate complex formation is 
equal to the rate of enzyme-substrate complex decay hence: 
9.14 
d[ES*] d[ES*]
 = -  = 0
dt dt
 
 
Substituting 9.13 into 9.14 gives: 
9.15 
33
33
3
3
is
k [E][S]-k [ES*] = 0
k [ES*] = k [E][S]
k
[ES*] =  [E][S]
k
[E][S]
= 
K
 
(where K
is = the substrate inhibition dissociation constant) 
 
In this case total enzyme concentration ([E]
T) can be written as: 
9.16  T0 [E]  = [E]  = [E]+[ES]+[ES*] 
(where [E]
0 = initial enzyme concentration) 
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Substituting 9.15 into 9.16 gives: 
9.17 
0
is
0
is
0
is
0
is
[E][S]
[E]  = [E]+[ES]+
[E][S]
[E]+  = [E] -[ES]
[S]
[E] 1 +  = [E] -[ES]
[E] -[ES]
[E]=   
[S]
1 +  
K
K
K
K
 
 
Substituting 9.17 into 9.5 gives: 
9.18 
0
is
0
is
0
is
0
is
0
is
[S] [E] -[ES]
 =  [ES]
[S]
1 +  
[S]
[S][E] -[S][ES] =  [ES] 1 +
[S]
[S][E]  =  [ES] 1 + +[S][ES] 
[S]
[S][E]  = [ES] 1 + +[S]
[S][E]
[ES] = 
[S]
1 + +[S]
M
M
M
M
M
K
K
K
K
K
K
K
K
K
K
 
 
Substituting 9.9 and 9.10 into 9.18 and cancelling rate constant k
2 from both sides 
gives the substrate inhibition equation: 
9.19 
is
V [S]
 = 
[S]
1 + +[S]
max
M K
K
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9.1.1.3  Reversible inhibition 
 
 
Figure 9.3 Reversible enzyme inhibition 
Where E = enzyme, S = substrate, I = inhibitor, ES = enzyme-substrate complex, EI = 
enzyme-inhibitor complex, ESI = enzyme-substrate-inhibitor complex, P = product, k
1-k
5 
=  association  rate  constants,  k
-1  and  k
-3-k
-5  =  dissociation  rate  constants  (k
-2  can  be 
ignored under initial rate conditions). 
 
Rate equations for reversible competitive, noncompetitive and uncompetitive inhibition 
(Figure  9.3)  can  be  derived  in  a  similar  way  to  competitive  substrate  inhibition,  as 
described in the previous Section. Derivations for each inhibitor modality are detailed 
below. 
 
Competitive reversible inhibition 
The rate of change of enzyme-inhibitor complex concentration is given as: 
9.20  33
d[EI]
 = k [E][I]-k [EI]
dt
 
 
Under steady-state approximation the rate of enzyme-substrate complex formation is 
equal to the rate of enzyme-substrate complex decay hence: 
9.21 
d[EI] d[EI]
 = -  = 0
dt dt
 
 
Substituting 9.20 into 9.21 gives: 
9.22 
33
33
3
3
i
k [E][I]-k [EI] = 0
k [EI] = k [E][I]
k
[EI] =  [E][I]
k
[E][I]
= 
K
 
(where K
i = the inhibitory dissociation constant) 
In this case total enzyme concentration ([E]
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9.23  T0 [E]  = [E]  = [E]+[ES]+[EI] 
(where [E]
0 = initial enzyme concentration) 
 
Substituting 9.22 into 9.23 gives: 
9.24 
0
i
0
i
0
i
0
i
[E][I]
[E]  = [E]+[ES]+
[E][I]
[E]+  = [E] -[ES]
[I]
[E] 1 +  = [E] -[ES]
[E] -[ES]
[E]=   
[I]
1 +  
K
K
K
K
 
 
Substituting 9.24 into 9.5 gives: 
9.25 
0
i
0
i
0
i
0
i
0
i
[S] [E] -[ES]
 =  [ES]
[I]
1 +  
[I]
[S][E] -[S][ES] =  [ES] 1 +
[I]
[S][E]  =  [ES] 1 + +[S][ES] 
[I]
[S][E]  = [ES] 1 + +[S]
[S][E]
[ES] = 
[I]
1 + +[S]
M
M
M
M
M
K
K
K
K
K
K
K
K
K
K
 
 
Substituting 9.9 and 9.10 into 9.25 and cancelling rate constant k
2 from both sides 
gives the competitive inhibition rate equation: 
9.26 
i
V [S]
 = 
[I]
1 + +[S]
max
M K
K
 
(where K
M(1+([I]/K
i)) = K
M
app) J C McKelvie    Chapter 9 
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Noncompetitive reversible inhibition 
The  rates  of  change  of  enzyme-inhibitor  and  enzyme-substrate-inhibitor  complex 
concentrations are given as: 
 
9.20  33
d[EI]
 = k [E][I]-k [EI]
dt
 
9.27  44
d[ESI]
 = k [ES][I]-k [ESI]
dt
 
 
Under steady-state approximation the rate of complex formation is equal to the rate of 
complex decay hence: 
9.21 
d[EI] d[EI]
 = -  = 0
dt dt
 
9.28 
d[ESI] d[ESI]
 = -  = 0
dt dt
 
 
Substituting 9.20 into 9.21 gives: 
9.22 
33
33
3
3
i
k [E][I]-k [EI] = 0
k [EI] = k [E][I]
k
[EI] =  [E][I]
k
[E][I]
= 
K
 
 (where K
i = the inhibitory dissociation constant) 
 
And substituting 9.20  33
d[EI]
 = k [E][I]-k [EI]
dt
 
9.27 into 9.21 
d[EI] d[EI]
 = -  = 0
dt dt
 
9.28 gives: 
9.29 
44
44
4
4
i
k [ES][I]-k [ESI] = 0
k [ESI] = k [ES][I]
k
[ESI] =  [ES][I]
k
[ES][I]
= 
K
 
(where K
i = the inhibitory dissociation constant and   = constant describing the degree 
to which inhibitor binding affects the affinity of the enzyme for substrate) 
 
In this case total enzyme concentration ([E]
T) can be written as: 
9.30  T0 [E]  = [E]  = [E]+[ES]+[EI]+[ESI] J C McKelvie    Chapter 9 
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(where [E]
0 = initial enzyme concentration) 
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Substituting 9.22 and 9.29 into 9.30 gives: 
9.31 
0
ii
0
ii
0
ii
0
i
i
[E][I] [ES][I]
[E]  = [E]+[ES]+ +
[E][I] [ES][I]
[E]+ = [E] -[ES]-
[I] [I]
[E] 1 +  = [E] -[ES] 1+
[I]
[E] -[ES] 1+
[E]= 
[I]
1 +  
KK
KK
KK
K
K
 
 
Substituting 9.31 into 9.5 gives: 
9.32 
0
i
i
0
ii
0
ii
0
i
[I]
[S] [E] -[ES] 1+
 =  [ES]
[I]
1 +  
[I] [I]
[S][E] -[S][ES] 1+  =  [ES] 1 +
[I] [I]
[S][E]  = [ES] 1 + +[S] 1+
[S][E]
[ES] = 
[I] [I
1 + +[S] 1+
M
M
M
M
K
K
K
K
K
K
KK
KK
K i
]
K
 
 
Substituting 9.9 and 9.10 into 9.32 and cancelling rate constant k
2 from both sides 
gives the noncompetitive inhibition rate equation: 
9.33 
ii
V [S]
 = 
[I] [I]
1 + +[S] 1+
max
M K
KK
 
 
Dividing the numerator and denominator of 9.33 by (1+([I]/ K
i)) gives: 
9.34 
i
i
i
V
[S]
[I]
1+
 = 
[I]
1+
+[S]
[I]
1+
max
M K
K
K
K
 
(where K
M((1+([I]/K
i))/(1+([I]/ K
i))) = K
M
app and V
max/(1+([I]/ K
i)) = V
max
app) 
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Uncompetitive reversible inhibition 
The rate of change of enzyme-substrate-inhibitor complex concentration is given as: 
9.35  44
d[ESI]
 = k [ES][I]-k [ESI]
dt
 
 
Under steady-state approximation the rate of complex formation is equal to the rate of 
complex decay hence: 
9.36 
d[ESI] d[ESI]
 = -  = 0
dt dt
 
 
Substituting 9.20  33
d[EI]
 = k [E][I]-k [EI]
dt
 
9.27 into 9.21 
d[EI] d[EI]
 = -  = 0
dt dt
 
9.28 gives: 
9.29 
44
44
4
4
i
k [ES][I]-k [ESI] = 0
k [ESI] = k [ES][I]
k
[ESI] =  [ES][I]
k
[ES][I]
= 
K
 
 (where K
i = the inhibitory dissociation constant and   = constant describing the degree 
to which inhibitor binding affects the affinity of the enzyme for substrate) 
 
In this case total enzyme concentration ([E]
T) can be written as: 
9.37  T0 [E]  = [E]  = [E]+[ES]+[ESI] 
(where [E]
0 = initial enzyme concentration) 
 
Substituting and 9.29 into 9.37 gives: 
9.38 
0
i
0
i
[ES][I]
[E]  = [E]+[ES]+
[I]
[E]= [E] -[ES] 1+
K
K
 
 
Substituting 9.38 into 9.5 gives: J C McKelvie    Chapter 9 
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9.39 
0
i
0
i
0
i
0
i
[I]
[S] [E] -[ES] 1+ =  [ES]
[I]
[S][E] -[S][ES] 1+  =  [ES]
[I]
[S][E]  = [ES] +[S] 1+
[S][E]
[ES] = 
[I]
+[S] 1+
M
M
M
M
K
K
K
K
K
K
K
K
 
Substituting 9.9 and 9.10 into 9.39 and cancelling rate constant k
2 from both sides 
gives the uncompetitive inhibition rate equation: 
9.40 
i
V [S]
 = 
[I]
+[S] 1+
max
M K
K
 
 
Dividing the numerator and denominator of 9.40 by (1+([I]/ K
i)) gives: 
9.41 
i
i
V
[S]
[I]
1+
 = 
1
+[S]
[I]
1+
max
M K
K
K
 
(where K
M(1/(1+([I]/ K
i))) = K
M
app and V
max/(1+([I]/ K
i)) = V
max
app) 
 
Determination of Ki 
Both competitive and uncompetitive reversible inhibition can be expressed in terms of 
the noncompetitive reversible inhibition rate equation: 
9.34 
i
i
i
V
[S]
[I]
1+
 = 
[I]
1+
+[S]
[I]
1+
max
M K
K
K
K
 
 
For competitive inhibition, where inhibitor can only bind free enzyme,   tends towards 
infinity and (1+([I]/K
i))>>(1+([I]/ K
i)). For uncompetitive inhibition, where inhibitor can 
only  bind  the  enzyme-substrate  complex,    tends  towards  0  and  (1+([I]/ 
K
i))>>(1+([I]/ K
i)). A general rate equation for reversible inhibition can therefore be 
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9.42 
V [S]
 = 
+[S]
max
M
app
app K
 
(where K
M
app = K
M((1+([I]/K
i))/(1+([I]/ K
i))) and V
max
app = V
max/(1+([I]/ K
i))) 
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Rearrangement  of  the  Michaelis-Menten  equation  (9.12)  gives  the  Lineweaver-Burk 
equation: 
9.43 
+[S] 1
 = 
V [S]
[S]
=  +
V [S] V [S]
11
=  +
V [S] V
M
max
M
max max
M
max max
K
K
K
 
 
The  same  rearrangement  can  be  made  for  the  general  reversible  inhibition  rate 
equation (9.42) to give:  
9.44 
1 1 1
 =  +
[S] VV
M
max max
app
app app
K
 
 
The gradients (K
M
app/V
max
app) and y-axis intercepts (1/V
max
app) of 1/  against 1/[S] plots can 
be replotted against inhibitor concentration and fitted to 9.45 and 9.46 respectively: 
9.45 
i
i
i
i
i
i
[I]
1+
[I]
1+
 = 
V V
[I]
1+
[I]
1+
= 
V
[I]
+
= 
V
=  [I]+
VV
M
M
max max
M
max
M
M
max
MM
max max
app
app
K
K
K
K
K
KK
K
K
 
K
K
K
K
 
9.46 
i
i
i
11
 = 
V V
[I]
1+
[I]
1+
= 
V
11
=  [I]+
VV
max max
max
max max
app  
K
K
K
 
 
K
i and  K
i can then be calculated from the negative of the x-axis intercept of replots 
fitted to 9.45 and 9.46 respectively. J C McKelvie    Chapter 9 
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The Cheng-Prusoff equation - competitive reversible inhibition 
Dividing 9.26 by 9.12 gives: 
9.47 
0
i
i
V [S] +[S]
 = 
V [S] 1+[I]
+[S]
+[S]
= 
1+[I]
+[S]
max iM
max
M
M
M
K
K
K
K
K
K
 
 
Substituting 
i/
0 = 0.5 and [I] = IC
50 into 9.47 gives: 
9.48 
50
i
50
i
i
50
50 i
+[S] 1
 = 
2 1+IC
+[S]
IC
2 +2[S] =  + +[S]
[S]+  = IC
[S]
IC  =  1 +
M
M
M
MM
M
M
M
K
K
K
KK
K
K
K
K
K
K
K
 
 
The Cheng-Prusoff equation - noncompetitive reversible inhibition 
Dividing 9.34 by 9.12 gives: 
9.49 
i
0
i
i
i
i
i
ii
V
[S]
1+[I]
+[S]
 = 
V [S] 1+[I]
+[S]
1+[I]
+[S]
1+[I]
= 
1+[I]
+[S]
1+[I]
+[S]
= 
1+[I] 1+[I]
+[S]
max
iM
max
M
M
M
M
M
K
K
K
K
K
K
K
K
K
K
K
K
KK
 
 
Substituting 
i/
0 = 0.5 and [I] = IC
50 into 9.49 gives: J C McKelvie    Chapter 9 
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9.50 
50 50
ii
50 50
ii
50 50
i
i
50
ii
+[S] 1
 = 
2 1+IC 1+IC
+[S]
IC [S]IC
2 +2[S] =  + +[S]+
IC +[S]IC
+[S] = 
+[S]
IC  = 
+[S]
+[S]
= 
[S]
+
M
M
M
MM
M
M
M
M
M
M
K
K
K
KK
K
K
K
K
K
K
KK
KK
K
K
KK
 
 
The Cheng-Prusoff equation - Uncompetitive reversible inhibition 
Dividing 9.41 by 9.12 gives: 
9.51 
i
0
i
i
i
i
V
[S]
1+[I]
+[S]
 = 
1 V [S] +[S]
1+[I]
+[S]
1+[I]
= 
+[S]
1+[I]
+[S]
= 
1+[I]
+[S]
max
iM
max
M
M
M
M
M
K
K
K
K
K
K
K
K
K
K
K
 
 
Substituting 
i/
0 = 0.5 and [I] = IC
50 into 9.49 gives: 
9.52 
50
i
50
i
50
i
ii
50
i
+[S] 1
 = 
2 1+IC
+[S]
[S]IC
2 +2[S] =  +[S]+
[S]IC
+[S] = 
+ [S]
IC  = 
[S]
=  1
[S]
M
M
MM
M
M
M
K
K
KK
K
K
K
K
K
K
KK
K
 J C McKelvie    Chapter 9 
  258   
9.1.1.4  Enzyme-inhibitor binding isotherm equation 
 
 
Figure 9.4 Reversible enzyme-inhibitor complex formation 
Where E = enzyme, I = inhibitor, EI = enzyme-inhibitor complex, k
1 = association rate 
constant, k
-1 = dissociation rate constant. 
 
The rate of change of enzyme-inhibitor complex concentration is given as: 
9.53  11
d[EI]
 = k [E][I]-k [EI]
dt
 
 
Under steady-state approximation the rate of enzyme-substrate complex formation is 
equal to the rate of enzyme-substrate complex decay hence: 
9.54 
d[EI] d[EI]
 = -  = 0
dt dt
 
 
Substituting 9.53 into 9.54 gives: 
9.55 
1 -1
1 -1
k [E][I]-k [EI] = 0
k [E][I] = k [EI]
 
 
Rearranging 9.55 to group the rate constants gives: 
9.56 
1
-1
k
[EI] =  [E][I]
k
[E][I]
= 
D K
 
(where K
D is the equilibrium dissociation binding constant (k
-1/k
1)) 
 
Substituting 9.10 into 9.11 gives: 
9.57 
cat
0T
k [S]
 = [E]
+[S] M K
 
(where 
0 is the uninhibited initial rate and k
cat is the catalytic rate constant k
2)  
 
In the presence of an inhibitor initial rate is proportional to the concentration of free 
enzyme: 
9.58 
cat
i
k [S]
 = [E]
+[S] M K
 
(where 
i is the inhibited initial rate) 
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The  fractional  enzyme  activity  in  the  presence  of  a  concentration  of  inhibitor  can 
therefore be given as (9.58/9.57): 
9.59 
i
0T
[E]
 = 
[E]
 
 
Substituting 9.61 into 9.59 gives: 
9.60 
iT
0T
T
[E] -[EI]
 = 
[E]
[EI]
=1-
[E]
 
 
The concentration of free enzyme and inhibitor can be expressed as: 
9.61  T [E] = [E] -[EI] 
9.62  T [I] = [I] -[EI] 
 
However, where [I]>>[E] 9.62 can be simplified to: 
9.63  T [I] = [I]  
 
Substituting 9.61 and 9.63 into 9.56 gives: 
9.64 
TT
T T T
T T T
TT
T
T
T
[E] -[EI] [I]
[EI] = 
[EI] = [E] [I] -[EI][I]
[EI]+[EI][I]  = [E] [I]
[E] [I]
[EI] = 
+[I]
[E]
= 
1+
[I]
D
D
D
D
D
K
K
K
K
K
 
 
Dividing both sides of 9.64 by [E]
T gives: 
9.65 
T
T
[EI] 1
 = 
[E] 1+
[I]
D K
 
 
Substituting 9.65 into 9.60 gives: 
9.66 
i
0
T
1
 = 1-
1+
[I]
D K
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Which can be rearranged to give: 
9.67 
i
T 0
1
 = 
[I]
1+
D K
 
 
Substituting  the  equilibrium  binding  constant  K
D  for  the  half  maximal  inhibitory 
constant IC
50 gives: 
9.68 
i
T 0
50
1
 = 
[I]
1+
IC
 
 
The binding stoichiometry of enzyme-inhibitor interactions can be accounted for by 
multiplying the [I]
T/IC
50 term by the Hill parameter (h) to give: 
9.69 
i
0 T
50
1
 = 
[I]
1+
IC
h  
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9.1.2 Fluorescence anisotropy equations 
 
 
Figure 9.5 Reversible enzyme-labelled substrate complex formation 
Where  E  =  enzyme,  S‟  =  fluorescently  labelled  substrate,  ES‟=  enzyme-labelled 
substrate complex, K
D = equilibrium dissociation binding constant. 
 
Observed fluorescence anisotropy (A
obs) represents a weighted average of the bound 
(A
B) and free (A
F) fluorophore and can be expressed as: 
9.70  obs B B F F A = F A +F A  
(where F
B and F
F are the fraction of bound and free substrate respectively) 
 
Including  a  correction  factor  (Q)  for  the  ratio  of  bound  and  free  fluorescence 
intensities, and substituting F
F for 1-F
B, 9.70 becomes: 
9.71 
B B B F
obs
B
QF A +F A
A = 
1-(1-Q)F
 
 
Rearranging 9.71 in terms of F
B gives: 
9.72 
obs obs B obs B B B F B F
obs B obs obs B B F F
obs F B B F B obs obs
obs F B B F obs obs
obs F B B obs F obs
obs F
B
B obs F obs
A -A F -A QF  = QF A +A -F A
A -F A -A Q  = F QA -A +A
A -A  = F QA -A +F A -A Q
A -A  = F QA -A +A -A Q
A -A  = F Q A -A -A +A
A -A
F  = 
Q A -A -A +A
 
 
Direct binding 
Binding of enzyme to labelled substrate (Figure 9.5) can be described as: 
9.73 
[E][S']
 = 
[ES']
D K  
 
The concentration of free enzyme and labelled substrate can be expressed as: 
9.74  T [E] = [E] -[ES'] 
9.75  T [S'] = [S'] -[ES'] 
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Substituting 9.74 and 9.75 into 9.73 gives: 
9.76 
TT
TT
[E] -[ES'] [S'] -[ES']
 = 
[ES']
[ES'] =  [E] -[ES'] [S'] -[ES']
D
D
K
K
 
 
Which can be rearranged to give a quadratic equation: 
9.77 
TT
2
T T T T
2
T T T T
0 =  [E] -[ES'] [S'] -[ES'] [ES']
= [E] [S'] -[E] [ES']-[S'] [ES']+[ES'] [ES']
=[ES'] - [E] +[S'] + [ES']+[E] [S']
D
D
D
-K
-K
K
 
 
Solving 9.77 gives two possible solutions, only one of which has physical meaning: 
9.78 
2
T T T T T T [E] +[S'] + - [E] +[S'] + -4[E] [S']
[ES'] = 
2
DD KK
 
 
Fraction of substrate bound can be expressed in terms of fraction of free substrate as: 
9.79 
BF
T
F  = 1-F
[S']
= 1-
[S']
 
 
Substituting 9.75 into 9.79 gives: 
9.80 
B
T
T
T
T
[S']
F  = 1-
[S']
[S'] -[ES']
= 1-
[S']
[ES']
= 
[S']
 
 
Substituting 9.78 into 9.80 gives: 
9.81 
2
T T T T T T
B
T
[E] +[S'] + - [E] +[S'] + -4[E] [S']
F  = 
2[S']
DD KK
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Competitive binding 
 
 
Figure  9.6  Reversible  competitive  inhibition  of  enzyme-labelled  substrate  complex 
formation 
Where E = enzyme, S‟ = fluorescently labelled substrate, I = inhibitor, ES‟= enzyme-
labelled  substrate  complex,  EI=  enzyme-inhibitor  complex,  K
D  =  equilibrium 
dissociation  binding  constant,  K
Dc  =  equilibrium  dissociation  competition  binding 
constant. 
 
Competitive  inhibition  of  enzyme-labelled  substrate  complex  formation  (Figure  9.6) 
can be described by 9.73, 9.75, 9.79 and: 
9.82 
[E][I]
 = 
[EI]
Dc K  
9.83  T [E] = [E] -[ES']-[EI] 
9.84  T [I] = [I] -[EI] 
 
Solving 9.73, 9.75, 9.79, 9.82, 9.83 and 9.84 for [I]
T and eliminating [R], [S‟], [ES‟], [I] 
and [EI] gives the cubic equation: 
9.85 
2
B T B T T B T
T
BB
F + [S'] F - +[S'] +[E] F +[E]
[I]  = 
1-F F
D D D D
D
cc K -K K K
K
 
 
Solving 9.85 for F
B gives a single physically meaning root expressed by: 
9.86 
2
B
2
2 d -3e -d
3 F  = 
3 +2 d -3e -d
3
D
cos
cos K
 
Where: 
T T T
T T T T
T
3
3 2
d =  + +[S'] +[I] -[E]
e =  [I] -[E] + [I] -[E] +
f = - [E]
-2d +9de-27f
 = arccos
2 d -3e
DD
D D D D
DD
c
cc
c
KK
K K K K
KK
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9.2 Plasmid Maps 
 
 
Figure 9.7 pBAD/HisA expression vector 
 
 
Figure 9.8 Y. pestis Dam expression vector 
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Figure 9.9 DpnI expression vector 
 
 
Figure 9.10 Gel-based and in culture gel-based Dam methylation assay plasmid 
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9.3 Oligonucleotides 
(
mA – N6-methyladenine, 
mC – 5-methylcytosine, F – Fluorescein, Cy – Cy3, D – Dabcyl, 
recognition sequence in bold, hairpin loop in italics) 
 
ODN1:  F-CCGGmATCCAGTTTTCTGGATCCGG-D 
ODN2:  F-CCGGmATCCAGTTTTCTGGmATCCGG-D 
ODN3:  CCGGATCCAGTTTTCTGGATCCGG 
ODN4:  Cy-CCTATGCGmCATCAGTTTTCTGATGmCGmCATAGG-D   
ODN5:  Cy-CCTATGmCGmCATCAGTTTTCTGATGmCGmCATAGG-D 
ODN6:  F-CCTATGCGmCATCAGTTTTCTGATGmCGmCATAGG-D 
ODN7:  F-CCTATGmCGmCATCAGTTTTCTGATGmCGmCATAGG-D 
ODN8:  F-TATAGGCGmCCCATGTTTTCATGGGmCGmCCTATA-D 
ODN9:  F-TATAGGmCGmCCCATGTTTTCATGGGmCGmCCTATA-D 
ODN10:  F-CCGGmATCCAGTTTTCTGGATCCGG-D 
ODN11:  F-CCGGmATCCAGTTTTCTGGmATCCGG-D 
ODN12:  CCGGmATCCAGTTTTCTGGATCCGG 
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9.4 Calibration plots 
 
9.4.1 Real-time break light Dam and DpnI activity assays 
Assays were prepared in 96 and 384 well plates in a total volume of 100 or 20 µl as 
described  in  Chapter  8,  Section  8.3.2.2,  and  supplemented  with  fully  methylated 
oligonucleotide  ODN2  (0-35  nM)  and  DpnI  (0.8  nM).  End  point  fluorescence  was 
measured  at  gain  settings  of  100-190,  and  plots  of  end-point  fluorescence  against 
total amount of DNA at various gain settings were fitted to a linear equation of the 
form y = y0+a*x, where a is the fluorescence change per unit of DNA turned over. 
 
 
Figure 9.11 Fluorescence calibration curve I 
End-point fluorescence versus amount of fully methylated oligonucleotide ODN2 for 96 
well plates at gain settings of 100 (filled circles), 120 (open circles) and 120 (filled 
triangles), and for 384 well plates at gain settings of 150 (open triangles), 170 (filled 
squares)  and  190  (open  squares).  Data  fitted  to  a  linear  equation  of  the  form  y  = 
y0+a*x. 
Assay conditions: 0.8 nM DpnI, 0-35 nM fully methylated oligonucleotide (ODN2), 20 
mM Tris, 80 mM NaCl, 8 mM MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.9. Total assay 
volume 100 or 20 µl, in 96 or 384 well plates, gain 100-190, temperature 30 °C. 
 
Table 9.1 Fluorescence calibration data I 
Plate  Gain Setting  F/fmole*  R2 
96 well  100  13.2 ± 0.4  0.996 
120  55.0 ± 1.7  0.993 
130  94.5 ± 3.1  0.999 
384 well  150  86.4 ± 2.5  0.994 
170  197 ± 5  0.996 
190  483 ± 23  0.995 
* Gradient (a) ± standard error of fit calculated from Figure 9.11 J C McKelvie    Chapter 9 
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9.4.2 Real-time break light DNMT1 activity assay 
Assays were prepared in 384 well plates in a total volume of 20 µl, as described in 
Chapter 8,  Section  8.3.2.4,  and  supplemented  with  fully  methylated oligonucleotide 
ODN7 (0-250 nM) and GlaI (0.25 U µl
-1). End point fluorescence was measured in a BMG 
Polarstar Omega at gain settings of 1250-1550, and plots of end-point fluorescence 
against total amount of DNA at various gain settings were fitted to a linear equation of 
the  form  y  =  y0+a*x,  where  a  is  the  fluorescence  change  per  unit  amount  of  DNA 
turned over.  
 
 
Figure 9.12 Fluorescence calibration curve II 
End-point  fluorescence  versus  amount  of  fully  methylated  oligonucleotide  ODN7  at 
gain settings of 1250 (filled circles) and 1550 (open circles). Data fitted to a linear 
equation of the form y = y0+a*x. 
Assay conditions: 0.25 U µl
-1 GlaI, 0-250 nM fully methylated oligonucleotide (ODN7), 
100 mM Tris, 12.5 mM NaCl, 5 mM MgCl
2, 0.1 mg ml
-1 BSA, 1 mM DTT, pH 7.5. Total 
assay volume 20 µl, in 384 well plates, gain 1250-1550, temperature 37 °C. 
 
Table 9.2 Fluorescence calibration data II 
Plate  Gain Setting  F/fmole*  R2 
384 well  1250  35.4 ± 4.6  0.982 
1550  201 ± 9  0.994 
* Gradient (a) ± standard error of fit calculated from Figure 9.12 
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9.5 Optimisation of the real-time break light Dam activity 
assay for E. coli Dam 
 
9.5.1 Enzyme concentration 
E. coli Dam activity assays were prepared in 384 well plates in a total volume of 20 µl 
as  described  in  Chapter  8,  Section  8.3.2.1.  Assays  were  maintained  at  37  °C  and 
supplemented with hemimethylated oligonucleotide ODN1 (200 nM), AdoMet (200 µM), 
E. coli Dam (1 nM) and DpnI (0.6-20 nM). Initial rate versus DpnI concentration data 
was fitted to an exponential rise to a maximum of the form f=a*(1-exp(-b*x)) and the 
optimal concentration of DpnI, where 94% maximum rate was achieved, was identified 
as 10 nM. 
 
   
Figure 9.13 DpnI concentration optimisation 
Background  subtracted  initial  rate  of  methylation  by  E.  coli  Dam.  Data  fitted  to  an 
exponential rise to a maximum of the form f=a*(1-exp(-b*x)), where a = maximum rate. 
Assay  conditions:  1  nM  E.  coli  Dam,  0-20  nM  DpnI,  200  nM  hemimethylated 
oligonucleotide (ODN1), 25 or 0 µM AdoMet, 20 mM Tris, 80 mM NaCl, 8 mM MgCl
2, 1 
mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, in 384 well 
plate, gain 150, temperature 37 °C. 
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9.5.2 Substrate concentrations 
9.5.2.1  DNA 
E. coli Dam K
M
DNA assays were prepared in 384 well plates in a total volume of 20 µl as 
described  in  Chapter  8,  Section  8.3.2.5.  Assays  were  maintained  at  37  °C  and 
supplemented  with hemimethylated oligonucleotide ODN1 (6-200 nM), AdoMet (200 
µM), DMSO (5%), E. coli Dam (0.5 nM) and DpnI (2, 10 or 15 nM). Initial rate versus DNA 
concentration data was fitted globally to Equation 2.5 with K
M and V
max shared, and K
M
DNA 
was identified as 28.0 ± 14.2 nM. 
 
 
Figure 9.14 Graphical determination of E. coli Dam K
M
DNA 
Background subtracted initial rate versus concentration of DNA with 2 (filled circles), 
10 (open circles) or 15 (filled triangles) nM DpnI. Data fitted globally to Equation 2.5 
with K
M and V
max shared. 
Assay conditions: 0.5 nM E. coli Dam, 2, 10 or 15 nM DpnI, 6-200 nM hemimethylated 
oligonucleotide (ODN1), 0 or 100 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 
mM MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, 
in 384 well plate, gain 130, 37 °C. 
 
9.5.2.2  AdoMet 
E. coli Dam K
M
AdoMet assays were prepared in 384 well plates in a total volume of 20 µl as 
described  in  Chapter  8,  Section  8.3.2.5.  Assays  were  maintained  at  37  °C  and 
supplemented  with hemimethylated oligonucleotide ODN1 (100 nM), AdoMet (0-100 
µM), E. coli Dam (1 nM) and DpnI (0.6-20 nM). Initial rate versus AdoMet concentration 
data was fitted to Equation 2.4B and K
M
AdoMet was identified as 5.56 ± 0.80 µM. 
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Figure 9.15 Graphical determination of E. coli Dam K
M
AdoMet 
Initial rate versus concentration of AdoMet. Data fitted to Equation 2.4B. 
Assay  conditions:  1  nM  Y.  pestis  Dam,  2  nM  DpnI,  30  nM  hemimethylated 
oligonucleotide (ODN1), 0-200 µM AdoMet, 5% DMSO, 20 mM Tris, 80 mM NaCl, 8 mM 
MgCl
2, 1 mM DTT, 0.1 mg ml
-1 BSA, 5% glycerol, pH 7.9. Total assay volume 20 µl, in 
384 well plate, gain 130, 37 °C. 
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9.6 Assay automation 
 
A Beckman Coulter Biomek 3000 laboratory automation workstation was used for the 
automated preparation of assays in 384 well plates. Automation programs (Table 9.3, 
Table  9.4  and  Table  9.5)  were  optimised  to  ensure  rapid  and  efficient  mixing  of 
components was achieved. 
 
Table 9.3 Dry well automated plate addition 
Step  Parameter  Value 
Prewet  Overage  5 µl 
  Delay  200 ms 
Mixing (prior to aspiration)  Volume  - 
  Aspirate height  - 
  Aspirate speed  - 
  Dispense height  - 
  Dispense speed  - 
Aspirate  Height  -3 mm (from the liquid) 
  Airgap  2 µl 
  Delay  200 ms 
  Speed
  20 µl s
-1 
Dispense  Delay  200 ms 
  Height  0.3 mm (from the bottom) 
  Speed
  20 µl s
-1 
Mixing  Volume  - 
  Aspirate height  - 
  Aspirate speed  - 
  Dispense height  - 
  Dispense speed  - 
Tip touch  Height  -1 mm (from the well top) 
  Speed  75% of maximum J C McKelvie    Chapter 9 
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Table 9.4 Wet well automated plate addition 
Step  Parameter  Value 
Prewet  Overage  5 µl 
  Delay  200 ms 
Mixing (prior to aspiration)  Volume  5 µl x 4 
  Aspirate height  -2 mm (from the liquid) 
  Aspirate speed  100 µl s
-1 
  Dispense height  -2 mm (from the liquid) 
  Dispense speed  100 µl s
-1 
Aspirate  Height  -2 mm (from the liquid) 
  Airgap  2 µl 
  Delay  200 ms 
  Speed
  20 µl s
-1 
Dispense  Delay  200 ms 
  Height  1.5 mm (from the bottom) 
  Speed
  40 µl s
-1 
Mixing  Volume  10 µl x 4 
  Aspirate height  1.5 mm (from the bottom) 
  Aspirate speed  100 µl s
-1 
  Dispense height  1.5 mm (from the bottom) 
  Dispense speed  100 µl s
-1 
Tip touch  Height  -1 mm (from the well top) 
  Speed  75% of maximum 
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Table 9.5 Automated assay initiation (enzyme addition) 
Step  Parameter  Value 
Prewet  Overage  5 µl 
  Delay  100 ms 
Mixing (prior to aspiration)  Volume  - 
  Aspirate height  - 
  Aspirate speed  - 
  Dispense height  - 
  Dispense speed  - 
Aspirate  Height  -2 mm (from the liquid) 
  Airgap  2 µl 
  Delay  100 ms 
  Speed
  20 µl s
-1 
Dispense  Delay  100 ms 
  Height  2 mm (from the bottom) 
  Speed
  20 µl s
-1 
Mixing  Volume  10 µl x 2 
  Aspirate height  2 mm (from the bottom) 
  Aspirate speed  50 µl s
-1 
  Dispense height  2 mm (from the bottom) 
  Dispense speed  50 µl s
-1 
Tip touch  Height  -1 mm (from the well top) 
  Speed  75% of maximum 
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9.7 HTS 
 
9.7.1 Plate layout 
384  well plates were divided into three sections and compounds  were screened 80 
compounds at a time with 8 positive and a negative control assays per compound set. 
Plate layout was as shown in Figure 9.16. 
 
  1  2  3  4  5  6  7 
A  +  1  2  3  4  5   
B    6  7  8  9  10  + 
C  -  11  12  13  14  15   
D    16  17  18  19  20  - 
E  +  21  22  23  24  25   
F    26  27  28  29  30  + 
G  -  31  32  33  34  35   
H    36  37  38  39  40  - 
I  +  41  42  43  44  45   
J    46  47  48  49  50  + 
K  -  51  52  53  54  55   
L    56  57  58  59  60  - 
M  +  61  62  63  64  65   
N    66  67  68  69  70  + 
O  -  71  72  73  74  75   
P    76  77  78  79  80  - 
Figure 9.16 HTS plate layout 
Single assay set, three assay sets in total per 384 well plate. + = positive control assay 
(no library compound), - = negative control assay (no library compound, no AdoMet), 1-
80 = complete assays. 
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9.7.2 Sublibraries 
9.7.2.1  Stibonic acid sublibrary 
NSC identifier shown in bold, for Y. pestis Dam screen hits, NSC identifier is shown in 
red. 
     
13731  13735  13740 
     
13741  13742  13743 
     
13744  13745  13746 
     
13748  13755  13758 
     
13759  13760  13765 
     
13771  13776  13778 
   
 
13782  13793  13794 J C McKelvie    Chapter 9 
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13935  15408  15575 
     
15577  15578  15583 
 
   
15584  15585  15591 
     
15596  17164  25176 
   
 
35015  115831  118018 
 
 
140279  221126 
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9.7.2.2  Phosphonic acid sublibrary 
NSC identifier shown in bold. 
 
 
     
419  420  13007  13559  13560 
 
       
13561  13562  13565  55744  87207 
   
     
129447  129452  129453  129456  129457 
         
129458  129459  129460  129461  129462 
         
129463  129464  129465  129466  129467 
         
129468  129469  129474  129475  129478 
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349096  400340  402274  407831  408071 
 
666474 
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9.8 mRNA profiling 
 
Experiments were carried out at dstl Porton Down under containment level 3 by Dr M. 
I. Richards. Overnight cultures of Y. pestis GB were used to inoculate BAB media (10 ml) 
supplemented with CaCl
2 (2.5 mM), 13782 (20 µg ml
-1) and DMSO (0.025%). Controls 
lacking 13782 were also prepared. Cultures were incubated (37 °C, 180 rpm) to an 
OD
590 of 0.4. Aliquots of culture (2 ml) were removed into Qiagen RNA Protect solution 
and  mRNA  extracted  using  the  Qiagen  RNeasy  kit  as  per  the  manufacturer‟s 
instructions. RNA concentration was determined by nanodrop quantification and 1 mg 
ml
-1 samples were prepared by ethanol precipitation followed by re-suspension with the 
appropriate volume of RNase-free water. Samples were stored at 
-80 °C until required. 
Hybridisations were carried out as described by Robinson et al. (40). 
 
Whole  genome  microarrays  based  on  strain  CO92  were  obtained  from  St  Georges‟ 
Hospital Bacterial Microarray group at the University of London.  All predicted CO92 
coding  sequences  are  represented  on  the  microarray.  Gene  numbers  refer  to  the 
published genome sequence annotation (273). Microarray slides were scanned using 
an  Affymetrix  428  scanner  (MWG  Biotech,  London,  UK)  with  GenePix  software.  
Subsequent GenePix analysis enabled spot quantification to be captured. Quantified 
data were loaded into Genespring 6.0 (Aglient, Cheshire, UK). Data were interpreted 
using  the  „log  of  ratio‟  with  the  cross-gene  error  model  switched  off.  A  2-fold 
difference in expression level between the wild-type and the mutant was set as the cut-
off.  Genes  that  demonstrated  at  least  a  2-fold  difference  in  expression  level  were 
tested by Student‟s t-test to determine that the difference was statistically significant. 
The  Benjamini  and  Hochberg  false  discovery  rate  was  used  to  correct  for  multiple 
testing.  The  results  are  a  compilation  of  the  gene  expression  profiles  of  three 
biological  replicates  grown  on  different  days  and  two  arrays  of  each  replicate  also 
performed on different days, resulting in a total of six arrays. 
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Table  9.6  Y.  pestis  genes  showing  >1.3-fold  up-regulation  during  growth  in  the 
presence of compound 13782 
 Gene ID  Annotation  Corrected 
p-value 
p-value  FC 
Absolute* 
Up-regulation 
nupC  Nucleoside permease  1.43E-03  2.28E-06  2.38 
pCD1-yscJ  Putative  type  III  secretion 
lipoprotein  
1.21E-02  1.06E-04  2.26 
YPO0473  Hypothetical protein  4.41E-03  2.11E-05  2.23 
YPO2605  Conserved  hypothetical 
protein 
1.65E-03  4.59E-06  2.14 
dacA  Cutative  penicillin-binding 
protein 5 
2.56E-02  4.49E-04  1.98 
fabF  3-oxoacyl-[acyl-carrier-protein] 
synthase II 
1.21E-02  9.97E-05  1.97 
topA  DNA topoisomerase I  6.96E-04  8.30E-07  1.96 
YPO1716  Putative transport protein  1.49E-03  3.08E-06  1.90 
pCD1-27  Putative  type  III  secretion 
protein 
4.93E-03  2.55E-05  1.88 
secD  Protein-export  membrane 
protein SecD 
2.44E-02  2.91E-04  1.88 
YPO2422  Conserved  hypothetical 
protein 
2.53E-02  3.34E-04  1.81 
dapX  Lipoprotein  2.53E-02  3.99E-04  1.80 
prfA  Peptide chain release factor 1  7.20E-03  4.01E-05  1.78 
ffh  Signal  recognition  particle 
protein 
7.65E-03  4.56E-05  1.77 
YPO2978  Putative membrane protein  4.13E-02  1.21E-03  1.76 
YPO2875  GTP-binding protein   2.53E-02  4.17E-04  1.76 
trmD  tRNA  (guanine-N1)-
methyltransferase 
3.53E-02  8.60E-04  1.72 
rpoH  RNA  polymerase  sigma-32 
factor 
2.53E-02  3.28E-04  1.69 
yapA  Putative  autotransporter 
protein 
4.64E-02  1.57E-03  1.67 
fabH  3-oxoacyl-[acyl-carrier-protein] 
synthase III 
2.85E-02  5.33E-04  1.66 
pCD1-sycE  Putative yopE chaperone  3.83E-02  1.04E-03  1.66 
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YPO2050  Conserved  hypothetical 
protein 
4.05E-02  1.18E-03  1.65 
pCD1-
yscX 
Putative  type  III  secretion 
protein 
2.93E-03  1.25E-05  1.62 
hemH  Ferrochelatase  3.53E-02  8.46E-04  1.60 
pyrG  CTP synthase  3.83E-02  1.07E-03  1.60 
YPO1575  Conserved  hypothetical 
protein 
4.97E-02  1.84E-03  1.59 
ribD  Riboflavin  biosynthesis 
protein RibD  
2.22E-02  2.39E-04  1.57 
cysP  Thiosulfate-binding protein  3.67E-02  9.42E-04  1.55 
nadD  Putative nicotinate-nucleotide  1.21E-02  1.01E-04  1.52 
purK  Phosphoribosylaminoimidazol
e carboxylase ATPase 
4.96E-02  1.79E-03  1.52 
rplM  50S ribosomal protein L13  3.53E-02  8.17E-04  1.51 
nuoF  NADH  dehydrogenase  I  chain 
F 
3.53E-02  8.70E-04  1.51 
atpI  ATP synthase protein I  1.21E-02  9.99E-05  1.51 
pCD1-73c  Hypothetical protein  3.08E-02  6.01E-04  1.50 
murB  UDP-N-
acetylenolpyruvoylglucosamin
e reductase 
2.53E-02  4.32E-04  1.50 
tatC  Sec-independent  protein 
translocase protein 
1.71E-02  1.64E-04  1.50 
mreC  Rod  shape-determining 
protein MreC 
4.67E-02  1.60E-03  1.49 
speE  Spermidine synthase  2.53E-02  4.01E-04  1.45 
tmk  Thymidylate kinase  2.53E-02  3.11E-04  1.40 
pPMT1-85  -  3.26E-02  6.48E-04  1.36 
YPO3170  Conserved  hypothetical 
protein 
4.36E-02  1.35E-03  1.35 
YPO3857  Conserved  hypothetical 
protein 
3.53E-02  8.35E-04  1.32 
guaC  GMP reductase  4.36E-02  1.35E-03  1.30 
* Absolute fold-change. 
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Table  9.7  Y.  pestis  genes  showing  >1.3-fold  down-regulation  during  growth  in  the 
presence of compound 13782 
 Gene ID  Annotation 
Corrected 
p-value 
p-value 
FCAbsolute
a 
Down-regulation 
YPO2304  Hypothetical protein  2.25E-02  2.60E-04  3.09 
katA  Catalase  2.93E-03  1.26E-05  2.87 
YPO1892  Putative oxidoreductase  2.53E-02  4.24E-04  2.74 
YPO3279 
Putative  sigma  54  modulation 
protein 
1.93E-02  1.98E-04  2.55 
YPO3744  Hypothetical protein  2.25E-02  2.59E-04  2.49 
YPO2675 
Putative  potassium  channel 
protein 
7.74E-03  4.92E-05  2.40 
uspA  Universal stress protein A  1.49E-03  3.57E-06  2.39 
YPO0735  Hypothetical protein  4.58E-02  1.53E-03  2.39 
nrdA 
Ribonucleoside-diphosphate 
reductase 1 alpha 
1.93E-02  2.00E-04  2.34 
narX  Nitrate/nitrite sensor protein  4.73E-02  1.68E-03  2.23 
23s rRNA  23S ribosomal RNA   3.53E-02  8.36E-04  2.12 
YPO0072 
Bifunctional  regulatory 
protein/DNA repair 
3.78E-02  1.01E-03  2.06 
YPO2705  Conserved hypothetical protein  2.93E-03  1.06E-05  1.99 
YPO2745  Conserved hypothetical protein  3.48E-02  7.20E-04  1.97 
YPO3556  Conserved hypothetical protein  3.89E-02  1.11E-03  1.97 
YPO1354  Putative lipoprotein  4.29E-02  1.30E-03  1.96 
YPO2935  Putative exported protein  2.93E-03  1.28E-05  1.94 
YPO1536 
Putative  iron-siderophore 
transport system 
4.58E-02  1.53E-03  1.90 
YPO2197 
Similar  to  Vibrio  cholerae 
probable sulphate 
3.06E-02  5.83E-04  1.88 
frdC 
Fumarate  reductase  hydrophobic 
protein 
4.43E-02  1.39E-03  1.88 
YPO1532 
Putative  siderophore  biosynthetic 
enzyme 
3.52E-02  7.42E-04  1.87 
dps  Putative DNA-binding protein  3.67E-02  9.64E-04  1.87 
YPO3649 
Putative  gamma 
carboxymuconolactone 
4.49E-02  1.45E-03  1.87 
YPO3527  Conserved hypothetical protein  4.67E-02  1.62E-03  1.84 
ureE  Urease accessory protein  2.53E-02  4.06E-04  1.78 J C McKelvie    Chapter 9 
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ureD  Urease accessory protein  2.67E-02  4.77E-04  1.76 
YPO1736  Putative membrane protein  3.83E-02  1.06E-03  1.74 
YPO0505  Conserved hypothetical protein  4.96E-02  1.80E-03  1.73 
YPO1683  Conserved hypothetical protein  1.21E-02  9.99E-05  1.72 
iucA 
Similar  to  Escherichia  coli 
aerobactin siderophore 
4.47E-02  1.42E-03  1.72 
YPO4020  Putative membrane protein  3.67E-02  9.53E-04  1.69 
ybtT 
Yersiniabactin  biosynthetic 
protein YbtT 
3.53E-02  8.61E-04  1.68 
YPO0966  Putative kinase  2.83E-02  5.17E-04  1.67 
YPO2672  Conserved hypothetical protein  3.60E-02  9.02E-04  1.66 
16s rRNA  16S ribosomal RNA  4.71E-02  1.65E-03  1.64 
napC  Cytochrome C-type protein NapC  1.30E-02  1.18E-04  1.64 
YPO0273 
Putative  type  III  secretion 
apparatus protein 
2.53E-02  4.14E-04  1.63 
cueR  Putative regulatory protein  2.53E-02  3.91E-04  1.62 
map  Methionine aminopeptidase  4.49E-02  1.47E-03  1.61 
YPO0511a  Hypothetical protein  1.17E-02  7.93E-05  1.60 
YPO1568  Hypothetical protein  3.53E-02  7.89E-04  1.58 
pheT 
Phenylalanyl-tRNA  synthetase 
beta chain 
4.24E-02  1.26E-03  1.52 
nrdG 
Anaerobic  ribonucleoside-
triphosphate reductase 
3.83E-02  1.08E-03  1.48 
YPO2846 
Putitive  ABC-transporter  ATP-
binding protein 
2.53E-02  4.29E-04  1.43 
YPO0265 
Putative type III secretion system 
apparatus 
3.34E-02  6.78E-04  1.38 
YPO0969  Hypothetical protein  4.96E-02  1.81E-03  1.37 
ssuB 
Putative  aliphatic  sulfonates 
transport 
2.53E-02  4.23E-04  1.37 
YPO3978  Putative regulatory protein  3.53E-02  8.05E-04  1.31 
* Absolute fold-change. 
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